
<html lang="en"     class="pb-page"  data-request-id="7e9a5f0d-441b-424b-9702-78e7b2edbb59"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.9b00002;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-7;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir" /></meta><meta name="dc.Creator" content="Murugaiah  A. M. Subbaiah" /></meta><meta name="dc.Creator" content="Sandhya  Mandlekar" /></meta><meta name="dc.Creator" content="Sridhar  Desikan" /></meta><meta name="dc.Creator" content="Thangeswaran  Ramar" /></meta><meta name="dc.Creator" content="Lakshumanan  Subramani" /></meta><meta name="dc.Creator" content="Mathiazhagan  Annadurai" /></meta><meta name="dc.Creator" content="Salil D.  Desai" /></meta><meta name="dc.Creator" content="Sarmistha  Sinha" /></meta><meta name="dc.Creator" content="Susan M.  Jenkins" /></meta><meta name="dc.Creator" content="Mark R.  Krystal" /></meta><meta name="dc.Creator" content="Murali  Subramanian" /></meta><meta name="dc.Creator" content="Srikanth  Sridhar" /></meta><meta name="dc.Creator" content="Shweta  Padmanabhan" /></meta><meta name="dc.Creator" content="Priyadeep  Bhutani" /></meta><meta name="dc.Creator" content="Rambabu  Arla" /></meta><meta name="dc.Creator" content="Shashyendra  Singh" /></meta><meta name="dc.Creator" content="Jaydeep  Sinha" /></meta><meta name="dc.Creator" content="Megha  Thakur" /></meta><meta name="dc.Creator" content="John F.  Kadow" /></meta><meta name="dc.Creator" content="Nicholas A.  Meanwell" /></meta><meta name="dc.Description" content="Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug faile..." /></meta><meta name="Description" content="Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug faile..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="April 2, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00002" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00002" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00002" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00002" /></link>
        
    
    

<title>Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00002" /></meta><meta property="og:title" content="Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0010.jpeg" /></meta><meta property="og:description" content="Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug failed to release 1 in rats, the introduction of a methylene spacer facilitated prodrug activation, but parent exposure was lower than that following direct administration of 1. Val amino acid and Val-Val dipeptides imparted low plasma exposure of the parent, although the exposure of the prodrugs was high, reflecting good absorption. Screening of additional amino acids resulted in the identification of an l-Phe ester that offered an improved exposure of 1 and reduced levels of the circulating prodrug. Further molecular editing focusing on the linker design culminated in the discovery of the self-immolative l-Phe-Sar dipeptide derivative 74 that gave four-fold improved AUC and eight-fold higher Ctrough values of 1 compared with oral administration of the drug itself, demonstrating a successful prodrug approach to the oral delivery of 1." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00002"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00002">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00002&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00002&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00002&amp;href=/doi/10.1021/acs.jmedchem.9b00002" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3553-3574</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b02026" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00010" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Murugaiah A. M. Subbaiah</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murugaiah A. M. Subbaiah</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#c8a5bdbabdafa9a1a9a0e6a9a6aca9b8b8a9a688bbb1a6afada6ada1a6bca4e6aba7a5"><span class="__cf_email__" data-cfemail="cba6beb9beacaaa2aaa3e5aaa5afaabbbbaaa58bb8b2a5acaea5aea2a5bfa7e5a8a4a6">[email protected]</span></a>. Phone: +91-9731600213.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murugaiah++A.+M.+Subbaiah">Murugaiah A. M. Subbaiah</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandhya Mandlekar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandhya Mandlekar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandhya++Mandlekar">Sandhya Mandlekar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sridhar Desikan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sridhar Desikan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biopharmaceutics, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sridhar++Desikan">Sridhar Desikan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thangeswaran Ramar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thangeswaran Ramar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thangeswaran++Ramar">Thangeswaran Ramar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lakshumanan Subramani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lakshumanan Subramani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lakshumanan++Subramani">Lakshumanan Subramani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mathiazhagan Annadurai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mathiazhagan Annadurai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Medicinal Chemistry, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mathiazhagan++Annadurai">Mathiazhagan Annadurai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Salil D. Desai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Salil D. Desai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biopharmaceutics, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Salil+D.++Desai">Salil D. Desai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarmistha Sinha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarmistha Sinha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarmistha++Sinha">Sarmistha Sinha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan M. Jenkins</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan M. Jenkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+M.++Jenkins">Susan M. Jenkins</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mark R. Krystal</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mark R. Krystal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Virology, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mark+R.++Krystal">Mark R. Krystal</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Murali Subramanian</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Murali Subramanian</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Murali++Subramanian">Murali Subramanian</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Srikanth Sridhar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Srikanth Sridhar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biopharmaceutics, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Srikanth++Sridhar">Srikanth Sridhar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shweta Padmanabhan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shweta Padmanabhan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shweta++Padmanabhan">Shweta Padmanabhan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Priyadeep Bhutani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Priyadeep Bhutani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Priyadeep++Bhutani">Priyadeep Bhutani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rambabu Arla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rambabu Arla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rambabu++Arla">Rambabu Arla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shashyendra Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shashyendra Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shashyendra++Singh">Shashyendra Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jaydeep Sinha</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jaydeep Sinha</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jaydeep++Sinha">Jaydeep Sinha</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Megha Thakur</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Megha Thakur</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmaceutical Candidate Optimization, Biocon-Bristol Myers Squibb R&D Centre, Biocon Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Megha++Thakur">Megha Thakur</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John F. Kadow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John F. Kadow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+F.++Kadow">John F. Kadow</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Nicholas A. Meanwell</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicholas A. Meanwell</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Discovery Chemistry and Molecular Technologies, Bristol-Myers Squibb Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicholas+A.++Meanwell">Nicholas A. Meanwell</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8857-1515" title="Orcid link">http://orcid.org/0000-0002-8857-1515</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00002&amp;href=/doi/10.1021%2Facs.jmedchem.9b00002" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3553–3574</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 2, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 January 2019</li><li><span class="item_label"><b>Published</b> online</span>2 April 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 April 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00002" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00002</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3553%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMurugaiah%2BA.%2BM.%2BSubbaiah%252C%2BSandhya%2BMandlekar%252C%2BSridhar%2BDesikan%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D7%26contentID%3Dacs.jmedchem.9b00002%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BPharmacokinetic%2BEvaluation%2Bof%2BPhosphate%2Band%2BAmino%2BAcid%2BEster%2BProdrugs%2Bfor%2BImproving%2Bthe%2BOral%2BBioavailability%2Bof%2Bthe%2BHIV-1%2BProtease%2BInhibitor%2BAtazanavir%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3574%26publicationDate%3DApril%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00002"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2308</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00002" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Pharmacokinetic Evaluation of Phosphate and Amino Acid Ester Prodrugs for Improving the Oral Bioavailability of the HIV-1 Protease Inhibitor Atazanavir&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Murugaiah&quot;,&quot;last_name&quot;:&quot;A. M. Subbaiah&quot;},{&quot;first_name&quot;:&quot;Sandhya&quot;,&quot;last_name&quot;:&quot;Mandlekar&quot;},{&quot;first_name&quot;:&quot;Sridhar&quot;,&quot;last_name&quot;:&quot;Desikan&quot;},{&quot;first_name&quot;:&quot;Thangeswaran&quot;,&quot;last_name&quot;:&quot;Ramar&quot;},{&quot;first_name&quot;:&quot;Lakshumanan&quot;,&quot;last_name&quot;:&quot;Subramani&quot;},{&quot;first_name&quot;:&quot;Mathiazhagan&quot;,&quot;last_name&quot;:&quot;Annadurai&quot;},{&quot;first_name&quot;:&quot;Salil&quot;,&quot;last_name&quot;:&quot;D. Desai&quot;},{&quot;first_name&quot;:&quot;Sarmistha&quot;,&quot;last_name&quot;:&quot;Sinha&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;M. Jenkins&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;R. Krystal&quot;},{&quot;first_name&quot;:&quot;Murali&quot;,&quot;last_name&quot;:&quot;Subramanian&quot;},{&quot;first_name&quot;:&quot;Srikanth&quot;,&quot;last_name&quot;:&quot;Sridhar&quot;},{&quot;first_name&quot;:&quot;Shweta&quot;,&quot;last_name&quot;:&quot;Padmanabhan&quot;},{&quot;first_name&quot;:&quot;Priyadeep&quot;,&quot;last_name&quot;:&quot;Bhutani&quot;},{&quot;first_name&quot;:&quot;Rambabu&quot;,&quot;last_name&quot;:&quot;Arla&quot;},{&quot;first_name&quot;:&quot;Shashyendra&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Jaydeep&quot;,&quot;last_name&quot;:&quot;Sinha&quot;},{&quot;first_name&quot;:&quot;Megha&quot;,&quot;last_name&quot;:&quot;Thakur&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;F. Kadow&quot;},{&quot;first_name&quot;:&quot;Nicholas&quot;,&quot;last_name&quot;:&quot;A. Meanwell&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;04&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;3553-3574&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00002&quot;},&quot;abstract&quot;:&quot;Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (1) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug failed to release 1 in rats, the introduction of a methylene spacer facilitated prodrug activation, but parent exposure was lower than that following direct administration of 1. Val amino acid and Val-Val dipeptides imparted low plasma exposure of the parent, although the exposure of the prodrugs was high, reflecting good absorption. Screening of additional amino acids resulted in the identification of an l-Phe ester that offered an improved exposure of 1 and reduced levels of the circulating prodrug. Further molecular editing focusing on the linker design culminated in the discovery of the self-immolative l-Phe-Sar dipeptide derivative 74 that gave four-fold improved AUC and eight-fold higher Ctrough values of 1 compared with oral administration of the drug itself, demonstrating a successful prodrug approach to the oral&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00002&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00002" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00002&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00002" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00002&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00002" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00002&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00002&amp;href=/doi/10.1021/acs.jmedchem.9b00002" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00002" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00002" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00002%26sid%3Dliteratum%253Aachs%26genre%3Darticle%26aulast%3DA.%2BM.%2BSubbaiah%26date%3D2019%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BPharmacokinetic%2BEvaluation%2Bof%2BPhosphate%2Band%2BAmino%2BAcid%2BEster%2BProdrugs%2Bfor%2BImproving%2Bthe%2BOral%2BBioavailability%2Bof%2Bthe%2BHIV-1%2BProtease%2BInhibitor%2BAtazanavir%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D7%26spage%3D3553%26epage%3D3574%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a>,</li><li><a href="/action/doSearch?ConceptID=291070" title="Pharmaceuticals">Pharmaceuticals</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/jmcmar.2019.62.issue-7/20190411/jmcmar.2019.62.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Phosphate and amino acid prodrugs of the HIV-1 protease inhibitor (PI) atazanavir (<b>1</b>) were prepared and evaluated to address solubility and absorption limitations. While the phosphate prodrug failed to release <b>1</b> in rats, the introduction of a methylene spacer facilitated prodrug activation, but parent exposure was lower than that following direct administration of <b>1</b>. Val amino acid and Val-Val dipeptides imparted low plasma exposure of the parent, although the exposure of the prodrugs was high, reflecting good absorption. Screening of additional amino acids resulted in the identification of an <span class="smallcaps smallerCapital">l</span>-Phe ester that offered an improved exposure of <b>1</b> and reduced levels of the circulating prodrug. Further molecular editing focusing on the linker design culminated in the discovery of the self-immolative <span class="smallcaps smallerCapital">l</span>-Phe-Sar dipeptide derivative <b>74</b> that gave four-fold improved AUC and eight-fold higher <i>C</i><sub>trough</sub> values of <b>1</b> compared with oral administration of the drug itself, demonstrating a successful prodrug approach to the oral delivery of <b>1</b>.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_22086" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_22086" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Combination antiretroviral therapy (cART), which is composed of HIV-1 inhibitors that target different aspects of the virus life cycle, is presently the most effective treatment for HIV-1 infection.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> These drug combinations, which include inhibitors of HIV-1 protease, integrase, and reverse transcriptase (nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs)), have transformed HIV-1 infection from a fatal diagnosis to a manageable chronic condition, resulting in a substantial enhancement of both life expectancy and quality for most patients.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Therapy with cART usually results in long-lasting suppression of viremia to undetectable levels that translates into a restoration of CD4 counts. HIV-1 PIs, which are in most cases used in combination with a pharmacokinetic (PK) enhancer that acts by inhibiting cytochrome P450 (CYP) enzymes, have played a critical role in the evolution of cART based on their efficacy and high genetic barrier toward the development of resistance.<a onclick="showRef(event, 'ref3 ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref3 ref4 ref5">(3−5)</a> Atazanavir (ATV, <b>1</b>) is an azapeptide-based PI that received marketing authorization by the US Federal Drug Administration (FDA) in 2003 and is a designated member of the WHO list of essential medicines.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> It is one of the nine PIs and one prodrug that have been granted marketing authorization by the FDA.<a onclick="showRef(event, 'ref4 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref7">(4,7)</a> Although <b>1</b> is available as a monotherapeutic agent for once daily (quaque die, QD) dosing, it is typically used in conjunction with a PK enhancer as a fixed-dose combination with either ritonavir [RTV, <b>3</b>] or, more recently, cobicistat that allows for a reduced dose of the PI while maintaining target <i>C</i><sub>trough</sub> levels.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The profile of <b>1</b> offers additional advantages over other PIs, including a more beneficial effect on lipid profiles and a low capsule burden; however, <b>1</b> brings its own side effect profile which includes hyperbilirubenimia.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As part of a class effect, <b>1</b> is known for modest oral bioavailability, with ∼79% of administered radioactivity recovered in the feces of humans, suggesting incomplete absorption and/or biliary excretion of the drug. This is reflected in the PK profile of <b>1</b> in preclinical species which exhibits 15% oral bioavailability in rats when dosed as a suspension and 36% in dogs from a capsule formulation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Similar to the observation in humans, the recovery of the unchanged drug from the feces was significant in both the rat (39%) and dog (79%) following oral administration. This profile can be attributed to suboptimal physicochemical properties that contribute to poor absorption and the susceptibility of <b>1</b> to metabolic modification, particularly by CYP3A4. Most prominently, <b>1</b> is characterized by poor aqueous solubility at higher pH values, modest absorptive permeability, high secretory efflux,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and, importantly, an extensive first-pass metabolism. Being a weak base, <b>1</b> shows high solubility at pH = 1.0 (relevant for dissolution in the stomach) but poor solubility at pH = 6.5 (relevant for solubility and absorption in the intestine), data captured in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Following administration of a combination of <b>1</b> and <b>3</b> with a 40 mg dose of a proton pump inhibitor (PPI), the exposure of <b>1</b> was reduced by 75%, demonstrating the dependence of the absorption of <b>1</b> on gut pH.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> Because of this pH effect on absorption, the use of histamine H<sub>2</sub> antagonists and PPIs, stomach acid modifiers that raise gastric pH, in conjunction with <b>1</b> requires caution, which can lead to reduced patient compliance. The pH-dependent absorption complicates inclusion of <b>1</b> in fixed-dose combination regimens, thereby reducing the clinical utility of the drug. Clinically, <b>1</b> is co-administered with a PK enhancer which suppresses metabolic degradation by inhibiting CYP3A enzymes. This approach facilitates an improved PK profile with higher oral bioavailability, a longer plasma <i>t</i><sub>1/2</sub>, and a higher plasma trough concentration of <b>1</b> than in the absence of the PK enhancer and allows for a QD rather than a twice daily (bis in die, BID) dosing schedule at the preferred dose.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> However, this also results in additional drug–drug interactions and related toxicities, which can also contribute to reduced patient compliance.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Physicochemical Properties and PK Profiling of <b>1</b><a onclick="showRef(event, 'ref6 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref6 ref16 ref17">(6,16,17)</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">value</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">molecular weight<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">704.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>c</i>log <i>D</i><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hydrogen-bond donor (HBD) count<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hydrogen-bond acceptor (HBA) count<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rotatable bond count<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">polar surface area (PSA)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">171 Å<sup>2</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></td><td class="colsep0 rowsep0" align="left">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aqueous solubility at 25 °C<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">pH 1.0 = 1.69 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 3.0 = 0.028 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 4.0 = <0.001 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 5.0 = <0.001 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 6.5 = <0.001 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">pH 7.4 = <0.001 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unbuffered aqueous solubility at 25 °C<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><0.001 mg/mL</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco-2 permeability <i>P</i><sub>app</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>A</i>–<i>B</i> = <15 nm/s</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>B</i>–<i>A</i> = 470 nm/s</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">efflux ratio: >31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> in rat hepatocytes<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">27 min</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">absolute bioavailability<sup>6</sup></td><td class="colsep0 rowsep0" align="left">rat: 15%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">dog: 36%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Physical properties calculated using ChemAxon Marvin Sketch software.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Data generated in-house.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></p></div></div></div><div class="NLM_p last">The consequences of the high excipient loading and pill burden associated with higher doses of <b>1</b> and the need for a PK enhancer inspired a feasibility study toward the development of prodrug approaches designed to improve the systemic delivery of <b>1</b>.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> In the context of a contemporary scenario that reflects limited drug discovery effort by the pharmaceutical industry to develop next-generation PIs with enhanced PK properties and improved resistance and safety profiles,<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> a strategy of improving the absorption, distribution, metabolism, and excretion (ADME) properties of existing PIs via formulation, prodrug, and other approaches assumes significance.<a onclick="showRef(event, 'ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref21 ref22 ref23">(18−23)</a> For example, deuterated analogues of <b>1</b>, which were prepared by replacing hydrogen atoms with deuterium isotopes at one or more sites, including those susceptible to metabolic modification, have been investigated as a means of enhancing metabolic stability.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> However, this approach, which takes advantage of the kinetic isotope effect to slow or redirect metabolism, resulted in only a marginal improvement in oral bioavailability, failing to provide a compound amenable to single pill combination regimens while also not addressing the pH-dependent absorption issue associated with <b>1</b>.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In spite of a growing interest in the exploration of prodrugs among all therapeutic classes,<a onclick="showRef(event, 'ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29">(26−29)</a> a prodrug approach has only rarely been investigated as a means of improving the PK profile of <b>1</b>.<a onclick="showRef(event, 'ref16 ref23'); return false;" href="javascript:void(0);" class="ref ref16 ref23">(16,23)</a> The discovery of a prodrug that would demonstrate improved oral exposure of <b>1</b> and potentially eliminate the requirement for the PK enhancer would represent a significant advancement for this antiviral agent.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20818" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20818" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We report herein the synthesis and evaluation of a series of phosphate- and amino acid ester-based prodrugs of <b>1</b> in an attempt to identify compounds that would confer an improved ADME profile. To the best of our knowledge, these prodrugs have never been investigated for <b>1</b>, although phosphate- and amino acid-based prodrugs have been explored with other PIs.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> We have previously described a conjugative acyl migration prodrug approach that improved the oral delivery <b>1</b> by relying upon the sequential enzyme-mediated release of an amine that was specifically designed to trigger an intramolecular acyl migration to deliver the parent drug.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> This approach was shown to enable enhanced exposure of <b>1</b> based on improved ADME properties by relying upon a sustained release of drug from the prodrug in vivo whilst also mitigating the pH-dependent absorption associated with <b>1</b>. As part of that initiative to identify effective prodrugs of <b>1</b>, we were particularly interested in prodrugs that could be derived in a more straightforward fashion from the parent drug itself by taking advantage of the secondary alcohol moiety, a transition state-mimicking pharmacophore, as a prodrug handle.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> The design consideration behind the selection of phosphate and amino acid promoieties was based on the physiological relevance and acceptable toxicological profile of these entities. The desired characteristics of a lead prodrug would broadly include (1) acceptable aqueous buffer stability and solubility at pH = 6.5 and 7.4; (2) enhanced absorptive flux; (3) reduced secretory efflux; (4) reduced metabolic clearance associated with unproductive metabolic pathways other than prodrug release; (5) quantitative bioconversion to the parent to maximize drug exposure that also embraces the potential for a sustained release of parent drug due to a slow rate of cleavage such that the prodrug acts as a depot;<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and (6) an acceptable in vivo toxicological profile for the prodrug, the released promoieties and the byproducts.</div><div class="NLM_p">As a potential approach to solving the pharmaceutical issues associated with the inherently poor aqueous solubility of <b>1</b> that result in dissolution-limited and pH-dependent absorption, the initial focus was directed toward the synthesis of phosphate derivatives, with the direct phosphate prodrug <b>2</b> selected as the first iteration.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37">(30−37)</a> This prodrug was designed to enhance the solubility of the drug in the gastrointestinal tract, with the release of the parent drug and nontoxic inorganic phosphate as a byproduct through a presystemic activation mechanism mediated by alkaline phosphatases (ALPs) that are abundantly expressed on the brush border membranes of enterocytes.<a onclick="showRef(event, 'ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32">(30−32)</a> While direct phosphate derivatives of <b>1</b> have not been described, phosphate monoesters of structural analogues of <b>1</b>, which are covalently modified by the attachment of water-soluble nonpeptidic oligomers, have been reported.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Phosphate prodrugs have been investigated for other marketed PIs including <b>3</b>, amprenavir (APV; <b>5</b>), and lopinavir (LPV, <b>7</b>), which are compounds <b>4</b>, <b>6</b>, and <b>8</b>, respectively, with fosamprenavir (<b>6</b>) approved by the FDA (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Fosamprenavir (<b>6</b>) was designed as a solubility-enhancing phosphate prodrug of <b>5</b> with the objective of allowing formulation of the molecule with a reduced excipient-to-drug ratio, thereby decreasing the high pill burden associated with <b>5</b> and providing a more patient-compliant regimen.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> The direct phosphate prodrug <b>2</b> was prepared from <b>1</b> in two synthetic steps that involved derivatization of the alcohol moiety with dibenzyl <i>N</i>,<i>N</i>-diisopropylphosphoramidite followed by oxidation with H<sub>2</sub>O<sub>2</sub> to afford the dibenzylphosphate intermediate <b>9</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Unmasking of the phosphate moiety by <i>O</i>-debenzylation using Pd/C-mediated hydrogenolysis was found to be cumbersome because of the concurrent cleavage of the <i>N</i>-4-(pyridin-2-yl)benzyl moiety of the parent. However, this was resolved by exposing <b>9</b> to CF<sub>3</sub>CO<sub>2</sub>H in the presence of anisole which facilitated selective <i>O</i>-debenzylation to afford <b>2</b>. Attempts to derive <b>2</b> directly from <b>1</b> in a single step using POCl<sub>3</sub> were not successful because of the absence of an isolable product.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PIs <b>1</b>, <b>3</b>, <b>5</b>, and <b>7</b> and their direct phosphate prodrugs (<b>2</b> is described in this article; <b>4</b>, <b>6</b>, and <b>8</b> have been reported in the literature<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Direct (<b>2</b>) and Methylene-Bridged (<b>11</b>) Phosphate-Based Prodrugs of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) dibenzyl <i>N</i>,<i>N</i>-diisopropylphosphoramidite, 1<i>H</i>-tetrazole (0.4 M in CH<sub>3</sub>CN), CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h, then 30% aqueous H<sub>2</sub>O<sub>2</sub> solution, 62%; (b) CF<sub>3</sub>CO<sub>2</sub>H, anisole, ClCH<sub>2</sub>CH<sub>2</sub>Cl, 0 °C to RT, 16 h, 72%; (c) Ac<sub>2</sub>O, AcOH, dimethyl sulfoxide (DMSO), RT 48 h, 79%; (d) <i>N</i>-iodosuccinimide, H<sub>3</sub>PO<sub>4</sub>, 4 Å molecular sieves, tetrahydrofuran (THF), 0 °C to RT, 30 min, then CH<sub>3</sub>OH, 1 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub> (solid), 45%.</p></p></figure><div class="NLM_p">For prodrug evaluation, we followed a simple, two-level screening tier that is composed of the determination of aqueous solution solubility and stability over the pH range of 1–6.5 followed by an in vivo PK evaluation in Sprague-Dawley (SD) rats involving oral administration of the prodrug at a 3 mg/kg-equivalent dose of <b>1</b>. Both the parent drug <b>1</b> and the prodrugs were formulated as solutions for dosing to rats to mitigate any potential impact of dissolution on the oral exposure. The phosphate monoester <b>2</b> showed high chemical stability, with a half-life of at least 250 h over the pH range of 1–6.5 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In contrast to the pH-dependent solubility associated with <b>1</b>, compound <b>2</b> showed good aqueous solubility across the pH range of 1–6.5, with a ∼250- and ∼2800-fold improved aqueous solubility at pH = 4 and 6.5, respectively, compared with <b>1</b>. The enhanced solubility profile at the higher pH of 6.5 is especially suited to mitigating the pH-dependent intestinal absorption of <b>1</b>. However, <b>2</b> failed to deliver measurable levels of <b>1</b> in the plasma of SD rats following oral administration, in spite of the enhanced aqueous solubility. Systemic levels of circulating prodrug were negligible, an observation that can be attributed to the poor passive permeability of the highly ionized phosphate pro-moiety at intestinal pH. To understand this in vivo outcome in rats, <b>2</b> was incubated with recombinant rat intestinal ALP (rIALP) with the result that negligible dephosphorylative turnover was observed within the incubation period of 120 min. Moreover, <b>2</b> was not susceptible to phosphate cleavage in the presence of human rIALP. On the basis of these in vitro results, the in vivo observation of the lack of systemic exposure of <b>1</b> from phosphate <b>2</b> can be attributed to its inefficient bioconversion to the parent drug in the intestine. To gain further insights into the structural impact of <b>2</b> on activation by ALP, rates of conversion of direct phosphate prodrugs of other PIs including <b>4</b>, <b>6</b>, and <b>8</b> were considered for a comparative review. Fosamprenavir (<b>6</b>) has been shown to undergo a high turnover in the ALP assay (<i>t</i><sub>1/2</sub> = 13.2 min) and also furnishes systemic exposure of <b>5</b> (APV) following oral administration to rats (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In contrast, the direct phosphate derivatives <b>4</b> and <b>8</b> of the PIs <b>3</b> and <b>7</b>, respectively, were not substrates for ALP-mediated dephosphorylation in vitro and <b>4</b> failed to furnish detectable systemic levels of <b>3</b> in rats following oral administration. An inspection of the structures of these prodrugs reveals a differentiated architecture associated with <b>6</b> that presumably facilitates its recognition by ALP enzymes when compared with the phosphates of the other PIs that include <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The peptidomimetic core of <b>1</b>, which closely resembles that of <b>3</b> and <b>7</b>, represents a pseudo-<i>C</i><sub>2</sub>-symmetric carboxamide-based, dipeptide isostere with an (<i>S</i>)-stereochemistry of the pharmacophoric secondary hydroxyl moiety.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In contrast, the peptidomimetic skeleton of <b>5</b> represents a sulfonamide-based dipeptide isostere with an (<i>R</i>)-configuration of the secondary alcohol. Thus, the accessibility of the promoiety groups of <b>2</b>, <b>4</b>, and <b>8</b> by ALP compared with <b>6</b> may differ significantly because of the differences in both the stereochemistry of the secondary alcohol and the P2′ amide structure in the vicinity of the phosphate ester moiety. On the basis of the experimental data obtained with <b>2</b> and structural comparisons with <b>4</b> and <b>8</b>, it can be concluded that unfavorable steric features around the phosphate of <b>2</b> prevented it from effectively engaging with the active site of ALP in a fashion that allows the enzymatic dephosphorylation to proceed with efficiency.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Aqueous Stability and Solubility Data of <b>1</b> and Its Prodrugs in the pH Range of 1–6.5<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="3" align="center">stability (<i>t</i><sub>1/2</sub>, h) at 37 °C</th><th class="rowsep1 colsep0" colspan="3" align="center">solubility (mg/mL) at 25 °C</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound #</th><th class="colsep0 rowsep0" align="center">prodrug moiety</th><th class="colsep0 rowsep0" align="center" char="."><i>c</i>log <i>D</i> (pH 6.5)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">pH 1</th><th class="colsep0 rowsep0" align="center">pH 4</th><th class="colsep0 rowsep0" align="center">pH 6.5</th><th class="colsep0 rowsep0" align="center">pH 1</th><th class="colsep0 rowsep0" align="center">pH 4</th><th class="colsep0 rowsep0" align="center">pH 6.5</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">1.69</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left"><0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">phosphate</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="left">334.3</td><td class="colsep0 rowsep0" align="left">334.3</td><td class="colsep0 rowsep0" align="left">250</td><td class="colsep0 rowsep0" align="left">>2.65</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">>2.87</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">POM</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td><td class="colsep0 rowsep0" align="left">0.2</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>0.93</td><td class="colsep0 rowsep0" align="left">>1.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">334.3</td><td class="colsep0 rowsep0" align="left">>1.39</td><td class="colsep0 rowsep0" align="left">>1.58</td><td class="colsep0 rowsep0" align="left">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Val</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>1.71</td><td class="colsep0 rowsep0" align="left">>1.95</td><td class="colsep0 rowsep0" align="left">0.67</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>2.15</td><td class="colsep0 rowsep0" align="left">>1.2</td><td class="colsep0 rowsep0" align="left">0.78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Val-<span class="smallcaps smallerCapital">d</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>2.4</td><td class="colsep0 rowsep0" align="left">>2.2</td><td class="colsep0 rowsep0" align="left">0.82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>2.0</td><td class="colsep0 rowsep0" align="left">>2.0</td><td class="colsep0 rowsep0" align="left">0.62</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">d</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>1.71</td><td class="colsep0 rowsep0" align="left">>1.42</td><td class="colsep0 rowsep0" align="left">0.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">Gly</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">39.09<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>1.2</td><td class="colsep0 rowsep0" align="left">>1.6</td><td class="colsep0 rowsep0" align="left">0.96<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">Sar</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>334.3</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>2.2</td><td class="colsep0 rowsep0" align="left">>2.4</td><td class="colsep0 rowsep0" align="left">0.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>,<i>N</i>-dimethyl-Gly</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">188<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>1.4</td><td class="colsep0 rowsep0" align="left">>1.7</td><td class="colsep0 rowsep0" align="left">0.36<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Ala</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">37.6</td><td class="colsep0 rowsep0" align="left">>1.3</td><td class="colsep0 rowsep0" align="left">>1.1</td><td class="colsep0 rowsep0" align="left">0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Ala</td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">37.6</td><td class="colsep0 rowsep0" align="left">>1.3</td><td class="colsep0 rowsep0" align="left">>1.7</td><td class="colsep0 rowsep0" align="left">0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Leu</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">71.6<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>0.45</td><td class="colsep0 rowsep0" align="left">>0.67</td><td class="colsep0 rowsep0" align="left">0.001<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Leu</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">>0.66</td><td class="colsep0 rowsep0" align="left">>0.62</td><td class="colsep0 rowsep0" align="left">0.041<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Met</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">103.8<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>1.63</td><td class="colsep0 rowsep0" align="left">>1.53</td><td class="colsep0 rowsep0" align="left">0.044<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Met</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">97.1<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>0.99</td><td class="colsep0 rowsep0" align="left">>0.89</td><td class="colsep0 rowsep0" align="left">0.045<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>1.5</td><td class="colsep0 rowsep0" align="left">>1.1</td><td class="colsep0 rowsep0" align="left">0.027</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>1.2</td><td class="colsep0 rowsep0" align="left">>1.2</td><td class="colsep0 rowsep0" align="left"><0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Tyr</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">214.9<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>0.98</td><td class="colsep0 rowsep0" align="left">>1.42</td><td class="colsep0 rowsep0" align="left">0.009<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-F-Phe</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">334.3<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>1.38</td><td class="colsep0 rowsep0" align="left">>0.98</td><td class="colsep0 rowsep0" align="left"><0.001<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Trp</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">167.2<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>1.04</td><td class="colsep0 rowsep0" align="left">>0.91</td><td class="colsep0 rowsep0" align="left">0.001<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>-BnGly</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">334.3</td><td class="colsep0 rowsep0" align="left">>0.99</td><td class="colsep0 rowsep0" align="left">>0.71</td><td class="colsep0 rowsep0" align="left"><0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">73.4</td><td class="colsep0 rowsep0" align="left">>2.9</td><td class="colsep0 rowsep0" align="left">>3.5</td><td class="colsep0 rowsep0" align="left">>0.64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">9.03</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">1.17</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe-Gly-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.9</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">88.5</td><td class="colsep0 rowsep0" align="left">>2.1</td><td class="colsep0 rowsep0" align="left">>2.3</td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>-Me-<span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">15.6</td><td class="colsep0 rowsep0" align="left">0.08</td><td class="colsep0 rowsep0" align="left">>2.7</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>,<i>N</i>-dimethyl-<span class="smallcaps smallerCapital">l</span>-Phe Sar-<b>1</b></td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="left">376.3</td><td class="colsep0 rowsep0" align="left">>500</td><td class="colsep0 rowsep0" align="left">>334.3</td><td class="colsep0 rowsep0" align="left">>1.2</td><td class="colsep0 rowsep0" align="left">>2.2</td><td class="colsep0 rowsep0" align="left">0.02</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">For stability studies, 30% CH<sub>3</sub>CN in buffer was used. Buffers used were 0.1 N aqueous HCl (pH = 1.0), acetate buffer (pH = 4.0), and phosphate buffer (pH = 6.5/7.4) at a concentration of 50 mM. ND = not determined.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last"><i>c</i>log <i>D</i> values were calculated using ChemAxon Marvin Sketch software.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">pH = 7.4.</p></div></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Comparison of in Vitro ALP-Mediated Cleavage Half-Life Data and Key Structural Features of Reported Phosphate Prodrugs of HIV-1 PIs with That of the Prodrugs <b>2</b> and <b>11</b> from the Parent Drug <b>1</b><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound #</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> in rat rIALP</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> in human rIALP</th><th class="colsep0 rowsep0" align="center">stereochemistry of OH</th><th class="colsep0 rowsep0" align="center">spacer</th><th class="colsep0 rowsep0" align="center">parent exposure in PK study</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>S</i></td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">13.2 min<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>R</i></td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">yes</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a><sup>,</sup><a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>S</i></td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="left">>120 min (NT)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">>120 min (NT)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><i>S</i></td><td class="colsep0 rowsep0" align="left">none</td><td class="colsep0 rowsep0" align="left">no</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">>10 min<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">21 min<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left"><i>S</i></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">yes</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">NT: no turnover of dephosphorylation.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Reported in the literature ref <a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Calf intestinal ALP.</p></div><div class="footnote" id="t3fn4"><sup><sup>d</sup></sup><p class="last">Data are reported in the mean of triplicates (CV < 10%).</p></div></div></div><div class="NLM_p">The failure of phosphate <b>2</b> to undergo cleavage by ALP and the insights gleaned into the potential steric issues underlying these observations inspired the design of the homologue <b>11</b>, which involved the installation of a methylene spacer between <b>1</b> and the phosphate in an effort to project the site of cleavage further away from the peptidomimetic core and reduce the steric encumbrance that presumably compromises recognition by ALP. The phosphonooxymethyl (POM) prodrug <b>11</b> was envisaged to undergo presystemic dephosphorylation to release an unstable <i>O</i>-hydroxymethyl intermediate that would degrade to <b>1</b> with the extrusion of formaldehyde.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This acetal-linked prodrug strategy was given consideration, in part, based on the observation that POM prodrugs of <b>3</b> and <b>7</b> have been reported to release their parent drugs in vivo in the rat and dog.<a onclick="showRef(event, 'ref15 ref31'); return false;" href="javascript:void(0);" class="ref ref15 ref31">(15,31)</a> The POM prodrug <b>11</b> was synthesized in two steps from <b>1</b>, as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The first step involved the conversion of <b>1</b> into the corresponding <i>O</i>-methylthiomethyl ether <b>10</b> through a Pummerer-type rearrangement accomplished by treatment with DMSO and Ac<sub>2</sub>O.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The second step involved the conversion of <b>10</b> to <b>11</b> through an <i>N</i>-iodosuccinimide-mediated nucleophilic displacement with orthophosphoric acid that was conducted in the presence of 4 Å molecular sieves (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Because phosphate <b>11</b> was found to be somewhat unstable in the free acid form, it was isolated as its disodium salt by adding Na<sub>2</sub>CO<sub>3</sub> at the completion of the reaction and purifying the crude product using buffer-free, reversed-phase high-performance liquid chromatography (HPLC). Phosphate <b>11</b> exhibited poor chemical stability at low pH (<i>t</i><sub>1/2</sub> = 12 min and 1.95 h at pH values of 1 and 2, respectively) and robust stability with elevated pH (<i>t</i><sub>1/2</sub> > 500 h at pH values of 4 and 6.5) (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The solution stability profile of <b>11</b> suggests that the POM moiety may degrade to some extent in the stomach but will be more stable in the intestine. Prodrug <b>11</b> displayed >900-fold improved solubility compared with <b>1</b> at pH values of 4 and 6.5. Following oral administration to SD rats, the prodrug was found to release the parent in vivo, providing systemic exposure of <b>1</b> that was only slightly lower than that following direct administration of <b>1</b> in a precipitation-resistant formulation. The relative oral bioavailability of <b>1</b> after dosing of <b>11</b> was 72% (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) while systemic circulation of <b>11</b> was found to be negligible, results that are consistent with cleavage of the POM prodrug at the brush border membrane of the intestinal mucosa prior to absorption. Following incubation with rat rIALP, prodrug <b>11</b> was found to undergo rapid enzyme-mediated cleavage to give <b>1</b>, with the <i>t</i><sub>1/2</sub> value of less than 10 min (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). In human rIALP, the cleavage half-life was 21 min, indicative of a slower rate of dephosphorylation compared with the rat enzyme. On the basis of the in vitro solubility and in vivo PK profiles, the POM prodrug in <b>11</b> appears to be a useful approach to mitigate the solubility-related pharmaceutical issues associated with <b>1</b>. However, it may also be inferred from the PK data that enhanced solubility alone cannot substantially increase the oral exposure of <b>1</b> if there exists a significant role for efflux and metabolism in influencing oral bioavailability. As a class, orally administered phosphate prodrugs may not be able to modulate the barriers of efflux and metabolism because of the lack of transcellular passive absorption associated with the presence of the polar ionized promoiety.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36,37)</a></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Data in SD Rats Obtained after Oral Administration of <b>1</b> at 3 mg/kg and Selected Prodrugs at an Equivalent Dose of 3 mg/kg of the Parent Drug<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound dosed</th><th class="colsep0 rowsep0" align="center">promoiety</th><th class="colsep0 rowsep0" align="center">analyte</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>last</sub> (nM h)</th><th class="colsep0 rowsep0" align="center">relative ATV AUC from the prodrug (%)</th><th class="colsep0 rowsep0" align="center">relative total AUC (prodrug + parent) (fold change)</th><th class="colsep0 rowsep0" align="center">prodrug/parent ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">266</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">384<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">POM</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">257</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">277</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">0.72</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">1.7</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">12.4</td><td class="colsep0 rowsep0" align="left">113</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">1529</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4731</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Val</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">10.1</td><td class="colsep0 rowsep0" align="left">167</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">990</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">3845</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">5.0</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="left">9.6<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">184<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">1179</td><td class="colsep0 rowsep0" align="left">3.0</td><td class="colsep0 rowsep0" align="left">3598</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Val-<span class="smallcaps smallerCapital">d</span>-Val-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">13.9<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">99<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">1430</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4894</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">384</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">374</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">Gly</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">162</td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">224</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="left">1.84</td><td class="colsep0 rowsep0" align="left">2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">617</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">484</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">Sar</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">9.0</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">29.6</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">0.14</td><td class="colsep0 rowsep0" align="left">0.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">8.9</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">23.7</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>,<i>N</i>-dimethyl-Gly</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">66.8</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">45.7</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">4.10</td><td class="colsep0 rowsep0" align="left">33.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">1407</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1519</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Ala</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">39</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">94</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">1.35</td><td class="colsep0 rowsep0" align="left">4.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">235</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">423</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Ala</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">4.3</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">0.23</td><td class="colsep0 rowsep0" align="left">10.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Leu</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">130</td><td class="colsep0 rowsep0" align="left">34</td><td class="colsep0 rowsep0" align="left">1.40</td><td class="colsep0 rowsep0" align="left">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">241</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">406</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Met</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">37</td><td class="colsep0 rowsep0" align="left">0.83</td><td class="colsep0 rowsep0" align="left">53</td><td class="colsep0 rowsep0" align="left">14</td><td class="colsep0 rowsep0" align="left">0.37</td><td class="colsep0 rowsep0" align="left">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">73</td><td class="colsep0 rowsep0" align="left">0.42</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">456</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">573</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="left">3.28</td><td class="colsep0 rowsep0" align="left">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">474</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">686</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">64</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">154</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">4.50</td><td class="colsep0 rowsep0" align="left">10.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">649</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">1575</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Tyr</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">99</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">103</td><td class="colsep0 rowsep0" align="left">27</td><td class="colsep0 rowsep0" align="left">0.46</td><td class="colsep0 rowsep0" align="left">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">63</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-F-Phe</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">305</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">463</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">0.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">288</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">430</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Trp</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">49</td><td class="colsep0 rowsep0" align="left">1.1</td><td class="colsep0 rowsep0" align="left">1.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">134</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">215</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>-BnGly</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">55</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">26</td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">8.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">701</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">833</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">794</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1533</td><td class="colsep0 rowsep0" align="left">399</td><td class="colsep0 rowsep0" align="left">4.0</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">d</span>-Phe-Gly-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">307</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">3.7</td><td class="colsep0 rowsep0" align="left">3.66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">300</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">1124</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>-Me-<span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">160</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">92</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>,<i>N</i>-dimethyl-<span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b></td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">285</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">359</td><td class="colsep0 rowsep0" align="left">93</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">2.80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">432</td><td class="colsep0 rowsep0" align="left">0.4</td><td class="colsep0 rowsep0" align="left">1033</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Values shown are mean ± SD (<i>n</i> = 3). Parent drug <b>1</b> was dosed at 3 mg/kg, while the prodrugs were dosed at an equivalent dose of 3 mg/kg of <b>1</b>. NA = not available, BLQ = below limit of quantification. The formulation used for these experiments was 10% v/v DMAc, 40% v/v PEG-400, 50% v/v of 30% w/v HPßCD in pH 4.0 citrate buffer (50 mM).</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">The oral bioavailability of <b>1</b> = 20%.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">AUC of the intermediate is also included in the AUC of the prodrug.</p></div></div></div><div class="NLM_p">Considering the limitations associated with the phosphate prodrugs <b>2</b> and <b>11</b>, the next phase of prodrug synthesis was directed toward the design of amino acid-based prodrugs. In light of the ALP-mediated activation challenges associated with the direct phosphate prodrug <b>2</b>, a critical element was to develop an understanding of whether direct amino acid prodrugs could undergo enzyme-mediated activation in vivo and further enhance the oral exposure of <b>1</b>. Amino acid ester prodrugs, which can undergo proteolytic cleavage by a number of specific and nonspecific esterases and peptidases found in the stomach, intestine, liver, and plasma, have found wide application across drug classes and therapeutic areas.<a onclick="showRef(event, 'ref27 ref28 ref38'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref38">(27,28,38)</a> Natural amino acids and their metabolites are useful promoieties because they are ubiquitous in the human body and their release in vivo may not pose a significant safety hazard. This kind of prodrug derivatization has been shown to improve aqueous solubility, enhance membrane permeability, modulate metabolic disposition and, in some cases, demonstrate prolonged release of the parent drug in vivo.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Some amino acid-based prodrugs have shown to improve intestinal absorption by taking advantage of active transport processes that can enhance the oral exposure of poorly permeable drugs, exemplified most effectively by valacyclovir (<b>13</b>) and valganciclovir (<b>15</b>), clinically successful prodrugs of acyclovir (<b>12</b>) and ganciclovir (<b>14</b>), respectively. In the case of <b>13</b> and <b>15</b>, the enhanced exposure can potentially be attributed to active transport mediated by oligopeptide transporters that includes the proton-coupled peptide transporter 1 (PepT1) expressed in the brush-border membrane of intestinal mucosa and/or reduced efflux associated with a lower affinity of the prodrugs to efflux transporters like P-glycoprotein (P-gp).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0011.gif" alt="" id="u1" /></img></div><div class="NLM_p">Design considerations involving the precedent of Val-based prodrugs <b>13</b> and <b>15</b> and previous exploration of the Val prodrugs <b>17</b>, <b>18</b>, and <b>20</b> of PIs like <b>7</b>, saquinavir (<b>16</b>), and nelfinavir (<b>19</b>), guided the initial investigation of prodrugs of <b>1</b> which focused on valine derivatives.<a onclick="showRef(event, 'ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44">(41−44)</a> The oral bioavailability of <b>12</b> was significantly improved by taking advantage of the <span class="smallcaps smallerCapital">l</span>-Val ester prodrug <b>13</b> which is recognized as a substrate by PepT1 and unmasked in vivo by valacyclovirase, a serine hydrolase enzyme that cleaves an α-amino ester bond with high specificity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Stereoisomeric Val amino acid and Val-Val dipeptide prodrugs of <b>16</b> have been reported to reduce efflux ratio in Caco-2 cells and to improve metabolic stability in rat liver microsomes (RLM) relative to <b>16</b>.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> We have briefly described the <span class="smallcaps smallerCapital">l</span>-Val amino acid prodrug of <b>1</b> in a previous publication in the context of designing a traceless acyl migration prodrug.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0012.gif" alt="" id="u2" /></img></div><div class="NLM_p">The diastereomeric Val amino acid prodrugs <b>23</b> and <b>24</b> derived from <b>1</b> were synthesized in two steps involving esterification of <b>1</b> with <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val using <i>N</i>,<i>N</i>′-dicyclohexylcarbodiimide (DCC) to afford <b>21</b> and <b>22</b>, respectively, followed by deprotection of the amine using 4 N HCl in dioxane to give <b>23</b> and <b>24</b>, which were isolated as their HCl salts (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The four stereoisomeric Val-Val dipeptide prodrugs <b>29–32</b> were synthetically derived from the corresponding amino acid prodrugs <b>23</b> and <b>24</b> by coupling with <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val using the HATU reagent with subsequent acid-mediated unmasking of the amino group (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Stereoisomeric Val-Based Ester <b>23</b> and <b>24</b> and Val–Val-Based Dipeptide Ester Prodrugs <b>29–32</b> of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val for <b>21</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val, DCC, 4-dimethylaminopyridine (DMAP), CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h; yields: <b>21</b> = 41%; <b>22</b> = 23%; (b) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT, 1 h; yields: <b>23</b> = 85%; <b>24</b> = 88%. (c) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val for <b>25</b> and <b>27</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val for <b>26</b> and <b>28</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h; yields: <b>25</b> = 45%, <b>26</b> = 42%, <b>27</b> = 58%, <b>28</b> = 64%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h; yields: <b>29</b> = 76%, <b>30</b> = 80%, <b>31</b> = 85%, <b>32</b> = 81%.</p></p></figure><div class="NLM_p">The Val-based amino acid and dipeptide prodrugs of <b>1</b> showed excellent chemical stability across the pH range of 1–6.5, with <i>t</i><sub>1/2</sub> values of greater than 330 h, data that are summarized in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. These compounds exhibited high aqueous solubility in the pH range of 1–6.5, with solubility decreasing with increasing pH. Importantly, these prodrugs demonstrated at least 500-fold higher solubility at pH 6.5 than <b>1</b>, suggesting the potential to mitigate not only dissolution-limited absorption but also pH-dependent absorption. Although the isomeric prodrugs might be expected to show different physical and chemical properties because of their diastereomeric nature, no significant differences in solution stability or solubility parameters were observed.</div><div class="NLM_p">With these data in hand, select Val-based compounds were progressed to oral PK studies in SD rats. Although the direct <span class="smallcaps smallerCapital">l</span>-Val and other amino acid prodrugs of PIs like <b>7</b>, <b>16</b>, and <b>19</b> have been reported, these studies have mainly focused on in vitro characterization for determining chemical stability, aqueous solubility, permeability, active transport, and/or metabolic stability.<a onclick="showRef(event, 'ref18 ref19 ref20 ref23 ref41 ref44 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20 ref23 ref41 ref44 ref46 ref47 ref48">(18−20,23,41,44,46−48)</a> Because PK data for most of these prodrugs are not readily available, it is difficult to assess their susceptibility to bioconversion in vivo and their capacity to improve the oral bioavailability of their respective parent PIs. In addition, there is an absence of a description of the effects of amino acid composition on the PK outcome that might have provided insights for the present study to guide the selection of amino acids. As is evident from the data compiled in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>, the amino acid-based prodrugs <b>23</b>, <b>24</b>, <b>29</b>, and <b>30</b> delivered lower plasma exposure of <b>1</b> than that observed following the direct administration of the parent drug. However, a significant systemic exposure of circulating prodrugs was observed and, in the case of the dipeptide-based prodrugs, varying levels of mono-amino acid ester intermediates were also noted. These in vivo PK studies facilitated three key conclusions: First, the direct Val amino acid and Val-Val dipeptide prodrugs were not susceptible to a substantial level of bioactivation, indicating that the crucial ester bond at the pharmacophoric 2° alcohol of <b>1</b> is recognized poorly by esterases and/or peptidases in the rat. Second, the observation of the formation of intermediate mono-amino acid esters in the case of dipeptide derivatives suggests a process of stepwise degradation of the dipeptide moieties to release amino acids, with subsequent degradation of these intermediates to release <b>1</b>. Third, as a result of the observation of a 10- to 14-fold higher relative total AUC (total AUC = AUC<sub>prodrug</sub> + AUC<sub>intermediate</sub> + AUC<sub>ATV</sub>) of amino acid- and dipeptide-based prodrugs compared with that of <b>1</b>, it appears that these prodrugs significantly mitigated the barriers to oral bioavailability associated with <b>1</b>, including solubility-limited absorption, efflux, and, possibly, CYP-mediated metabolism. In terms of the influence of stereochemistry of the amino acid moieties, the <span class="smallcaps smallerCapital">l</span>-Val prodrug <b>23</b> showed slightly better exposure than the <span class="smallcaps smallerCapital">d</span>-Val prodrug <b>24</b>. In the case of the dipeptide-based prodrugs, the <span class="smallcaps smallerCapital">d</span>-Val-<span class="smallcaps smallerCapital">d</span>-Val prodrug <b>30</b> showed slightly higher exposure than the corresponding <span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val prodrug <b>29</b>. In addition, the <span class="smallcaps smallerCapital">d</span>-Val amino acid ester intermediate <b>24</b> from the <span class="smallcaps smallerCapital">d</span>-Val-<span class="smallcaps smallerCapital">d</span>-Val prodrug <b>30</b> was observed in circulation at significantly higher levels than the <span class="smallcaps smallerCapital">l</span>-Val amino acid ester <b>23</b> derived from the <span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val dipeptide <b>29</b>, indicating an effect of stereochemical recognition on the rate of enzymatic activation of the peptidic bond.</div><div class="NLM_p">With the limitations posed by the <span class="smallcaps smallerCapital">l</span>-Val-based prodrugs, an expansion of the scope of the amino acid promoiety was explored in an attempt to further develop SARs associated with the susceptibility to bioactivation. A small set of 5 different amino acid ester prodrugs (Gly and its <i>N</i>-methyl analogues, Ala, Leu, Met, and Phe) was considered. These can be divided into three categories: amino acids that lack an α-carbon substituent (Gly and its mono- and di-<i>N</i>-methyl analogues); amino acids that possess a smaller Cα-substituent than that of <span class="smallcaps smallerCapital">l</span>-Val (Ala); and amino acids that have a larger Cα-substituent than <span class="smallcaps smallerCapital">l</span>-Val (Leu, Met, and Phe). Of particular interest were amino acid promoieties like Gly and Ala with smaller Cα-substituents than that of <span class="smallcaps smallerCapital">l</span>-Val, based on the hypothesis that the corresponding prodrugs may be susceptible to a higher level of bioactivation compared with <span class="smallcaps smallerCapital">l</span>-Val because of the reduced steric hindrance adjacent to the ester moiety. In support of this hypothesis, brivanib alaninate (BMS-582664, <b>33</b>) has been shown to undergo rapid and efficient enzyme-mediated hydrolysis, both in vitro and in vivo, to release the active drug.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0013.gif" alt="" id="u3" /></img></div><div class="NLM_p">Prodrugs <b>44–54</b> were synthesized following the two-step procedure depicted in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, and the data for these compounds are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a> (solubility and stability) and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> (PK profiles). This set of prodrugs showed excellent stability (<i>t</i><sub>1/2</sub> greater than 330 h) at pH = 1 and 4 but stabilities varied at pH = 6.5, with <i>t</i><sub>1/2</sub> values ranging from 25 to 500 h (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). With the exception of the Phe derivatives, these prodrugs displayed lower stability at pH 6.5 (<i>t</i><sub>1/2</sub> = 25–188 h), when compared with the Val-based prodrugs. The solution stability at pH = 6.5 increased in the order of Gly ≈ Ala < Leu < Met < Phe ≈ Val, suggesting a trend of decreasing hydrolytic susceptibility with increasing steric crowding around the amino acid ester bond of <b>1</b>. Among the Gly-based prodrugs, the chemical stability increased in the order of Sar (<b>45</b>) < Gly (<b>44</b>) < <i>N</i>,<i>N</i>-dimethyl-Gly (<b>46</b>) at pH = 6.5, indicating that the introduction of one methyl group resulted in a slightly lower stability, but the introduction of two methyl groups resulted in ∼4-fold improved stability when compared with the Gly-based prototype <b>44</b>. As was observed in the case of Val prodrugs, there were no significant differences in buffer stability and solubility between the diastereomeric prodrugs. All of these prodrugs showed very high solubility at pH = 1 and 4 (≥450 μg/mL) but more variable solubility at pH = 6.5 (<1 to 930 μg/mL). Amino acid prodrugs like <b>44–46</b> (Gly and its <i>N</i>-Me derivatives) and <b>47</b> and <b>48</b> (Ala), which had smaller Cα-substituents than the <span class="smallcaps smallerCapital">l</span>-Val derivative <b>23</b>, showed aqueous solubility of greater than 360 μg/mL at pH = 6.5, comparable to that of <b>23</b> (500 μg/mL). In contrast, the Leu, Met, and Phe esters <b>50–54</b> displayed significantly reduced buffer solubility, in the range of 1–45 μg/mL at pH = 6.5, which can be attributed to the increased lipophilicity associated with the Cα-substituents which are bulkier than that in <b>23</b>.</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amino Acid Prodrugs of <b>1</b> in Which Smaller or Larger Amino Acid Residues than That of <span class="smallcaps smallerCapital">l</span>-Val Are Explored<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <i>N</i>-Boc-amino acid except in the case of <b>46</b>, for which dimethylgycine was used, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14–16 h; yields: <b>34</b> = 76%, <b>35</b> = 64%, <b>46</b> = 57%, <b>36</b> = 64%, <b>37</b> = 60%, <b>38</b> = 37%, <b>39</b> = 42%, <b>40</b> = 49%, <b>41</b> = 45%, <b>42</b> = 74%, <b>43</b> = 71%; (b) for all N-Boc derivatives: 4 N HCl in dioxane, 0 °C to RT, 1–2 h.; yield: <b>44</b> = 89%, <b>45</b> = 19%, <b>47</b> = 98%, <b>48</b> = 99%, <b>49</b> = 76%, <b>50</b> = 80%, <b>51</b> = 94%, <b>52</b> = 94%, <b>53</b> = 85%, <b>54</b> = 95%.</p></p></figure><div class="NLM_p">Select prodrugs were progressed into rat PK studies to compare the AUC profiles and prodrug-to-parent ratios with that of the <span class="smallcaps smallerCapital">l</span>-Val prodrug <b>23</b>. The <span class="smallcaps smallerCapital">l</span>-Phe derivative <b>53</b> showed significantly improved oral exposure of <b>1</b>, with a 50% higher plasma exposure (AUC<sub>last</sub>) observed than that following direct dosing of <b>1</b> and a 14-fold higher plasma AUC of <b>1</b> than that following dosing of <b>23</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The oral exposure of <b>53</b> was also two-fold higher than that of the solubility-enhancing POM prodrug <b>11</b>, suggesting potential advantages of amino acid-based prodrugs to overcome additional barriers to oral bioavailability. Prodrug <b>53</b> also exhibited a significantly reduced prodrug/parent ratio of 1.2 compared with the ratio of 113 observed with the <span class="smallcaps smallerCapital">l</span>-Val prodrug <b>23</b>, suggesting that the <span class="smallcaps smallerCapital">l</span>-Phe ester <b>53</b> was more readily recognized by proteolytic enzymes than <b>23</b>. In addition, <b>53</b> showed a nine-fold lower prodrug/parent ratio when compared with the <span class="smallcaps smallerCapital">d</span>-Phe-based prodrug <b>54</b>, indicative of a more efficient proteolytic bioactivation of the natural <span class="smallcaps smallerCapital">l</span>-Phe prodrug <b>53</b> than the unnatural <span class="smallcaps smallerCapital">d</span>-Phe congener <b>54</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). All of the other prodrugs in this set produced a lower exposure of <b>1</b> than that obtained following the direct administration of parent drug, although prodrugs <b>44</b> (Gly), <b>47</b> (<span class="smallcaps smallerCapital">l</span>-Ala), and <b>49</b> (<span class="smallcaps smallerCapital">l</span>-Leu) showed at least a two-fold better exposure of <b>1</b> when compared with <b>23</b>. Of the three Gly-based prodrugs examined, <b>44</b> exhibited the highest exposure of <b>1</b>, with the relative AUC values increasing in the order of Sar (<b>45</b>, 12%) < <i>N</i>,<i>N</i>-dimethylGly (<b>46</b>, 22%) < Gly (<b>44</b>, 58%). Of the two pairs of stereoisomeric prodrugs that were evaluated, <b>47</b> and <b>53</b> showed at least three-fold higher exposure than their corresponding <span class="smallcaps smallerCapital">d</span>-amino acid homologues <b>48</b> and <b>54</b>, respectively. In terms of relative total AUC (combined exposures of <b>1</b> + prodrug), the <span class="smallcaps smallerCapital">d</span>-Phe derivative <b>54</b> exhibited the highest exposure (4.5-fold) followed by the <i>N</i>,<i>N</i>-dimethyl glycine ester <b>46</b> (4.1-fold) and the <span class="smallcaps smallerCapital">l</span>-Phe derivative <b>53</b> (3.3-fold). However, the total AUC values associated with these prodrugs were still lower than that of the Val-based prodrugs (10–12-fold higher AUC compared with the AUC obtained following direct dosing of <b>1</b>).</div><div class="NLM_p">Encouraged by the improved plasma exposure of <b>1</b> following dosing of the <span class="smallcaps smallerCapital">l</span>-Phe derivative <b>53</b> at a dose of 3 mg/kg, the PK performance of the prodrug in a dose-escalation study was investigated (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). At doses equivalent to 6 mg/kg and 30 mg/kg of <b>1</b>, prodrug <b>53</b> exhibited approximately 2-fold and 34-fold higher exposure of the parent drug compared with the exposure obtained following administration of <b>53</b> at a dose equivalent to 3 mg/kg of <b>1</b>. Dosing of <b>53</b> afforded 4-fold and 65-fold higher total exposure of <b>1</b> + prodrug at 6 and 30 mg/kg equivalent doses, respectively, when compared with the exposure obtained following the direct dosing of <b>1</b> at a dose of 3 mg/kg. While the systemic exposure of <b>1</b> after dosing at the equivalent of 6 mg/kg of <b>53</b> was dose-proportional, the oral exposure at 30 mg/kg dose was more than dose-proportional. Prodrug <b>53</b> exhibited a decreasing prodrug-to-parent ratio with increasing dose, indicating a higher level of bioactivation as the dose was escalated. At 3- and 6-mg/kg-equivalent doses, the trough concentration of <b>1</b> from dosing with <b>53</b> measured at 24 h post-dose was below the limit of quantification (BLQ), although <b>1</b> was detectable at a concentration of 1 nM following a 30 mg/kg-equivalent dose. While the parent drug <b>1</b> furnished a <i>C</i><sub>min</sub> of 0.25 nM at 3 mg/kg dose, the absence of measurable trough levels of <b>1</b> from <b>53</b> indicates the inferiority of this prodrug compared with the parent on this important PK parameter. One of the important criteria for the selection of a prodrug candidate is that it should exhibit a <i>C</i><sub>trough</sub> of <b>1</b> that is comparable to or improved over the <i>C</i><sub>trough</sub> obtained following direct administration of the parent.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Dose-Escalation PK Data for the <span class="smallcaps smallerCapital">l</span>-Phe Prodrug <b>53</b> at Doses Equivalent to 6 and 30 mg/kg of <b>1</b><a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">dose<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">analyte</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>last</sub> (nM h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>trough</sub> at 24 h (nM)</th><th class="colsep0 rowsep0" align="center">relative ATV exposure from the prodrug (%)</th><th class="colsep0 rowsep0" align="center" char=".">relative total AUC (prodrug + parent) (fold change)</th><th class="colsep0 rowsep0" align="center" char=".">prodrug/parent ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">266</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">384</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">456</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">573</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left">149</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">474</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">686</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">550</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">913</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left">238</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">874</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="left">680</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">4720</td><td class="colsep0 rowsep0" align="char" char=".">0.8</td><td class="colsep0 rowsep0" align="left">19670</td><td class="colsep0 rowsep0" align="left">1.0</td><td class="colsep0 rowsep0" align="left">5122</td><td class="colsep0 rowsep0" align="char" char=".">65.3</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">2314</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="left">5409</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Values shown are mean ± SD (<i>n</i> = 3). NA = not available, BLQ = below limit of quantification. The formulation used for these experiments was 10% v/v DMAc, 40% v/v PEG-400, 50% v/v of 30% w/v HPßCD in pH 4.0 citrate buffer (50 mM).</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Dose for <b>53</b> = equivalent dose of the parent.</p></div></div></div><div class="NLM_p">Having identified <b>53</b> as the lead prodrug from this cohort, a set of profiling studies was undertaken that were designed to understand pharmaceutical aspects, mechanism of bioactivation, and key safety aspects associated with hepatic uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) inhibition. The aqueous solubility of <b>53</b> was evaluated in additional buffers where it differentiated from <b>1</b> in the pH range of 3–6.5, with 27- to 4100-fold improved solubility (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). The dissolution and solubility profile of <b>53</b> in biorelevant simulated small intestinal media which more effectively mimic the physiological conditions of the small intestine than simple buffers was also evaluated because this can be a useful approach to predicting the performance of a formulation in vivo while assessing the potential for a food effect as part of the modeling of the drug absorption process (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> In both fasted-state simulated intestinal fluids (FaSSIF) and fed-state simulated intestinal fluids (FeSSIF), which contain natural solubilizers like bile salts and lecithin in amounts similar to natural intestinal fluids, <b>53</b> displayed an acceptable solubility of 0.13–0.5 g/mL.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Extended aqueous Solubility Profiling of the <span class="smallcaps smallerCapital">l</span>-Phe Prodrug <b>53</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">aqueous solubility (mg/mL)</th><th class="colsep0 rowsep0" align="center"> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">medium</th><th class="colsep0 rowsep0" align="center" char="."><b>53</b></th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center">fold improved solubility of <b>53</b> vs <b>1</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 1 buffer</td><td class="colsep0 rowsep0" align="char" char=".">>1.5</td><td class="colsep0 rowsep0" align="left">1.69</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 3 buffer</td><td class="colsep0 rowsep0" align="char" char=".">>3.2</td><td class="colsep0 rowsep0" align="left">0.028</td><td class="colsep0 rowsep0" align="left">114</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 4 citrate buffer</td><td class="colsep0 rowsep0" align="char" char=".">>1.1</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left">1100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 4 acetate buffer</td><td class="colsep0 rowsep0" align="char" char=".">>4.1</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left">4100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 5 buffer</td><td class="colsep0 rowsep0" align="char" char=".">1.3</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left">1300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 6.5 buffer</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pH 7.4 buffer</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="left"><0.001</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FaSSIF</td><td class="colsep0 rowsep0" align="char" char=".">0.13</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FeSSIF</td><td class="colsep0 rowsep0" align="char" char=".">>0.5</td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">ND = not determined.</p></div></div></div><div class="NLM_p">Prodrug <b>53</b> was found to be stable following incubation with simulated gastric fluid (SGF) containing pepsin, an endopeptidase that is one of the main digestive enzymes produced in the stomach (see Figure 3, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). Pepsin is known to specifically cleave peptides at amino acid residues <span class="smallcaps smallerCapital">l</span>-Phe, <span class="smallcaps smallerCapital">l</span>-Met, <span class="smallcaps smallerCapital">l</span>-Leu, and <span class="smallcaps smallerCapital">l</span>-Trp when adjacent to a hydrophobic amino acid and the high gastric stability of <b>53</b> may be linked to the lack of susceptibility of the prodrug ester bond to pepsin.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, <b>53</b> was found to be unstable in simulated intestinal fluid (SIF) containing pancreatin, with the formation of <b>1</b> as the only product observed following incubation. This suggests that pancreatin, which is a mixture of several digestive enzymes (including lipase, amylase, and protease) produced in the pancreas by exocrine cells and is mainly responsible for the intestinal breakdown of peptides, might have contributed to the cleavage of the ester prodrug moiety of <b>53</b> in SIF.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> These data also suggest the potential for significant metabolic activation in the intestine and are consistent with the high intestinal turnover observed in rat closed loop studies (vide infra).</div><div class="NLM_p">To further understand the mechanistic aspects of bioconversion, the metabolic susceptibility of <b>53</b> was evaluated in four different experiments as follows: (a) incubation in rat hepatocytes in the absence of additives; (b) incubation in rat hepatocytes in the presence of the esterase inhibitor phenylmethylsulfonyl fluoride (PMSF); (c) incubation in rat hepatocytes in the presence of the CYP 450 inhibitor 1-aminobenzotriazole (ABT); and (d) incubation in rat hepatocytes in the presence of both PMSF and ABT. PMSF is known to inhibit proteases (e.g., trypsin, chymotrypsin, thrombin, and papain) by reacting with the active site serine residue. As a non-isoform-specific and mechanism-based inhibitor of CYP enzymes, ABT is widely used to determine the relative contribution of oxidative metabolism in preclinical studies.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Significant turnover of <b>53</b> was observed in control rat hepatocytes, with a half-life of 42 min (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and Figure 4, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). However, this half-life was longer than that of the parent (27 min), indicating a modest reduction in the metabolic clearance of the prodrug compared with the parent drug (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). In the presence of PMSF, the rate of metabolic depletion of the prodrug in rat hepatocytes was reduced further, with the <i>t</i><sub>1/2</sub> value extending to 77 min. Following co-incubation of <b>53</b> in rat hepatocytes in the presence of ABT, the half-life exceeded the assay time of 120 min, indicating that the metabolism of <b>53</b> was almost completely halted under these assay conditions. The combined presence of both PMSF and ABT in rat hepatocytes further improved the metabolic stability of <b>53</b> (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and Figure 4a, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). The significant enhancement in the elimination half-life of <b>53</b> in the presence of ABT compared with that in rat hepatocytes alone suggests that the prodrug is subject to direct metabolic clearance mediated by CYP 450 enzymes. In addition, the impact of esterase inhibition on the elimination rate of <b>53</b> was significantly less than the impact of CYP inhibition, indicating that the CYP-mediated metabolism was substantially higher than esterase-mediated degradation.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Metabolic Stability Profile of <span class="smallcaps smallerCapital">l</span>-Phe Prodrug <b>53</b> in Rat Hepatocytes in the Absence or Presence of Esterase and/or CYP Inhibitors</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">additive</th><th class="rowsep1 colsep0" colspan="2" align="center">degradation data</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PMSF</th><th class="colsep0 rowsep0" align="center">ABT</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center" char="."><i>k</i><sub>obs</sub> (min<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="char" char=".">0.0164</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="char" char=".">0.0009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">no</td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">>120</td><td class="colsep0 rowsep0" align="char" char=".">0.0042</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">yes</td><td class="colsep0 rowsep0" align="left">>120</td><td class="colsep0 rowsep0" align="char" char=".">0.0014</td></tr></tbody></table></div></div><div class="NLM_p">The formation of <b>1</b> from <b>53</b> was also monitored when the prodrug was incubated in rat hepatocytes alone or in the presence of PMSF and/or ABT (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> and Figure 4b, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). The generation of <b>1</b> from <b>53</b> was minimal in the presence of PMSF alone or with a mixture of PMSF and ABT in rat hepatocytes, results that suggest that PMSF inhibits the esterase-mediated cleavage of <b>53</b> to deliver <b>1</b>. In contrast, the abundance of <b>1</b> was maximal in the presence of ABT alone, with the amount of <b>1</b> observed in the presence of ABT reduced by more than 90% by the addition of PMSF. This observation indicates that suppression of unproductive metabolism of <b>53</b> and/or <b>1</b> by ABT in the absence of inhibition of esterase-mediated prodrug conversion led to the highest levels of <b>1</b> in rat hepatocytes. Combining these results, it can be concluded that the formation of <b>1</b> from <b>53</b> is predominantly mediated by esterase-dependent prodrug activation. Although the in vitro system demonstrates efficient cleavage of <b>53</b> in hepatocytes, conversion of <b>53</b> into <b>1</b> following IV dosing is lower when compared with PO dosing, suggesting the potential for a contribution from intestinal metabolism in prodrug activation. Assuming proteolytic ester cleavage of <b>53</b>, the prodrug is expected to release <span class="smallcaps smallerCapital">l</span>-Phe as the byproduct in vivo, a ubiquitous natural amino acid that should not present a safety concern. However, regulation of the intake of <span class="smallcaps smallerCapital">l</span>-Phe may be required in those individuals who express a genetic polymorphism in phenylalanine hydroxylase, an enzyme that metabolizes <span class="smallcaps smallerCapital">l</span>-Phe to <span class="smallcaps smallerCapital">l</span>-Tyr in the human body.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div class="NLM_p">An assessment of the activation of <b>53</b> in the intestine using a closed loop rat intestinal model was conducted to understand the bioconversion of the prodrug prior to or during absorption. The in situ intestinal perfusion technique in rodents has been useful as a model to understand the mechanisms underlying intestinal drug absorption.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> The introduction of the mesenteric vein cannulation, which allows for the determination of the appearance of compounds in the blood, is particularly useful for evaluating mechanistic aspects of the absorption of compounds and prodrugs undergoing intestinal metabolism. Following cassette dosing of <b>53</b> and the low permeability marker nadolol at a dose of 1 mg/kg to rats, the observed levels of <b>1</b> in the mesenteric vein plasma were about 50% of prodrug <b>53</b>, suggesting the occurrence of significant prodrug activation in rat intestine (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a> and Figure 5, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). The parent drug <b>1</b> was also observed to be produced in intestinal tissue (29% of the prodrug <b>53</b>) and intestinal contents (50% of <b>53</b>). In the case of nadolol, the amount absorbed into plasma was 1.3% and recovery was 61%. Overall, these data imply that in the rat, the intestine plays a significant role in the conversion of <b>53</b> to <b>1</b>. While the ratio of prodrug <b>53</b> to parent <b>1</b> in plasma in the closed loop study was ∼2:1 (32% of parent <b>1</b>; 68% of <b>53</b>) following a dose of 1 mg/kg, the relative plasma concentration of parent and prodrug in the conventional oral PK study was 1:1. In addition, the prodrug was found to be highly stable in rat blood in vitro, with a <i>t</i><sub>1/2</sub> value of greater than 120 min. Taking all of these factors into account, it can be suggested that the initial formation of <b>1</b> from <b>53</b> occurs in the intestine with further conversion occurring in the liver.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Assessment of the Activation of <b>53</b> in the Intestine Using a Closed Loop Intestinal Model Conducted in the Rat<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">recovered percentage of dose of prodrug administered</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">mesenteric vein plasma (%)</th><th class="colsep0 rowsep0" align="center">intestinal homogenate (%)</th><th class="colsep0 rowsep0" align="center">intestinal content (%)</th><th class="colsep0 rowsep0" align="center">recovery (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">2.8 ± 0.02</td><td class="colsep0 rowsep0" align="left">5.6 ± 1.0</td><td class="colsep0 rowsep0" align="left">32 ± 3.8</td><td class="colsep0 rowsep0" align="left">41 ± 2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">1.4 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.6 ± 0.2</td><td class="colsep0 rowsep0" align="left">16.1 ± 1.9</td><td class="colsep0 rowsep0" align="left">19 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">total</td><td class="colsep0 rowsep0" align="left">4.2</td><td class="colsep0 rowsep0" align="left">7.2</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nadolol</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.1</td><td class="colsep0 rowsep0" align="left">14 ± 1.0</td><td class="colsep0 rowsep0" align="left">45 ± 11</td><td class="colsep0 rowsep0" align="left">61 ± 10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">Cassette dosing of the prodrug 53 and nadolol at 1 mg/kg each; formulation vehicle = PEG 400/TPGS/pH 6.5 buffer (25:5:70); values shown are mean ± SD (<i>n</i> = 3).</p></div></div></div><div class="NLM_p">Patients who are treated with <b>1</b> can experience asymptomatic hyperbilirubinemia because <b>1</b> is known to inhibit UGT1A1, thereby interfering with the glucuronidation and elimination of bilirubin.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> The potential for inhibition of bilirubin glucuronidation by the <span class="smallcaps smallerCapital">l</span>-Phe prodrug <b>53</b> was assessed in vitro following separate incubations with recombinant human and cynomolgus monkey UGT1A1 protein as well as human and RLMs. For the purpose of comparison under the same experimental conditions, UGT1A1 IC<sub>50</sub> data for <b>1</b> were also generated. As is evident from the data compiled in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, prodrug <b>53</b> showed four- to nine-fold lower inhibition of UGT1A1 when compared with <b>1</b>. In a human rUGT1A1 study, <b>53</b> exhibited ∼9-fold lower inhibitory potency than <b>1</b> while in human liver microsomes (HLM), <b>53</b> demonstrated ∼4-fold reduced potential for inhibition of glucuronidation than <b>1</b>. The lower activity of prodrug <b>53</b> toward UGT1A1 inhibition compared with the parent was consistent in other species including the cynomolgus monkey (rUGT1A1) and rat (rUGT1A1 and RLM). However, the potential advantage of the reduced inhibitory effect on UGT1A1 needs to be carefully considered in the context of the <i>C</i><sub>max</sub> and free drug concentrations of both the released parent <b>1</b> and <b>53</b> at the efficacious dose.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Cross-Species UGT1A1 Inhibition Profile of <b>1</b> and the <span class="smallcaps smallerCapital">l</span>-Phe-Based Prodrug <b>53</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">substrate</th><th class="colsep0 rowsep0" align="center">enzyme preparation</th><th class="colsep0 rowsep0" align="center" char=".">prodrug <b>53</b> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">parent <b>1</b> IC<sub>50</sub> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">prodrug selectivity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bilirubin</td><td class="colsep0 rowsep0" align="left">human rUGT1A1</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char=".">9.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">cynomolgus monkey rUGT1A1</td><td class="colsep0 rowsep0" align="char" char=".">11.9</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">17.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">β-estradiol</td><td class="colsep0 rowsep0" align="left">rat rUGT1A1</td><td class="colsep0 rowsep0" align="char" char=".">12.6</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">HLM</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">0.6</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">RLM</td><td class="colsep0 rowsep0" align="char" char=".">19.5</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td></tr></tbody></table></div></div><div class="NLM_p">With these data in hand, the design considerations for further optimization of the profile of <b>53</b> focused on analogues that encompassed both relatively simple structural variations that included substitution on the phenyl ring of the promoiety and more complex variations in which the phenyl ring was replaced with a heteroaryl variant or the benzyl group was translocated from the α-carbon to the amino group. This phase of the study explored four different amino acid ester prodrugs, all bearing an aryl group, with the objective of further optimizing the prodrug performance as a means of improving exposure and, particularly, the trough concentration of <b>1</b> measured at 24 h postdose. The <span class="smallcaps smallerCapital">l</span>-Tyr prodrug <b>59</b> was explored in an effort to understand whether a potential metabolite of <b>53</b> would offer differentiation in terms of rate of in vivo conversion to the parent. This is in line with the results of biotransformation studies conducted with <b>53</b> which suggested that hydroxylation of <span class="smallcaps smallerCapital">l</span>-Phe promoiety was one of the metabolic pathways. Compound <b>59</b> was synthesized in 4 steps as depicted in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. The phenolic hydroxyl of <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Tyr <b>55</b> was protected as its silyl ether by treatment with TBDMS-Cl to afford <b>56</b> which was converted to the ester <b>57</b> by DCC-mediated coupling with <b>1</b>. Treatment of <b>57</b> with TBAF removed the silicon protecting group and afforded intermediate <b>58</b> which was subjected to amine deprotection on treatment with 4 N HCl in dioxane to afford the <span class="smallcaps smallerCapital">l</span>-Tyr derivative <b>59</b>.</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the <span class="smallcaps smallerCapital">l</span>-Tyrosine-Based Amino Acid Ester Prodrug <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) TBDMS-Cl, imidazole, DMF, RT, 16 h, 62%; (b) <b>1</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 68%; (c) TBAF, THF, 0 °C, 1 h, 72%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h, 84%.</p></p></figure><div class="NLM_p">The effect introducing a fluorine substituent to the phenyl ring of the <span class="smallcaps smallerCapital">l</span>-Phe element of <b>53</b> was examined because the strategic incorporation of this element can productively modulate several aspects of molecular properties that encompass molecular conformation, p<i>K</i><sub>a</sub>, lipophilicity, intrinsic potency, permeability, metabolic pathways, and PK properties.<a onclick="showRef(event, 'ref58 ref59 ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref58 ref59 ref60 ref61">(58−61)</a> Thus, the 4-fluoro-Phe derivative <b>64</b> was prepared because this substitution may influence oxidative metabolism of <b>53</b> should that occur in vivo. Prodrug <b>64</b> was synthesized in four steps, as delineated in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. The readily available amino ester intermediate <b>60</b> was protected as its Boc derivative <b>61</b>, which in turn was subjected to hydrolysis using LiOH to afford the <i>N</i>-Boc amino acid <b>62</b>. DCC-mediated coupling of <b>62</b> with <b>1</b> afforded <b>63</b> which was converted to the final compound <b>64</b> following acid-aided removal of the Boc group.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 4-Fluorophenylalanine Amino Acid Ester Prodrug <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 2 h, 95%; (b) LiOH, THF, H<sub>2</sub>O, 0 °C, 2 h, 93%; (c) <b>1</b>, <b>62</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 58%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h, 74%.</p></p></figure><div class="NLM_p">The <span class="smallcaps smallerCapital">l</span>-Trp prodrug <b>66</b> was prepared from <b>1</b> following the two-step procedure captured in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> while the <i>N</i>-benzylglycine (<i>N</i>-BnGly) prodrug <b>71</b> was given consideration as part of the effort to understand the potential impact of migrating the Cα-benzyl group from carbon to nitrogen on PK properties. This prodrug was synthesized in four steps from commercially available <i>N</i>-benzylglycine ethyl ester, as depicted in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>.</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <span class="smallcaps smallerCapital">l</span>-Trp Amino Acid Ester Prodrug <b>66</b> and <i>N</i>-Benzylglycine Amino Acid Ester Prodrug <b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <i>N</i>-Boc-Trp, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h, 52%; (b) 4 N HCl in dioxane, 0 °C to RT, 1 h, 68%. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT, 12 h, 92%; (d) LiOH, THF, H<sub>2</sub>O, 0 °C, 2 h, 95%; (e) <b>69</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 89%; (f) 4 N HCl in dioxane, 0 °C, 1 h, 95%.</p></p></figure><div class="NLM_p">Compounds <b>59</b>, <b>64</b>, <b>66</b>, and <b>71</b> exhibited acceptable stability across the pH range, although these prodrugs showed lower stability than <b>53</b> at pH = 6.5 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). However, these prodrugs showed improved stability compared with the Gly, Ala, Leu, and Met prodrugs <b>44</b>, and <b>47</b>–<b>52</b>, suggesting that the presence of an aromatic group in the amino acid residue contributes to reduced hydrolytic susceptibility at pH = 6.5. While <b>59</b>, <b>64</b>, <b>66</b>, and <b>71</b> showed excellent solubility of at least 700 μg/mL at pH = 1 and 4, these prodrugs showed significantly reduced solubility of less than 10 μg/mL at pH = 6.5, attributable to the negative impact of the presence of a hydrophobic aryl group.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> This series of prodrugs exhibited plasma exposure of the parent that increased in the order <b>71</b> < <b>59</b> < <b>66</b> < <b>64</b> following oral administration to rats (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Prodrug <b>64</b> demonstrated a higher plasma AUC of <b>1</b> than that of the direct administration of the parent drug but the trough concentration of <b>1</b> from <b>64</b> was BLQ. The introduction of a 4-fluoro or 4-hydroxy substituent on the phenyl ring of <b>53</b> did not result in an improved exposure of <b>1</b>. Considering the total AUC of parent and prodrug, the <span class="smallcaps smallerCapital">l</span>-F-Phe (<b>64</b>) and <i>N</i>-Bn-Gly (<b>71</b>) promoieties were found to be better than the promoieties <span class="smallcaps smallerCapital">l</span>-Tyr (<b>59</b>) and <span class="smallcaps smallerCapital">l</span>-Trp (<b>66</b>). While <b>64</b> and <b>71</b> provided a similar total AUC, <b>64</b> was found to undergo ∼8-fold higher conversion in vivo resulting in an improved AUC profile of <b>1</b> from <b>64</b>. Unfortunately, none of these prodrugs offered an advantage in terms of higher parent exposure over the lead prodrug <b>53</b>.</div><div class="NLM_p">While <b>53</b> and <b>64</b> offered the benefit of improving the oral exposure of the parent, scope existed to further improve the oral bioavailability of <b>1</b> from these prodrugs and importantly demonstrate measurable levels of <b>1</b> at 24 h postdose that is critical for the systemic suppression of viral load. In this direction, the installation of a linker between <b>1</b> and the <span class="smallcaps smallerCapital">l</span>-Phe promoiety that was simpler than the <span class="smallcaps smallerCapital">l</span>-Val elements studied earlier was explored in an effort to improve the efficiency of release of parent from the prodrug (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). This design concept was inspired by published observations that dipeptide ester prodrugs can undergo intramolecular cyclization at physiological pH in which the terminal amine the dipeptide moiety attacks the ester carbonyl group, leading to the release of the parent drug along with the formation of a diketopiperazine byproduct.<a onclick="showRef(event, 'ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref65">(63−65)</a> This chemo-activatable prodrug strategy was considered to offer the potential to address the bioactivation challenges that were encountered with the direct amino acid ester prodrugs discussed earlier. As a precedent, neladenoson bis-alanate, a clinical prodrug candidate of the partial adenosine A1 receptor agonist neladenoson, has recently been shown to significantly improve the oral bioavailability of the parent compound without the presence of circulating prodrug.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> The stability pattern of the Val-Val dipeptides gave some insight into the design of the requisite linker. For example, the Val-Val dipeptide <b>29</b> displayed very high aqueous stability of <i>t</i><sub>1/2</sub> of more than 500 h at pH = 6.5, indicating that this prodrug is not able to efficiently engage in an intramolecular cyclization to generate the parent <b>1</b> under the conditions of elevated pH. This can be attributed to the high steric crowding around the ester bond of <b>29</b> because of the presence of the isopropyl element adjacent to the Val ester. In the case of dipeptide prodrugs of <b>12</b>, it has been shown that the rate of decomposition is significantly decreased following the incorporation of sterically hindered amino acids into the dipeptide backbone and that the effect is more pronounced when a bulky β-branched amino acid like <span class="smallcaps smallerCapital">l</span>-Val is present as the C-terminal residue that is directly attached to the drug.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> It was postulated that Gly, which does not possess a Cα-substituent, might be a good choice as a linker to promote a facile, self-immolative internal cyclization of <b>72</b> to generate the diketopiperazine <b>73</b> and parent <b>1</b>, as depicted in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. The Gly–Phe dipeptide prodrugs of various drugs that include acyclovir have previously been investigated as carrier prodrugs for delivering the active parents via a nonenzymatic process.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> While the kinetics associated with self-immolation of prodrug <b>72</b> are inherent to the structure, it was hypothesized that the introduction of a substituent on the Phe–Gly amide NH would provide a means of modulating the rate of ring closure, allowing a measure of control over drug release. Thus, the amide conformer topology would be influenced by N-methylation which would assist in bringing the terminal amine and ester carbonyl group in close proximity, thereby enhancing the propensity for cyclization.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Taking all of these factors into consideration, Gly and Sar were chosen as the amino acid linkers, leading to the design of <span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b> (<b>72</b>) and <span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b> (<b>74</b>) as potential prodrugs. On the basis of the design principle, these prodrugs would be expected to be stable in the stomach as the hydrochloride salt but hypothesized to convert to a free base in the intestine or during or after absorption, triggering a facile intramolecular cyclization to liberate the parent <b>1</b> and the diketopiperazine byproduct <b>73</b> or <b>75</b>.</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Linker-Enabled Chemo-Activatable Prodrug Design To Improve the Bioactivation of Prodrug <b>53</b> with the Prodrug Moieties Depicted in Blue</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A set of 5 prodrugs was prepared by the routes depicted in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a> to develop SARs around solution stability, aqueous solubility, the rate of cyclization, and the potential for in vivo delivery, as measured by the exposure of <b>1</b> and prodrugs in plasma following oral administration. While prodrugs <b>72</b> and <b>78</b> were prepared from <b>44</b> in two steps, the remaining prodrugs <b>74</b>, <b>81</b>, and <b>82</b> were prepared from the readily available Sar prodrug <b>45</b> in two steps. Along with <b>72</b> and <b>74</b>, the synthesis of the three additional prodrugs <b>78</b>, <b>81</b>, and <b>82</b> was undertaken with the primary objective of broadening the SARs associated with these cyclization-activated prodrugs. The <span class="smallcaps smallerCapital">d</span>-Phe-Sar-<b>1</b> prodrug <b>78</b> was explored to understand whether the stereochemical switch in the promoiety would differentiate this diastereomer from <b>72</b> in terms of cyclization kinetics and oral exposure profile. Prodrug <b>81</b> was designed to understand the impact of N-methylation of the nucleophilic amine on modulating conversion kinetics of <b>74</b> and on plasma exposure of <b>1</b>, whereas the <i>N</i>,<i>N</i>-dimethyl-<span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b> prodrug <b>82</b> was evaluated specifically as a means of gleaning insight into the behavior of a prodrug incapable of undergoing cyclization-based self-immolation at physiological pH due to blockade of the amino terminus. Contrary to the possibility of chemical-mediated activation mechanism of <b>72</b>, <b>74</b>, <b>78</b>, and <b>81</b>, conversion of prodrug <b>82</b> would be expected to proceed by either an enzyme-mediated cleavage or by a general base-catalyzed process to deliver the parent in vivo.</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b> (<b>72</b>), <span class="smallcaps smallerCapital">d</span>-Phe-Gly-<b>1</b> (<b>78</b>), <span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b> (<b>74</b>), and the <i>N</i>-Me and <i>N</i>,<i>N</i>-Dimethyl Homologues <b>81</b> and <b>82</b> as Potential Dipeptide Ester-Based Prodrugs of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <b>44</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Phe for <b>76</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Phe for <b>77</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h; yields: <b>76</b> = 64%; <b>77</b> = 65%; (b) <b>45</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Phe for <b>79</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-<i>N</i>-MePhe for <b>80</b>, or <span class="smallcaps smallerCapital">l</span>-<i>N</i>,<i>N</i>-dimethylPhe for <b>82</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h; yields: <b>79</b> = 81%; <b>80</b> = 32%; <b>82</b> = 35%; (c) 4 N HCl in dioxane, 0 °C to RT, 1 h; yields: <b>72</b> = 72%; <b>78</b> = 93%; <b>74</b> = 98%; <b>81</b> = 87%.</p></p></figure><div class="NLM_p">While the <span class="smallcaps smallerCapital">l</span>-Phe (<b>53</b>) and <span class="smallcaps smallerCapital">d</span>-Phe (<b>54</b>) derivatives exhibited high aqueous stability across the pH range of 1–6.5, the introduction of a Gly linker, as in the case of <b>72</b> (<span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b>) and <b>78</b> (<span class="smallcaps smallerCapital">d</span>-Phe-Sar-<b>1</b>), resulted in more than five-fold reduced stability at pH 6.5, with no impact on the high chemical stability observed at pH values of ≤4 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Prodrug <b>78</b>, which incorporates an unnatural <span class="smallcaps smallerCapital">d</span>-Phe in the promoiety (<i>t</i><sub>1/2</sub> = 89 h), revealed slightly higher stability than the diasteromeric prodrug <b>72</b> with a natural <span class="smallcaps smallerCapital">l</span>-Phe in the promoiety (<i>t</i><sub>1/2</sub> = 74 h). The reduced stability of the dipeptide prodrugs at pH 6.5 can be attributed to the tendency to undergo deprotonation at higher pH values which will facilitate intramolecular cyclization to release <b>1</b>. Self-immolative activation was further accelerated in the <span class="smallcaps smallerCapital">l</span>-Phe-Sar prodrug <b>74</b> where the <i>N</i>-methyl group would lead to significant population of the <i>cis</i>-amide topology which is primed for cyclization to the diketopiperazine to release <b>1</b>. At a pH value of 6.5, <span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b> (<b>74</b>) cyclized completely within 60 min, with a <i>t</i><sub>1/2</sub> estimated to be on the order of 5 min. The intramolecular cyclization of <b>74</b> in pH 6.5 buffer was confirmed with the observation of formation of the corresponding diketopiperazine <b>75</b> by LCMS as the only byproduct (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a> and <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>). Monomethylation of the nucleophilic terminal amine of <b>74</b> gave <b>81</b> which offered no differentiation in solution stability at pH = 6.5; however, the dimethyl homologue <b>82</b> was considerably more stable at pH values of ≥4 than <b>74</b>, consistent with the inability of this prodrug to undergo facile intramolecular chemo-activated cyclization. The facility with which the <span class="smallcaps smallerCapital">l</span>-Phe-Gly prodrug <b>72</b> cyclizes to release <b>1</b> contrasts with the relative stability of the <span class="smallcaps smallerCapital">l</span>-Val-<span class="smallcaps smallerCapital">l</span>-Val derivative <b>29</b>, indicating that the absence of the Cα-alkyl moiety enables intramolecular cyclization through population of a <i>cis</i>-amide conformation favorable for cyclization. While prodrugs <b>72</b> and <b>78</b> showed excellent solubility of at least 2000 μg/mL at pH values of 1 and 4, these prodrugs demonstrated acceptable solubility of more than 200 μg/mL at pH = 6.5, representing a more than 200-fold improvement in solubility compared with <b>1</b>. The installation of the Gly linker in prodrugs <b>72</b> and <b>78</b> was found to offer more than 20-fold and 200-fold increased solubility, respectively, compared with the monoester counterparts <b>53</b> and <b>54</b> that lack the linker. Prodrugs <b>74</b> and <b>81</b> demonstrated excellent aqueous solubility of more than 1000 μg/mL at pH = 1, but the solubility could not be determined at pH = 4 and 6.5 because of the limited chemical stability under these conditions. However, the enhanced stability of <b>82</b> allowed determination of the solubility across the pH range with this prodrug, demonstrating solubility of greater than 1200 μg/mL at pH 1–4 although the solubility was a more modest 20 μg/mL at pH = 6.5.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Rate of Formation of the Cyclic Byproduct <b>75</b> along with <b>1</b> Associated with the Degradation of Prodrug <b>74</b> at pH = 6.5 in Buffer<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">time (min)</th><th class="colsep0 rowsep0" align="center"><b>74</b></th><th class="colsep0 rowsep0" align="center" char="."><b>75</b> (%)</th><th class="colsep0 rowsep0" align="center" char="."><b>1</b> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="left">86.1%</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">10.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">2.0%</td><td class="colsep0 rowsep0" align="char" char=".">29.7</td><td class="colsep0 rowsep0" align="char" char=".">68.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">NA<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">31.0</td><td class="colsep0 rowsep0" align="char" char=".">69.0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">NA = data not available.</p></div></div></div><div class="NLM_p">Following oral administration of <b>72</b>, <b>74</b>, <b>78</b>, <b>81</b>, and <b>82</b> at a 3 mg/kg-equivalent dose of <b>1</b>, these prodrugs were found to deliver the parent in vivo, with the measured AUC values of <b>1</b> increasing in the order of <b>72</b> < <b>81</b> < <b>78</b> < <b>82</b> < <b>74</b>, results that are compiled in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. Prodrug <b>74</b> demonstrated the highest exposure of <b>1</b>, with a relative oral AUC of ∼400% compared with that of <b>1</b>, indicating a superior performance compared with all of the other prodrugs that have been investigated as part of this study. Importantly, <b>74</b> delivered an eight-fold higher <i>C</i><sub>trough</sub> concentration of <b>1</b> in the rat measured at 24 h postdose compared with administration of <b>1</b> in contrast with the earlier prodrugs, none of which furnished a measurable <i>C</i><sub>trough</sub> level of <b>1</b>. The relative oral bioavailability of <b>1</b> from <b>74</b> was four-fold higher (80%) compared with that of <b>1</b> following direct administration (20%). The prodrug/parent ratio measured for <b>82</b> was 2800-fold higher than that of <b>74</b>. This indicated that the bioconversion of <b>82</b>, which was mainly designed to undergo enzymatic hydrolysis, was a slow process, reflecting the challenges associated with prodrug activation mediated by proteases. However, the PK profile of <b>82</b> suggests that this prodrug may be suitable for a sustained release of the parent. The <span class="smallcaps smallerCapital">d</span>-Phe-Gly-<b>1</b> prodrug <b>78</b> afforded 20% higher oral exposure than the stereoisomeric <span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b> prodrug <b>72</b> while the introduction of methyl group on the <i>N</i>-terminal amino group of <b>74</b> was found to be less favorable, with the observation of 17-fold reduced systemic exposure of parent from <b>81</b>.</div><div class="NLM_p">Encouraged by the superior plasma exposure and <i>C</i><sub>trough</sub> value of <b>1</b> released from the <span class="smallcaps smallerCapital">l</span>-Phe-Sar prodrug <b>74</b> at an equivalent dose of 3 mg/kg, the PK performance of the prodrug in a dose-escalation study was investigated (<a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a> and Figure 6, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). At a dose equivalent to 30 mg/kg of <b>1</b>, prodrug <b>74</b> exhibited 11-fold higher exposure of <b>1</b> compared with the exposure obtained following administration of <b>74</b> at a dose equivalent to 3 mg/kg of <b>1</b>. This indicates that the systemic exposure of <b>1</b> at a 30 mg/kg-equivalent dose was dose-proportional. Prodrug <b>74</b> also delivered a 16-fold higher <i>C</i><sub>trough</sub> level of <b>1</b> at the 30 mg/kg-equivalent dose of <b>1</b> than that of the 3 mg/kg-equivalent dose. Systemic circulation of <b>74</b> was not observed, indicating a robust reversal of the prodrug to <b>1</b> following dose escalation. The potential in vivo byproduct <b>75</b> was not monitored in these studies and although this compound has been reported in the literature, its toxicological profile remains to be understood.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The potential safety concerns associated with the prodrug <b>74</b> itself appear to be limited because of the absence of systemic circulation of the prodrug.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. PK Data for the Prodrug <b>74</b> Following Dose Escalation</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">analyte</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub> (nM)</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>last</sub> (nM h)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>trough</sub> (nM) at 24 h</th><th class="colsep0 rowsep0" align="center">relative AUC of <b>1</b> from the prodrug<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> (%)</th><th class="colsep0 rowsep0" align="center">prodrug/parent ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">794</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">1533</td><td class="colsep0 rowsep0" align="left">1.9</td><td class="colsep0 rowsep0" align="left">399</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">0.3</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">8756</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">16580</td><td class="colsep0 rowsep0" align="left">30.4</td><td class="colsep0 rowsep0" align="left">4318</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left">BLQ</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">The prodrug <b>74</b> was dosed at an equivalent dose of 3 mg/kg and 30 mg/kg of the parent. Values shown are mean ± SD (<i>n</i> = 3). Abbreviations used: NA = not applicable or not available, BLQ = below limit of quantification.</p></div></div></div><div class="NLM_p">The parent drug <b>1</b> appears to be the substrate for several transporters which, in turn, contributes to reduced oral systemic bioavailability, intracellular concentration, and brain bioavailability. As a class, PIs are the substrates for the ATP-binding cassette family of drug efflux transporters including P-gp, multidrug resistant proteins (MRPs), and breast cancer resistance protein (BCRP) and also anionic and cationic transporters like organic anion transporting polypeptide (OATP) and organic cation transporter (OCT).<a onclick="showRef(event, 'ref9 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref9 ref69 ref70">(9,69,70)</a> These transporters are differentially expressed at the important sites of drug disposition, including the intestine, lymphocytes, liver, brain, and kidney and, hence, play a significant role in the disposition of PIs, influencing oral absorption, tissue distribution, and cellular accumulation. Amino acid prodrugs of PIs have previously been shown to enhance absorptive permeability by engaging an active transport system and reducing efflux.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The apparent bidirectional Caco-2 permeability coefficients for <b>1</b> and select prodrugs was determined in an effort to understand whether the prodrugs could evade efflux transporters. The Caco-2 permeability assay represents an important in vitro system with which to predict human intestinal permeability and the absorption of oral drugs. In the co-solvent Caco-2 assay, <b>1</b> showed low apical-to-basolateral and high basolateral-to-apical permeability (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>) with the secretory flux of <b>1</b> >14-fold higher than its absorptive flux. These results are consistent with the literature characterization, indicating that <b>1</b> is a substrate for efflux transporters.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Surprisingly, none of the tested prodrugs showed improved apical-to-basolateral permeability compared with the parent, irrespective of whether the cLog <i>D</i> values of these prodrugs were similar to or higher than that of <b>1</b> (<a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a></a>). However, the prodrugs differentiated from <b>1</b> in that they showed reduced potential for transepithelial efflux, suggestive of lower affinity of the prodrugs for the efflux transporters when compared with <b>1</b> (Figure 7, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). Amongst the prodrugs, <b>46</b> showed the highest efflux potential despite having the lowest HBD count (4), whereas <b>59</b>, which has the highest HBD count (6), exhibited the lowest efflux ratio, suggesting an absence of a correlation between efflux and HBD count. With the exception of the <span class="smallcaps smallerCapital">l</span>-Tyr prodrug <b>59</b>, all of the prodrugs evaluated showed a 3- to 12-fold improvement in total oral systemic exposure of prodrug and <b>1</b> in rats, when compared with the direct administration of <b>1</b>. On the basis of the in vitro Caco-2 permeability data, it can be hypothesized that reduced efflux partly contributes to the in vivo observation of improved total AUC of prodrug + <b>1</b>. This is supported by the observation of a 12-fold increase in the brain-to-plasma ratio (<i>C</i><sub>brain</sub>/<i>C</i><sub>plasma</sub>) following IV administration of <b>1</b> to mice treated with the P-gp inhibitor elacridor compared with vehicle-treated mice.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Surprisingly, the Tyr prodrug <b>59</b> did not significantly improve the total AUC of prodrug + <b>1</b>, although it showed the lowest efflux potential out of the prodrugs tested. Unlike other prodrugs, the Tyr prodrug <b>59</b> possesses a phenolic functionality that has calculated a p<i>K</i><sub>a</sub> value of 9.5, indicating that ionization in the intestine as a limiter of oral absorption can be ruled out.</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Evaluation of the Permeability of Select Amino acid Prodrugs across a Caco-2 Monolayer</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">Caco-2 <i>P</i><sub>app</sub> (nm/s)<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">AUC (nM h)</th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">promoiety</th><th class="colsep0 rowsep0" align="center" char="."><i>c</i>log <i>D</i> (pH 6.5)<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">HBD/HBA count<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PSA<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center"><i>A</i>–<i>B</i></th><th class="colsep0 rowsep0" align="center"><i>B</i>–<i>A</i></th><th class="colsep0 rowsep0" align="center">efflux ratio</th><th class="colsep0 rowsep0" align="center">prodrug</th><th class="colsep0 rowsep0" align="center"><b>1</b></th><th class="colsep0 rowsep0" align="center" char=".">total AUC<sub>(prodrug+ATV)</sub>/AUC<sub>ATV</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">5/7</td><td class="colsep0 rowsep0" align="left">171</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">203</td><td class="colsep0 rowsep0" align="left">>14</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">384</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Val</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">5/7</td><td class="colsep0 rowsep0" align="left">205</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">122</td><td class="colsep0 rowsep0" align="left">>8.1</td><td class="colsep0 rowsep0" align="left">4731</td><td class="colsep0 rowsep0" align="left">42</td><td class="colsep0 rowsep0" align="char" char=".">12.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left"><i>N</i>,<i>N</i>-dimethyl-Gly</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="left">4/8</td><td class="colsep0 rowsep0" align="left">181</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">132</td><td class="colsep0 rowsep0" align="left">>8.8</td><td class="colsep0 rowsep0" align="left">1519</td><td class="colsep0 rowsep0" align="left">45.7</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Phe</td><td class="colsep0 rowsep0" align="char" char=".">5.7</td><td class="colsep0 rowsep0" align="left">5/8</td><td class="colsep0 rowsep0" align="left">203</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">131</td><td class="colsep0 rowsep0" align="left">>8.7</td><td class="colsep0 rowsep0" align="left">686</td><td class="colsep0 rowsep0" align="left">573</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left"><span class="smallcaps smallerCapital">l</span>-Tyr</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="left">6/9</td><td class="colsep0 rowsep0" align="left">223</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">>4.7</td><td class="colsep0 rowsep0" align="left">75</td><td class="colsep0 rowsep0" align="left">103</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">4-F-<span class="smallcaps smallerCapital">l</span>-Phe</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="left">5/8</td><td class="colsep0 rowsep0" align="left">203</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">>5.5</td><td class="colsep0 rowsep0" align="left">430</td><td class="colsep0 rowsep0" align="left">463</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">BnGly</td><td class="colsep0 rowsep0" align="char" char=".">6.1</td><td class="colsep0 rowsep0" align="left">5/8</td><td class="colsep0 rowsep0" align="left">189</td><td class="colsep0 rowsep0" align="left"><15</td><td class="colsep0 rowsep0" align="left">96</td><td class="colsep0 rowsep0" align="left">>6.4</td><td class="colsep0 rowsep0" align="left">833</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup><sup>a</sup></sup><p class="last">Physical properties (<i>c</i>log <i>D</i>, HBD count, HBA count, and PSA) were calculated using ChemAxon Marvin Sketch software.</p></div><div class="footnote" id="t12fn2"><sup><sup>b</sup></sup><p class="last">Targeted concentration is 2 μM. Transport medium: 4% HSA in HBSS; permeability values have been calculated based on prodrug appearance only. Negligible levels of <b>1</b> were observed at the end of the incubation.</p></div></div></div><div class="NLM_p">An analysis of the complete set of the solubility data over the pH range of 6.5–7.4, which is considered to be the most relevant for intestinal absorption, indicates that the phosphate prodrugs <b>2</b> and <b>11</b> exhibited superior solubility, with the direct phosphate ester <b>2</b> showing the highest solubility (Figure 8, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). The direct phosphate prodrug <b>2</b> exhibited two-fold higher solubility than the POM prodrug <b>11</b>, indicating that the introduction of a methylene spacer contributes to slightly reduced aqueous solubility. Among the amino acid prodrugs, those compounds with no amino acid side chain elements <b>44</b> (Gly), <b>45</b> (Sar), and <b>46</b> (<i>N</i>,<i>N</i>-dimethyl-Gly) or with smaller residues like Me (Ala derivatives <b>47</b> and <b>48</b>) and iPr (Val derivatives <b>23</b> and <b>24</b>) exhibited high solubility, with a more than >200-fold advantage compared with <b>1</b>. Those prodrugs with either a more lipophilic side chain (Leu and Met derivatives <b>49</b>–<b>52</b>) or an aryl group (Phe derivatives <b>53</b>, <b>54</b>, and <b>64</b>, Trp derivative <b>66</b>, Tyr <b>59</b> and the Bn-Gly derivative <b>71</b>) showed significantly decreased solubility that was in the range of 1–45 μg/mL. The dipeptide ester prodrugs <b>29</b>–<b>32</b>, <b>72</b>, and <b>78</b> demonstrated consistent increases in solubility of at least 230 μg/mL in spite of the presence of two isopropyl moieties or an aromatic group. The only exception was the dipeptide prodrug <b>82</b> bearing a 3° amine, which showed at least 10-fold reduced solubility that can be attributed to the lack of 1° or 2° amine group. Consistent with this, the tertiary amine-based prodrugs <b>46</b> and <b>82</b> exhibited ∼2.5-fold and 32-fold lower solubility than their primary amine counterparts <b>44</b> and <b>72</b>, respectively. Expansion of the mono-Val amino acid esters <b>23</b> and <b>24</b> to the Val-Val dipeptide esters <b>29</b>–<b>32</b> did not exert a significant impact on the aqueous solubility.</div><div class="NLM_p">An analysis of the AUC of <b>1</b> released from the prodrugs indicated that Phe-based, direct amino acid prodrugs with (<i>S</i>)-stereochemistry or Phe-based, dipeptide promoieties with the exception of <b>72</b> and <b>81</b> showed AUC values of <b>1</b> in the range of 307–1533 nM h, a profile that is similar to or higher than the AUC obtained after direct administration of <b>1</b> (Figure 9, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). These results suggest that the <span class="smallcaps smallerCapital">l</span>-Phe derivatives <b>53</b> and <b>64</b> are more readily recognized by hydrolytic enzymes than the other amino acid-based prodrugs, contributing to the release of a higher amount of <b>1</b> from these prodrug moieties. The remainder of the amino acid prodrugs without a Cα substituent (Gly and its derivatives <b>44-46</b>) or with a Cα substituent (<b>47</b> and <b>48</b> (Ala), <b>23</b> and <b>24</b> (Val), <b>51</b> and <b>52</b> (Met), <b>66</b> (Trp), and <b>49</b> and <b>50</b> (Leu)) showed a lower AUC exposure of <b>1</b> when compared with dosing of the parent drug. Of the three <span class="smallcaps smallerCapital">l</span>- and <span class="smallcaps smallerCapital">d</span>-stereisomeric pairs of amino acid prodrugs <b>23</b>/<b>24</b>, <b>47</b>/<b>48</b>, and <b>53</b>/<b>54</b> prepared, the <span class="smallcaps smallerCapital">l</span>-amino acid prodrugs released a 2- to 12-fold higher amount of <b>1</b> in vivo. However, this trend was reversed in the case of the <span class="smallcaps smallerCapital">l</span>- and <span class="smallcaps smallerCapital">d</span>-stereoisomeric pairs of dipeptide prodrugs <b>29</b>/<b>30</b> (Val-Val-<b>1</b>) and <b>72</b> and <b>78 (</b>Phe-Sar-<b>1</b>)</div><div class="NLM_p">An analysis of the total AUC comprising the sum of the AUC of <b>1</b> arising from the prodrug and AUC of the circulating prodrug was undertaken to better understand the overall performance of these prodrugs in mitigating the physiological barriers for oral drug delivery. The prodrugs examined furnished a 1.1- to 14-fold higher relative total AUC of <b>1</b> compared with the AUC that was obtained after oral dosing of <b>1</b>, with the exception of <b>11</b>, <b>45</b>, <b>48</b>, <b>51</b>, <b>59</b>, <b>72</b>, and <b>81</b> (Figure 10, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). These data further revealed the superior performance of the Val-based amino acid derivatives <b>23</b> and <b>24</b> and the dipeptide prodrugs <b>29</b> and <b>30</b>, which offer 10- to 14-fold higher total oral AUCs than when dosing <b>1</b> directly. This indicates that prodrugs with Val or Val-Val residues are the most effective at mitigating the barriers to oral bioavailability through a combination of enhanced solubility, reduced efflux and reduced metabolism. However, these prodrugs do not appear to offer advantages in improving the absorptive permeability, another barrier for bioavailability. The Phe-derived direct prodrugs <b>53</b>, <b>54</b> and <b>64</b> and dipeptide prodrugs <b>74</b>, <b>78</b>, and <b>82</b> also displayed higher relative total AUC values of <b>1</b> with a 2- to 4-fold enhancement compared with administration of a parent drug. With respect to the stereoisomeric pairs studied, there was no consistent trend with respect to the particular configuration of the amino acid moiety.</div><div class="NLM_p last">In the early stages of the program, the prodrugs of <b>1</b> were tested for HIV-1 protease inhibition and antiviral activity in a HIV-1 replicating virus assay hosted by MT2 cells (see Table 13 and Figure 11, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>). Although compounds with prodrug elements attached to the pharmacophoric hydroxyl moiety would not be expected to inhibit HIV-1 protease in a biochemical assay, the prodrug may be subject to cleavage in cell-based antiviral assays. Although the initial prodrugs prepared were tested in both assays, there was not a significant correlation between the activity observed in the biochemical and cell-based assays because factors including the permeability of the compound and activation of the prodrug by cellular enzymes are expected to play a role in the expression of cellular antiviral activity. As a consequence, later prodrugs were profiled only in the cell-based assay. Control compound <b>1</b> exhibited potent inhibition in the enzymatic assay (IC<sub>50</sub> = 0.3 nM) as well as in the cellular assay (EC<sub>50</sub> = 0.7 nM). Those prodrugs tested in the HIV-1 protease assay expressed inhibition with IC<sub>50</sub> values in the range of 4–1145 nM, with cellular EC<sub>50</sub> values observed across the range of 0.9–1250 nM. Prodrugs <b>23</b>, <b>24</b>, <b>29</b>, <b>30</b>, <b>44</b>, <b>46</b>, and <b>48</b> displayed enzymatic and cellular inhibitory activities that represented a less than three-fold difference between IC<sub>50</sub> and EC<sub>50</sub> values. The other prodrugs <b>31</b>, <b>32</b>, <b>47</b>, <b>53</b>, and <b>54</b> showed a significant 19- to 42-fold difference between the IC<sub>50</sub> and EC<sub>50</sub> values. Prodrugs <b>47</b>, <b>53</b>, and <b>54</b> exhibited markedly higher HIV-1 inhibitory activity in the cell-based assay compared with the IC<sub>50</sub> values. In general, <span class="smallcaps smallerCapital">l</span>-amino acid-based prodrugs exhibited better cellular anti-HIV-1 activity than <span class="smallcaps smallerCapital">d</span>-amino acid-based prodrugs (compare <b>23</b> and <b>24</b>, <b>47</b> and <b>48</b>, <b>49</b> and <b>50</b>, <b>51</b> and <b>52</b> and <b>53</b> and <b>54</b> in Table 13, the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>), consistent with the hypothesis that the natural amino acid esters can undergo cellular activation more readily to release the parent than the unnatural counterparts. Another SAR pattern in HIV-1 inhibitory activity that was apparent was the markedly lower cellular activity of Val mono-amino acid esters and Val-Val dipeptide esters (EC<sub>50</sub> values range from 84 to 1250 nM) than the other amino acid esters (EC<sub>50</sub> values range from 0.7 to 17 nM), as evident from the data compiled graphically in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Figure 10</a>. Thus, those prodrugs which have no branching on the β-carbon of the amino acid showed higher antiviral activity than the Val prodrugs which possess β-branching. One of the possible reasons behind this observation is that the prodrugs that lack branching on the β-carbon of the amino acid moiety may be subject to a higher rate of enzymatic cleavage to release <b>1</b> which mediates the antiviral activity in cell culture. Additional studies are required to confirm if amino acid or dipeptide prodrugs are intrinsically active or if the activity is derived from the parent after hydrolytic conversion of the prodrugs to <b>1</b> in HIV infected cells.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66448" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66448" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A survey of the in vitro and in vivo performance of a series of phosphate and amino acid-based prodrugs of the HIV-1 PI <b>1</b> identified the <span class="smallcaps smallerCapital">l</span>-Phe-Sar ester <b>74</b> as a prodrug that overcomes some of the pharmaceutics and absorption-related limitations associated with <b>1</b>. The design of <b>74</b> takes advantage of a self-immolative process of drug release in which cyclization of the promoiety to a diketopiperazine occurs at neutral pH and is facilitated by the presence of a sarcosine linker to exert conformational bias toward the presence of the <i>cis</i>-amide conformation. Oral dosing of <b>74</b> to rats provided a four-fold improved exposure and an eight-fold improved <i>C</i><sub>24<i>h</i></sub> value of <b>1</b> compared with an equivalent dose of the parent drug with the observation of only very low levels of circulating prodrug. In a dose escalation study, a dose-proportional increase in both plasma concentration and trough concentration of <b>1</b> was observed following oral administration of <b>74</b> at doses of up to 30 mg/kg. While the performance and profile of <b>74</b> in rats is encouraging, realization of its full potential as a delivery vehicle for <b>1</b> will require additional PK studies in higher species to more fully understand the relevance to human exposure predictions. The pH-activatable immolative prodrug design described herein appears to offer a viable strategy for facilitating the activation of prodrugs to release the parent drugs in those circumstances where hydrolytic enzymes may have difficulty in accessing the promoieties because of the steric hindrance presented by structural elements embedded in the parent molecule and may have broader applications.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i25">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Details of materials and general methods are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">Supporting Information</a>. The analytical purity of the compounds was assessed by HPLC analysis and determined to be ≥95%, unless otherwise noted. The following HPLC methods were used to determine the analytical purity of the compounds.<ul class="NLM_list-list_type-label" id="list1"><li><p class="inline">(i) Analytical HPLC method A: column = Sunfire C18 [150 × 4.6 mm] 3.5 μm; buffer = 0.05% CF<sub>3</sub>CO<sub>2</sub>H in H<sub>2</sub>O; mobile phase A = buffer/MeCN [95:5]; mobile phase B = MeCN/buffer [95:5]; 10% B to 100% B; run time = 23 min; flow rate = 1.0 mL/min).</p></li><li><p class="inline">(ii) Analytical HPLC method B: column = XBridge phenyl C18 [150 × 4.6 mm] 3.5 m; buffer = 0.05% CF<sub>3</sub>CO<sub>2</sub>H in H<sub>2</sub>O; mobile phase A = buffer: MeCN [95:5]; mobile phase B = MeCN: buffer [95:5]; 10% B to 100% B; run time = 23 min; flow rate = 1.0 mL/min).</p></li><li><p class="inline">(iii) Analytical HPLC method C: column = Kinetex Evo C18 [100 × 4.6 mm] 2.6 μm; buffer = 0.05% CF<sub>3</sub>CO<sub>2</sub>H in H<sub>2</sub>O; mobile phase A = buffer/MeCN [95:5]; mobile phase B = MeCN/buffer [95:5]; 10% B to 100% B; run time = 23 min; flow rate = 1.0 mL/min).</p></li><li><p class="inline">(iv) Analytical HPLC method D: column = Kinetex Biphenyl C18 [100 × 4.6 mm] 2.6 μm; buffer = 0.05% CF<sub>3</sub>CO<sub>2</sub>H in H<sub>2</sub>O; mobile phase A = buffer: MeCN [95:5]; mobile phase B = MeCN: buffer [95:5]; 10% B to 100% B; run time = 23 min; flow rate = 1.0 mL/min).</p></li></ul></div><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Experimental Procedures</h3><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> Methyl ((5<i>S</i>,8<i>S</i>,9<i>S</i>,14<i>S</i>)-8-Benzyl-5-(<i>tert</i>-butyl)-15,15-dimethyl-3,6,13-trioxo-9-(phosphonooxy)-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)carbamate (<b>2</b>)</h4><div class="NLM_p last">To a stirred solution of <b>9</b> (200 mg, 0.21 mmol) in ClCH<sub>2</sub>CH<sub>2</sub>Cl (5 mL) were added CF<sub>3</sub>CO<sub>2</sub>H (2 mL, 26.0 mmol) and anisole (0.2 mL, 1.83 mmol). The reaction mixture was stirred at room temperature for 16 h, concentrated under high vacuum at 30 °C to leave a colorless gum. The crude product was purified using RP-HPLC (column: Sunfire C18 (19 × 150 mm) 5 μm; mobile phase A: 0.1% CF<sub>3</sub>CO<sub>2</sub>H in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 20 mL/min; gradient (T/%B): 0/10, 10/50). The pooled HPLC fractions were concentrated using high vacuum at 30 °C. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to afford the title compound as a white solid (120 mg, 0.150 mmol, 72% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.77–9.63 (m, 1H), 8.81–8.64 (m, 1H), 8.11–7.99 (m, 2H), 7.95–7.86 (m, 2H), 7.85–7.77 (m, 1H), 7.64–7.54 (m, 2H), 7.52–7.43 (m, 1H), 7.30–7.10 (m, 5H), 6.85–6.63 (m, 2H), 4.75–4.57 (m, 1H), 4.34–4.10 (m, 2H), 4.03–3.89 (m, 1H), 3.73–3.59 (m, 2H), 3.57–3.53 (m, 3H), 3.43–3.26 (m, 3H), 3.02–2.71 (m, 4H), 0.93–0.57 (m, 18H); LCMS (ES) <i>m</i>/<i>z</i>: 785.2 [M + H]<sup>+</sup>. Analytical HPLC-RT and purity: method C = 6.40 min and 99.60% method D = 5.16 min and 99.80%; HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>38</sub>H<sub>54</sub>N<sub>6</sub>O<sub>10</sub>P, 785.3634; found, 785.3622.</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> Methyl ((5<i>S</i>,8<i>S</i>,9<i>S</i>,14<i>S</i>)-8-Benzyl-9-((bis(benzyloxy)phosphoryl)oxy)-5-(<i>tert</i>-butyl)-15,15-dimethyl-3,6,13-trioxo-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)carbamate (<b>9</b>)</h4><div class="NLM_p last">To a stirred solution of <b>1</b> (1 g, 1.42 mmol) in CH<sub>3</sub>CN (15 mL) were added tetrazole (0.099 g, 1.42 mmol) and dibenzyl diisopropylphosphoramidite (0.72 mL, 2.13 mmol). The reaction mixture was stirred at room temperature for 8 h and cooled to 0 °C, and an aqueous solution of H<sub>2</sub>O<sub>2</sub> (0.222 mL, 2.84 mmol) was added. The reaction mixture was stirred at 0 °C for 10 min and then partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with 10% aqueous Na<sub>2</sub>CO<sub>3</sub> solution and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum to afford a colorless oil. The crude product was purified by preparative HPLC (column: YMC TRIAT (20 × 250 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 20 mL/min; gradient (T/%B): 0/60, 2/60, 15/80). The pooled HPLC fractions were concentrated under reduced pressure below 30 °C. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as an off-white solid (900 mg, 62.4%). <sup>1</sup>H NMR (400 MHz, CH<sub>3</sub>OH-<i>d</i><sub>3</sub>): δ 8.63–8.56 (m, 1H), 7.90–7.85 (m, 1H), 7.84–7.77 (m, 3H), 7.84–7.76 (m, 3H), 7.76–7.70 (m, 1H), 7.48–7.42 (m, 2H), 7.40–7.34 (m, 11H), 7.24–7.14 (m, 4H), 6.57–6.46 (m, 1H), 5.17–5.07 (m, 4H), 4.64–4.53 (m, 1H), 4.19–4.08 (m, 1H), 4.00–3.89 (m, 2H), 3.72–3.60 (m, 4H), 3.55–3.45 (m, 4H), 3.24–3.13 (m, 2H), 2.95–2.75 (m, 2H), 1.02–0.56 (m, 18H); LCMS (ES) <i>m</i>/<i>z</i>: 965.5 [M + H]<sup>+</sup>.</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> Methyl ((5<i>S</i>,8<i>S</i>,9<i>S</i>,14<i>S</i>)-8-Benzyl-5-(<i>tert</i>-butyl)-15,15-dimethyl-9-((methylthio)methoxy)-3,6,13-trioxo-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)carbamate (<b>10</b>)</h4><div class="NLM_p last">Acetic anhydride (1.34 mL, 14.2 mmol) and CH<sub>3</sub>CO<sub>2</sub>H (2.44 mL, 42.6 mmol) were added to a stirred solution of <b>1</b> (1.0 g, 1.42 mmol) in DMSO (2.6 mL, 36.9 mmol). The homogeneous reaction mixture was stirred at room temperature for 2 days before being partitioned between EtOAc and H<sub>2</sub>O. The organic layer was washed with 10% aqueous Na<sub>2</sub>CO<sub>3</sub> solution followed by brine solution and dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under reduced pressure to afford 2.1 g of crude compound, which was divided into two equal portions. The first half was triturated with Et<sub>2</sub>O, the solid filtered, washed with Et<sub>2</sub>O, and dried under vacuum to afford 600 mg as an off white solid. The second half was purified by reversed phase HPLC (column: Sunfire C18 (150 × 19 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN/iPrOH (70:30); flow rate: 20 mL/min; gradient: 0/40, 2/40, 17/70). The pooled HPLC fractions were concentrated under high vacuum below 30 °C. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 16 h to afford 260 mg of an off white solid. The combined title product was obtained as an off white solid (860 mg, 1.13 mmol, 79% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.98 (s, 1H), 8.71–8.59 (m, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.94–7.90 (m, 1H), 7.86 (dt, <i>J</i> = 2.0, 7.8 Hz, 1H), 7.60 (br d, <i>J</i> = 9.0 Hz, 1H), 7.41 (d, <i>J</i> = 8.5 Hz, 2H), 7.33 (ddd, <i>J</i> = 1.5, 4.8, 7.3 Hz, 1H), 7.25–7.08 (m, 5H), 6.81 (br d, <i>J</i> = 9.0 Hz, 1H), 6.63 (br d, <i>J</i> = 9.5 Hz, 1H), 5.11 (br d, <i>J</i> = 11.5 Hz, 1H), 4.90 (d, <i>J</i> = 11.5 Hz, 1H), 4.31 (br s, 1H), 4.01–3.83 (m, 3H), 3.78 (br s, 1H), 3.69 (br d, <i>J</i> = 9.5 Hz, 1H), 3.52 (d, <i>J</i> = 6.0 Hz, 6H), 2.95–2.79 (m, 3H), 2.78–2.71 (m, 1H), 2.17 (s, 3H), 0.76 (m, 18H); LCMS (ES) <i>m</i>/<i>z</i>: 765.4 [M + H]<sup>+</sup>. Analytical HPLC-RT and purity: method C = 4.64 min and 99.60% method D = 6.13 min and 99.5%; HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>57</sub>N<sub>6</sub>O<sub>7</sub>S, 765.9905; found, 765.3977.</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> Disodium Methyl ((5<i>S</i>,8<i>S</i>,9<i>S</i>,14<i>S</i>)-8-Benzyl-5-(<i>tert</i>-butyl)-15,15-dimethyl-3,6,13-trioxo-9-((phosphonooxy)methoxy)-11-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,11,12-tetraazahexadecan-14-yl)carbamate (<b>11</b>)</h4><div class="NLM_p last">Powdered 4 Å molecular sieves (200.0 mg) and phosphoric acid (0.027 mL, 0.52 mmol) were added to a stirred solution of <b>10</b> (0.08 g, 0.105 mmol) in THF (3.0 mL). The mixture was cooled to 0 °C, NIS (0.035 g, 0.157 mmol) was added, and the mixture was stirred at room temperature for 30 min. CH<sub>3</sub>OH was added followed by 1.0 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution until the reaction mixture became colorless. The pH of the mixture was adjusted to 10 with solid Na<sub>2</sub>CO<sub>3</sub> and filtered. The filtrate was concentrated under reduced pressure to afford a residue which was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 16 h. The crude material was purified by using reversed phase preparative HPLC (column: X-Bridgephenyl (250 × 19 mm) 5 μm; mobile phase A: Milli-Q H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 20 mL/min; gradient: 0/10, 10/30). The pooled HPLC fractions were concentrated under high vacuum below 30 °C. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 16 h to afford the title compound as an off white solid (42 mg, 0.048 mmol, 45% yield). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.66–8.55 (m, 1H), 8.23–8.16 (m, 1H), 8.06–7.97 (m, 1H), 7.83–7.74 (m, 2H), 7.70–7.51 (m, 3H), 7.31–7.14 (m, 5H), 5.26–5.03 (m, 2H), 4.61–4.43 (m, 1H), 4.08–3.96 (m, 1H), 3.91–3.72 (m, 2H), 3.68 (s, 3H), 3.58–3.46 (m, 2H), 3.43 (s, 3H), 3.02–2.75 (m, 4H), 0.82–0.80 (m, 18H). LCMS (ES) <i>m</i>/<i>z</i>: 815.2 [M + H]<sup>+</sup>. Analytical HPLC-RT and purity: method C = 4.10 min and 99.30% method D = 5.22 min and 98.8%; HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>39</sub>H<sub>56</sub>N<sub>6</sub>O<sub>11</sub>P, 815.3739; found, 815.3726.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>R</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanoate (<b>22</b>)</h4><div class="NLM_p last">(<i>R</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanoic acid (0.055 g, 0.255 mmol), DCC (0.088 g, 0.426 mmol), and DMAP (5.2 mg, 0.043 mmol) were added to a solution of <b>1</b> (0.150 g, 0.213 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the reaction mixture was stirred at RT overnight before adding H<sub>2</sub>O (1 × 50 mL). The mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL), the combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to afford an off-white solid (250 mg). The crude material was purified by preparative HPLC (column: XBridge phenyl C18 (19 × 150 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 16 mL/min; gradient: 80% isocratic mobile phase B in mobile phase A in 20 min). The pooled HPLC fractions were concentrated under reduced pressure below 30 °C. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as an off-white solid (45 mg, 23%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.81 (br s, 1H), 8.65 (td, <i>J</i> = 2.5, 1.0 Hz, 1H), 7.95–7.81 (m, 5H), 7.36–7.30 (m, 3H), 7.23–7.12 (m, 6H), 6.70 (dd, <i>J</i> = 9.0, 5.0 Hz, 2H), 4.99 (t, <i>J</i> = 6.5 Hz, 1H), 4.69 (br s, 1H), 4.16 (dd, <i>J</i> = 8.8, 5.8 Hz, 1H), 4.02–3.93 (m, 3H), 3.65 (d, <i>J</i> = 9.5 Hz, 1H), 3.56 (s, 3H), 3.42 (s, 3H), 3.03–2.87 (m, 2H), 2.67 (dt, <i>J</i> = 4.0, 2.0 Hz, 2H), 2.19–2.09 (m, 1H), 1.41 (s, 9H), 0.94 (d, <i>J</i> = 7.0 Hz, 6H), 0.86 (s, 9H), 0.76 (s, 9H); LCMS (ES): <i>m</i>/<i>z</i>: 904.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method B = 9.839 min and 99.67%.</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>R</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-Amino-3-methylbutanoate Dihydrochloride (<b>24</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in Et<sub>2</sub>O solution (0.134 mL, 4.42 mmol) was added to <b>22</b> (0.040 g, 0.044 mmol) in a 5 mL round-bottom flask cooled to 0 °C. The reaction mixture was stirred at RT for 1 h before being concentrated under vacuum. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as a light yellow solid (35 mg; 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.06 (s, 1H), 8.72 (d, <i>J</i> = 4.5 Hz, 1H), 8.60 (br s, 3H), 8.15–8.03 (m, 2H), 7.99–7.92 (m, 3H), 7.54 (br s, 1H), 7.43 (d, <i>J</i> = 8.0 Hz, 2H), 7.26–7.12 (m, 5H), 6.75 (d, <i>J</i> = 10.0 Hz, 1H), 6.68 (d, <i>J</i> = 9.5 Hz, 1H), 5.17 (t, <i>J</i> = 6.5 Hz, 1H), 4.06–3.90 (m, 5H), 3.68–3.62 (m, 1H), 3.55 (s, 3H), 3.41 (s, 3H), 3.05–2.90 (m, 2H), 2.78–2.65 (m, 2H), 2.36–2.26 (m, 1H), 1.10–1.05 (m, 6H), 0.83 (s, 9H), 0.76 (s, 9H); LCMS (ES) <i>m</i>/<i>z</i>: 804.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method A = 6.015 min and 99.04% method B = 7.144 min and 97.75%; HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>43</sub>H<sub>61</sub>N<sub>7</sub>O<sub>8</sub>, 804.4654; found, 804.4661.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>S</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanamido)-3-methylbutanoate (<b>25</b>)</h4><div class="NLM_p last">(<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-methylbutanoic acid (0.041 g, 0.187 mmol), DIPEA (0.109 mL, 0.622 mmol) and HATU (0.047 g, 0.124 mmol) was added to a solution of <b>23</b> (0.100 g, 0.124 mmol) in DMF (10 mL), and the mixture was stirred overnight at RT. H<sub>2</sub>O (1 × 50 mL) was added, and the mixture was extracted with EtOAc (3 × 50 mL). The combined organic layer was washed with brine (1 × 50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to leave a gum (150 mg). The crude compound was purified by preparative HPLC (column: XBridge phenyl (20 × 250 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 17 mL/min; gradient: 30–70% mobile phase B in mobile phase A in 10 min). The pooled HPLC fractions were concentrated under reduced pressure below 30 °C. The solid residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as an off-white solid (60 mg, 45%). <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.88–8.78 (m, 1H), 8.68–8.60 (m, 1H), 8.00–7.79 (m, 6H), 7.38–7.26 (m, 3H), 7.17 (s, 5H), 6.88–6.77 (m, 1H), 6.74–6.62 (m, 2H), 5.08–4.97 (m, 1H), 4.72–4.61 (m, 1H), 4.55–4.45 (m, 1H), 4.05–3.79 (m, 4H), 3.69–3.61 (m, 1H), 3.56 (s, 3H), 3.42 (s, 3H), 3.04–2.85 (m, 2H), 2.75–2.55 (m, 2H), 2.24–2.08 (m, 1H), 2.02–1.91 (m, 1H), 1.38 (s, 9H), 0.95 (s, 6H), 0.90–0.70 (m, 24H); LCMS (ES) <i>m</i>/<i>z</i>: 1003.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method B = 10.542 min and 94.69%.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>S</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>S</i>)-2-Amino-3-methylbutanamido)-3-methylbutanoate Dihydrochloride (<b>29</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in Et<sub>2</sub>O (0.15 mL, 4.98 mmol) was added to <b>25</b> (0.050 g, 0.050 mmol) in a 5 mL round-bottom flask cooled to 0 °C. The mixture was allowed to warm to RT and stirred for 1 h before being concentrated under vacuum. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as light yellow solid (38 mg; 76%). <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.71 (d, <i>J</i> = 5.5 Hz, 1H), 8.60 (t, <i>J</i> = 7.8 Hz, 1H), 8.27 (d, <i>J</i> = 8.3 Hz, 1H), 7.97 (t, <i>J</i> = 6.8 Hz, 1H), 7.76 (d, <i>J</i> = 8.3 Hz, 2H), 7.62 (d, <i>J</i> = 8.0 Hz, 2H), 7.29–7.16 (m, 5H), 4.98 (br s, 1H), 4.35 (d, <i>J</i> = 6.8 Hz, 1H), 4.06 (d, <i>J</i> = 12.8 Hz, 1H), 3.90 (d, <i>J</i> = 5.8 Hz, 1H), 3.87–3.77 (m, 2H), 3.64 (s, 3H), 3.52–3.43 (m, 2H), 3.33 (br s, 3H), 3.03–2.93 (m, 1H), 2.91–2.80 (m, 2H), 2.75–2.73 (m, 1H), 2.28–2.12 (m, 2H), 1.06–0.96 (m, 12H), 0.83 (s, 9H), 0.66 (s, 9H); LCMS (ES) <i>m</i>/<i>z</i>: 903.9 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method A = 6.351 min and 97.53% method B = 6.923 min and 97.50%; HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>48</sub>H<sub>70</sub>N<sub>8</sub>O<sub>9</sub>, 903.5339; found, 903.5330.</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>tert</i>-Butoxycarbonyl)amino)acetate (<b>34</b>)</h4><div class="NLM_p last">2-((<i>tert</i>-Butoxycarbonyl)amino)acetic acid (0.045 g, 0.255 mmol), DCC (0.088 g, 0.426 mmol), and DMAP (5.20 mg, 0.043 mmol) were added to a solution of <b>1</b> (0.150 g, 0.213 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL), and the was mixture stirred for 14 h at RT. H<sub>2</sub>O (1 × 50 mL) was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to leave an off-white solid. The crude compound was purified by preparative HPLC (column: XBridge phenyl (19 × 250 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 18 mL/min; gradient: 30–60% mobile phase B in mobile phase A in 8 min). The pooled HPLC fractions were concentrated under reduced pressure below 30 °C; the residual solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as an off-white solid (140 mg, 76%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.96 (s, 1H), 8.69–8.58 (m, 1H), 7.99–7.78 (m, 5H), 7.41–7.28 (m, 3H), 7.27–7.09 (m, 6H), 6.73–6.60 (m, 2H), 5.07 (t, <i>J</i> = 5.8 Hz, 1H), 4.52 (br s, 1H), 4.05–3.91 (m, 3H), 3.88 (d, <i>J</i> = 6.0 Hz, 1H), 3.84–3.71 (m, 1H), 3.66 (d, <i>J</i> = 9.5 Hz, 1H), 3.55 (s, 3H), 3.43 (s, 3H), 3.07 (dd, <i>J</i> = 13.3, 5.8 Hz, 1H), 2.91 (dd, <i>J</i> = 13.1, 7.5 Hz, 1H), 2.76–2.57 (m, 2H), 1.41 (s, 9H), 0.81 (s, 9H), 0.74 (s, 9H); LCMS (ES) <i>m</i>/<i>z</i>: 861.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method B = 9.011 min and 99.83%.</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>tert</i>-Butoxycarbonyl) (methyl)amino)acetate (<b>35</b>)</h4><div class="NLM_p last">2-((<i>tert</i>-Butoxycarbonyl)(methyl)amino)acetic acid (268 mg, 1.419 mmol), DMAP (87 mg, 0.709 mmol), and DCC (293 mg, 1.419 mmol) were added to a solution of <b>1</b> (500 mg, 0.709 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL), and the mixture was stirred overnight at RT. The mixture was concentrated under vacuum, and the residue was purified by preparative HPLC. The pooled HPLC fractions were concentrated under reduced pressure below 30 °C, the residual solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as a white solid (400 mg; 64%). <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.64–8.57 (m, 1H), 7.97–7.78 (m, 5H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.41–7.33 (m, 1H), 7.24 (s, 5H), 5.31–5.17 (m, 1H), 4.69–4.50 (m, 1H), 4.32–3.91 (m, 5H), 3.77–3.49 (m, 7H), 3.12–2.99 (m, 5H), 2.97–2.84 (m, 1H), 2.79–2.62 (m, 1H), 1.50 (d, <i>J</i> = 19.6 Hz, 9H), 0.96–0.76 (m, 18H); LCMS (ES) <i>m</i>/<i>z</i>: 877.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method B = 9.689 min and 99.53%.</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>S</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>tert</i>-Butoxycarbonyl)amino)-3-phenylpropanoate (<b>42</b>)</h4><div class="NLM_p last">(<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-3-phenylpropanoic acid (0.059 g, 0.221 mmol), DCC (0.076 g, 0.369 mmol), and DMAP (4.51 mg, 0.037 mmol) were added to a solution of <b>1</b> (0.130 g, 0.184 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (15 mL), and the mixture was stirred at RT for 16 h. H<sub>2</sub>O was added (1 × 50 mL), the mixture was extracted with EtOAc (3 × 50 mL), and the combined organic layer was washed with brine (1 × 50 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated to leave an off-white solid. The crude compound was purified by preparative HPLC (column: Sunfire C18 (19 × 150 mm) 5 μm; mobile phase A: 10 mM NH<sub>4</sub>OAc in H<sub>2</sub>O; mobile phase B: CH<sub>3</sub>CN; flow rate: 18 mL/min; gradient: 50–70% mobile phase B in mobile phase A in 8 min). The pooled HPLC fractions were concentrated under reduced pressure below 30 °C, the residual solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as an off-white solid (130 mg, 74%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.89 (s, 1H), 8.65 (dd, <i>J</i> = 6.5, 1.0 Hz, 1H), 7.93 (d, <i>J</i> = 8.0 Hz, 2H), 7.91–7.82 (m, 2H), 7.70 (d, <i>J</i> = 10.0 Hz, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 2H), 7.35–7.26 (m, 6H), 7.25–7.12 (m, 6H), 6.72 (d, <i>J</i> = 10.0 Hz, 1H), 6.66 (d, <i>J</i> = 9.0 Hz, 1H), 5.02 (br s, 1H), 4.61 (br s, 1H), 4.35 (br s, 1H), 4.00 (t, <i>J</i> = 11.0 Hz, 3H), 3.67 (d, <i>J</i> = 9.0 Hz, 1H), 3.54 (s, 3H), 3.43 (s, 3H), 3.26 (d, <i>J</i> = 4.5 Hz, 1H), 3.12–3.03 (m, 1H), 3.01–2.85 (m, 2H), 2.73–2.58 (m, 2H), 1.32 (s, 9H), 0.87 (s, 9H), 0.74 (s, 9H).; LCMS (ES) <i>m</i>/<i>z</i>: 952.9 [M + H]<sup>+</sup>. Analytical HPLC-RT and purity: method A = 17.030 min and 99.76% method B = 18.399 min and 99.83%.</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-Aminoacetate Dihydrochloride (<b>44</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in dioxane (0.441 mL, 14.50 mmol) was added to <b>34</b> (0.125 g, 0.145 mmol) in a 5 mL round-bottom flask maintained at 0 °C. The mixture was stirred for 1 h at RT before being concentrated under vacuum. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O; the solution was frozen and lyophilized for 12 h to obtain the title product as a light yellow solid (110 mg; 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.19 (s, 1H), 8.77 (d, <i>J</i> = 4.5 Hz, 1H), 8.59 (br s, 3H), 8.25 (br s, 1H), 8.16 (d, <i>J</i> = 8.0 Hz, 1H), 8.02–7.93 (m, 3H), 7.66 (br s, 1H), 7.48 (d, <i>J</i> = 8.0 Hz, 2H), 7.28–7.11 (m, 5H), 6.71 (d, <i>J</i> = 9.5 Hz, 1H), 6.75 (d, <i>J</i> = 9.5 Hz, 1H), 5.16 (t, <i>J</i> = 6.5 Hz, 1H), 4.65 (br s, 1H), 4.06–3.88 (m, 2H), 3.75–3.62 (m, 2H), 3.56 (s, 3H), 3.53–3.44 (m, 2H), 3.40 (s, 3H), 3.07–2.90 (m, 2H), 2.79–2.64 (m, 2H), 0.82 (s, 9H), 0.75 (s, 9H).; LCMS (ES) <i>m</i>/<i>z</i>: 762.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method A = 5.954 min and 99.11% method B = 6.730 min and 99.08%. HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>40</sub>H<sub>55</sub>N<sub>7</sub>O<sub>8</sub>, 762.4185; found, 762.4193.</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-(Methylamino)acetate Dihydrochloride (<b>45</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in dioxane (1.0 mL, 32.9 mmol) was added to <b>35</b> (0.2 g, 0.228 mmol) in a 5 mL round-bottom flask maintained at 0 °C. The reaction mixture was warmed to RT and stirred for 2 h before being concentrated under vacuum. The residue was triturated with Et<sub>2</sub>O and the ethereal layer decanted. The residual solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as a white solid (38 mg; 19%). <sup>1</sup>H NMR (400 MHz, DMSO) δ = 9.45–9.25 (m, 2H), 9.18–9.06 (m, 1H), 8.81–8.62 (m, 1H), 7.98–7.96 (m, 5H), 7.54–7.39 (m, 3H), 7.21 (br s, 5H), 6.84–6.61 (m, 2H), 5.25–5.11 (m, 1H), 4.63–4.50 (m, 1H), 4.13–3.89 (m, 5H), 3.68–3.62 (m, 1H), 3.55–3.50 (m, 3H), 3.42 (s, 3H), 3.08–2.89 (m, 2H), 2.69 (s, 5H), 0.85 (s, 9H), 0.75 (s, 9H); LCMS (ES) <i>m</i>/<i>z</i>: 776.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method A = 5.886 min and 98.13% method B = 6.902 min and 98.94%. HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>41</sub>H<sub>57</sub>N<sub>7</sub>O<sub>8</sub>, 776.4341; found, 776.4343.</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>S</i>)-(5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-Amino-3-phenylpropanoate, Dihydrochloride (<b>53</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in dioxane (4.47 mL, 147 mmol) was added to <b>42</b> (2.800 g, 2.94 mmol) in a round-bottom flask maintained at 0 °C. The reaction mixture was warmed to RT and stirred for 1 h before being concentrated under vacuum. The residue was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, and the solution was frozen and lyophilized for 12 h to obtain the title product as an off-white solid (2.50 g; 85%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.20 (s, 1H), 8.82 (br s, 3H), 8.74 (d, <i>J</i> = 4.5 Hz, 1H), 8.17 (br s, 1H), 8.14–8.07 (m, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 2H), 7.91 (d, <i>J</i> = 9.5 Hz, 1H), 7.60 (br s, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 2H), 7.40–7.32 (m, 4H), 7.32–7.25 (m, 1H), 7.24–7.12 (m, 5H), 6.82 (d, <i>J</i> = 9.5 Hz, 1H), 6.72 (d, <i>J</i> = 10.0 Hz, 1H), 5.07 (t, <i>J</i> = 6.5 Hz, 1H), 4.74–4.65 (m, 1H), 4.38 (d, <i>J</i> = 5.5 Hz, 1H), 4.02–3.92 (m, 3H), 3.65 (d, <i>J</i> = 9.5 Hz, 1H), 3.53 (s, 3H), 3.41–3.32 (m, 4H), 3.29–3.21 (m, 1H), 3.01–2.88 (m, 2H), 2.67 (d, <i>J</i> = 7.0 Hz, 2H), 0.83 (s, 9H), 0.74 (s, 9H).; LCMS (ES) <i>m</i>/<i>z</i>: 852.4 [M + H]<sup>+</sup>; analytical HPLC-RT and purity: method A = 6.879 min and 99.67% method B = 8.304 min and 99.65%. HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>47</sub>H<sub>61</sub>N<sub>7</sub>O<sub>8</sub>, 852.4654; found, 852.4660.</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>S</i>)-2-Amino-<i>N</i>-methyl-3-phenylpropanamido)acetate, Dihydrochloride (<b>74</b>)</h4><div class="NLM_p last">A solution of 4 M HCl in dioxane (1 mL, 32.9 mmol) was added to <b>79</b> (65 mg, 0.064 mmol) in a 5 mL flask maintained at 0 °C. The reaction mixture was warmed to RT and stirred for 1 h before being concentrated under vacuum. The residue was triturated with Et<sub>2</sub>O, the ethereal layer was decanted, and the residual solid was dried under vacuum. The solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as white solid (63.95 mg; 98%). <sup>1</sup>H NMR (400 MHz, CH<sub>3</sub>OH-<i>d</i><sub>6</sub>): δ 8.86–8.79 (m, 1H), 8.68–8.56 (m, 1H), 8.38–8.28 (m, 1H), 8.21–7.88 (m, 3H), 7.75–7.65 (m, 2H), 7.42–7.30 (m, 5H), 7.20–7.10 (m, 5H), 5.29–5.17 (m, 1H), 4.81–4.71 (m, 2H), 4.52–4.36 (m, 1H), 4.28–4.01 (m, 3H), 3.94 (s, 1H), 3.81–3.57 (m, 5H), 3.52 (s, 2H), 3.28–3.12 (m, 2H), 3.11–2.96 (m, 5H), 2.92–2.64 (m, 2H), 0.91–0.73 (m, 18H); LCMS (ES) <i>m</i>/<i>z</i>: 923.4 [M + H]<sup>+</sup>; HPLC-RT and purity: (a) method A = 7.199 min and 96.7%; (b) method B = 7.519 min and 96.9%. HRMS (ESI/Orbitrap) <i>m</i>/<i>z</i>: [M + H]<sup>+</sup> calcd for C<sub>50</sub>H<sub>66</sub>N<sub>8</sub>O<sub>9</sub>, 923.5026; found, 923.5032.</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (5<i>S</i>,10<i>S</i>,11<i>S</i>,14<i>S</i>)-11-Benzyl-5,14-di-<i>tert</i>-butyl-3,6,13,16-tetraoxo-8-(4-(pyridin-2-yl)benzyl)-2,17-dioxa-4,7,8,12,15-pentaazaoctadecan-10-yl 2-((<i>S</i>)-2-((<i>tert</i>-Butoxycarbonyl)amino)-<i>N</i>-methyl-3-phenylpropanamido)acetate (<b>79</b>)</h4><div class="NLM_p last">To a stirred solution of <b>45</b> (0.2 g, 0.236 mmol) in DMF (8 mL), DIPEA (0.206 mL, 1.178 mmol) was added followed by HATU (0.134 g, 0.353 mmol) and Boc-Phe-OH (0.125 g, 0.471 mmol). The reaction mixture was stirred at RT for 8 h before being partitioned between H<sub>2</sub>O and EtOAc. The organic layer was separated and washed with brine solution (1 × 25 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under vacuum at 50 °C to leave the crude product which was purified by preparative HPLC. The pooled HPLC fractions were concentrated under reduced pressure below 30 °C. The residual solid was dissolved in a mixture of CH<sub>3</sub>CN and H<sub>2</sub>O, frozen, and lyophilized for 12 h to obtain the title product as a white solid (0.2 g, 81%). <sup>1</sup>H NMR (400 MHz, DMSO): δ 9.06–8.94 (m, 1H), 8.68–8.60 (m, 1H), 8.01–7.79 (m, 5H), 7.42–7.30 (m, 4H), 7.30–7.22 (m, 3H), 7.20–7.13 (m, 6H), 7.09–6.97 (m, 1H), 6.73–6.62 (m, 2H), 5.28–5.05 (m, 1H), 4.89–4.64 (m, 1H), 4.56–4.40 (m, 2H), 4.32–4.08 (m, 2H), 4.01–3.86 (m, 3H), 3.70–3.52 (m, 3H), 3.45–3.40 (m, 4H), 3.13–3.05 (m, 2H), 3.00–2.96 (m, 1H), 2.91–2.70 (m, 4H), 2.68–2.60 (m, 1H), 1.33–1.22 (m, 9H), 0.84–0.68 (m, 18H) <i>m</i>/<i>z</i>: 1023.7 [M + H]<sup>+</sup>; HPLC-RT: (a) method B = 10.351 min.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i43"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00002" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17636" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17636" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00002" class="ext-link">10.1021/acs.jmedchem.9b00002</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Figures 3−11 and Table 13; experimental section (synthesis) = experimental procedures of prodrugs (<b>23</b>, <b>30</b>, <b>31</b>, <b>32</b>, <b>46</b>, <b>47</b>, <b>48</b>, <b>49</b>, <b>51</b>, <b>52</b>, <b>54</b>, <b>59</b>, <b>64</b>, <b>66</b>, <b>71</b>, <b>78</b>, <b>81</b>, and <b>82</b>);  details of in vitro and in vivo experiments = stability evaluation in aqueous buffer; stability evaluation in bio-relevant media; solubility evaluation in aqueous buffer; pharmacokinetic evaluation; ex vivo stability in whole blood; alkaline phosphatase assay: determination of prodrug cleavage rate in vitro; rat hepatocyte study with and without PMSF/ABT; procedure for UGT1A1 assay; antiviral assays (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_001.csv">jm9b00002_si_001.csv (10.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf">jm9b00002_si_002.pdf (1.35 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00002" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47840" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47840" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murugaiah A. M. Subbaiah</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b465e595e4c4a424a43054a454f4a5b5b4a456b5852454c4e454e42455f4705484446"><span class="__cf_email__" data-cfemail="3c51494e495b5d555d54125d52585d4c4c5d527c4f45525b59525955524850125f5351">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandhya Mandlekar</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sridhar Desikan</span> - <span class="hlFld-Affiliation affiliation">Department of Biopharmaceutics, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span>; 
    <span>Present Address:
                        Formulation Division, R&D, Dr. Reddy’s Laboratories Ltd., Bachupally, Qutubullapur, Hyderabad, Telangana, 500090, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thangeswaran Ramar</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lakshumanan Subramani</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mathiazhagan Annadurai</span> - <span class="hlFld-Affiliation affiliation">Department
of Medicinal Chemistry, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Salil D. Desai</span> - <span class="hlFld-Affiliation affiliation">Department of Biopharmaceutics, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarmistha Sinha</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan M. Jenkins</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
Candidate Optimization, , and , Bristol-Myers Squibb
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span>Present Address:
                        ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark R. Krystal</span> - <span class="hlFld-Affiliation affiliation">Department of Virology, , and , Bristol-Myers Squibb
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span>Present Address:
                        ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Murali Subramanian</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Srikanth Sridhar</span> - <span class="hlFld-Affiliation affiliation">Department of Biopharmaceutics, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shweta Padmanabhan</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Priyadeep Bhutani</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rambabu Arla</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shashyendra Singh</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jaydeep Sinha</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Megha Thakur</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical Candidate
Optimization, , and , Biocon-Bristol Myers Squibb
R&D Centre, Biocon
Park, Bommasandra IV Phase, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John F. Kadow</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry and Molecular Technologies, , and , Bristol-Myers Squibb
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span>Present Address:
                        ViiV Healthcare, 36 East Industrial Road, Branford, CT 06405, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicholas A. Meanwell</span> - <span class="hlFld-Affiliation affiliation">Department of Discovery Chemistry and Molecular Technologies, , and , Bristol-Myers Squibb
Research and Development, P.O. Box 4000, Princeton, New Jersey 08543-4000, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-8857-1515" title="Orcid link">http://orcid.org/0000-0002-8857-1515</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i46">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50615" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50615" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Drs. Ramakanth Sarabu, Arvind Mathur, and Percy Carter for their support and inspiration. We thank Drs. Punit Marathe, Michael Hageman, and Bruce Car for productive discussions. We acknowledge the Discovery Analytical Sciences team for the analytical support.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">1-aminobenzotriazole</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption distribution metabolism and excretion</p></td></tr><tr><td class="NLM_term">ALP</td><td class="NLM_def"><p class="first last">alkaline phosphatase</p></td></tr><tr><td class="NLM_term">APV</td><td class="NLM_def"><p class="first last">amprenavir</p></td></tr><tr><td class="NLM_term">ATV</td><td class="NLM_def"><p class="first last">Atazanavir</p></td></tr><tr><td class="NLM_term">BCRP</td><td class="NLM_def"><p class="first last">breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">BID</td><td class="NLM_def"><p class="first last">bis in die</p></td></tr><tr><td class="NLM_term">BLQ</td><td class="NLM_def"><p class="first last">below limit of quantification</p></td></tr><tr><td class="NLM_term">cART</td><td class="NLM_def"><p class="first last">combination anti-retroviral therapy</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">DMAc</td><td class="NLM_def"><p class="first last">dimethylacetamide</p></td></tr><tr><td class="NLM_term"><i>N</i>,<i>N</i>-dimethyl-Gly</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylglycine</p></td></tr><tr><td class="NLM_term">FaSSIF</td><td class="NLM_def"><p class="first last">fasted state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Federal Drug Administration</p></td></tr><tr><td class="NLM_term">FeSSIF</td><td class="NLM_def"><p class="first last">fed state simulated intestinal fluid</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen bond acceptor</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donor</p></td></tr><tr><td class="NLM_term">HPßCD</td><td class="NLM_def"><p class="first last">hydroxypropyl ß-cyclodextrin</p></td></tr><tr><td class="NLM_term">LPV</td><td class="NLM_def"><p class="first last">lopinavir</p></td></tr><tr><td class="NLM_term">MRP</td><td class="NLM_def"><p class="first last">multi-drug resistant protein</p></td></tr><tr><td class="NLM_term">NNRTI</td><td class="NLM_def"><p class="first last">non-nucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">NRTI</td><td class="NLM_def"><p class="first last">nucleoside reverse transcriptase inhibitor</p></td></tr><tr><td class="NLM_term">OATP</td><td class="NLM_def"><p class="first last">organic anion transporting polypeptide</p></td></tr><tr><td class="NLM_term">OCT</td><td class="NLM_def"><p class="first last">organic cation transporter</p></td></tr><tr><td class="NLM_term">PepT1</td><td class="NLM_def"><p class="first last">peptidase transporter 1</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">protease inhibitor</p></td></tr><tr><td class="NLM_term">PMSF</td><td class="NLM_def"><p class="first last">phenylmethylsulfonyl fluoride</p></td></tr><tr><td class="NLM_term">POM</td><td class="NLM_def"><p class="first last">phosphonooxymethyl</p></td></tr><tr><td class="NLM_term">PPI</td><td class="NLM_def"><p class="first last">proton pump inhibitor</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">QD</td><td class="NLM_def"><p class="first last">quaque die</p></td></tr><tr><td class="NLM_term">rIALP</td><td class="NLM_def"><p class="first last">recombinant intestinal alkaline phosphatase</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">RTV</td><td class="NLM_def"><p class="first last">ritonavir</p></td></tr><tr><td class="NLM_term">UGT1A1</td><td class="NLM_def"><p class="first last">uridine diphosphate glucuronosyltransferase 1A1</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41737" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41737" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 70 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordyce, M.</span></span> <span> </span><span class="NLM_article-title">Current status and prospects of HIV treatment</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.coviro.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=27023283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2nsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=50-56&author=T.+Cihlarauthor=M.+Fordyce&title=Current+status+and+prospects+of+HIV+treatment&doi=10.1016%2Fj.coviro.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and prospects of HIV treatment</span></div><div class="casAuthors">Cihlar, Tomas; Fordyce, Marshall</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">50-56</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Current antiviral treatments can reduce HIV-assocd. morbidity, prolong survival, and prevent HIV transmission.  Combination antiretroviral therapy (cART) contg. preferably three active drugs from two or more classes is required for durable virol. suppression.  Regimen selection is based on virol. efficacy, potential for adverse effects, pill burden and dosing frequency, drug-drug interaction potential, resistance test results, comorbid conditions, social status, and cost.  With prolonged virol. suppression, improved clin. outcomes, and longer survival, patients will be exposed to antiretroviral agents for decades.  Therefore, maximizing the safety and tolerability of cART is a high priority.  Emergence of resistance and/or lack of tolerability in individual patients require availability of a range of treatment options.  Development of new drugs is focused on improving safety (e.g. tenofovir alafenamide) and/or resistance profile (e.g. doravirine) within the existing drug classes, combination therapies with improved adherence (e.g. single-tablet regimens), novel mechanisms of action (e.g. attachment inhibitors, maturation inhibitors, broadly neutralizing antibodies), and treatment simplification with infrequent dosing (e.g. long-acting injectables).  In parallel with cART innovations, research and development efforts focused on agents that target persistent HIV reservoirs may lead to prolonged drug-free remission and HIV cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHDvTzsN1MbVg90H21EOLACvtfcHk0lifWkgj4ZOt6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2nsrw%253D&md5=8f134da24f9491b3b2ac68bf7086de0f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DFordyce%26aufirst%3DM.%26atitle%3DCurrent%2520status%2520and%2520prospects%2520of%2520HIV%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2016%26volume%3D18%26spage%3D50%26epage%3D56%26doi%3D10.1016%2Fj.coviro.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modur, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althoff, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchacz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebo, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korthuis, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napravnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahata, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gange, S. J.</span></span> <span> </span><span class="NLM_article-title">The North American AIDS Collaboration on Research and Design (NA-ACCORD) of leDEA. Closing the Gap: Increases in Life Expectancy Among Treated HIV-Positive Individuals in the United States and Canada</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e81355</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0081355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1371%2Fjournal.pone.0081355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24367482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=H.+Samjiauthor=A.+Cesconauthor=R.+S.+Hoggauthor=S.+P.+Modurauthor=K.+N.+Althoffauthor=K.+Buchaczauthor=A.+N.+Burchellauthor=M.+Cohenauthor=K.+A.+Geboauthor=M.+J.+Gillauthor=A.+Justiceauthor=G.+Kirkauthor=M.+B.+Kleinauthor=P.+T.+Korthuisauthor=J.+Martinauthor=S.+Napravnikauthor=S.+B.+Rourkeauthor=T.+R.+Sterlingauthor=M.+J.+Silverbergauthor=S.+Deeksauthor=L.+P.+Jacobsonauthor=R.+J.+Boschauthor=M.+M.+Kitahataauthor=J.+J.+Goedertauthor=R.+Mooreauthor=S.+J.+Gange&title=The+North+American+AIDS+Collaboration+on+Research+and+Design+%28NA-ACCORD%29+of+leDEA.+Closing+the+Gap%3A+Increases+in+Life+Expectancy+Among+Treated+HIV-Positive+Individuals+in+the+United+States+and+Canada&doi=10.1371%2Fjournal.pone.0081355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada</span></div><div class="casAuthors">Samji, Hasina; Cescon, Angela; Hogg, Robert S.; Modur, Sharada P.; Althoff, Keri N.; Buchacz, Kate; Burchell, Ann N.; Cohen, Mardge; Gebo, Kelly A.; Gill, M. John; Justice, Amy; Kirk, Gregory; Klein, Marina B.; Korthuis, P. Todd; Martin, Jeff; Napravnik, Sonia; Rourke, Sean B.; Sterling, Timothy R.; Silverberg, Michael J.; Deeks, Stephen; Jacobson, Lisa P.; Bosch, Ronald J.; Kitahata, Mari M.; Goedert, James J.; Moore, Richard; Gange, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81355/1-e81355/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Combination antiretroviral therapy (ART) has significantly increased survival among HIV-pos. adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized.  We aim to est. temporal changes in life expectancy among HIV-pos. adults on ART from 2000-2007 in the U.S. and Canada.  Methods: Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART.  Mortality rates were calcd. using participants' person-time from Jan. 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring Dec. 31, 2007.  Life expectancy at age 20, defined as the av. no. of addnl. years that a person of a specific age will live, provided the current age-specific mortality rates remain const., was estd. using abridged life tables.  Results: The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths.  Life expectancy increased from 36.1 [std. error (SE) 0.5] to 51.4 [SE 0.5] years from 2000-2002 to 2006-2007.  Men and women had comparable life expectancies in all periods except the last (2006-2007).  Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3.  Conclusions: A 20-yr-old HIV-pos. adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.  Differences by sex, race, HIV transmission risk group, and CD4 count remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodU0sf4oNl_rVg90H21EOLACvtfcHk0lio67UW1px_Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFelu74%253D&md5=feac75560fc0fb2d4066e4ba09537398</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081355%26sid%3Dliteratum%253Aachs%26aulast%3DSamji%26aufirst%3DH.%26aulast%3DCescon%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DR.%2BS.%26aulast%3DModur%26aufirst%3DS.%2BP.%26aulast%3DAlthoff%26aufirst%3DK.%2BN.%26aulast%3DBuchacz%26aufirst%3DK.%26aulast%3DBurchell%26aufirst%3DA.%2BN.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DGebo%26aufirst%3DK.%2BA.%26aulast%3DGill%26aufirst%3DM.%2BJ.%26aulast%3DJustice%26aufirst%3DA.%26aulast%3DKirk%26aufirst%3DG.%26aulast%3DKlein%26aufirst%3DM.%2BB.%26aulast%3DKorthuis%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DNapravnik%26aufirst%3DS.%26aulast%3DRourke%26aufirst%3DS.%2BB.%26aulast%3DSterling%26aufirst%3DT.%2BR.%26aulast%3DSilverberg%26aufirst%3DM.%2BJ.%26aulast%3DDeeks%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DL.%2BP.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DKitahata%26aufirst%3DM.%2BM.%26aulast%3DGoedert%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520North%2520American%2520AIDS%2520Collaboration%2520on%2520Research%2520and%2520Design%2520%2528NA-ACCORD%2529%2520of%2520leDEA.%2520Closing%2520the%2520Gap%253A%2520Increases%2520in%2520Life%2520Expectancy%2520Among%2520Treated%2520HIV-Positive%2520Individuals%2520in%2520the%2520United%2520States%2520and%2520Canada%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0081355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2849-2878&author=P.+Zhanauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Anti-HIV+Drug+Discovery+and+Development%3A+Current+Innovations+and+Future+Trends&doi=10.1021%2Facs.jmedchem.5b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span></div><div class="casAuthors">Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2849-2878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and addnl. therapeutic agents with novel action modes or targets.  From this perspective, we first review current strategies of antiretroviral drug discovery and optimization, with the aid of selected examples from the recent literature.  We highlight the development of phosphate ester-based prodrugs as a means to improve the aq. soly. of HIV inhibitors, and the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance.  Finally, we discuss future directions for research, including opportunities for exploitation of novel antiretroviral targets, and the strategy of activation of latent HIV reservoirs as a means to eradicate the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sWUJPJgQN7Vg90H21EOLACvtfcHk0lio67UW1px_Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E&md5=de3f5aee273b0dd6f7e84e20410d06d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00497%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAnti-HIV%2520Drug%2520Discovery%2520and%2520Development%253A%2520Current%2520Innovations%2520and%2520Future%2520Trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2849%26epage%3D2878%26doi%3D10.1021%2Facs.jmedchem.5b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prato, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5172</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5172-5208&author=A.+K.+Ghoshauthor=H.+L.+Osswaldauthor=G.+Prato&title=Recent+Progress+in+the+Development+of+HIV-1+Protease+Inhibitors+for+the+Treatment+of+HIV%2FAIDS&doi=10.1021%2Facs.jmedchem.5b01697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.; Prato, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5172-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors continue to play an important role in the treatment of HIV/AIDS, transforming this deadly ailment into a more manageable chronic infection.  Over the years, intensive research has led to a variety of approved protease inhibitors for the treatment of HIV/AIDS.  In this review, we outline current drug design and medicinal chem. efforts toward the development of next-generation protease inhibitors beyond the currently approved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DisuSRbQXbVg90H21EOLACvtfcHk0lio67UW1px_Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D&md5=e0994f3d84ab627d3ac3f757e8d11725</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01697%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26aulast%3DPrato%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520in%2520the%2520Development%2520of%2520HIV-1%2520Protease%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520HIV%252FAIDS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5172%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.5b01697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midde, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patters, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cory, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Investigational Protease Inhibitors as Antiretroviral Therapies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1212837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1080%2F13543784.2016.1212837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1189-1200&author=N.+M.+Middeauthor=B.+J.+Pattersauthor=P.+Raoauthor=T.+J.+Coryauthor=S.+Kumar&title=Investigational+Protease+Inhibitors+as+Antiretroviral+Therapies&doi=10.1080%2F13543784.2016.1212837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1212837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1212837%26sid%3Dliteratum%253Aachs%26aulast%3DMidde%26aufirst%3DN.%2BM.%26aulast%3DPatters%26aufirst%3DB.%2BJ.%26aulast%3DRao%26aufirst%3DP.%26aulast%3DCory%26aufirst%3DT.%2BJ.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DInvestigational%2520Protease%2520Inhibitors%2520as%2520Antiretroviral%2520Therapies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1189%26epage%3D1200%26doi%3D10.1080%2F13543784.2016.1212837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farajallah, A.</span>; <span class="NLM_string-name">Bunch, R. T.</span>; <span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Atazanavir</span>.  <i>Antiviral Drugs</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">New Jersey</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2F9780470929353.ch1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1-17&author=A.+Farajallah&author=R.+T.+Bunch&author=N.+A.+Meanwell&title=Antiviral+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F9780470929353.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470929353.ch1%26sid%3Dliteratum%253Aachs%26aulast%3DFarajallah%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Atazanavir%26btitle%3DAntiviral%2520Drugs%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2011%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugavero, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sax, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landovitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volberding, P. A.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1001/jama.2016.8900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1001%2Fjama.2016.8900" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=191-210&author=H.+F.+G%C3%BCnthardauthor=M.+S.+Saagauthor=C.+A.+Bensonauthor=C.+del+Rioauthor=J.+J.+Eronauthor=J.+E.+Gallantauthor=J.+F.+Hoyauthor=M.+J.+Mugaveroauthor=P.+E.+Saxauthor=M.+A.+Thompsonauthor=R.+T.+Gandhiauthor=R.+J.+Landovitzauthor=D.+M.+Smithauthor=D.+M.+Jacobsenauthor=P.+A.+Volberding&title=Antiretroviral+Drugs+for+Treatment+and+Prevention+of+HIV+Infection+in+Adults%3A+2016+Recommendations+of+the+International+Antiviral+Society-USA+Panel&doi=10.1001%2Fjama.2016.8900"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.8900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.8900%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnthard%26aufirst%3DH.%2BF.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3Ddel%2BRio%26aufirst%3DC.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DGallant%26aufirst%3DJ.%2BE.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DMugavero%26aufirst%3DM.%2BJ.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DGandhi%26aufirst%3DR.%2BT.%26aulast%3DLandovitz%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DJacobsen%26aufirst%3DD.%2BM.%26aulast%3DVolberding%26aufirst%3DP.%2BA.%26atitle%3DAntiretroviral%2520Drugs%2520for%2520Treatment%2520and%2520Prevention%2520of%2520HIV%2520Infection%2520in%2520Adults%253A%25202016%2520Recommendations%2520of%2520the%2520International%2520Antiviral%2520Society-USA%2520Panel%26jtitle%3DJAMA%26date%3D2016%26volume%3D316%26spage%3D191%26epage%3D210%26doi%3D10.1001%2Fjama.2016.8900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span> </span><span class="NLM_article-title">Appendix B, Table 3. Characteristics of Protease Inhibitors</span>. <a href="https://aidsinfo.nih.gov/guidelines/htmltables/1/5482" class="extLink">https://aidsinfo.nih.gov/guidelines/htmltables/1/5482</a> (accessed
March 23, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Appendix+B%2C+Table+3.+Characteristics+of+Protease+Inhibitors.+https%3A%2F%2Faidsinfo.nih.gov%2Fguidelines%2Fhtmltables%2F1%2F5482+%28accessed%0AMarch+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAppendix%2520B%252C%2520Table%25203.%2520Characteristics%2520of%2520Protease%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kis, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zastre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug Interactions</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1064</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0942-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs11095-012-0942-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1050-1064&author=O.+Kisauthor=J.+A.+Zastreauthor=M.+T.+Hoqueauthor=S.+L.+Walmsleyauthor=R.+Bendayan&title=Role+of+Drug+Efflux+and+Uptake+Transporters+in+Atazanavir+Intestinal+Permeability+and+Drug-Drug+Interactions&doi=10.1007%2Fs11095-012-0942-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0942-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0942-y%26sid%3Dliteratum%253Aachs%26aulast%3DKis%26aufirst%3DO.%26aulast%3DZastre%26aufirst%3DJ.%2BA.%26aulast%3DHoque%26aufirst%3DM.%2BT.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DRole%2520of%2520Drug%2520Efflux%2520and%2520Uptake%2520Transporters%2520in%2520Atazanavir%2520Intestinal%2520Permeability%2520and%2520Drug-Drug%2520Interactions%26jtitle%3DPharm.%2520Res.%26date%3D2013%26volume%3D30%26spage%3D1050%26epage%3D1064%26doi%3D10.1007%2Fs11095-012-0942-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, R.</span></span> <span> </span><span class="NLM_article-title">Effect of Low-Dose Omeprazole (20 mg daily) on the Pharmacokinetics of Multiple-Dose Atazanavir with Ritonavir in Healthy Subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1177/0091270010367651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1177%2F0091270010367651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=20457590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=368-377&author=L.+Zhuauthor=A.+Perssonauthor=L.+Mahnkeauthor=T.+Eleyauthor=T.+Liauthor=X.+Xuauthor=S.+Agarwalaauthor=J.+Dragoneauthor=R.+Bertz&title=Effect+of+Low-Dose+Omeprazole+%2820+mg+daily%29+on+the+Pharmacokinetics+of+Multiple-Dose+Atazanavir+with+Ritonavir+in+Healthy+Subjects&doi=10.1177%2F0091270010367651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects</span></div><div class="casAuthors">Zhu, Li; Persson, Anna; Mahnke, Lisa; Eley, Timothy; Li, Tong; Xu, Xiaohui; Agarwala, Sangeeta; Dragone, Jeffrey; Bertz, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Atazanavir, a potent protease inhibitor of human immunodeficiency virus (HIV), exhibits pH-dependent soly.  Previous studies have indicated that coadministration with omeprazole 40 mg once daily significantly decreased atazanavir exposure by approx. 75%.  Concomitant use of omeprazole and atazanavir is currently not recommended.  This study investigated a clin. effective, low dose of omeprazole (20 mg daily) on atazanavir pharmacokinetics in 56 healthy volunteers given atazanavir/ritonavir 300/100 and 400/100 mg once daily.  All atazanavir/ritonavir plus omeprazole combinations resulted in atazanavir area under the concn.-time curve (AUC) and trough concns. (Cmin) comparable to or exceeding those obsd. with atazanavir 400 mg without omeprazole.  Compared with atazanavir/ritonavir 300/100 mg without omeprazole, atazanavir/ritonavir 300/100 mg plus omeprazole reduced atazanavir AUC and Cmin by 42% and 46%, resp.  Increasing the atazanavir/ritonavir dose to 400/100 mg attenuated the effect of omeprazole, resulting in approx. 30% lower atazanavir Cmin, with all individual Cmin values exceeded by greater than 10-fold the population mean protein binding-adjusted EC90 against wild-type HIV.  The effect of omeprazole on atazanavir/ritonavir 400/100 mg was similar whether given 1 h prior to atazanavir/ritonavir or sepd. by 12 h.  No unexpected adverse events were noted.  This study found that omeprazole 20 mg once daily has significantly less profound effects on atazanavir pharmacokinetics than previously obsd. with omeprazole 40 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnkxGQbEYZCLVg90H21EOLACvtfcHk0li-UYmpwPaHyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslCksLk%253D&md5=26a2c81d4aec030986d354b8b500032e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F0091270010367651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010367651%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMahnke%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DAgarwala%26aufirst%3DS.%26aulast%3DDragone%26aufirst%3DJ.%26aulast%3DBertz%26aufirst%3DR.%26atitle%3DEffect%2520of%2520Low-Dose%2520Omeprazole%2520%252820%2520mg%2520daily%2529%2520on%2520the%2520Pharmacokinetics%2520of%2520Multiple-Dose%2520Atazanavir%2520with%2520Ritonavir%2520in%2520Healthy%2520Subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D51%26spage%3D368%26epage%3D377%26doi%3D10.1177%2F0091270010367651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1038/clpt.2014.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fclpt.2014.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24733008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFeqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=266-277&author=L.+Zhangauthor=F.+Wuauthor=S.+C.+Leeauthor=H.+Zhaoauthor=L.+Zhang&title=pH-Dependent+Drug-Drug+Interactions+for+Weak+Base+Drugs%3A+Potential+Implications+for+New+Drug+Development&doi=10.1038%2Fclpt.2014.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development</span></div><div class="casAuthors">Zhang, L.; Wu, F.; Lee, S. C.; Zhao, H.; Zhang, L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">266-277</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Absorption of an orally administered drug with pH-dependent soly. may be altered when it is coadministered with a gastric acid-reducing agent (ARA).  Assessing a drug's potential for pH-dependent drug-drug interactions (DDIs), considering study design elements for such DDI studies, and interpreting and communicating study results in the drug labeling to guide drug dosing are important for drug development.  We collected pertinent information related to new mol. entities approved from Jan. 2003 to May 2013 by the US Food and Drug Administration for which clin. DDI studies with ARAs were performed.  On the basis of assessments of data on pH soly. and in vivo DDIs with ARAs, we proposed a conceptual framework for assessing the need for clin. pH-dependent DDI studies for weak base drugs (WBDs).  Important study design considerations include selection of ARAs and timing of dosing of an ARA relative to the WBD in a DDI study.  Labeling implications for drugs having DDIs with ARAs are also illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3unViZXPrILVg90H21EOLACvtfcHk0lhSxKOzvJNTSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFeqsrs%253D&md5=08cdc41a8f08ebe58dfa3ec62d24bbb6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.87%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DpH-Dependent%2520Drug-Drug%2520Interactions%2520for%2520Weak%2520Base%2520Drugs%253A%2520Potential%2520Implications%2520for%2520New%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D266%26epage%3D277%26doi%3D10.1038%2Fclpt.2014.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Causemaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esslinger, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podsadecki, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span> <span> </span><span class="NLM_article-title">Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1177/0091270007313392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1177%2F0091270007313392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18440920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVGqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=553-562&author=C.+E.+Kleinauthor=Y.-L.+Chiuauthor=Y.+Caiauthor=K.+Beckauthor=K.+R.+Kingauthor=S.+J.+Causemakerauthor=T.+Doanauthor=H.-U.+Esslingerauthor=T.+J.+Podsadeckiauthor=G.+J.+Hanna&title=Effects+of+Acid-Reducing+Agents+on+the+Pharmacokinetics+of+Lopinavir%2FRitonavir+and+Ritonavir-Boosted+Atazanavir&doi=10.1177%2F0091270007313392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir</span></div><div class="casAuthors">Klein, Cheri E.; Chiu, Yi-Lin; Cai, Yan; Beck, Katrin; King, Kathryn R.; Causemaker, Sonja J.; Doan, Thao; Esslinger, Hans-Ulrich; Podsadecki, Thomas J.; Hanna, George J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A total of 71 HIV-neg. healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg once daily (qd) or atazanavir 300 mg + ritonavir 100 mg qd from study days 1 to 15 with a moderate-fat meal.  One hour before breakfast, either omeprazole 40 mg qd was administered on study days 11 through 15, or a single dose of ranitidine 150 mg was administered on study day 11.  Lopinavir, atazanavir, and ritonavir pharmacokinetics were detd. on study days 10, 11, and 15 and compared using point ests. and 90% confidence intervals (CIs).  The point ests. for lopinavir Cmax and AUCτ were in the range of 0.92 to 1.08, with 90% CI contained within the range of 0.80 to 1.25 after coadministration of omeprazole or ranitidine.  The point ests. for atazanavir Cmax and AUCτ were decreased by 48% to 62% with the upper bound of the 90% CI ≤0.55 after coadministration of omeprazole or ranitidine.  The results indicated that lopinavir bioavailability was not affected by the coadministration of omeprazole or ranitidine.  In contrast, atazanavir bioavailability was decreased by 48% to 62% when coadministered with ritonavir and either omeprazole or ranitidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2f0nv0c5je7Vg90H21EOLACvtfcHk0lhSxKOzvJNTSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVGqsb8%253D&md5=ac4c7748d69adbe54169aa8241f0acad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F0091270007313392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007313392%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DC.%2BE.%26aulast%3DChiu%26aufirst%3DY.-L.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DBeck%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DK.%2BR.%26aulast%3DCausemaker%26aufirst%3DS.%2BJ.%26aulast%3DDoan%26aufirst%3DT.%26aulast%3DEsslinger%26aufirst%3DH.-U.%26aulast%3DPodsadecki%26aufirst%3DT.%2BJ.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26atitle%3DEffects%2520of%2520Acid-Reducing%2520Agents%2520on%2520the%2520Pharmacokinetics%2520of%2520Lopinavir%252FRitonavir%2520and%2520Ritonavir-Boosted%2520Atazanavir%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D553%26epage%3D562%26doi%3D10.1177%2F0091270007313392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Atazanavir-Containing Antiretroviral Regimens, With or Without Ritonavir, in Patients Who Are HIV-Positive and Treatment-Naive</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1002/phar.1205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fphar.1205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23456732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=284-294&author=R.+J.+Bertzauthor=A.+Perssonauthor=E.+Chungauthor=L.+Zhuauthor=J.+Zhangauthor=D.+McGrathauthor=D.+Grasela&title=Pharmacokinetics+and+Pharmacodynamics+of+Atazanavir-Containing+Antiretroviral+Regimens%2C+With+or+Without+Ritonavir%2C+in+Patients+Who+Are+HIV-Positive+and+Treatment-Naive&doi=10.1002%2Fphar.1205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naive</span></div><div class="casAuthors">Bertz, Richard J.; Persson, Anna; Chung, Ellen; Zhu, Li; Zhang, Jenny; McGrath, Donnie; Grasela, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Objective. To investigate the pharmacokinetic and pharmacodynamic relationships of the human immunodeficiency virus (HIV)-protease inhibitor atazanavir (ATV) in the presence and absence of the pharmacokinetic booster ritonavir, utilizing ATV plasma trough concns. (Ctrough) and clin. biomarkers of antiviral efficacy and safety over 48 wk.  Design. Randomized, open-label, multicenter, study designed to compare the efficacy and safety of ATV 300 mg plus ritonavir 100 mg (ATV300/r) with that of ATV 400 mg (ATV400).  Setting. Thirty clinic sites across 10 countries in Africa, Europe, North America, and South America.  Patients. Patients who were HIV-pos. and treatment-naive.  Interventions. Randomized to once-daily ATV400 (105 patients) or ATV300/r (95 patients) plus lamivudine and extended-release stavudine.  Measurements and Main Results. The Ctrough approx. 24 h after the prior unobserved dose was measured through week 48.  Composite Ctrough (i.e., the geometric mean of all trough concns. over the 48 wk), population inhibitory quotient ([IQ], i.e., Ctrough divided population estd. protein binding adjusted effective concn. at 90% [EC90, 14 ng/mL]), composite population IQ (i.e., ATV composite trough divided by population estd. protein binding adjusted EC90), HIV RNA, CD4 cell counts, and metabolic and safety parameters were also assessed.  For ATV400 and ATV300/r, resp., geometric mean composite Ctrough (CV%) were 127 (106) ng/mL and 670 (63) ng/mL, geometric mean composite population IQ were 9 and 48, and composite Ctrough values of HIV EC90 or more were achieved in 98% and 100% of patients.  High ATV Ctrough was assocd. with low HIV RNA at week 48; however, 88% of patients had HIV RNA less than 400 copies/mL in the lowest composite Ctrough quartile.  There was no clear relationship between ATV Ctrough and changes in CD4 cell count.  Increases in total bilirubin or jaundice were assocd. with higher Ctrough.  Modest increases in triglycerides and cholesterol were assocd. with the addn. of ritonavir.  Conclusion. ATV-contg. regimens with or without ritonavir achieved ATV exposures that provide robust antiretroviral efficacy and acceptable tolerability in treatment-naive patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw5YndphA5LLVg90H21EOLACvtfcHk0lhSxKOzvJNTSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFKgu78%253D&md5=4f3b45514c9157203f76f8911aada1a0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fphar.1205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1205%26sid%3Dliteratum%253Aachs%26aulast%3DBertz%26aufirst%3DR.%2BJ.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMcGrath%26aufirst%3DD.%26aulast%3DGrasela%26aufirst%3DD.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Atazanavir-Containing%2520Antiretroviral%2520Regimens%252C%2520With%2520or%2520Without%2520Ritonavir%252C%2520in%2520Patients%2520Who%2520Are%2520HIV-Positive%2520and%2520Treatment-Naive%26jtitle%3DPharmacotherapy%26date%3D2013%26volume%3D33%26spage%3D284%26epage%3D294%26doi%3D10.1002%2Fphar.1205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furfine, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studenberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaltenstein, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1128/aac.48.3.791-798.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1128%2Faac.48.3.791-798.2004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=791-798&author=E.+S.+Furfineauthor=C.+T.+Bakerauthor=M.+R.+Haleauthor=D.+J.+Reynoldsauthor=J.+A.+Salisburyauthor=A.+D.+Searleauthor=S.+D.+Studenbergauthor=D.+Toddauthor=R.+D.+Tungauthor=A.+Spaltenstein&title=Preclinical+Pharmacology+and+Pharmacokinetics+of+GW433908%2C+a+Water-Soluble+Prodrug+of+the+Human+Immunodeficiency+Virus+Protease+Inhibitor+Amprenavir&doi=10.1128%2Faac.48.3.791-798.2004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1128%2Faac.48.3.791-798.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Faac.48.3.791-798.2004%26sid%3Dliteratum%253Aachs%26aulast%3DFurfine%26aufirst%3DE.%2BS.%26aulast%3DBaker%26aufirst%3DC.%2BT.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSalisbury%26aufirst%3DJ.%2BA.%26aulast%3DSearle%26aufirst%3DA.%2BD.%26aulast%3DStudenberg%26aufirst%3DS.%2BD.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DSpaltenstein%26aufirst%3DA.%26atitle%3DPreclinical%2520Pharmacology%2520and%2520Pharmacokinetics%2520of%2520GW433908%252C%2520a%2520Water-Soluble%2520Prodrug%2520of%2520the%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Inhibitor%2520Amprenavir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D791%26epage%3D798%26doi%3D10.1128%2Faac.48.3.791-798.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grampovnik, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flosi, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span> <span> </span><span class="NLM_article-title">Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2964</span>– <span class="NLM_lpage">2970</span>, <span class="refDoi"> DOI: 10.1021/jm900080g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900080g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2964-2970&author=D.+A.+DeGoeyauthor=D.+J.+Grampovnikauthor=W.+J.+Flosiauthor=K.+C.+Marshauthor=X.+C.+Wangauthor=L.+L.+Kleinauthor=K.+F.+McDanielauthor=Y.+Liuauthor=M.+A.+Longauthor=W.+M.+Katiauthor=A.+Mollaauthor=D.+J.+Kempf&title=Water-Soluble+Prodrugs+of+the+Human+Immunodeficiency+Virus+Protease+Inhibitors+Lopinavir+and+Ritonavir&doi=10.1021%2Fjm900080g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir</span></div><div class="casAuthors">DeGoey, David A.; Grampovnik, David J.; Flosi, William J.; Marsh, Kennan C.; Wang, Xiu C.; Klein, Larry L.; McDaniel, Keith F.; Liu, Yaya; Long, Michelle A.; Kati, Warren M.; Molla, Akhteruzzaman; Kempf, Dale J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2964-2970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We studied the synthesis, cleavage rates, and oral administration of prodrugs of the HIV protease inhibitors (PIs) lopinavir and ritonavir.  Phosphate esters attached directly to the central hydroxyl groups of these PIs did not demonstrate enzyme-mediated cleavage in vitro and did not provide measurable plasma levels of the parent drugs in vivo.  However, oxymethylphosphate (OMP) and oxyethylphosphate (OEP) prodrugs provided improved rates of cleavage, high levels of aq. soly., and high plasma levels of the parent drugs when dosed orally in rats and dogs.  Dosing unformulated capsules contg. the solid prodrugs led to plasma levels equiv. to those obsd. for dosing formulated solns. of the parent drugs.  A direct synthetic process for the prepn. of OMP and OEP prodrugs was developed, and the improved synthetic method may be applicable to the prepn. of analogous sol. prodrugs of other drug classes with limited soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeiB07ekQMJ7Vg90H21EOLACvtfcHk0ljC47s6I2n96A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFeltLs%253D&md5=6e64ddfeabd5725929cac142bdfe782d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900080g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900080g%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DGrampovnik%26aufirst%3DD.%2BJ.%26aulast%3DFlosi%26aufirst%3DW.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BC.%26aulast%3DKlein%26aufirst%3DL.%2BL.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DM.%2BA.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26atitle%3DWater-Soluble%2520Prodrugs%2520of%2520the%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Inhibitors%2520Lopinavir%2520and%2520Ritonavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2964%26epage%3D2970%26doi%3D10.1021%2Fjm900080g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annadurai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span> <span> </span><span class="NLM_article-title">Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4176</span>– <span class="NLM_lpage">4188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00277</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00277" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4176-4188&author=M.+A.+M.+Subbaiahauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=L.+Subramaniauthor=M.+Annaduraiauthor=T.+Ramarauthor=S.+D.+Desaiauthor=S.+Sinhaauthor=M.+Subramanianauthor=S.+Mandlekarauthor=S.+Sridharauthor=S.+Padmanabhanauthor=P.+Bhutaniauthor=R.+Arlaauthor=S.+M.+Jenkinsauthor=M.+R.+Krystalauthor=C.+Wangauthor=R.+Sarabu&title=Coupling+of+an+Acyl+Migration+Prodrug+Strategy+with+Bio-activation+To+Improve+Oral+Delivery+of+the+HIV-1+Protease+Inhibitor+Atazanavir&doi=10.1021%2Facs.jmedchem.8b00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir</span></div><div class="casAuthors">Subbaiah, Murugaiah A. M.; Meanwell, Nicholas A.; Kadow, John F.; Subramani, Lakshumanan; Annadurai, Mathiazhagan; Ramar, Thangeswaran; Desai, Salil D.; Sinha, Sarmistha; Subramanian, Murali; Mandlekar, Sandhya; Sridhar, Srikanth; Padmanabhan, Shweta; Bhutani, Priyadeep; Arla, Rambabu; Jenkins, Susan M.; Krystal, Mark R.; Wang, Chunfu X.; Sarabu, Ramakanth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4176-4188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors (PIs), which include atazanavir (ATV, 1), remain important medicines to treat HIV-1 infection.  However, they are characterized by poor oral bioavailability and a need for boosting with a pharmacokinetic enhancer, which results in addnl. drug-drug interactions that are sometimes difficult to manage.  We investigated a chemo-activated, acyl migration-based prodrug design approach to improve the pharmacokinetic profile of 1 but failed to obtain improved oral bioavailability over dosing the parent drug in rats.  This strategy was refined by conjugating the amine with a promoiety designed to undergo bio-activation, as a means of modulating the subsequent chemo-activation.  This culminated in a lead prodrug that (1) yielded substantially better oral drug delivery of 1 when compared to the parent itself, the simple acyl migration-based prodrug, and the corresponding simple L-Val prodrug, (2) acted as a depot which resulted in a sustained release of the parent drug in vivo, and (3) offered the benefit of mitigating the pH-dependent absorption assocd. with 1, thereby potentially reducing the risk of decreased bioavailability with concurrent use of stomach-acid-reducing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHg6TEf3Z8rVg90H21EOLACvtfcHk0ljC47s6I2n96A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOhu74%253D&md5=eba90dbf8098b7062b869684569217cc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00277%26sid%3Dliteratum%253Aachs%26aulast%3DSubbaiah%26aufirst%3DM.%2BA.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DSubramani%26aufirst%3DL.%26aulast%3DAnnadurai%26aufirst%3DM.%26aulast%3DRamar%26aufirst%3DT.%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DBhutani%26aufirst%3DP.%26aulast%3DArla%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSarabu%26aufirst%3DR.%26atitle%3DCoupling%2520of%2520an%2520Acyl%2520Migration%2520Prodrug%2520Strategy%2520with%2520Bio-activation%2520To%2520Improve%2520Oral%2520Delivery%2520of%2520the%2520HIV-1%2520Protease%2520Inhibitor%2520Atazanavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4176%26epage%3D4188%26doi%3D10.1021%2Facs.jmedchem.8b00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Website: Atazanavir Documents</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf</a> (accessed June 09, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=FDA&title=Website%3A+Atazanavir+Documents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWebsite%253A%2520Atazanavir%2520Documents%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokulgandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.3390/ph7040433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2Fph7040433" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=433-452&author=M.+Patelauthor=N.+Mandavaauthor=M.+Gokulgandhiauthor=D.+Palauthor=A.+Mitra&title=Amino+Acid+Prodrugs%3A+An+Approach+to+Improve+the+Absorption+of+HIV-1+Protease+Inhibitor%2C+Lopinavir&doi=10.3390%2Fph7040433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3390%2Fph7040433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph7040433%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMandava%26aufirst%3DN.%26aulast%3DGokulgandhi%26aufirst%3DM.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%26atitle%3DAmino%2520Acid%2520Prodrugs%253A%2520An%2520Approach%2520to%2520Improve%2520the%2520Absorption%2520of%2520HIV-1%2520Protease%2520Inhibitor%252C%2520Lopinavir%26jtitle%3DPharmaceuticals%26date%3D2014%26volume%3D7%26spage%3D433%26epage%3D452%26doi%3D10.3390%2Fph7040433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Interaction of Dipeptide Prodrugs of Saquinavir with Multidrug Resistance Protein-2 (MRP-2): Evasion of MRP-2 Mediated Efflux</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2008.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18620036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGjsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2008&pages=44-51&author=R.+Jainauthor=S.+Agarwalauthor=N.+K.+Mandavaauthor=Y.+Shengauthor=A.+K.+Mitra&title=Interaction+of+Dipeptide+Prodrugs+of+Saquinavir+with+Multidrug+Resistance+Protein-2+%28MRP-2%29%3A+Evasion+of+MRP-2+Mediated+Efflux&doi=10.1016%2Fj.ijpharm.2008.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): Evasion of MRP-2 mediated efflux</span></div><div class="casAuthors">Jain, Ritesh; Agarwal, Sheetal; Mandava, Nanda Kishore; Sheng, Ye; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">44-51</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Saquinavir (SQV), the first protease inhibitor approved by FDA to treat HIV-1 infection.  This drug is a well-known substrate for multidrug resistance protein-2 (MRP-2).  The objective of this study was to investigate whether derivatization of SQV to dipeptide prodrugs, valine-valine-saquinavir (Val-Val-SQV) and glycine-valine-saquinavir (Gly-Val-SQV), targeting peptide transporter can circumvent MRP-2 mediated efflux.  Uptake and transport studies were carried out across MDCKII-MRP2 cell monolayers to investigate the interaction of SQV and its prodrugs with MRP-2.  In situ single pass intestinal perfusion expts. in rat jejunum were performed to calc. intestinal absorption rate consts. and permeabilities of SQV, Val-Val-SQV and Gly-Val-SQV.  Uptake studies demonstrated that the prodrugs have significantly lower interaction with MRP-2 relative to SQV.  Transepithelial transport of Val-Val-SQV and Gly-Val-SQV across MDCKII-MRP2 cells exhibited an enhanced absorptive flux and reduced secretory flux as compared to SQV.  Intestinal perfusion studies revealed that synthesized prodrugs have higher intestinal permeabilities relative to SQV.  Enhanced absorption of Val-Val-SQV and Gly-Val-SQV relative to SQV can be attributed to their translocation by the peptide transporter in the jejunum.  In the presence of MK-571, a MRP family inhibitor, there was a significant increase in the permeabilities of SQV and Gly-Val-SQV indicating that these compds. are probably substrates for MRP-2.  However, there was no change in the permeability of Val-Val-SQV with MK-571 indicating lack of any interaction of Val-Val-SQV with MRP-2.  In conclusion, peptide transporter targeted prodrug modification of MRP-2 substrates may lead to shielding of these drug mols. from MRP-2 efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB0DXWIBhdRbVg90H21EOLACvtfcHk0ljzHak0-3RSsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGjsL3P&md5=99ce56ebbefb0dc21cf9ee8d3458246b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DMandava%26aufirst%3DN.%2BK.%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DInteraction%2520of%2520Dipeptide%2520Prodrugs%2520of%2520Saquinavir%2520with%2520Multidrug%2520Resistance%2520Protein-2%2520%2528MRP-2%2529%253A%2520Evasion%2520of%2520MRP-2%2520Mediated%2520Efflux%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D362%26spage%3D44%26epage%3D51%26doi%3D10.1016%2Fj.ijpharm.2008.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvvuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Intestinal Absorption of Novel-Dipeptide Prodrugs of Saquinavir in Rats</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2006.11.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2006.11.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=17207946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFWqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2007&pages=233-240&author=R.+Jainauthor=S.+Duvvuriauthor=V.+Kansaraauthor=N.+K.+Mandavaauthor=A.+K.+Mitra&title=Intestinal+Absorption+of+Novel-Dipeptide+Prodrugs+of+Saquinavir+in+Rats&doi=10.1016%2Fj.ijpharm.2006.11.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats</span></div><div class="casAuthors">Jain, Ritesh; Duvvuri, Sridhar; Kansara, Viral; Mandava, Nanda Kishore; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-240</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Saquinavir (SQV) was the first human immunovirus-1 (HIV-1) protease inhibitor approved by FDA.  However, P-glycoprotein (P-gp), an efflux pump limits its oral and brain bioavailabilities.  The objective of this study was to investigate whether prodrug modification of SQV to dipeptide prodrugs Valine-Valine-Saquinavir (Val-Val-SQV) and Glycine-Valine-Saquinavir (Gly-Val-SQV) targeting intestinal peptide transporter can enhance intestinal permeability of SQV by circumventing P-gp mediated efflux.  Single pass intestinal perfusion expts. in rat jejunum were performed to calc. the absorption rate const. and intestinal permeability of SQV, Val-Val-SQV and Gly-Val-SQV.  Equimolar concn. (25 μM) of SQV, Val-Val-SQV and Gly-Val-SQV were employed in the perfusion studies.  Perfusion expts. were also carried out in the presence of cyclosporine (10 μM) and glycyl-sarcosine (20 mM).  Absorption rate consts. in rat jejunum (ka) for SQV, Val-Val-SQV and Gly-Val-SQV were found to be 14.1±3.4 × 10-3, 65.8±4.3 × 10-3, and 25.6±5.7 × 10-3 min-1, resp.  Enhanced absorption of Val-Val-SQV and Gly-Val-SQV relative to SQV can be attributed to their translocation by the peptide transporter in the jejunum.  Significant permeability enhancement of SQV across rat jejunum was obsd. in the presence of cyclosporine 10 μM (P-gp inhibitor).  However, permeability of Val-Val-SQV was unchanged in the presence of cyclosporine suggesting lack of any interaction of the prodrug with efflux pump.  Intestinal absorption of Val-Val-SQV was significantly inhibited in the presence of gly-sar indicating the involvement of peptide transporter in intestinal absorption.  In conclusion, peptide transporter targeted prodrug modification of P-gp substrates could lead to shielding of these drug mols. from efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCQlWPmIAp7Vg90H21EOLACvtfcHk0ljzHak0-3RSsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFWqur4%253D&md5=4dd0fadb9e584c506d43696afa24cc98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2006.11.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2006.11.058%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DDuvvuri%26aufirst%3DS.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DMandava%26aufirst%3DN.%2BK.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DIntestinal%2520Absorption%2520of%2520Novel-Dipeptide%2520Prodrugs%2520of%2520Saquinavir%2520in%2520Rats%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2007%26volume%3D336%26spage%3D233%26epage%3D240%26doi%3D10.1016%2Fj.ijpharm.2006.11.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiso, Y.</span></span> <span> </span><span class="NLM_article-title">Water-Soluble Prodrugs of Dipeptide HIV Protease Inhibitors Based on O→N Intramolecular Acyl Migration: Design, Synthesis and Kinetic Study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2003.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.bmc.2003.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=159-170&author=Y.+Hamadaauthor=H.+Matsumotoauthor=S.+Yamaguchiauthor=T.+Kimuraauthor=Y.+Hayashiauthor=Y.+Kiso&title=Water-Soluble+Prodrugs+of+Dipeptide+HIV+Protease+Inhibitors+Based+on+O%E2%86%92N+Intramolecular+Acyl+Migration%3A+Design%2C+Synthesis+and+Kinetic+Study&doi=10.1016%2Fj.bmc.2003.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DKiso%26aufirst%3DY.%26atitle%3DWater-Soluble%2520Prodrugs%2520of%2520Dipeptide%2520HIV%2520Protease%2520Inhibitors%2520Based%2520on%2520O%25E2%2586%2592N%2520Intramolecular%2520Acyl%2520Migration%253A%2520Design%252C%2520Synthesis%2520and%2520Kinetic%2520Study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D159%26epage%3D170%26doi%3D10.1016%2Fj.bmc.2003.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span> <span> </span><span class="NLM_article-title">Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline</span>. <i>Curr. Opin. Investig. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=384-390&author=A.+H.+Corbettauthor=A.+D.+Kashuba&title=Fosamprenavir.+Vertex+Pharmaceuticals%2FGlaxoSmithKline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorbett%26aufirst%3DA.%2BH.%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26atitle%3DFosamprenavir.%2520Vertex%2520Pharmaceuticals%252FGlaxoSmithKline%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D384%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Design Strategies in the Prodrugs of HIV-1 Protease Inhibitors to Improve the Pharmaceutical Properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2017.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28865281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=865-883&author=M.+A.+M.+Subbaiahauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Design+Strategies+in+the+Prodrugs+of+HIV-1+Protease+Inhibitors+to+Improve+the+Pharmaceutical+Properties&doi=10.1016%2Fj.ejmech.2017.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties</span></div><div class="casAuthors">Subbaiah, Murugaiah A. M.; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">865-883</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Combination antiretroviral therapy (cART) is currently the most effective treatment for HIV-1 infection.  HIV-1 protease inhibitors (PIs) are an important component of some regimens of cART.  However, PIs are known for sub-optimal ADME properties, resulting in poor oral bioavailability.  This often necessitates high drug doses, combination with pharmacokinetic enhancers and/or special formulations in order to effectively deliver PIs, which may lead to a high pill burden and reduced patient compliance.  As a remedy, improving the ADME properties of existing drugs via prodrug and other approaches has been pursued in addn. to the development of next generation PIs with improved pharmacokinetic, resistance and side effect profiles.  Phosphate prodrugs have been explored to address the soly.-limiting absorption and high excipient load.  Prodrug design to target carrier-mediated drug delivery has also been explored.  Amino acid prodrugs have been shown to improve permeability by engaging active transport mechanisms, reduce efflux and mitigate first pass metab. while acyl migration prodrugs have been shown to improve soly.  Prodrug design efforts have led to the identification of one marketed agent, fosamprenavir, and clin. studies with two other prodrugs.  Several of the reported approaches lack detailed in vivo characterization and hence the potential preclin. or clin. benefits of these approaches are yet to be fully detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXFlPJppF87Vg90H21EOLACvtfcHk0lgFn4XFdJ8LLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7vP&md5=89e387c7e8056efc76e6bbcb39f2745b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DSubbaiah%26aufirst%3DM.%2BA.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDesign%2520Strategies%2520in%2520the%2520Prodrugs%2520of%2520HIV-1%2520Protease%2520Inhibitors%2520to%2520Improve%2520the%2520Pharmaceutical%2520Properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D865%26epage%3D883%26doi%3D10.1016%2Fj.ejmech.2017.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span>; <span class="NLM_string-name">Tung, R. D.</span></span> <span> </span><span class="NLM_article-title">Azapeptide Derivatives</span>. U.S. Patent <span class="NLM_patent">8,158,805 B2</span>, Apr 17, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+L.+Harbeson&author=R.+D.+Tung&title=Azapeptide+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26atitle%3DAzapeptide%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span> </span><span class="NLM_article-title">Concert Pharmaceuticals,
Inc.’s Patent Owner Preliminary Response</span>. <a href="https://www.concertpharma.com/wp-content/uploads/2017/07/Concert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf" class="extLink">https://www.concertpharma.com/wp-content/uploads/2017/07/Concert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf</a> (accessed Oct 6, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Concert+Pharmaceuticals%2C%0AInc.%E2%80%99s+Patent+Owner+Preliminary+Response.+https%3A%2F%2Fwww.concertpharma.com%2Fwp-content%2Fuploads%2F2017%2F07%2FConcert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf+%28accessed+Oct+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DConcert%2520Pharmaceuticals%252C%250AInc.%25E2%2580%2599s%2520Patent%2520Owner%2520Preliminary%2520Response%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clas, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nofsinger, R.</span></span> <span> </span><span class="NLM_article-title">Chemistry-enabled drug delivery (prodrugs): recent progress and challenges</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.drudis.2013.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23993918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKks7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=79-87&author=S.-D.+Clasauthor=R.+I.+Sanchezauthor=R.+Nofsinger&title=Chemistry-enabled+drug+delivery+%28prodrugs%29%3A+recent+progress+and+challenges&doi=10.1016%2Fj.drudis.2013.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry-enabled drug delivery (prodrugs): recent progress and challenges</span></div><div class="casAuthors">Clas, Sophie-Dorothee; Sanchez, Rosa I.; Nofsinger, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prodrugs can be used to enhance the properties of an active pharmaceutical ingredient or drug, generally by improving soly. and/or permeability of the compd.  However, discovery teams duly spend considerable time and resources on structure-activity optimization and formulation-enabled drug delivery technologies to achieve the target exposures and biopharmaceutical properties, when early implementation of prodrugs could lead to an improved drug mol.  The goal of this review is to provide an overview of the achievements during the past few years in developing prodrugs and highlighting the challenges of following this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1m5igWvkrd7Vg90H21EOLACvtfcHk0lgFn4XFdJ8LLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKks7%252FE&md5=5cb21edde8503992ffd6e990bfb7361c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DClas%26aufirst%3DS.-D.%26aulast%3DSanchez%26aufirst%3DR.%2BI.%26aulast%3DNofsinger%26aufirst%3DR.%26atitle%3DChemistry-enabled%2520drug%2520delivery%2520%2528prodrugs%2529%253A%2520recent%2520progress%2520and%2520challenges%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D79%26epage%3D87%26doi%3D10.1016%2Fj.drudis.2013.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kärkkäinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, K. B.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - Recent Approvals and a Glimpse of the Pipeline</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejps.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28782609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCltL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=146-161&author=J.+Rautioauthor=J.+K%C3%A4rkk%C3%A4inenauthor=K.+B.+Sloan&title=Prodrugs+-+Recent+Approvals+and+a+Glimpse+of+the+Pipeline&doi=10.1016%2Fj.ejps.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - Recent approvals and a glimpse of the pipeline</span></div><div class="casAuthors">Rautio, Jarkko; Karkkainen, Jussi; Sloan, Kenneth B.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">146-161</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prodrugs offer a versatile strategy to overcome flaws of viable drug candidates or clin. approved drugs.  However, the strategic importance of prodrugs in the pharmaceutical industry has often been challenged, and prodrugs are often considered as the last option after lead optimization and when the selected drug candidate has faced significant pharmaceutical and pharmacokinetic limitations.  Based on recent success in marketed drugs, prodrug strategy should clearly be considered already in early stages of lead optimization.  During the past five years or so, prodrugs have accounted for about 10% of all small mol. wt. drugs that have come to the market.  In 2015 alone, the FDA approved seven prodrugs, which gives a prodrug prevalence of over 20% among the small mols. or over 15% among the total amt. of the FDA approved drugs that year.  A great no. of various prodrugs are also undergoing late stage clin. trials.  The pharmaceutical industry will therefore continue to depend on prodrugs for the foreseeable future.  In this review, we will present the state of the art in the design of the prodrugs launched by the FDA since 2015.  We will also provide an overview of some interesting late stage clin. prodrug candidates.  We hope this review will demonstrate potential of prodrug strategies and facilitates the use of prodrugs in drug discovery projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLKCLtvVGvnrVg90H21EOLACvtfcHk0lgFn4XFdJ8LLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCltL3I&md5=2b46aa04e046ad089828ca95e40762a3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DK%25C3%25A4rkk%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DSloan%26aufirst%3DK.%2BB.%26atitle%3DProdrugs%2520-%2520Recent%2520Approvals%2520and%2520a%2520Glimpse%2520of%2520the%2520Pipeline%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D109%26spage%3D146%26epage%3D161%26doi%3D10.1016%2Fj.ejps.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walther, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelikin, A. N.</span></span> <span> </span><span class="NLM_article-title">Prodrugs in Medicinal Chemistry and Enzyme Prodrug Therapies</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.addr.2017.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28676386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=65-77&author=R.+Waltherauthor=J.+Rautioauthor=A.+N.+Zelikin&title=Prodrugs+in+Medicinal+Chemistry+and+Enzyme+Prodrug+Therapies&doi=10.1016%2Fj.addr.2017.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs in medicinal chemistry and enzyme prodrug therapies</span></div><div class="casAuthors">Walther, Raoul; Rautio, Jarkko; Zelikin, Alexander N.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prodrugs are cunning derivs. of therapeutic agents designed to improve the pharmacokinetics profile of the drug.  Within a prodrug, pharmacol. activity of the drug is masked and is recovered within the human body upon bioconversion of the prodrug, a process that is typically mediated by enzymes.  This concept is highly successful and a significant fraction of marketed therapeutic formulations is based on prodrugs.  An advanced subset of prodrugs can be engineered such as to achieve site-specific bioconversion of the prodrug - to comprise the highly advantageous "enzyme prodrug therapy", EPT.  Design of prodrugs for EPT is similar to the prodrugs in general medicinal use in that the pharmacol. activity of the drug is masked, but differs significantly in that site-specific bioconversion is a prime consideration, and the enzymes typically used for EPT are non-mammalian and/or with low systemic abundance in the human body.  This review focuses on the design of prodrugs for EPT in terms of the choice of an enzyme and the corresponding prodrug for bioconversion.  We also discuss the recent success of "self immolative linkers" which significantly empower and diversify the prodrug design, and present methodologies for the design of prodrugs with extended blood residence time.  The review aims to be of specific interest for medicinal chemists, biomedical engineers, and pharmaceutical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocjq5rReX-uLVg90H21EOLACvtfcHk0lgFn4XFdJ8LLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiur7P&md5=38f4eda3c05eb3c3917410e695749761</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DWalther%26aufirst%3DR.%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DZelikin%26aufirst%3DA.%2BN.%26atitle%3DProdrugs%2520in%2520Medicinal%2520Chemistry%2520and%2520Enzyme%2520Prodrug%2520Therapies%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D118%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.addr.2017.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M. J.</span></span> <span> </span><span class="NLM_article-title">The Expanding Role of Prodrugs in Contemporary Drug Design and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+J.+Hageman&title=The+Expanding+Role+of+Prodrugs+in+Contemporary+Drug+Design+and+Development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0lhyk-ohTiFRKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Expanding%2520Role%2520of%2520Prodrugs%2520in%2520Contemporary%2520Drug%2520Design%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder Tagore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anumula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmaiah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. P. B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallipatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramarao, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of Rat Intestinal Alkaline Phosphatase - Role of Crown Domain in Mammalian Alkaline Phosphatases</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.jsb.2013.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2013&pages=182-192&author=K.+Ghoshauthor=D.+Mazumder+Tagoreauthor=R.+Anumulaauthor=B.+Lakshmaiahauthor=P.+P.+B.+S.+Kumarauthor=S.+Singaramauthor=T.+Matanauthor=S.+Kallipattiauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=M.+Ramarao&title=Crystal+Structure+of+Rat+Intestinal+Alkaline+Phosphatase+-+Role+of+Crown+Domain+in+Mammalian+Alkaline+Phosphatases&doi=10.1016%2Fj.jsb.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMazumder%2BTagore%26aufirst%3DD.%26aulast%3DAnumula%26aufirst%3DR.%26aulast%3DLakshmaiah%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DP.%2BP.%2BB.%2BS.%26aulast%3DSingaram%26aufirst%3DS.%26aulast%3DMatan%26aufirst%3DT.%26aulast%3DKallipatti%26aufirst%3DS.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DRamarao%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520Rat%2520Intestinal%2520Alkaline%2520Phosphatase%2520-%2520Role%2520of%2520Crown%2520Domain%2520in%2520Mammalian%2520Alkaline%2520Phosphatases%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D184%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.jsb.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruchury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratap Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katnapally, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoganand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmaiah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder Tagore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span> <span> </span><span class="NLM_article-title">Characterization of Recombinantly Expressed Rat and Monkey Intestinal Alkaline Phosphatases: In Vitro Studies and In Vivo Correlations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.051987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.113.051987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1425-1432&author=M.+Subramanianauthor=S.+Paruchuryauthor=S.+Pratap+Singhauthor=R.+Arlaauthor=S.+Pahwaauthor=S.+Janaauthor=P.+Katnapallyauthor=V.+Yoganandauthor=B.+Lakshmaiahauthor=D.+Mazumder+Tagoreauthor=K.+Ghoshauthor=P.+Maratheauthor=S.+Mandlekar&title=Characterization+of+Recombinantly+Expressed+Rat+and+Monkey+Intestinal+Alkaline+Phosphatases%3A+In+Vitro+Studies+and+In+Vivo+Correlations&doi=10.1124%2Fdmd.113.051987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.051987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.051987%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DParuchury%26aufirst%3DS.%26aulast%3DPratap%2BSingh%26aufirst%3DS.%26aulast%3DArla%26aufirst%3DR.%26aulast%3DPahwa%26aufirst%3DS.%26aulast%3DJana%26aufirst%3DS.%26aulast%3DKatnapally%26aufirst%3DP.%26aulast%3DYoganand%26aufirst%3DV.%26aulast%3DLakshmaiah%26aufirst%3DB.%26aulast%3DMazumder%2BTagore%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMandlekar%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Recombinantly%2520Expressed%2520Rat%2520and%2520Monkey%2520Intestinal%2520Alkaline%2520Phosphatases%253A%2520In%2520Vitro%2520Studies%2520and%2520In%2520Vivo%2520Correlations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1425%26epage%3D1432%26doi%3D10.1124%2Fdmd.113.051987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloysius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.-q.</span></span> <span> </span><span class="NLM_article-title">Enzyme-Mediated Hydrolytic Activation of Prodrugs</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.apsb.2011.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyns73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=143-159&author=Y.-h.+Yangauthor=H.+Aloysiusauthor=D.+Inoyamaauthor=Y.+Chenauthor=L.-q.+Hu&title=Enzyme-Mediated+Hydrolytic+Activation+of+Prodrugs&doi=10.1016%2Fj.apsb.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme-mediated hydrolytic activation of prodrugs</span></div><div class="casAuthors">Yang, Yan-Hui; Aloysius, Herve; Inoyama, Daigo; Chen, Yu; Hu, Long-qin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-159</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Prodrug design is an important part of drug discovery.  Prodrugs can offer many advantages over parent drugs such as increased soly., enhanced stability, improved bioavailability, reduced side effects and better selectivity.  Many prodrugs have been used successfully in the clinic; examples include oseltamivir in anti-influenza therapy, enalapril in anti-hypertension therapy, capecitabine in cancer therapy and omeprazole in the treatment of peptic ulcer.  A key step in prodrug design is the incorporation of an activation mechanism that can convert the prodrug into the active species in an efficient and/or controlled manner to meet the needs of a given medical application.  Prodrug activation can be achieved through enzyme-mediated hydrolytic or oxido-reductive processes while activation of some prodrugs may proceed through pure chem. nonenzymic processes.  This review focuses on the hydrolytic enzymes that have been used in prodrug activation, including transferases, hydrolases and lyases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrT-fkNcjO57Vg90H21EOLACvtfcHk0lhyk-ohTiFRKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyns73N&md5=d9f6bcace0e13b232b258db4592421c1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.-h.%26aulast%3DAloysius%26aufirst%3DH.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.-q.%26atitle%3DEnzyme-Mediated%2520Hydrolytic%2520Activation%2520of%2520Prodrugs%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2011%26volume%3D1%26spage%3D143%26epage%3D159%26doi%3D10.1016%2Fj.apsb.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggs-Sauthier, J.</span></span> <span> </span><span class="NLM_article-title">Water Soluble Non-Peptidic Oligomer-Lipophilic Moieties-Protease Inhibitor Conjugates, Especially Containing Atazanavir and Tipranavir as the Protease Inhibitors, Their Preparation, Pharmacokinetics and Anti-HIV-1 Agents</span>. WO <span class="NLM_patent">2010144869 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Riggs-Sauthier&title=Water+Soluble+Non-Peptidic+Oligomer-Lipophilic+Moieties-Protease+Inhibitor+Conjugates%2C+Especially+Containing+Atazanavir+and+Tipranavir+as+the+Protease+Inhibitors%2C+Their+Preparation%2C+Pharmacokinetics+and+Anti-HIV-1+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiggs-Sauthier%26aufirst%3DJ.%26atitle%3DWater%2520Soluble%2520Non-Peptidic%2520Oligomer-Lipophilic%2520Moieties-Protease%2520Inhibitor%2520Conjugates%252C%2520Especially%2520Containing%2520Atazanavir%2520and%2520Tipranavir%2520as%2520the%2520Protease%2520Inhibitors%252C%2520Their%2520Preparation%252C%2520Pharmacokinetics%2520and%2520Anti-HIV-1%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhareshwar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, V. J.</span></span> <span> </span><span class="NLM_article-title">Your Prodrug Releases Formaldehyde: Should You be Concerned? No!</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">4184</span>– <span class="NLM_lpage">4193</span>, <span class="refDoi"> DOI: 10.1002/jps.21319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fjps.21319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=4184-4193&author=S.+S.+Dhareshwarauthor=V.+J.+Stella&title=Your+Prodrug+Releases+Formaldehyde%3A+Should+You+be+Concerned%3F+No%21&doi=10.1002%2Fjps.21319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fjps.21319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21319%26sid%3Dliteratum%253Aachs%26aulast%3DDhareshwar%26aufirst%3DS.%2BS.%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DYour%2520Prodrug%2520Releases%2520Formaldehyde%253A%2520Should%2520You%2520be%2520Concerned%253F%2520No%2521%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D4184%26epage%3D4193%26doi%3D10.1002%2Fjps.21319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, Y.</span></span> <span> </span><span class="NLM_article-title">Protection of Tertiary Hydroxyl Groups as Methylthiomethyl Ethers</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)71324-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fs0040-4039%2800%2971324-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1976&pages=65-66&author=K.+Yamadaauthor=K.+Katoauthor=H.+Nagaseauthor=Y.+Hirata&title=Protection+of+Tertiary+Hydroxyl+Groups+as+Methylthiomethyl+Ethers&doi=10.1016%2Fs0040-4039%2800%2971324-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2800%2971324-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252800%252971324-4%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DY.%26atitle%3DProtection%2520of%2520Tertiary%2520Hydroxyl%2520Groups%2520as%2520Methylthiomethyl%2520Ethers%26jtitle%3DTetrahedron%2520Lett.%26date%3D1976%26volume%3D17%26spage%3D65%26epage%3D66%26doi%3D10.1016%2Fs0040-4039%2800%2971324-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - an Efficient Way to Breach Delivery and Targeting Barriers</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2287</span>, <span class="refDoi"> DOI: 10.2174/156802611797183230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F156802611797183230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=21671868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2265-2287&author=K.+M.+Huttunenauthor=J.+Rautio&title=Prodrugs+-+an+Efficient+Way+to+Breach+Delivery+and+Targeting+Barriers&doi=10.2174%2F156802611797183230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - an efficient way to breach delivery and targeting barriers</span></div><div class="casAuthors">Huttunen, Kristiina M.; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2265-2287</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of prodrugs that are chem. modified bioreversible derivs. of active drug compds. to alter their undesired properties has been expanded widely during the last decades.  Despite the com. success the prodrugs have afforded, the concept is still quite unknown among many scientist.  Furthermore, many scientists regard prodrugs as a pure interest of academic research groups and not as a feasible soln. to improve the delivery or targeting properties of new chem. entities, drug candidates failed in clin. trials, or drugs withdrawn from the market.  Although there are still unmet needs that require addressing, prodrugs should be seen as fine-tuning tools for the successful drug research and development.  This review represents the potential of prodrugs to improve the drug delivery by enhanced aq. soly. or permeability as well as describes several targeted prodrug strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkj5wHsNs0rbVg90H21EOLACvtfcHk0liRtMeLG9QwhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL&md5=9674c0c859bbc3b33dce4caac8e8add3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F156802611797183230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611797183230%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs%2520-%2520an%2520Efficient%2520Way%2520to%2520Breach%2520Delivery%2520and%2520Targeting%2520Barriers%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2265%26epage%3D2287%26doi%3D10.2174%2F156802611797183230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otofokun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Enhancers in HIV Therapeutics</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0167-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs40262-014-0167-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=25164142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=865-872&author=K.+B.+Larsonauthor=K.+Wangauthor=C.+Delilleauthor=I.+Otofokunauthor=E.+P.+Acosta&title=Pharmacokinetic+Enhancers+in+HIV+Therapeutics&doi=10.1007%2Fs40262-014-0167-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Enhancers in HIV Therapeutics</span></div><div class="casAuthors">Larson, Kajal B.; Wang, Kun; Delille, Cecile; Otofokun, Igho; Acosta, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Maximal and durable viral load suppression is one of the most important goals of HIV therapy and is directly related to adequate drug exposure.  Protease inhibitors (PIs), an important component of the antiretroviral armada, were historically assocd. with poor oral bioavailability and high pill burden.  However, because the PIs are metabolized by cytochrome P 450 (CYP) 3A enzymes, intentional inhibition of these enzymes leads to higher drug exposure, lower pill burden, and therefore simplified dosing schedules with this class of drug.  This is the basis of pharmacokinetic enhancement.  In HIV therapy, two pharmacokinetic enhancers or boosting agents are used: ritonavir and cobicistat.  Both agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than ritonavir.  Unlike ritonavir, cobicistat does not have antiretroviral activity.  Cobicistat has been evaluated in clin. trials and was recently approved in the USA as a fixed-dose combination with the integrase inhibitor, elvitegravir and two nucleos(t)ide analogs.  Addnl. studies are examg. cobicistat in fixed-dose combinations with various PIs.  In this review, we summarize current knowledge of these agents and clin. relevant drug regimens and ongoing trials.  Studies with elvitegravir and the novel PI TMC319011 are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgjPsIIAS3K7Vg90H21EOLACvtfcHk0liRtMeLG9QwhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK&md5=b4fe83cebea17842fa9cda633e76ff2e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0167-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0167-9%26sid%3Dliteratum%253Aachs%26aulast%3DLarson%26aufirst%3DK.%2BB.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DDelille%26aufirst%3DC.%26aulast%3DOtofokun%26aufirst%3DI.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26atitle%3DPharmacokinetic%2520Enhancers%2520in%2520HIV%2520Therapeutics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D865%26epage%3D872%26doi%3D10.1007%2Fs40262-014-0167-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vig, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Amino Acids as Promoieties in Prodrug Design and Development</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.addr.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23099277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Onu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1370-1385&author=B.+S.+Vigauthor=K.+M.+Huttunenauthor=K.+Laineauthor=J.+Rautio&title=Amino+Acids+as+Promoieties+in+Prodrug+Design+and+Development&doi=10.1016%2Fj.addr.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acids as promoieties in prodrug design and development</span></div><div class="casAuthors">Vig, Balvinder S.; Huttunen, Kristiina M.; Laine, Krista; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1370-1385</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Prodrugs are biol. inactive agents that upon biotransformation in vivo result in active drug mols.  Since prodrugs might alter the tissue distribution, efficacy and the toxicity of the parent drug, prodrug design should be considered at the early stages of preclin. development.  In this regard, natural and synthetic amino acids offer wide structural diversity and physicochem. properties.  This review covers the use of amino acid prodrugs to improve poor soly., poor permeability, sustained release, i.v. delivery, drug targeting, and metabolic stability of the parent drug.  In addn., practical considerations and challenges assocd. with the development of amino acid prodrugs are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHefiEPLfVLVg90H21EOLACvtfcHk0lid1bJudWSavw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Onu77E&md5=96ed2b459752d10fd7dc0cba6147dd01</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DVig%26aufirst%3DB.%2BS.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DLaine%26aufirst%3DK.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DAmino%2520Acids%2520as%2520Promoieties%2520in%2520Prodrug%2520Design%2520and%2520Development%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1370%26epage%3D1385%26doi%3D10.1016%2Fj.addr.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.2174/1389557517666170216151601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F1389557517666170216151601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=818-833&author=M.+Kre%C4%8Dmerov%C3%A1&title=Amino+Acid+Ester+Prodrugs+of+Nucleoside+and+Nucleotide+Antivirals&doi=10.2174%2F1389557517666170216151601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1389557517666170216151601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557517666170216151601%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26atitle%3DAmino%2520Acid%2520Ester%2520Prodrugs%2520of%2520Nucleoside%2520and%2520Nucleotide%2520Antivirals%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D818%26epage%3D833%26doi%3D10.2174%2F1389557517666170216151601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span> <span> </span><span class="NLM_article-title">A Mini-Review: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.xphs.2016.05.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=2515-2526&author=T.+Murakami&title=A+Mini-Review%3A+Usefulness+of+Transporter-Targeted+Prodrugs+in+Enhancing+Membrane+Permeability&doi=10.1016%2Fj.xphs.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DT.%26atitle%3DA%2520Mini-Review%253A%2520Usefulness%2520of%2520Transporter-Targeted%2520Prodrugs%2520in%2520Enhancing%2520Membrane%2520Permeability%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D105%26spage%3D2515%26epage%3D2526%26doi%3D10.1016%2Fj.xphs.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubertin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro Biological Evaluation of Valine-Containing Prodrugs Derived From Clinically Used HIV-Protease Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1506</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2007.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2007.08.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=1506-1518&author=D.+Rocheauthor=J.+Greinerauthor=A.-M.+Aubertinauthor=P.+Vierling&title=Synthesis+and+in+vitro+Biological+Evaluation+of+Valine-Containing+Prodrugs+Derived+From+Clinically+Used+HIV-Protease+Inhibitors&doi=10.1016%2Fj.ejmech.2007.08.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DAubertin%26aufirst%3DA.-M.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520Biological%2520Evaluation%2520of%2520Valine-Containing%2520Prodrugs%2520Derived%2520From%2520Clinically%2520Used%2520HIV-Protease%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D1506%26epage%3D1518%26doi%3D10.1016%2Fj.ejmech.2007.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Evasion of P-Glycoprotein, Cytochrome P450 3A, and Hydrolases by Peptide Prodrug Modification of Saquinavir</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3199</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1002/jps.23193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fjps.23193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=3199-3213&author=Z.+Wangauthor=D.+Palauthor=A.+K.+Mitra&title=Stereoselective+Evasion+of+P-Glycoprotein%2C+Cytochrome+P450+3A%2C+and+Hydrolases+by+Peptide+Prodrug+Modification+of+Saquinavir&doi=10.1002%2Fjps.23193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjps.23193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23193%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DStereoselective%2520Evasion%2520of%2520P-Glycoprotein%252C%2520Cytochrome%2520P450%25203A%252C%2520and%2520Hydrolases%2520by%2520Peptide%2520Prodrug%2520Modification%2520of%2520Saquinavir%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D3199%26epage%3D3213%26doi%3D10.1002%2Fjps.23193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couet, W.</span></span> <span> </span><span class="NLM_article-title">Investigation of Oral Bioavailability and Brain Distribution of the Ind(8)-Val Conjugate of Indinavir in Rodents</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1211/0022357055786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1211%2F0022357055786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=15831205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFegu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=453-458&author=M.+P.+de+Oliveiraauthor=J.-C.+Olivierauthor=C.+Pariatauthor=D.+Rocheauthor=J.+Greinerauthor=P.+Vierlingauthor=W.+Couet&title=Investigation+of+Oral+Bioavailability+and+Brain+Distribution+of+the+Ind%288%29-Val+Conjugate+of+Indinavir+in+Rodents&doi=10.1211%2F0022357055786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of oral bioavailability and brain distribution of the ind(8)-val conjugate of indinavir in rodents</span></div><div class="casAuthors">de Oliveira, Manuela; Olivier, Jean-Christophe; Pariat, Claudine; Roche, Dominique; Greiner, Jacques; Vierling, Pierre; Couet, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-458</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">Protease inhibitors are successfully used for the treatment of acquired immune deficiency syndrome (AIDS) although their biopharmaceutical characteristics are not optimal.  Prodrugs have therefore been synthesized to increase protease inhibitor bioavailability and brain distribution.  Among several compds. tested, a valine deriv. of indinavir (Ind(8)-Val) showed promising characteristics using an in-vitro Caco-2 cell model.  The objective of this study was to further investigate this compd. using in-situ and in-vivo approaches.  The pharmacokinetics of indinavir (Ind) and Ind(8)-Val were investigated in rats after i.v. and oral administration.  Free indinavir resulting from in-vivo hydrolysis of Ind(8)-Val could not be detected in the plasma of rats receiving Ind(8)-Val.  Furthermore Ind(8)-Val bioavailability was only 32% on av. compared with 76% for indinavir, and effective permeability coeffs. detd. with a single-pass intestinal perfusion method were close to 25×106 cm s-1 for the two compds.  Brain-to-plasma concn. ratios in the post equil. phase after i.v. administration to mice were 9.7±8.1% for indinavir and 2.5±2.7% for Ind(8)-Val.  In conclusion, the promising biopharmaceutical characteristics of Ind(8)-Val suggested from previous in-vitro expts. with the Caco-2 cell model were not confirmed by in-situ and in-vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW3fvBpyh6JbVg90H21EOLACvtfcHk0lid1bJudWSavw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFegu7w%253D&md5=76c7d7a56a8335e40fcd3362e672a3c5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1211%2F0022357055786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357055786%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%26aufirst%3DM.%2BP.%26aulast%3DOlivier%26aufirst%3DJ.-C.%26aulast%3DPariat%26aufirst%3DC.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DVierling%26aufirst%3DP.%26aulast%3DCouet%26aufirst%3DW.%26atitle%3DInvestigation%2520of%2520Oral%2520Bioavailability%2520and%2520Brain%2520Distribution%2520of%2520the%2520Ind%25288%2529-Val%2520Conjugate%2520of%2520Indinavir%2520in%2520Rodents%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2005%26volume%3D57%26spage%3D453%26epage%3D458%26doi%3D10.1211%2F0022357055786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddu, S. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Peptide Prodrugs: Improved Oral Absorption of Lopinavir, a HIV Protease Inhibitor</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2008.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18455890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVemsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=7-14&author=S.+Agarwalauthor=S.+H.+S.+Bodduauthor=R.+Jainauthor=S.+Samantaauthor=D.+Palauthor=A.+K.+Mitra&title=Peptide+Prodrugs%3A+Improved+Oral+Absorption+of+Lopinavir%2C+a+HIV+Protease+Inhibitor&doi=10.1016%2Fj.ijpharm.2008.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor</span></div><div class="casAuthors">Agarwal, Sheetal; Boddu, S. H. S.; Jain, Ritesh; Samanta, Swapan; Pal, Dhananjay; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">7-14</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lopinavir (LVR) is extensively metabolized by CYP3A4 and is prevented from entering the cells by membrane efflux pumps such as P-gp and MRP2.  In an approach to evade the first-pass metab. and efflux of LVR, peptide prodrugs of LVR [valine-valine-lopinavir (VVL) and glycine-valine-lopinavir (GVL)] were synthesized.  Prodrugs were identified with 1H and 13C NMR spectra and LC/MS/MS was employed to evaluate their mass and purity.  Soly. studies indicated that the prodrugs have enhanced aq. solubilities relative to parent LVR.  Accumulation and transport data of VVL and GVL across MDCKII-MDR1 and MDCKII-MRP2 cells indicated evasion of prodrugs' efflux by P-gp and MRP2 significantly.  Permeability studies across Caco-2 cells indicated that the prodrugs are transported by peptide transporters and have increased permeability as compared with LVR.  VVL and GVL exhibited significantly better degrdn. rate consts. as compared with LVR in rat liver microsomes.  Enzymic stability studies in Caco-2 cell homogenate indicated that the peptide prodrugs are first converted to the ester intermediate (amino acid prodrug VL) and then finally to the parent drug.  Overall, the advantages of utilizing peptide prodrugs include chem. modification of the compd. to achieve targeted delivery via peptide transporters present across the intestinal epithelium, significant evasion of efflux and CYP3A4 mediated metab. and significantly better soly. profiles.  Therefore, in vitro studies demonstrated that peptide prodrug derivatization of LVR may be an effective strategy for evading its efflux and enhancing its systemic concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1bkGqQyezkLVg90H21EOLACvtfcHk0lhwVy1tWTDc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVemsL8%253D&md5=acf0ec922a0871812c5b2c848015dba0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DBoddu%26aufirst%3DS.%2BH.%2BS.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DPeptide%2520Prodrugs%253A%2520Improved%2520Oral%2520Absorption%2520of%2520Lopinavir%252C%2520a%2520HIV%2520Protease%2520Inhibitor%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D359%26spage%3D7%26epage%3D14%26doi%3D10.1016%2Fj.ijpharm.2008.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Prodrug Activation by Human Valacyclovirase, an α-Amino Acid Ester Hydrolase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9327</span>, <span class="refDoi"> DOI: 10.1074/jbc.m709530200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1074%2Fjbc.m709530200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=9318-9327&author=L.+Laiauthor=Z.+Xuauthor=J.+Zhouauthor=K.-D.+Leeauthor=G.+L.+Amidon&title=Molecular+Basis+of+Prodrug+Activation+by+Human+Valacyclovirase%2C+an+%CE%B1-Amino+Acid+Ester+Hydrolase&doi=10.1074%2Fjbc.m709530200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m709530200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m709530200%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.-D.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DMolecular%2520Basis%2520of%2520Prodrug%2520Activation%2520by%2520Human%2520Valacyclovirase%252C%2520an%2520%25CE%25B1-Amino%2520Acid%2520Ester%2520Hydrolase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D9318%26epage%3D9327%26doi%3D10.1074%2Fjbc.m709530200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouquayrol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubertin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of HIV Protease Inhibitors-Saquinavir, Indinavir and Nelfinavir-Derived from Diglycerides or Amino Acids: Synthesis, Stability and Anti-HIV Activity</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1039/b313119j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1039%2Fb313119j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=14747863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=345-357&author=B.+Gaucherauthor=M.+Rouquayrolauthor=D.+Rocheauthor=J.+Greinerauthor=A.-M.+Aubertinauthor=P.+Vierling&title=Prodrugs+of+HIV+Protease+Inhibitors-Saquinavir%2C+Indinavir+and+Nelfinavir-Derived+from+Diglycerides+or+Amino+Acids%3A+Synthesis%2C+Stability+and+Anti-HIV+Activity&doi=10.1039%2Fb313119j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity</span></div><div class="casAuthors">Gaucher, Berangere; Rouquayrol, Marielle; Roche, Dominique; Greiner, Jacques; Aubertin, Anne-Marie; Vierling, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-357</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">With the aim of improving the pharmacol. properties of current protease inhibitors (PIs), the synthesis of various acyl and carbamate amino acid- or diglyceride-contg. prodrugs derived from saquinavir, indinavir and nelfinavir, their in vitro stability with respect to hydrolysis and their anti-HIV activity in CEM-SS and MT4 cells have been investigated.  L-Leucine (Leu) and L-phenylalanine (Phe) were connected through their carboxyl to the PIs while L-tyrosine (Tyr) was conjugated through its arom. hydroxyl via various spacer units.  Hydrolysis of the prodrug with liberation of the active free drug was crucial for antiviral activity.  The Leu- and Phe-PI prodrugs released the active free drug very rapidly (half-lives of hydrolysis in buffer at 37 °C of 3-4 h).  The Tyr-PI conjugates with a -C(O)(CH2)4- linker exhibited half-lives in the 40-70 h range and antiviral activities in the 21-325 nM range (from 2 to 22 nM for the free PIs).  The chem. very stable carbamate "peptidomimetic" Tyr-PI prodrugs (no hydrolysis detected after 7 days in buffer) displayed a very low anti-HIV activity or were even inactive (EC50 from 2300 nM to >10 μM).  A very low antiviral activity was measured for the diglyceride-substituted saquinavir and for all of the disubstituted indinavir and nelfinavir prodrugs.  All these prodrugs probably released the active parent PI too slowly under the antiviral assay conditions.  These results combined with those from transepithelial transport studies (Rouquayrol et al., 2002) indicate that conjugation of amino acids (through their carboxyl) to the PIs constitutes a most appealing alternative which could improve the intestinal absorption of the PIs and reduce their recognition by efflux carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC3qjx69Fa-rVg90H21EOLACvtfcHk0lhwVy1tWTDc0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFaktA%253D%253D&md5=00f94d6f534db3eea634f640f323a010</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2Fb313119j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313119j%26sid%3Dliteratum%253Aachs%26aulast%3DGaucher%26aufirst%3DB.%26aulast%3DRouquayrol%26aufirst%3DM.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DAubertin%26aufirst%3DA.-M.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DProdrugs%2520of%2520HIV%2520Protease%2520Inhibitors-Saquinavir%252C%2520Indinavir%2520and%2520Nelfinavir-Derived%2520from%2520Diglycerides%2520or%2520Amino%2520Acids%253A%2520Synthesis%252C%2520Stability%2520and%2520Anti-HIV%2520Activity%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2004%26volume%3D2%26spage%3D345%26epage%3D357%26doi%3D10.1039%2Fb313119j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouquayrol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1023/a:1020913631309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1023%2Fa%3A1020913631309" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1704-1712&author=M.+Rouquayrolauthor=B.+Gaucherauthor=D.+Rocheauthor=J.+Greinerauthor=P.+Vierling&title=Transepithelial+Transport+of+Prodrugs+of+the+HIV+Protease+Inhibitors+Saquinavir%2C+Indinavir%2C+and+Nelfinavir+Across+Caco-2+Cell+Monolayers&doi=10.1023%2Fa%3A1020913631309"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1020913631309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1020913631309%26sid%3Dliteratum%253Aachs%26aulast%3DRouquayrol%26aufirst%3DM.%26aulast%3DGaucher%26aufirst%3DB.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DTransepithelial%2520Transport%2520of%2520Prodrugs%2520of%2520the%2520HIV%2520Protease%2520Inhibitors%2520Saquinavir%252C%2520Indinavir%252C%2520and%2520Nelfinavir%2520Across%2520Caco-2%2520Cell%2520Monolayers%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D1704%26epage%3D1712%26doi%3D10.1023%2Fa%3A1020913631309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usansky, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.107.017483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=863-869&author=H.+H.+Usanskyauthor=P.+Huauthor=P.+J.+Sinko&title=Differential+Roles+of+P-Glycoprotein%2C+Multidrug+Resistance-Associated+Protein+2%2C+and+CYP3A+on+Saquinavir+Oral+Absorption+in+Sprague-Dawley+Rats&doi=10.1124%2Fdmd.107.017483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017483%26sid%3Dliteratum%253Aachs%26aulast%3DUsansky%26aufirst%3DH.%2BH.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DDifferential%2520Roles%2520of%2520P-Glycoprotein%252C%2520Multidrug%2520Resistance-Associated%2520Protein%25202%252C%2520and%2520CYP3A%2520on%2520Saquinavir%2520Oral%2520Absorption%2520in%2520Sprague-Dawley%2520Rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D863%26epage%3D869%26doi%3D10.1124%2Fdmd.107.017483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pursley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R. A.</span></span> <span> </span><span class="NLM_article-title">Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.110.037341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=891-903&author=J.+Gongauthor=J.+Ganauthor=J.+Caceres-Cortesauthor=L.+J.+Christopherauthor=V.+Aroraauthor=E.+Massonauthor=D.+Williamsauthor=J.+Pursleyauthor=A.+Allentoffauthor=M.+Lagoauthor=S.+B.+Tranauthor=R.+A.+Iyer&title=Metabolism+and+Disposition+of+%5B14C%5DBrivanib+Alaninate+after+Oral+Administration+to+Rats%2C+Monkeys%2C+and+Humans&doi=10.1124%2Fdmd.110.037341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037341%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DChristopher%26aufirst%3DL.%2BJ.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPursley%26aufirst%3DJ.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DLago%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DS.%2BB.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26atitle%3DMetabolism%2520and%2520Disposition%2520of%2520%255B14C%255DBrivanib%2520Alaninate%2520after%2520Oral%2520Administration%2520to%2520Rats%252C%2520Monkeys%252C%2520and%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D891%26epage%3D903%26doi%3D10.1124%2Fdmd.110.037341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortillo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brivanib Alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1976</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1021/jm7013309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.-w.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+Brivanib+Alaninate+%28%28S%29-%28%28R%29-1-%284-%284-Fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+A+Novel+Prodrug+of+Dual+Vascular+Endothelial+Growth+Factor+Receptor-2+and+Fibroblast+Growth+Factor+Receptor-1+Kinase+Inhibitor+%28BMS-540215%29&doi=10.1021%2Fjm7013309"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.-w.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520Brivanib%2520Alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-Fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520A%2520Novel%2520Prodrug%2520of%2520Dual%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520and%2520Fibroblast%2520Growth%2520Factor%2520Receptor-1%2520Kinase%2520Inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980%26doi%3D10.1021%2Fjm7013309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bou-Chacra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melo, K. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, I. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stippler, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesisoglou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löbenberg, R.</span></span> <span> </span><span class="NLM_article-title">Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System</span>. <i>AAPS J</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1208/s12248-017-0085-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1208%2Fs12248-017-0085-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28516359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVKnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=989-1001&author=N.+Bou-Chacraauthor=K.+J.+C.+Meloauthor=I.+A.+C.+Moralesauthor=E.+S.+Stipplerauthor=F.+Kesisoglouauthor=M.+Yazdanianauthor=R.+L%C3%B6benberg&title=Evolution+of+Choice+of+Solubility+and+Dissolution+Media+After+Two+Decades+of+Biopharmaceutical+Classification+System&doi=10.1208%2Fs12248-017-0085-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System</span></div><div class="casAuthors">Bou-Chacra, Nadia; Melo, Katherine Jasmine Curo; Morales, Ivan Andres Cordova; Stippler, Erika S.; Kesisoglou, Filippos; Yazdanian, Mehran; Lobenberg, Raimar</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">989-1001</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The introduction of the biopharmaceutics drug classification system (Biopharmaceutics Classification System (BCS)), in 1995, provided a simple way to describe the biopharmaceutics behavior of a drug.  Soly. and permeability are among the major parameters, which det. the fraction dose absorbed of a drug substance and consequently its chances to be bioavailable.  The purpose of this review is to summarize the evolution of the media used for detg. soly. and dissoln. and how this can be used in modern drug development.  Over the years, physiol. adapted media and buffers were introduced with the intention to better predict the in vivo soly. and dissoln. of drug substances.  Water, buffer solns., compendial media, micellar solubilization media, and biorelevant media are reviewed.  At this time point, there is no universal medium available which can be used to predict every drug substance's soly. or a drug product's in vivo dissoln. behavior.  However, there have been many improvements and addns. made to media to optimize their in vivo predictability; for example, the current phosphate concns. in buffers seem to be too high to correlate with the carbonate buffer concns. in vivo.  Biorelevant media were updated to correlate them better with the compn. of human intestinal fluids.  The BCS was introduced into regulatory sciences as a scientific risk management tool to waive bioequivalence studies under certain conditions.  Today's different guidance documents define the dose-soly. ratio differently.  As shown for amoxicillin, this can cause more confusion than certainty for globally operating companies.  Harmonization of BCS guidelines is highly desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEO5cC3Eo0TLVg90H21EOLACvtfcHk0ljZGqo0RtzLKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVKnt7Y%253D&md5=e687a9536f08f2fc2cab0503fc5c2795</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1208%2Fs12248-017-0085-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-017-0085-5%26sid%3Dliteratum%253Aachs%26aulast%3DBou-Chacra%26aufirst%3DN.%26aulast%3DMelo%26aufirst%3DK.%2BJ.%2BC.%26aulast%3DMorales%26aufirst%3DI.%2BA.%2BC.%26aulast%3DStippler%26aufirst%3DE.%2BS.%26aulast%3DKesisoglou%26aufirst%3DF.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DL%25C3%25B6benberg%26aufirst%3DR.%26atitle%3DEvolution%2520of%2520Choice%2520of%2520Solubility%2520and%2520Dissolution%2520Media%2520After%2520Two%2520Decades%2520of%2520Biopharmaceutical%2520Classification%2520System%26jtitle%3DAAPS%2520J%26date%3D2017%26volume%3D19%26spage%3D989%26epage%3D1001%26doi%3D10.1208%2Fs12248-017-0085-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A. W.</span></span> <span> </span><span class="NLM_article-title">Toward Oral Delivery of Biopharmaceuticals: an Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">966</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1021/mp500809f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500809f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=966-973&author=J.+Wangauthor=V.+Yadavauthor=A.+L.+Smartauthor=S.+Tajiriauthor=A.+W.+Basit&title=Toward+Oral+Delivery+of+Biopharmaceuticals%3A+an+Assessment+of+the+Gastrointestinal+Stability+of+17+Peptide+Drugs&doi=10.1021%2Fmp500809f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span></div><div class="casAuthors">Wang, Jie; Yadav, Vipul; Smart, Alice L.; Tajiri, Shinichiro; Basit, Abdul W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">966-973</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major barrier to successful oral delivery of peptide and protein mols. is their inherent instability in the lumen of the gastrointestinal tract.  The aim of this study was to det. the stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, desmopressin, oxytocin, [Arg8]-vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, buserelin, histrelin, [D-Ser]4-gonadorelin, deslorelin, and goserelin) in gastric and small intestinal fluids from both humans and pigs, and in simulated gastric and intestinal fluids.  In human gastric fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon, and insulin were metabolized rapidly, while the smaller peptides showed good stability.  In human small intestinal fluid, however, both small and large peptides degraded rapidly with the exception of the cyclic peptide ciclosporin and the disulfide-bridge contg. peptides octreotide and desmopressin, which showed good stability.  The stability of peptides in both simulated gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid.  However, it was not possible to establish such a correlation with the small intestinal fluids because of the rapid rate of peptide degrdn.  This work has identified the mol. features in the structure of a wide range of peptides that influence their stability in the environment of the gastrointestinal tract, which in turn will allow for better selection of peptide candidates for oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraciXJLe-z4rVg90H21EOLACvtfcHk0lhS9tRwhBmFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D&md5=a29abd913a44604892e879e735818ff9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fmp500809f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500809f%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DSmart%26aufirst%3DA.%2BL.%26aulast%3DTajiri%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%2BW.%26atitle%3DToward%2520Oral%2520Delivery%2520of%2520Biopharmaceuticals%253A%2520an%2520Assessment%2520of%2520the%2520Gastrointestinal%2520Stability%2520of%252017%2520Peptide%2520Drugs%26jtitle%3DMol.%2520Pharm.%26date%3D2015%26volume%3D12%26spage%3D966%26epage%3D973%26doi%3D10.1021%2Fmp500809f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Characterization of CYP Inhibition by 1-Aminobenzotriazole in Rats</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1002/bdd.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fbdd.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26637499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=200-211&author=K.+E.+Parrishauthor=J.+Maoauthor=J.+Chenauthor=A.+Jaochicoauthor=J.+Lyauthor=Q.+Hoauthor=S.+Mukadamauthor=M.+Wright&title=In+Vitro+and+in+Vivo+Characterization+of+CYP+Inhibition+by+1-Aminobenzotriazole+in+Rats&doi=10.1002%2Fbdd.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats</span></div><div class="casAuthors">Parrish, Karen E.; Mao, Jialin; Chen, Jacob; Jaochico, Allan; Ly, Justin; Ho, Quynh; Mukadam, Sophie; Wright, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">200-211</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">1-Aminobenzotriazole (ABT) is a non-isoform specific, time-dependent inhibitor of cytochrome P 450 (CYP) enzymes used extensively in preclin. studies to det. the relative contribution of oxidative metab.  Although ABT has been widely used, the extent and duration of its inhibitory effect is not well understood.  The purpose of this study is to characterize ABT inhibition of CYP in rats at both the hepatic and intestinal levels.  In vivo studies using midazolam (p.o. and i.v.), as a probe for CYP activity, demonstrated that CYP inhibition was not complete even at the highest dose (300 mg/kg).  Addnl. in vivo studies demonstrated that even at 26 h following ABT administration, there was significant CYP inhibition remaining.  In vitro studies, conducted in both rat liver microsomes and rat hepatocytes, confirm that ABT is a time-dependent inhibitor of rat CYP orthologs.  However, in rat liver microsomes, there was more than 15% CYP activity remaining following a 60 min preincubation at 2 mM ABT and 5-10% of CYP activity was remaining in rat hepatocytes suspended in rat plasma following a 60 min preincubation at 2 mM ABT. 1-Aminobenzotriazole is a useful tool in elucidating the oxidative component of metab. in preclin. species; however, conclusions made from the preclin. use of ABT should not operate under the assumption that CYP enzymic activity is completely inhibited.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCr2m85zI_mrVg90H21EOLACvtfcHk0lhS9tRwhBmFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kgtbg%253D&md5=2e90ecb17737f79dd6dca368150f0f94</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2000%26sid%3Dliteratum%253Aachs%26aulast%3DParrish%26aufirst%3DK.%2BE.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DQ.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Characterization%2520of%2520CYP%2520Inhibition%2520by%25201-Aminobenzotriazole%2520in%2520Rats%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D200%26epage%3D211%26doi%3D10.1002%2Fbdd.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vockley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antshel, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braverman, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S. A.</span></span> <span> </span><span class="NLM_article-title">Phenylalanine Hydroxylase Deficiency: Diagnosis and Management Guideline</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/gim.2013.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fgim.2013.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24385074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=188-200&author=J.+Vockleyauthor=H.+C.+Anderssonauthor=K.+M.+Antshelauthor=N.+E.+Bravermanauthor=B.+K.+Burtonauthor=D.+M.+Frazierauthor=J.+Mitchellauthor=W.+E.+Smithauthor=B.+H.+Thompsonauthor=S.+A.+Berry&title=Phenylalanine+Hydroxylase+Deficiency%3A+Diagnosis+and+Management+Guideline&doi=10.1038%2Fgim.2013.157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylalanine hydroxylase deficiency: diagnosis and management guideline</span></div><div class="casAuthors">Vockley, Jerry; Andersson, Hans C.; Antshel, Kevin M.; Braverman, Nancy E.; Burton, Barbara K.; Frazier, Dianne M.; Mitchell, John; Smith, Wendy E.; Thompson, Barry H.; Berry, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-200</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metab. to be identified through population screening.  Early identification and treatment prevent the most dramatic clin. sequelae of the disorder, but new neurodevelopmental and psychol. problems have emerged in individuals treated from birth.  The addnl. unanticipated recognition of a toxic effect of elevated maternal phenylalanine on fetal development has added to a general call in the field for treatment for life.  Two major conferences sponsored by the National Institutes of Health held >10 years apart reviewed the state of knowledge in the field of phenylalanine hydroxylase deficiency, but there are no generally accepted recommendations for therapy.  The purpose of this guideline is to review the strength of the medical literature relative to the treatment of phenylalanine hydroxylase deficiency and to develop recommendations for diagnosis and therapy of this disorder.  Evidence review from the original National Institutes of Health consensus conference and a recent update by the Agency for Healthcare Research and Quality was used to address key questions in the diagnosis and treatment of phenylalanine hydroxylase deficiency by a working group established by the American College of Medical Genetics and Genomics.  The group met by phone and in person over the course of a year to review these reports, develop recommendations, and identify key gaps in our knowledge of this disorder.  Above all, treatment of phenylalanine hydroxylase deficiency must be life long, with a goal of maintaining blood phenylalanine in the range of 120-360 μmol/l.  Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future.  Pharmacotherapy for phenylalanine hydroxylase deficiency is in early stages with one approved medication (sapropterin, a deriv. of the natural cofactor of phenylalanine hydroxylase) and others under development.  Eventually, treatment of phenylalanine hydroxylase deficiency will be individualized with multiple medications and alternative medical foods available to tailor therapy.  The primary goal of therapy should be to lower blood phenylalanine, and any interventions, including medications, or combination of therapies that help to achieve that goal in an individual, without other neg. consequences, should be considered appropriate therapy.  Significant evidence gaps remain in our understanding of the optimum therapies for phenylalanine hydroxylase deficiency, nonphenylalanine effects of these therapies, and long-term sequelae of even well-treated disease in children and adults.  Genet Med16 2, 188-200.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64nbBJSww4rVg90H21EOLACvtfcHk0lhS9tRwhBmFRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wktrw%253D&md5=f156c3f31bd14daa6f439b19c120727d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fgim.2013.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2013.157%26sid%3Dliteratum%253Aachs%26aulast%3DVockley%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DH.%2BC.%26aulast%3DAntshel%26aufirst%3DK.%2BM.%26aulast%3DBraverman%26aufirst%3DN.%2BE.%26aulast%3DBurton%26aufirst%3DB.%2BK.%26aulast%3DFrazier%26aufirst%3DD.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DW.%2BE.%26aulast%3DThompson%26aufirst%3DB.%2BH.%26aulast%3DBerry%26aufirst%3DS.%2BA.%26atitle%3DPhenylalanine%2520Hydroxylase%2520Deficiency%253A%2520Diagnosis%2520and%2520Management%2520Guideline%26jtitle%3DGenet.%2520Med.%26date%3D2014%26volume%3D16%26spage%3D188%26epage%3D200%26doi%3D10.1038%2Fgim.2013.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stappaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span> <span> </span><span class="NLM_article-title">In Situ Perfusion in Rodents to Explore Intestinal Drug Absorption: Challenges and Opportunities</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>478</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.11.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2014.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=25448559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2015&pages=665-681&author=J.+Stappaertsauthor=J.+Brouwersauthor=P.+Annaertauthor=P.+Augustijns&title=In+Situ+Perfusion+in+Rodents+to+Explore+Intestinal+Drug+Absorption%3A+Challenges+and+Opportunities&doi=10.1016%2Fj.ijpharm.2014.11.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities</span></div><div class="casAuthors">Stappaerts, Jef; Brouwers, Joachim; Annaert, Pieter; Augustijns, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">478</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">665-681</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The in situ intestinal perfusion technique in rodents is a very important absorption model, not only because of its predictive value, but it is also very suitable to unravel the mechanisms underlying intestinal drug absorption.  This literature overview covers a no. of specific applications for which the in situ intestinal perfusion set-up can be applied in favor of established in vitro absorption tools, such as the Caco-2 cell model.  Qualities including the expression of drug transporters and metabolizing enzymes relevant for human intestinal absorption and compatibility with complex solvent systems render the in situ technique the most designated absorption model to perform transporter-metab. studies or to evaluate the intestinal absorption from biorelevant media.Over the years, the in situ intestinal perfusion model has exhibited an exceptional ability to adapt to the latest challenges in drug absorption profiling.  For instance, the introduction of the mesenteric vein cannulation allows detg. the appearance of compds. in the blood and is of great use, esp. when evaluating the absorption of compds. undergoing intestinal metab.  Moreover, the use of the closed loop intestinal perfusion set-up is interesting when compds. or perfusion media are scarce.  Compatibility with emerging trends in pharmaceutical profiling, such as the use of knockout or transgenic animals, generates unparalleled possibilities to gain mechanistic insight into specific absorption processes.Notwithstanding the fact that the in situ expts. are tech. challenging and relatively time-consuming, the model offers great opportunities to gain insight into the processes detg. intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0fIWKFc_khrVg90H21EOLACvtfcHk0ljNjUUZb9heeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7vL&md5=54243d5d40352b910b434b41d8059b8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DStappaerts%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DJ.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIn%2520Situ%2520Perfusion%2520in%2520Rodents%2520to%2520Explore%2520Intestinal%2520Drug%2520Absorption%253A%2520Challenges%2520and%2520Opportunities%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2015%26volume%3D478%26spage%3D665%26epage%3D681%26doi%3D10.1016%2Fj.ijpharm.2014.11.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chando, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patten, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">In vitro Inhibition of UDP Glucuronosyltransferases by Atazanavir and Other HIV Protease Inhibitors and the Relationship of This Property to In Vivo Bilirubin Glucuronidation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.005447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.105.005447" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1729-1739&author=D.+Zhangauthor=T.+J.+Chandoauthor=D.+W.+Everettauthor=C.+J.+Pattenauthor=S.+S.+Dehalauthor=W.+G.+Humphreys&title=In+vitro+Inhibition+of+UDP+Glucuronosyltransferases+by+Atazanavir+and+Other+HIV+Protease+Inhibitors+and+the+Relationship+of+This+Property+to+In+Vivo+Bilirubin+Glucuronidation&doi=10.1124%2Fdmd.105.005447"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.005447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.005447%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChando%26aufirst%3DT.%2BJ.%26aulast%3DEverett%26aufirst%3DD.%2BW.%26aulast%3DPatten%26aufirst%3DC.%2BJ.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DIn%2520vitro%2520Inhibition%2520of%2520UDP%2520Glucuronosyltransferases%2520by%2520Atazanavir%2520and%2520Other%2520HIV%2520Protease%2520Inhibitors%2520and%2520the%2520Relationship%2520of%2520This%2520Property%2520to%2520In%2520Vivo%2520Bilirubin%2520Glucuronidation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1729%26epage%3D1739%26doi%3D10.1124%2Fdmd.105.005447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gammal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haidar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwuchukwu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarellos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whirl-Carrillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schackman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caudle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1002/cpt.269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fcpt.269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26417955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A280%3ADC%252BC283mslSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=363-369&author=R.+Gammalauthor=M.+Courtauthor=C.+Haidarauthor=O.+Iwuchukwuauthor=A.+Gaurauthor=M.+Alvarellosauthor=C.+Guillemetteauthor=J.+Lennoxauthor=M.+Whirl-Carrilloauthor=S.+Brummelauthor=M.+Ratainauthor=T.+Kleinauthor=B.+Schackmanauthor=K.+Caudleauthor=D.+Haas&title=Clinical+Pharmacogenetics+Implementation+Consortium+%28CPIC%29+Guideline+forUGT1A1and+Atazanavir+Prescribing&doi=10.1002%2Fcpt.269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing</span></div><div class="casAuthors">Gammal R S; Haidar C E; Caudle K E; Court M H; Iwuchukwu O F; Iwuchukwu O F; Gaur A H; Alvarellos M; Whirl-Carrillo M; Klein T E; Guillemette C; Lennox J L; Brummel S S; Ratain M J; Schackman B R; Haas D W</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin.  Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir.  Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37).  We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvlVeXfe9CxVWTCLT8lX9SfW6udTcc2eYbetER3BfwRrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283mslSktQ%253D%253D&md5=1bdc1d8bcc2d722fe6ac0c3ce8b65880</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fcpt.269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.269%26sid%3Dliteratum%253Aachs%26aulast%3DGammal%26aufirst%3DR.%26aulast%3DCourt%26aufirst%3DM.%26aulast%3DHaidar%26aufirst%3DC.%26aulast%3DIwuchukwu%26aufirst%3DO.%26aulast%3DGaur%26aufirst%3DA.%26aulast%3DAlvarellos%26aufirst%3DM.%26aulast%3DGuillemette%26aufirst%3DC.%26aulast%3DLennox%26aufirst%3DJ.%26aulast%3DWhirl-Carrillo%26aufirst%3DM.%26aulast%3DBrummel%26aufirst%3DS.%26aulast%3DRatain%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DSchackman%26aufirst%3DB.%26aulast%3DCaudle%26aufirst%3DK.%26aulast%3DHaas%26aufirst%3DD.%26atitle%3DClinical%2520Pharmacogenetics%2520Implementation%2520Consortium%2520%2528CPIC%2529%2520Guideline%2520forUGT1A1and%2520Atazanavir%2520Prescribing%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D99%26spage%3D363%26epage%3D369%26doi%3D10.1002%2Fcpt.269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.-Y.</span></span> <span> </span><span class="NLM_article-title">Application of Fluorine in Drug Design During 2010-2015 Years: A Mini-Review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/1389557515666151016124957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F1389557515666151016124957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26471967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFGisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=683-692&author=B.-C.+Wangauthor=L.-J.+Wangauthor=B.+Jiangauthor=S.-Y.+Wangauthor=N.+Wuauthor=X.-Q.+Liauthor=D.-Y.+Shi&title=Application+of+Fluorine+in+Drug+Design+During+2010-2015+Years%3A+A+Mini-Review&doi=10.2174%2F1389557515666151016124957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fluorine in Drug Design During 2010-2015 Years: A Mini-Review</span></div><div class="casAuthors">Wang, Bao-Cheng; Wang, Li-Jun; Jiang, Bo; Wang, Shuai-Yu; Wu, Ning; Li, Xiang-Qian; Shi, Da-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">683-692</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: The widespread application of fluorine in drug design benefits from distinctive properties.  Incorporation of fluorine can pos. modulate certain pharmacokinetics properties, including lipophilicity, eletrophilicity, metabolic stability, chem. stability, et al., which were of interest to medicinal chemists.  Herein, fluorinated compds., which have been designed and evaluated for anticancer, antimicrobial, anti-inflammatory and antivirus activity, et al. during the last 6 years (2010-2015) are summarized.  Conclusion: The emphasis is to highlight the importance of fluorinated compds. and the changes in the properties of compds. when introducing fluorine atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6wbFwaGSx7Vg90H21EOLACvtfcHk0ljNjUUZb9heeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFGisbc%253D&md5=a2061775cb12ab5e2bf264f2a6727bf2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F1389557515666151016124957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557515666151016124957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.-C.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DShi%26aufirst%3DD.-Y.%26atitle%3DApplication%2520of%2520Fluorine%2520in%2520Drug%2520Design%2520During%25202010-2015%2520Years%253A%2520A%2520Mini-Review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D683%26epage%3D692%26doi%3D10.2174%2F1389557515666151016124957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation of Fluorine into Taxoid Anticancer Agents for Medicinal Chemistry and Chemical Biology Studies</span>. <i>J. Fluorine Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.jfluchem.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.jfluchem.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28824201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=10-23&author=I.+Ojima&title=Strategic+Incorporation+of+Fluorine+into+Taxoid+Anticancer+Agents+for+Medicinal+Chemistry+and+Chemical+Biology+Studies&doi=10.1016%2Fj.jfluchem.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic incorporation of fluorine into taxoid anticancer agents for medicinal chemistry and chemical biology studies</span></div><div class="casAuthors">Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-23</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This account exemplifies our recent progress on the strategic incorporation of fluorine and organofluorine groups to taxoid anticancer agents and their tumor-targeted drug delivery systems (TTDDSs) for medicinal chem. and chem. biol. studies.  Novel 3'-difluorovinyltaxoids were strategically designed to block the metab. by cytochrome P 450, synthesized, and evaluated for their cytotoxicity against drug-sensitive and multidrug-resistant (MDR) human cancer cell lines. 3'-Difluorovinyltaxoids exhibited impressive activities against these cancer cell lines.  More significantly, a representative 3'-difluorovinyltaxoid exhibited 230-33,000 times higher potency than conventional anticancer drugs against cancer stem cell-enriched HCT-116 cell line.  Studies on the mechanism of action (MOA) of these fluorotaxoids were performed by tubulin polymn. assay, morphol. anal. by electron microscopy (EM) and protein binding assays.  Novel 19F NMR probes, BLT-F2 and BLT-S-F6, were designed by strategically incorporating fluorine, CF3 and CF3O groups into tumor-targeting drug conjugates.  These 19F-probes were designed and synthesized to investigate the mechanism of linker cleavage and factors that influence their plasma and metabolic stability by real-time 19F NMR anal.  Time-resolved 19F NMR study on probe BLT-F2 revealed a stepwise mechanism for the release of a fluorotaxoid, which might not be detected by other anal. methods.  Probe BLT-S-F6 were very useful to study the stability and reactivity of the drug delivery system in human blood plasma by 19F NMR.  The clean anal. of the linker stability and reactivity of drug conjugates in blood plasma by HPLC and 1H NMR is very challenging, but the use of 19F NMR and suitable 19F probes can provide a practical soln. to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2bDu_ckk8bVg90H21EOLACvtfcHk0lgzf8deDW031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlGntw%253D%253D&md5=b421b53c8371829b4ca44bbec7980a0e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DStrategic%2520Incorporation%2520of%2520Fluorine%2520into%2520Taxoid%2520Anticancer%2520Agents%2520for%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%2520Studies%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2017%26volume%3D198%26spage%3D10%26epage%3D23%26doi%3D10.1016%2Fj.jfluchem.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of Fluorine in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+Fluorine+in+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lgzf8deDW031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+Fluorinated+Motifs+in+the+Design+and+Application+of+Bioisosteres+for+Drug+Design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgzf8deDW031g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520Fluorinated%2520Motifs%2520in%2520the%2520Design%2520and%2520Application%2520of%2520Bioisosteres%2520for%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lg1TcxTOhDQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span> <span> </span><span class="NLM_article-title">Dipeptide Prodrugs of the Glutamate Modulator Riluzole</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=752-756&author=J.+C.+Pelletierauthor=S.+Chenauthor=H.+Bianauthor=R.+Shahauthor=G.+R.+Smithauthor=J.+E.+Wrobelauthor=A.+B.+Reitz&title=Dipeptide+Prodrugs+of+the+Glutamate+Modulator+Riluzole&doi=10.1021%2Facsmedchemlett.8b00189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00189%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DWrobel%26aufirst%3DJ.%2BE.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3DDipeptide%2520Prodrugs%2520of%2520the%2520Glutamate%2520Modulator%2520Riluzole%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D752%26epage%3D756%26doi%3D10.1021%2Facsmedchemlett.8b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Cyclization-Activated Prodrugs</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2484</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.3390/12112484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2F12112484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18065953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=2484-2506&author=P.+Gomesauthor=N.+Valeauthor=R.+Moreira&title=Cyclization-Activated+Prodrugs&doi=10.3390%2F12112484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclization-activated prodrugs</span></div><div class="casAuthors">Gomes, Paula; Vale, Nuno; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2484-2506</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Many drugs suffer from an extensive 1st-pass metab. leading to drug inactivation and/or prodn. of toxic metabolites, which makes them attractive targets for prodrug design.  The classical prodrug approach, which involves enzyme-sensitive covalent linkage between the parent drug and a carrier moiety, is a well established strategy to overcome bioavailability/toxicity issues.  However, the development of prodrugs that can regenerate the parent drug through non-enzymic pathways has emerged as an alternative approach in which prodrug activation is not influenced by inter- and intraindividual variability that affects enzymic activity.  Cyclization-activated prodrugs were capturing the attention of medicinal chemists since the middle-1980s, and reached maturity in prodrug design in the late 1990s.  Many different strategies were exploited in recent years concerning the development of intramolecularly-activated prodrugs spanning from analgesics to anti-HIV therapeutic agents.  Intramol. pathways have also a key role in 2-step prodrug activation, where an initial enzymic cleavage step is followed by a cyclization-elimination reaction that releases the active drug.  This work is a brief overview of research on cyclization-activated prodrugs from the last 2 decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLCsEijlOS_bVg90H21EOLACvtfcHk0lg1TcxTOhDQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Ontg%253D%253D&md5=6e16d7b3a7d3914f60b84acc24a2339c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2F12112484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252F12112484%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DP.%26aulast%3DVale%26aufirst%3DN.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DCyclization-Activated%2520Prodrugs%26jtitle%3DMolecules%26date%3D2007%26volume%3D12%26spage%3D2484%26epage%3D2506%26doi%3D10.3390%2F12112484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Cyclization-Activated Prodrugs. Synthesis, Reactivity and Toxicity of Dipeptide Esters of Paracetamol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.bmcl.2005.01.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1595-1598&author=C.+Santosauthor=M.+L.+Mateusauthor=A.+P.+Santosauthor=R.+Moreiraauthor=E.+de+Oliveiraauthor=P.+Gomes&title=Cyclization-Activated+Prodrugs.+Synthesis%2C+Reactivity+and+Toxicity+of+Dipeptide+Esters+of+Paracetamol&doi=10.1016%2Fj.bmcl.2005.01.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DMateus%26aufirst%3DM.%2BL.%26aulast%3DSantos%26aufirst%3DA.%2BP.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3Dde%2BOliveira%26aufirst%3DE.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DCyclization-Activated%2520Prodrugs.%2520Synthesis%252C%2520Reactivity%2520and%2520Toxicity%2520of%2520Dipeptide%2520Esters%2520of%2520Paracetamol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1595%26epage%3D1598%26doi%3D10.1016%2Fj.bmcl.2005.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht-Küpper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrichs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerchen, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nell, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Süssmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakalopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span> <span> </span><span class="NLM_article-title">Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fcmdc.201700151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28488817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntl2isb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=728-737&author=D.+Meibomauthor=B.+Albrecht-K%C3%BCpperauthor=N.+Diedrichsauthor=W.+H%C3%BCbschauthor=R.+Kastauthor=T.+Kr%C3%A4merauthor=U.+Krenzauthor=H.-G.+Lerchenauthor=J.+Mittendorfauthor=P.+G.+Nellauthor=F.+S%C3%BCssmeierauthor=A.+Vakalopoulosauthor=K.+Zimmermann&title=Neladenoson+Bialanate+Hydrochloride%3A+A+Prodrug+of+a+Partial+Adenosine+A1+Receptor+Agonist+for+the+Chronic+Treatment+of+Heart+Diseases&doi=10.1002%2Fcmdc.201700151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases</span></div><div class="casAuthors">Meibom, Daniel; Albrecht-Kuepper, Barbara; Diedrichs, Nicole; Huebsch, Walter; Kast, Raimund; Kraemer, Thomas; Krenz, Ursula; Lerchen, Hans-Georg; Mittendorf, Joachim; Nell, Peter G.; Suessmeier, Frank; Vakalopoulos, Alexandros; Zimmermann, Katja</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">728-737</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Adenosine is known to be released under a variety of physiol. and pathophysiol. conditions to facilitate the protection and regeneration of injured ischemic tissues.  The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies assocd. with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies.  When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacol. effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation.  These unwanted effects can be overcome by using partial A1R agonists.  Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window.  This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks.  To circumvent soly. and formulation issues for neladenoson, a prodrug approach was pursued.  The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved soly. and exposure after oral administration.  Neladenoson bialanate hydrochloride is currently being evaluated in clin. trials for the treatment of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo712AVDyOUF7Vg90H21EOLACvtfcHk0ljeqe7tRg3_7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntl2isb8%253D&md5=e913933109888fd5897ab943605b2a65</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700151%26sid%3Dliteratum%253Aachs%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DAlbrecht-K%25C3%25BCpper%26aufirst%3DB.%26aulast%3DDiedrichs%26aufirst%3DN.%26aulast%3DH%25C3%25BCbsch%26aufirst%3DW.%26aulast%3DKast%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DT.%26aulast%3DKrenz%26aufirst%3DU.%26aulast%3DLerchen%26aufirst%3DH.-G.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DNell%26aufirst%3DP.%2BG.%26aulast%3DS%25C3%25BCssmeier%26aufirst%3DF.%26aulast%3DVakalopoulos%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DK.%26atitle%3DNeladenoson%2520Bialanate%2520Hydrochloride%253A%2520A%2520Prodrug%2520of%2520a%2520Partial%2520Adenosine%2520A1%2520Receptor%2520Agonist%2520for%2520the%2520Chronic%2520Treatment%2520of%2520Heart%2520Diseases%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D728%26epage%3D737%26doi%3D10.1002%2Fcmdc.201700151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. S. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouveia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for Dipeptide Prodrugs of Acyclovir: Implications for Prodrug Design</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2008.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2339-2346&author=C.+R.+Santosauthor=R.+Capelaauthor=C.+S.+G.+P.+Pereiraauthor=E.+Valenteauthor=L.+Gouveiaauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=R.+Moreiraauthor=P.+Gomes&title=Structure-Activity+Relationships+for+Dipeptide+Prodrugs+of+Acyclovir%3A+Implications+for+Prodrug+Design&doi=10.1016%2Fj.ejmech.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DCapela%26aufirst%3DR.%26aulast%3DPereira%26aufirst%3DC.%2BS.%2BG.%2BP.%26aulast%3DValente%26aufirst%3DE.%26aulast%3DGouveia%26aufirst%3DL.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520Dipeptide%2520Prodrugs%2520of%2520Acyclovir%253A%2520Implications%2520for%2520Prodrug%2520Design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2339%26epage%3D2346%26doi%3D10.1016%2Fj.ejmech.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Picaso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, M. Y.</span></span> <span> </span><span class="NLM_article-title">Efficient Microwave Assisted Syntheses of 2,5-Diketopiperazines in Aqueous Media</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2836</span>– <span class="NLM_lpage">2849</span>, <span class="refDoi"> DOI: 10.3390/molecules14082836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2Fmolecules14082836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=19701127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVShtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=2836-2849&author=L.+P%C3%A9rez-Picasoauthor=J.+Escalanteauthor=H.+Olivoauthor=M.+Y.+Rios&title=Efficient+Microwave+Assisted+Syntheses+of+2%2C5-Diketopiperazines+in+Aqueous+Media&doi=10.3390%2Fmolecules14082836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient microwave assisted syntheses of 2,5-diketopiperazines in aqueous media</span></div><div class="casAuthors">Perez-Picaso, Lemuel; Escalante, Jaime; Olivo, Horacio F.; Rios, Maria Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2836-2849</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">Aq. in situ one-pot N-Boc-deprotection-cyclization of Nα-Boc-dipeptidyl-tert-Bu (Boc = tert-butoxycarbonyl) and Me esters under microwave irradn. afforded 2,5-diketopiperazines (DKPs) in excellent yields.  This protocol is rapid, safe, environmentally friendly, and highly efficient, and showed that the tert-butoxy moiety is also an excellent leaving group for these cyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLNSJTOYunB7Vg90H21EOLACvtfcHk0ljeqe7tRg3_7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVShtbrM&md5=cc9d2776dc2c2712ccf13e641853c945</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3390%2Fmolecules14082836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules14082836%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Picaso%26aufirst%3DL.%26aulast%3DEscalante%26aufirst%3DJ.%26aulast%3DOlivo%26aufirst%3DH.%26aulast%3DRios%26aufirst%3DM.%2BY.%26atitle%3DEfficient%2520Microwave%2520Assisted%2520Syntheses%2520of%25202%252C5-Diketopiperazines%2520in%2520Aqueous%2520Media%26jtitle%3DMolecules%26date%3D2009%26volume%3D14%26spage%3D2836%26epage%3D2849%26doi%3D10.3390%2Fmolecules14082836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">la Porte, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">Role of P-Glycoprotein in the Distribution of the HIV Protease Inhibitor Atazanavir in the Brain and Male Genital Tract</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1722</span>, <span class="refDoi"> DOI: 10.1128/aac.02031-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1128%2Faac.02031-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1713-1722&author=K.+R.+Robillardauthor=G.+N.+Y.+Chanauthor=G.+Zhangauthor=W.+la+Porteauthor=R.+Bendayan&title=Role+of+P-Glycoprotein+in+the+Distribution+of+the+HIV+Protease+Inhibitor+Atazanavir+in+the+Brain+and+Male+Genital+Tract&doi=10.1128%2Faac.02031-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2Faac.02031-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Faac.02031-13%26sid%3Dliteratum%253Aachs%26aulast%3DRobillard%26aufirst%3DK.%2BR.%26aulast%3DChan%26aufirst%3DG.%2BN.%2BY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3Dla%2BPorte%26aufirst%3DW.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DRole%2520of%2520P-Glycoprotein%2520in%2520the%2520Distribution%2520of%2520the%2520HIV%2520Protease%2520Inhibitor%2520Atazanavir%2520in%2520the%2520Brain%2520and%2520Male%2520Genital%2520Tract%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1713%26epage%3D1722%26doi%3D10.1128%2Faac.02031-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kis, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">In vitro and In situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2404</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.1007/s11095-014-1336-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs11095-014-1336-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2404-2419&author=O.+Kisauthor=S.+L.+Walmsleyauthor=R.+Bendayan&title=In+vitro+and+In+situ+Evaluation+of+pH-Dependence+of+Atazanavir+Intestinal+Permeability+and+Interactions+with+Acid-Reducing+Agents&doi=10.1007%2Fs11095-014-1336-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs11095-014-1336-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-014-1336-0%26sid%3Dliteratum%253Aachs%26aulast%3DKis%26aufirst%3DO.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520and%2520In%2520situ%2520Evaluation%2520of%2520pH-Dependence%2520of%2520Atazanavir%2520Intestinal%2520Permeability%2520and%2520Interactions%2520with%2520Acid-Reducing%2520Agents%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D2404%26epage%3D2419%26doi%3D10.1007%2Fs11095-014-1336-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ashley N. Matthew, Florian Leidner, Gordon J. Lockbaum, Mina Henes, Jacqueto Zephyr, Shurong Hou, Desaboini Nageswara Rao, Jennifer Timm, Linah N. Rusere, Debra A. Ragland, Janet L. Paulsen, Kristina Prachanronarong, Djade I. Soumana, Ellen A. Nalivaika, Nese Kurt Yilmaz, Akbar Ali, <span class="NLM_string-name hlFld-ContribAuthor">Celia A. Schiffer</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3238-3270. <a href="https://doi.org/10.1021/acs.chemrev.0c00648" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00648%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DDrug%252BDesign%252BStrategies%252Bto%252BAvoid%252BResistance%252Bin%252BDirect-Acting%252BAntivirals%252Band%252BBeyond%26aulast%3DMatthew%26aufirst%3DAshley%2BN.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D22062020%26date%3D07012021%26volume%3D121%26issue%3D6%26spage%3D3238%26epage%3D3270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">John T. Randolph, Eric A. Voight, Stephen N. Greszler, Brice E. Uno, James N. Newton, Kenneth M. Gleason, DeAnne Stolarik, Cecilia Van Handel, Daniel A. J. Bow, <span class="NLM_string-name hlFld-ContribAuthor">David A. DeGoey</span>. </span><span class="cited-content_cbyCitation_article-title">Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (19)
                                     , 11034-11044. <a href="https://doi.org/10.1021/acs.jmedchem.0c00956" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00956</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00956%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DProdrug%252BStrategies%252Bto%252BImprove%252Bthe%252BSolubility%252Bof%252Bthe%252BHCV%252BNS5A%252BInhibitor%252BPibrentasvir%252B%252528ABT-530%252529%26aulast%3DRandolph%26aufirst%3DJohn%2BT.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04062020%26date%3D17092020%26date%3D03092020%26volume%3D63%26issue%3D19%26spage%3D11034%26epage%3D11044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yonggao  Zheng</span>, <span class="hlFld-ContribAuthor ">Yanwei  Zhao</span>, <span class="hlFld-ContribAuthor ">Suyan  Tao</span>, <span class="hlFld-ContribAuthor ">Xingxing  Li</span>, <span class="hlFld-ContribAuthor ">Xionglve  Cheng</span>, <span class="hlFld-ContribAuthor ">Gangzhong  Jiang</span>, <span class="hlFld-ContribAuthor ">Xiaobing  Wan</span>. </span><span class="cited-content_cbyCitation_article-title">Green Esterification of Carboxylic Acids Promoted by
              tert
              ‐Butyl Nitrite. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (18)
                                     , 2713-2718. <a href="https://doi.org/10.1002/ejoc.202100326" title="DOI URL">https://doi.org/10.1002/ejoc.202100326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202100326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202100326%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DGreen%252BEsterification%252Bof%252BCarboxylic%252BAcids%252BPromoted%252Bby%252Btert%252B%2525E2%252580%252590Butyl%252BNitrite%26aulast%3DZheng%26aufirst%3DYonggao%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D18%26spage%3D2713%26epage%3D2718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nikhilesh V.  Dhuria</span>, <span class="hlFld-ContribAuthor ">Bianka  Haro</span>, <span class="hlFld-ContribAuthor ">Amit  Kapadia</span>, <span class="hlFld-ContribAuthor ">Khadjia A.  Lobo</span>, <span class="hlFld-ContribAuthor ">Bernice  Matusow</span>, <span class="hlFld-ContribAuthor ">Mary A.  Schleiff</span>, <span class="hlFld-ContribAuthor ">Christina  Tantoy</span>, <span class="hlFld-ContribAuthor ">Jasleen K.  Sodhi</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in predicting CYP-independent metabolism. </span><span class="cited-content_cbyCitation_journal-name">Drug Metabolism Reviews</span><span> <strong>2021,</strong> <em>53 </em>
                                    (2)
                                     , 188-206. <a href="https://doi.org/10.1080/03602532.2021.1923728" title="DOI URL">https://doi.org/10.1080/03602532.2021.1923728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/03602532.2021.1923728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F03602532.2021.1923728%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Metabolism%2520Reviews%26atitle%3DRecent%252Bdevelopments%252Bin%252Bpredicting%252BCYP-independent%252Bmetabolism%26aulast%3DDhuria%26aufirst%3DNikhilesh%2BV.%26date%3D2021%26date%3D2021%26volume%3D53%26issue%3D2%26spage%3D188%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Murugesan  Shyamsundar</span>, <span class="hlFld-ContribAuthor ">Siddheshwar Kisan  Chauthe</span>, <span class="hlFld-ContribAuthor ">Lakshumanan  Subramani</span>, <span class="hlFld-ContribAuthor ">Murugaiah A. M.  Subbaiah</span>, <span class="hlFld-ContribAuthor ">Anuradha  Gupta</span>, <span class="hlFld-ContribAuthor ">Lakshmikant  Bajpai</span>, <span class="hlFld-ContribAuthor ">Muralidhararao  Bagadi</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>. </span><span class="cited-content_cbyCitation_article-title">Separation and preparative purification of
              l
              ‐ and
              d
              ‐valine ester: Diastereomeric conjugates of atazanavir using a combination of 2‐propanol and acetonitrile in reversed‐phase high‐performance liquid chromatography. </span><span class="cited-content_cbyCitation_journal-name">SEPARATION SCIENCE PLUS</span><span> <strong>2021,</strong> <em>4 </em>
                                    (1)
                                     , 16-23. <a href="https://doi.org/10.1002/sscp.202000046" title="DOI URL">https://doi.org/10.1002/sscp.202000046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/sscp.202000046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fsscp.202000046%26sid%3Dliteratum%253Aachs%26jtitle%3DSEPARATION%2520SCIENCE%2520PLUS%26atitle%3DSeparation%252Band%252Bpreparative%252Bpurification%252Bof%252Bl%252B%2525E2%252580%252590%252Band%252Bd%252B%2525E2%252580%252590valine%252Bester%25253A%252BDiastereomeric%252Bconjugates%252Bof%252Batazanavir%252Busing%252Ba%252Bcombination%252Bof%252B2%2525E2%252580%252590propanol%252Band%252Bacetonitrile%252Bin%252Breversed%2525E2%252580%252590phase%252Bhigh%2525E2%252580%252590performance%252Bliquid%252Bchromatography%26aulast%3DShyamsundar%26aufirst%3DMurugesan%26date%3D2021%26date%3D2020%26volume%3D4%26issue%3D1%26spage%3D16%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luis  Menéndez-Arias</span>, <span class="hlFld-ContribAuthor ">Samara  Martín-Alonso</span>, <span class="hlFld-ContribAuthor ">Estrella  Frutos-Beltrán</span>. </span><span class="cited-content_cbyCitation_article-title">An Update on Antiretroviral Therapy. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 31-61. <a href="https://doi.org/10.1007/978-981-16-0267-2_2" title="DOI URL">https://doi.org/10.1007/978-981-16-0267-2_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-16-0267-2_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-16-0267-2_2%26sid%3Dliteratum%253Aachs%26atitle%3DAn%252BUpdate%252Bon%252BAntiretroviral%252BTherapy%26aulast%3DMen%25C3%25A9ndez-Arias%26aufirst%3DLuis%26date%3D2021%26date%3D2021%26spage%3D31%26epage%3D61%26pub%3DSpringer%2520Singapore%26atitle%3DAntiviral%252BDrug%252BDiscovery%252Band%252BDevelopment%26aulast%3DLiu%26aufirst%3DXinyong%26date%3D2021%26volume%3D1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rodrigo Vieira  Gonzaga</span>, <span class="hlFld-ContribAuthor ">Lucas Adriano  do Nascimento</span>, <span class="hlFld-ContribAuthor ">Soraya Silva  Santos</span>, <span class="hlFld-ContribAuthor ">Bruna Araujo  Machado Sanches</span>, <span class="hlFld-ContribAuthor ">Jeanine  Giarolla</span>, <span class="hlFld-ContribAuthor ">Elizabeth Igne  Ferreira</span>. </span><span class="cited-content_cbyCitation_article-title">Perspectives About Self-Immolative Drug Delivery Systems. </span><span class="cited-content_cbyCitation_journal-name">Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>109 </em>
                                    (11)
                                     , 3262-3281. <a href="https://doi.org/10.1016/j.xphs.2020.08.014" title="DOI URL">https://doi.org/10.1016/j.xphs.2020.08.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.xphs.2020.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.xphs.2020.08.014%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DPerspectives%252BAbout%252BSelf-Immolative%252BDrug%252BDelivery%252BSystems%26aulast%3DGonzaga%26aufirst%3DRodrigo%2BVieira%26date%3D2020%26volume%3D109%26issue%3D11%26spage%3D3262%26epage%3D3281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gengqi  Liu</span>, <span class="hlFld-ContribAuthor ">Jonathan F.  Lovell</span>, <span class="hlFld-ContribAuthor ">Lei  Zhang</span>, <span class="hlFld-ContribAuthor ">Yumiao  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2020,</strong> <em>21 </em>
                                    (17)
                                     , 6380. <a href="https://doi.org/10.3390/ijms21176380" title="DOI URL">https://doi.org/10.3390/ijms21176380</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms21176380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms21176380%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStimulus-Responsive%252BNanomedicines%252Bfor%252BDisease%252BDiagnosis%252Band%252BTreatment%26aulast%3DLiu%26aufirst%3DGengqi%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D17%26spage%3D6380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanjeev  Kumar</span>, <span class="hlFld-ContribAuthor ">Firoz A.  Jaipuri</span>, <span class="hlFld-ContribAuthor ">Jesse P.  Waldo</span>, <span class="hlFld-ContribAuthor ">Hima  Potturi</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Marcinowicz</span>, <span class="hlFld-ContribAuthor ">James  Adams</span>, <span class="hlFld-ContribAuthor ">Clarissa  Van Allen</span>, <span class="hlFld-ContribAuthor ">Hong  Zhuang</span>, <span class="hlFld-ContribAuthor ">Nicholas  Vahanian</span>, <span class="hlFld-ContribAuthor ">Charles  Link</span>, <span class="hlFld-ContribAuthor ">Erik L.  Brincks</span>, <span class="hlFld-ContribAuthor ">Mario R.  Mautino</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>198 </em>, 112373. <a href="https://doi.org/10.1016/j.ejmech.2020.112373" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112373</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112373&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112373%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bindoximod%252Bprodrugs%252Band%252Bcharacterization%252Bof%252Bclinical%252Bcandidate%252BNLG802%26aulast%3DKumar%26aufirst%3DSanjeev%26date%3D2020%26volume%3D198%26spage%3D112373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Dai</span>, <span class="hlFld-ContribAuthor ">Hai  Huang</span>, <span class="hlFld-ContribAuthor ">Yang  Zhu</span>, <span class="hlFld-ContribAuthor ">Junjie  Cheng</span>, <span class="hlFld-ContribAuthor ">Ai-Zong  Shen</span>, <span class="hlFld-ContribAuthor ">Yangzhong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Combating metastasis of breast cancer cells with a carboplatin analogue containing an all-trans retinoic acid ligand. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2020,</strong> <em>49 </em>
                                    (16)
                                     , 5039-5043. <a href="https://doi.org/10.1039/D0DT00507J" title="DOI URL">https://doi.org/10.1039/D0DT00507J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0DT00507J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0DT00507J%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DCombating%252Bmetastasis%252Bof%252Bbreast%252Bcancer%252Bcells%252Bwith%252Ba%252Bcarboplatin%252Banalogue%252Bcontaining%252Ban%252Ball-trans%252Bretinoic%252Bacid%252Bligand%26aulast%3DDai%26aufirst%3DYi%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D16%26spage%3D5039%26epage%3D5043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fangyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Long-Sheng  Zheng</span>, <span class="hlFld-ContribAuthor ">Qi-Wei  Lang</span>, <span class="hlFld-ContribAuthor ">Congcong  Yin</span>, <span class="hlFld-ContribAuthor ">Ting  Wu</span>, <span class="hlFld-ContribAuthor ">Phannarath  Phansavath</span>, <span class="hlFld-ContribAuthor ">Gen-Qiang  Chen</span>, <span class="hlFld-ContribAuthor ">Virginie  Ratovelomanana-Vidal</span>, <span class="hlFld-ContribAuthor ">Xumu  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Rh(
              iii
              )-Catalyzed diastereoselective transfer hydrogenation: an efficient entry to key intermediates of HIV protease inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (21)
                                     , 3119-3122. <a href="https://doi.org/10.1039/C9CC09793G" title="DOI URL">https://doi.org/10.1039/C9CC09793G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC09793G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC09793G%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DRh%252528%252Biii%252B%252529-Catalyzed%252Bdiastereoselective%252Btransfer%252Bhydrogenation%25253A%252Ban%252Befficient%252Bentry%252Bto%252Bkey%252Bintermediates%252Bof%252BHIV%252Bprotease%252Binhibitors%26aulast%3DWang%26aufirst%3DFangyuan%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D21%26spage%3D3119%26epage%3D3122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyu  Liu</span>, <span class="hlFld-ContribAuthor ">Heng  Song</span>, <span class="hlFld-ContribAuthor ">Xiaofang  Zhai</span>, <span class="hlFld-ContribAuthor ">Chen-Ho  Tung</span>, <span class="hlFld-ContribAuthor ">Wenguang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Cobalt-catalyzed regioselective hydrohydrazination of epoxides. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2020,</strong> <em>18 </em>
                                    (8)
                                     , 1572-1576. <a href="https://doi.org/10.1039/D0OB00037J" title="DOI URL">https://doi.org/10.1039/D0OB00037J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0OB00037J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0OB00037J%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DCobalt-catalyzed%252Bregioselective%252Bhydrohydrazination%252Bof%252Bepoxides%26aulast%3DLiu%26aufirst%3DXiangyu%26date%3D2020%26date%3D2020%26volume%3D18%26issue%3D8%26spage%3D1572%26epage%3D1576" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chang-Shun  Liu</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Yan-Nan  Hu</span>, <span class="hlFld-ContribAuthor ">Jin-Lian  Dai</span>, <span class="hlFld-ContribAuthor ">Biao  Ma</span>, <span class="hlFld-ContribAuthor ">Qing-Fa  Tang</span>, <span class="hlFld-ContribAuthor ">Xiao-Mei  Tan</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Self-Microemulsifying Drug Delivery System for Improved Oral Delivery and Hypnotic Efficacy of Ferulic Acid</p>. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Nanomedicine</span><span> <strong>2020,</strong> <em>Volume 15 </em>, 2059-2070. <a href="https://doi.org/10.2147/IJN.S240449" title="DOI URL">https://doi.org/10.2147/IJN.S240449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/IJN.S240449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FIJN.S240449%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Nanomedicine%26atitle%3D%25253Cp%25253ESelf-Microemulsifying%252BDrug%252BDelivery%252BSystem%252Bfor%252BImproved%252BOral%252BDelivery%252Band%252BHypnotic%252BEfficacy%252Bof%252BFerulic%252BAcid%25253C%25252Fp%25253E%26aulast%3DLiu%26aufirst%3DChang-Shun%26date%3D2020%26date%3D2020%26volume%3DVolume%252015%26spage%3D2059%26epage%3D2070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing  Li</span>, <span class="hlFld-ContribAuthor ">Liuwei  Meng</span>, <span class="hlFld-ContribAuthor ">Siru  Zhou</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Deng</span>, <span class="hlFld-ContribAuthor ">Na  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Ji</span>, <span class="hlFld-ContribAuthor ">Yichun  Peng</span>, <span class="hlFld-ContribAuthor ">Junhao  Xing</span>, <span class="hlFld-ContribAuthor ">Gongmei  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Rapid generation of novel benzoic acid–based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>180 </em>, 509-523. <a href="https://doi.org/10.1016/j.ejmech.2019.07.045" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.07.045</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.07.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.07.045%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRapid%252Bgeneration%252Bof%252Bnovel%252Bbenzoic%252Bacid%2525E2%252580%252593based%252Bxanthine%252Bderivatives%252Bas%252Bhighly%252Bpotent%25252C%252Bselective%252Band%252Blong%252Bacting%252BDPP-4%252Binhibitors%25253A%252BScaffold-hopping%252Band%252Bprodrug%252Bstudy%26aulast%3DLi%26aufirst%3DQing%26date%3D2019%26volume%3D180%26spage%3D509%26epage%3D523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arduino  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jean  Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Jóhannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Maria  Sousa</span>, <span class="hlFld-ContribAuthor ">Paula  Gomes</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">F.  Luque</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">M.  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Luigi  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–5. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (13)
                                     , 2415. <a href="https://doi.org/10.3390/molecules24132415" title="DOI URL">https://doi.org/10.3390/molecules24132415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24132415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24132415%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525935%26aulast%3DMangoni%26aufirst%3DArduino%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D13%26spage%3D2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of PIs <b>1</b>, <b>3</b>, <b>5</b>, and <b>7</b> and their direct phosphate prodrugs (<b>2</b> is described in this article; <b>4</b>, <b>6</b>, and <b>8</b> have been reported in the literature<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Direct (<b>2</b>) and Methylene-Bridged (<b>11</b>) Phosphate-Based Prodrugs of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) dibenzyl <i>N</i>,<i>N</i>-diisopropylphosphoramidite, 1<i>H</i>-tetrazole (0.4 M in CH<sub>3</sub>CN), CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h, then 30% aqueous H<sub>2</sub>O<sub>2</sub> solution, 62%; (b) CF<sub>3</sub>CO<sub>2</sub>H, anisole, ClCH<sub>2</sub>CH<sub>2</sub>Cl, 0 °C to RT, 16 h, 72%; (c) Ac<sub>2</sub>O, AcOH, dimethyl sulfoxide (DMSO), RT 48 h, 79%; (d) <i>N</i>-iodosuccinimide, H<sub>3</sub>PO<sub>4</sub>, 4 Å molecular sieves, tetrahydrofuran (THF), 0 °C to RT, 30 min, then CH<sub>3</sub>OH, 1 M Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub> (solid), 45%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Stereoisomeric Val-Based Ester <b>23</b> and <b>24</b> and Val–Val-Based Dipeptide Ester Prodrugs <b>29–32</b> of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val for <b>21</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val, DCC, 4-dimethylaminopyridine (DMAP), CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h; yields: <b>21</b> = 41%; <b>22</b> = 23%; (b) 4 N HCl in dioxane, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT, 1 h; yields: <b>23</b> = 85%; <b>24</b> = 88%. (c) <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Val for <b>25</b> and <b>27</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Val for <b>26</b> and <b>28</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h; yields: <b>25</b> = 45%, <b>26</b> = 42%, <b>27</b> = 58%, <b>28</b> = 64%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h; yields: <b>29</b> = 76%, <b>30</b> = 80%, <b>31</b> = 85%, <b>32</b> = 81%.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Amino Acid Prodrugs of <b>1</b> in Which Smaller or Larger Amino Acid Residues than That of <span class="smallcaps smallerCapital">l</span>-Val Are Explored<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <i>N</i>-Boc-amino acid except in the case of <b>46</b>, for which dimethylgycine was used, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14–16 h; yields: <b>34</b> = 76%, <b>35</b> = 64%, <b>46</b> = 57%, <b>36</b> = 64%, <b>37</b> = 60%, <b>38</b> = 37%, <b>39</b> = 42%, <b>40</b> = 49%, <b>41</b> = 45%, <b>42</b> = 74%, <b>43</b> = 71%; (b) for all N-Boc derivatives: 4 N HCl in dioxane, 0 °C to RT, 1–2 h.; yield: <b>44</b> = 89%, <b>45</b> = 19%, <b>47</b> = 98%, <b>48</b> = 99%, <b>49</b> = 76%, <b>50</b> = 80%, <b>51</b> = 94%, <b>52</b> = 94%, <b>53</b> = 85%, <b>54</b> = 95%.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the <span class="smallcaps smallerCapital">l</span>-Tyrosine-Based Amino Acid Ester Prodrug <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) TBDMS-Cl, imidazole, DMF, RT, 16 h, 62%; (b) <b>1</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 68%; (c) TBAF, THF, 0 °C, 1 h, 72%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h, 84%.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 4-Fluorophenylalanine Amino Acid Ester Prodrug <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, RT, 2 h, 95%; (b) LiOH, THF, H<sub>2</sub>O, 0 °C, 2 h, 93%; (c) <b>1</b>, <b>62</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 58%; (d) 4 N HCl in dioxane, 0 °C to RT, 1 h, 74%.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <span class="smallcaps smallerCapital">l</span>-Trp Amino Acid Ester Prodrug <b>66</b> and <i>N</i>-Benzylglycine Amino Acid Ester Prodrug <b>71</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <i>N</i>-Boc-Trp, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 14 h, 52%; (b) 4 N HCl in dioxane, 0 °C to RT, 1 h, 68%. (c) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to RT, 12 h, 92%; (d) LiOH, THF, H<sub>2</sub>O, 0 °C, 2 h, 95%; (e) <b>69</b>, DCC, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, RT, 16 h, 89%; (f) 4 N HCl in dioxane, 0 °C, 1 h, 95%.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Linker-Enabled Chemo-Activatable Prodrug Design To Improve the Bioactivation of Prodrug <b>53</b> with the Prodrug Moieties Depicted in Blue</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/medium/jm-2019-00002n_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <span class="smallcaps smallerCapital">l</span>-Phe-Gly-<b>1</b> (<b>72</b>), <span class="smallcaps smallerCapital">d</span>-Phe-Gly-<b>1</b> (<b>78</b>), <span class="smallcaps smallerCapital">l</span>-Phe-Sar-<b>1</b> (<b>74</b>), and the <i>N</i>-Me and <i>N</i>,<i>N</i>-Dimethyl Homologues <b>81</b> and <b>82</b> as Potential Dipeptide Ester-Based Prodrugs of <b>1</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-7/acs.jmedchem.9b00002/20190404/images/large/jm-2019-00002n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00002&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions. (a) <b>44</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Phe for <b>76</b> or <i>N</i>-Boc-<span class="smallcaps smallerCapital">d</span>-Phe for <b>77</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h; yields: <b>76</b> = 64%; <b>77</b> = 65%; (b) <b>45</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-Phe for <b>79</b>, <i>N</i>-Boc-<span class="smallcaps smallerCapital">l</span>-<i>N</i>-MePhe for <b>80</b>, or <span class="smallcaps smallerCapital">l</span>-<i>N</i>,<i>N</i>-dimethylPhe for <b>82</b>, HATU, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, RT, 8 h; yields: <b>79</b> = 81%; <b>80</b> = 32%; <b>82</b> = 35%; (c) 4 N HCl in dioxane, 0 °C to RT, 1 h; yields: <b>72</b> = 72%; <b>78</b> = 93%; <b>74</b> = 98%; <b>81</b> = 87%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i48">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16325" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16325" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 70 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fordyce, M.</span></span> <span> </span><span class="NLM_article-title">Current status and prospects of HIV treatment</span>. <i>Curr. Opin. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1016/j.coviro.2016.03.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.coviro.2016.03.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=27023283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28Xksl2nsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2016&pages=50-56&author=T.+Cihlarauthor=M.+Fordyce&title=Current+status+and+prospects+of+HIV+treatment&doi=10.1016%2Fj.coviro.2016.03.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Current status and prospects of HIV treatment</span></div><div class="casAuthors">Cihlar, Tomas; Fordyce, Marshall</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Virology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">50-56</span>CODEN:
                <span class="NLM_cas:coden">COVUAF</span>;
        ISSN:<span class="NLM_cas:issn">1879-6257</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">Current antiviral treatments can reduce HIV-assocd. morbidity, prolong survival, and prevent HIV transmission.  Combination antiretroviral therapy (cART) contg. preferably three active drugs from two or more classes is required for durable virol. suppression.  Regimen selection is based on virol. efficacy, potential for adverse effects, pill burden and dosing frequency, drug-drug interaction potential, resistance test results, comorbid conditions, social status, and cost.  With prolonged virol. suppression, improved clin. outcomes, and longer survival, patients will be exposed to antiretroviral agents for decades.  Therefore, maximizing the safety and tolerability of cART is a high priority.  Emergence of resistance and/or lack of tolerability in individual patients require availability of a range of treatment options.  Development of new drugs is focused on improving safety (e.g. tenofovir alafenamide) and/or resistance profile (e.g. doravirine) within the existing drug classes, combination therapies with improved adherence (e.g. single-tablet regimens), novel mechanisms of action (e.g. attachment inhibitors, maturation inhibitors, broadly neutralizing antibodies), and treatment simplification with infrequent dosing (e.g. long-acting injectables).  In parallel with cART innovations, research and development efforts focused on agents that target persistent HIV reservoirs may lead to prolonged drug-free remission and HIV cure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpHDvTzsN1MbVg90H21EOLACvtfcHk0lhLYYukb2MOHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xksl2nsrw%253D&md5=8f134da24f9491b3b2ac68bf7086de0f</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.coviro.2016.03.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coviro.2016.03.004%26sid%3Dliteratum%253Aachs%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DFordyce%26aufirst%3DM.%26atitle%3DCurrent%2520status%2520and%2520prospects%2520of%2520HIV%2520treatment%26jtitle%3DCurr.%2520Opin.%2520Virol.%26date%3D2016%26volume%3D18%26spage%3D50%26epage%3D56%26doi%3D10.1016%2Fj.coviro.2016.03.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samji, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cescon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modur, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althoff, K. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchacz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burchell, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebo, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Justice, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korthuis, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Napravnik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rourke, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sterling, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverberg, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deeks, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, L. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosch, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitahata, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gange, S. J.</span></span> <span> </span><span class="NLM_article-title">The North American AIDS Collaboration on Research and Design (NA-ACCORD) of leDEA. Closing the Gap: Increases in Life Expectancy Among Treated HIV-Positive Individuals in the United States and Canada</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e81355</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0081355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1371%2Fjournal.pone.0081355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24367482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFelu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=H.+Samjiauthor=A.+Cesconauthor=R.+S.+Hoggauthor=S.+P.+Modurauthor=K.+N.+Althoffauthor=K.+Buchaczauthor=A.+N.+Burchellauthor=M.+Cohenauthor=K.+A.+Geboauthor=M.+J.+Gillauthor=A.+Justiceauthor=G.+Kirkauthor=M.+B.+Kleinauthor=P.+T.+Korthuisauthor=J.+Martinauthor=S.+Napravnikauthor=S.+B.+Rourkeauthor=T.+R.+Sterlingauthor=M.+J.+Silverbergauthor=S.+Deeksauthor=L.+P.+Jacobsonauthor=R.+J.+Boschauthor=M.+M.+Kitahataauthor=J.+J.+Goedertauthor=R.+Mooreauthor=S.+J.+Gange&title=The+North+American+AIDS+Collaboration+on+Research+and+Design+%28NA-ACCORD%29+of+leDEA.+Closing+the+Gap%3A+Increases+in+Life+Expectancy+Among+Treated+HIV-Positive+Individuals+in+the+United+States+and+Canada&doi=10.1371%2Fjournal.pone.0081355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada</span></div><div class="casAuthors">Samji, Hasina; Cescon, Angela; Hogg, Robert S.; Modur, Sharada P.; Althoff, Keri N.; Buchacz, Kate; Burchell, Ann N.; Cohen, Mardge; Gebo, Kelly A.; Gill, M. John; Justice, Amy; Kirk, Gregory; Klein, Marina B.; Korthuis, P. Todd; Martin, Jeff; Napravnik, Sonia; Rourke, Sean B.; Sterling, Timothy R.; Silverberg, Michael J.; Deeks, Stephen; Jacobson, Lisa P.; Bosch, Ronald J.; Kitahata, Mari M.; Goedert, James J.; Moore, Richard; Gange, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">e81355/1-e81355/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Background: Combination antiretroviral therapy (ART) has significantly increased survival among HIV-pos. adults in the United States (U.S.) and Canada, but gains in life expectancy for this region have not been well characterized.  We aim to est. temporal changes in life expectancy among HIV-pos. adults on ART from 2000-2007 in the U.S. and Canada.  Methods: Participants were from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), aged ≥20 years and on ART.  Mortality rates were calcd. using participants' person-time from Jan. 1, 2000 or ART initiation until death, loss to follow-up, or administrative censoring Dec. 31, 2007.  Life expectancy at age 20, defined as the av. no. of addnl. years that a person of a specific age will live, provided the current age-specific mortality rates remain const., was estd. using abridged life tables.  Results: The crude mortality rate was 19.8/1,000 person-years, among 22,937 individuals contributing 82,022 person-years and 1,622 deaths.  Life expectancy increased from 36.1 [std. error (SE) 0.5] to 51.4 [SE 0.5] years from 2000-2002 to 2006-2007.  Men and women had comparable life expectancies in all periods except the last (2006-2007).  Life expectancy was lower for individuals with a history of injection drug use, non-whites, and in patients with baseline CD4 counts <350 cells/mm3.  Conclusions: A 20-yr-old HIV-pos. adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.  Differences by sex, race, HIV transmission risk group, and CD4 count remain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodU0sf4oNl_rVg90H21EOLACvtfcHk0lhfuQDO6zeEMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFelu74%253D&md5=feac75560fc0fb2d4066e4ba09537398</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0081355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0081355%26sid%3Dliteratum%253Aachs%26aulast%3DSamji%26aufirst%3DH.%26aulast%3DCescon%26aufirst%3DA.%26aulast%3DHogg%26aufirst%3DR.%2BS.%26aulast%3DModur%26aufirst%3DS.%2BP.%26aulast%3DAlthoff%26aufirst%3DK.%2BN.%26aulast%3DBuchacz%26aufirst%3DK.%26aulast%3DBurchell%26aufirst%3DA.%2BN.%26aulast%3DCohen%26aufirst%3DM.%26aulast%3DGebo%26aufirst%3DK.%2BA.%26aulast%3DGill%26aufirst%3DM.%2BJ.%26aulast%3DJustice%26aufirst%3DA.%26aulast%3DKirk%26aufirst%3DG.%26aulast%3DKlein%26aufirst%3DM.%2BB.%26aulast%3DKorthuis%26aufirst%3DP.%2BT.%26aulast%3DMartin%26aufirst%3DJ.%26aulast%3DNapravnik%26aufirst%3DS.%26aulast%3DRourke%26aufirst%3DS.%2BB.%26aulast%3DSterling%26aufirst%3DT.%2BR.%26aulast%3DSilverberg%26aufirst%3DM.%2BJ.%26aulast%3DDeeks%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DL.%2BP.%26aulast%3DBosch%26aufirst%3DR.%2BJ.%26aulast%3DKitahata%26aufirst%3DM.%2BM.%26aulast%3DGoedert%26aufirst%3DJ.%2BJ.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DGange%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520North%2520American%2520AIDS%2520Collaboration%2520on%2520Research%2520and%2520Design%2520%2528NA-ACCORD%2529%2520of%2520leDEA.%2520Closing%2520the%2520Gap%253A%2520Increases%2520in%2520Life%2520Expectancy%2520Among%2520Treated%2520HIV-Positive%2520Individuals%2520in%2520the%2520United%2520States%2520and%2520Canada%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0081355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">2849</span>– <span class="NLM_lpage">2878</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00497</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00497" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=2849-2878&author=P.+Zhanauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=X.+Liu&title=Anti-HIV+Drug+Discovery+and+Development%3A+Current+Innovations+and+Future+Trends&doi=10.1021%2Facs.jmedchem.5b00497"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends</span></div><div class="casAuthors">Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik; Liu, Xinyong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2849-2878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The early effectiveness of combinatorial antiretroviral therapy (cART) in the treatment of HIV infection has been compromised to some extent by rapid development of multidrug-resistant HIV strains, poor bioavailability, and cumulative toxicities, and so there is a need for alternative strategies of antiretroviral drug discovery and addnl. therapeutic agents with novel action modes or targets.  From this perspective, we first review current strategies of antiretroviral drug discovery and optimization, with the aid of selected examples from the recent literature.  We highlight the development of phosphate ester-based prodrugs as a means to improve the aq. soly. of HIV inhibitors, and the introduction of the substrate envelope hypothesis as a new approach for overcoming HIV drug resistance.  Finally, we discuss future directions for research, including opportunities for exploitation of novel antiretroviral targets, and the strategy of activation of latent HIV reservoirs as a means to eradicate the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3sWUJPJgQN7Vg90H21EOLACvtfcHk0lhfuQDO6zeEMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslCjur3E&md5=de3f5aee273b0dd6f7e84e20410d06d7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00497%26sid%3Dliteratum%253Aachs%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DAnti-HIV%2520Drug%2520Discovery%2520and%2520Development%253A%2520Current%2520Innovations%2520and%2520Future%2520Trends%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D2849%26epage%3D2878%26doi%3D10.1021%2Facs.jmedchem.5b00497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osswald, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prato, G.</span></span> <span> </span><span class="NLM_article-title">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5172</span>– <span class="NLM_lpage">5208</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01697</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01697" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5172-5208&author=A.+K.+Ghoshauthor=H.+L.+Osswaldauthor=G.+Prato&title=Recent+Progress+in+the+Development+of+HIV-1+Protease+Inhibitors+for+the+Treatment+of+HIV%2FAIDS&doi=10.1021%2Facs.jmedchem.5b01697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS</span></div><div class="casAuthors">Ghosh, Arun K.; Osswald, Heather L.; Prato, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5172-5208</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors continue to play an important role in the treatment of HIV/AIDS, transforming this deadly ailment into a more manageable chronic infection.  Over the years, intensive research has led to a variety of approved protease inhibitors for the treatment of HIV/AIDS.  In this review, we outline current drug design and medicinal chem. efforts toward the development of next-generation protease inhibitors beyond the currently approved drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4DisuSRbQXbVg90H21EOLACvtfcHk0lhfuQDO6zeEMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVyhsL0%253D&md5=e0994f3d84ab627d3ac3f757e8d11725</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01697%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DOsswald%26aufirst%3DH.%2BL.%26aulast%3DPrato%26aufirst%3DG.%26atitle%3DRecent%2520Progress%2520in%2520the%2520Development%2520of%2520HIV-1%2520Protease%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520HIV%252FAIDS%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5172%26epage%3D5208%26doi%3D10.1021%2Facs.jmedchem.5b01697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Midde, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patters, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cory, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S.</span></span> <span> </span><span class="NLM_article-title">Investigational Protease Inhibitors as Antiretroviral Therapies</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1189</span>– <span class="NLM_lpage">1200</span>, <span class="refDoi"> DOI: 10.1080/13543784.2016.1212837</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1080%2F13543784.2016.1212837" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2016&pages=1189-1200&author=N.+M.+Middeauthor=B.+J.+Pattersauthor=P.+Raoauthor=T.+J.+Coryauthor=S.+Kumar&title=Investigational+Protease+Inhibitors+as+Antiretroviral+Therapies&doi=10.1080%2F13543784.2016.1212837"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1080%2F13543784.2016.1212837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2016.1212837%26sid%3Dliteratum%253Aachs%26aulast%3DMidde%26aufirst%3DN.%2BM.%26aulast%3DPatters%26aufirst%3DB.%2BJ.%26aulast%3DRao%26aufirst%3DP.%26aulast%3DCory%26aufirst%3DT.%2BJ.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DInvestigational%2520Protease%2520Inhibitors%2520as%2520Antiretroviral%2520Therapies%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2016%26volume%3D25%26spage%3D1189%26epage%3D1200%26doi%3D10.1080%2F13543784.2016.1212837" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Farajallah, A.</span>; <span class="NLM_string-name">Bunch, R. T.</span>; <span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Atazanavir</span>.  <i>Antiviral Drugs</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">New Jersey</span>, <span class="NLM_year">2011</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">17</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2F9780470929353.ch1" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&pages=1-17&author=A.+Farajallah&author=R.+T.+Bunch&author=N.+A.+Meanwell&title=Antiviral+Drugs"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1002%2F9780470929353.ch1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1002%252F9780470929353.ch1%26sid%3Dliteratum%253Aachs%26aulast%3DFarajallah%26aufirst%3DA.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Atazanavir%26btitle%3DAntiviral%2520Drugs%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2011%26spage%3D1%26epage%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Günthard, H. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saag, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benson, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">del Rio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eron, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugavero, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sax, P. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landovitz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volberding, P. A.</span></span> <span> </span><span class="NLM_article-title">Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">210</span>, <span class="refDoi"> DOI: 10.1001/jama.2016.8900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1001%2Fjama.2016.8900" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2016&pages=191-210&author=H.+F.+G%C3%BCnthardauthor=M.+S.+Saagauthor=C.+A.+Bensonauthor=C.+del+Rioauthor=J.+J.+Eronauthor=J.+E.+Gallantauthor=J.+F.+Hoyauthor=M.+J.+Mugaveroauthor=P.+E.+Saxauthor=M.+A.+Thompsonauthor=R.+T.+Gandhiauthor=R.+J.+Landovitzauthor=D.+M.+Smithauthor=D.+M.+Jacobsenauthor=P.+A.+Volberding&title=Antiretroviral+Drugs+for+Treatment+and+Prevention+of+HIV+Infection+in+Adults%3A+2016+Recommendations+of+the+International+Antiviral+Society-USA+Panel&doi=10.1001%2Fjama.2016.8900"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1001%2Fjama.2016.8900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2016.8900%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25BCnthard%26aufirst%3DH.%2BF.%26aulast%3DSaag%26aufirst%3DM.%2BS.%26aulast%3DBenson%26aufirst%3DC.%2BA.%26aulast%3Ddel%2BRio%26aufirst%3DC.%26aulast%3DEron%26aufirst%3DJ.%2BJ.%26aulast%3DGallant%26aufirst%3DJ.%2BE.%26aulast%3DHoy%26aufirst%3DJ.%2BF.%26aulast%3DMugavero%26aufirst%3DM.%2BJ.%26aulast%3DSax%26aufirst%3DP.%2BE.%26aulast%3DThompson%26aufirst%3DM.%2BA.%26aulast%3DGandhi%26aufirst%3DR.%2BT.%26aulast%3DLandovitz%26aufirst%3DR.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BM.%26aulast%3DJacobsen%26aufirst%3DD.%2BM.%26aulast%3DVolberding%26aufirst%3DP.%2BA.%26atitle%3DAntiretroviral%2520Drugs%2520for%2520Treatment%2520and%2520Prevention%2520of%2520HIV%2520Infection%2520in%2520Adults%253A%25202016%2520Recommendations%2520of%2520the%2520International%2520Antiviral%2520Society-USA%2520Panel%26jtitle%3DJAMA%26date%3D2016%26volume%3D316%26spage%3D191%26epage%3D210%26doi%3D10.1001%2Fjama.2016.8900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span> </span><span class="NLM_article-title">Appendix B, Table 3. Characteristics of Protease Inhibitors</span>. <a href="https://aidsinfo.nih.gov/guidelines/htmltables/1/5482" class="extLink">https://aidsinfo.nih.gov/guidelines/htmltables/1/5482</a> (accessed
March 23, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Appendix+B%2C+Table+3.+Characteristics+of+Protease+Inhibitors.+https%3A%2F%2Faidsinfo.nih.gov%2Fguidelines%2Fhtmltables%2F1%2F5482+%28accessed%0AMarch+23%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DAppendix%2520B%252C%2520Table%25203.%2520Characteristics%2520of%2520Protease%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kis, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zastre, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoque, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">Role of Drug Efflux and Uptake Transporters in Atazanavir Intestinal Permeability and Drug-Drug Interactions</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">1050</span>– <span class="NLM_lpage">1064</span>, <span class="refDoi"> DOI: 10.1007/s11095-012-0942-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs11095-012-0942-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2013&pages=1050-1064&author=O.+Kisauthor=J.+A.+Zastreauthor=M.+T.+Hoqueauthor=S.+L.+Walmsleyauthor=R.+Bendayan&title=Role+of+Drug+Efflux+and+Uptake+Transporters+in+Atazanavir+Intestinal+Permeability+and+Drug-Drug+Interactions&doi=10.1007%2Fs11095-012-0942-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs11095-012-0942-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-012-0942-y%26sid%3Dliteratum%253Aachs%26aulast%3DKis%26aufirst%3DO.%26aulast%3DZastre%26aufirst%3DJ.%2BA.%26aulast%3DHoque%26aufirst%3DM.%2BT.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DRole%2520of%2520Drug%2520Efflux%2520and%2520Uptake%2520Transporters%2520in%2520Atazanavir%2520Intestinal%2520Permeability%2520and%2520Drug-Drug%2520Interactions%26jtitle%3DPharm.%2520Res.%26date%3D2013%26volume%3D30%26spage%3D1050%26epage%3D1064%26doi%3D10.1007%2Fs11095-012-0942-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahnke, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eley, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragone, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, R.</span></span> <span> </span><span class="NLM_article-title">Effect of Low-Dose Omeprazole (20 mg daily) on the Pharmacokinetics of Multiple-Dose Atazanavir with Ritonavir in Healthy Subjects</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">368</span>– <span class="NLM_lpage">377</span>, <span class="refDoi"> DOI: 10.1177/0091270010367651</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1177%2F0091270010367651" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=20457590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjslCksLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=368-377&author=L.+Zhuauthor=A.+Perssonauthor=L.+Mahnkeauthor=T.+Eleyauthor=T.+Liauthor=X.+Xuauthor=S.+Agarwalaauthor=J.+Dragoneauthor=R.+Bertz&title=Effect+of+Low-Dose+Omeprazole+%2820+mg+daily%29+on+the+Pharmacokinetics+of+Multiple-Dose+Atazanavir+with+Ritonavir+in+Healthy+Subjects&doi=10.1177%2F0091270010367651"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects</span></div><div class="casAuthors">Zhu, Li; Persson, Anna; Mahnke, Lisa; Eley, Timothy; Li, Tong; Xu, Xiaohui; Agarwala, Sangeeta; Dragone, Jeffrey; Bertz, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">368-377</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Atazanavir, a potent protease inhibitor of human immunodeficiency virus (HIV), exhibits pH-dependent soly.  Previous studies have indicated that coadministration with omeprazole 40 mg once daily significantly decreased atazanavir exposure by approx. 75%.  Concomitant use of omeprazole and atazanavir is currently not recommended.  This study investigated a clin. effective, low dose of omeprazole (20 mg daily) on atazanavir pharmacokinetics in 56 healthy volunteers given atazanavir/ritonavir 300/100 and 400/100 mg once daily.  All atazanavir/ritonavir plus omeprazole combinations resulted in atazanavir area under the concn.-time curve (AUC) and trough concns. (Cmin) comparable to or exceeding those obsd. with atazanavir 400 mg without omeprazole.  Compared with atazanavir/ritonavir 300/100 mg without omeprazole, atazanavir/ritonavir 300/100 mg plus omeprazole reduced atazanavir AUC and Cmin by 42% and 46%, resp.  Increasing the atazanavir/ritonavir dose to 400/100 mg attenuated the effect of omeprazole, resulting in approx. 30% lower atazanavir Cmin, with all individual Cmin values exceeded by greater than 10-fold the population mean protein binding-adjusted EC90 against wild-type HIV.  The effect of omeprazole on atazanavir/ritonavir 400/100 mg was similar whether given 1 h prior to atazanavir/ritonavir or sepd. by 12 h.  No unexpected adverse events were noted.  This study found that omeprazole 20 mg once daily has significantly less profound effects on atazanavir pharmacokinetics than previously obsd. with omeprazole 40 mg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnkxGQbEYZCLVg90H21EOLACvtfcHk0lh2od1iUIPICA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjslCksLk%253D&md5=26a2c81d4aec030986d354b8b500032e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1177%2F0091270010367651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270010367651%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DMahnke%26aufirst%3DL.%26aulast%3DEley%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DAgarwala%26aufirst%3DS.%26aulast%3DDragone%26aufirst%3DJ.%26aulast%3DBertz%26aufirst%3DR.%26atitle%3DEffect%2520of%2520Low-Dose%2520Omeprazole%2520%252820%2520mg%2520daily%2529%2520on%2520the%2520Pharmacokinetics%2520of%2520Multiple-Dose%2520Atazanavir%2520with%2520Ritonavir%2520in%2520Healthy%2520Subjects%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2011%26volume%3D51%26spage%3D368%26epage%3D377%26doi%3D10.1177%2F0091270010367651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span> <span> </span><span class="NLM_article-title">pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">266</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1038/clpt.2014.87</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fclpt.2014.87" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24733008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXovFeqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2014&pages=266-277&author=L.+Zhangauthor=F.+Wuauthor=S.+C.+Leeauthor=H.+Zhaoauthor=L.+Zhang&title=pH-Dependent+Drug-Drug+Interactions+for+Weak+Base+Drugs%3A+Potential+Implications+for+New+Drug+Development&doi=10.1038%2Fclpt.2014.87"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development</span></div><div class="casAuthors">Zhang, L.; Wu, F.; Lee, S. C.; Zhao, H.; Zhang, L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">266-277</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Absorption of an orally administered drug with pH-dependent soly. may be altered when it is coadministered with a gastric acid-reducing agent (ARA).  Assessing a drug's potential for pH-dependent drug-drug interactions (DDIs), considering study design elements for such DDI studies, and interpreting and communicating study results in the drug labeling to guide drug dosing are important for drug development.  We collected pertinent information related to new mol. entities approved from Jan. 2003 to May 2013 by the US Food and Drug Administration for which clin. DDI studies with ARAs were performed.  On the basis of assessments of data on pH soly. and in vivo DDIs with ARAs, we proposed a conceptual framework for assessing the need for clin. pH-dependent DDI studies for weak base drugs (WBDs).  Important study design considerations include selection of ARAs and timing of dosing of an ARA relative to the WBD in a DDI study.  Labeling implications for drugs having DDIs with ARAs are also illustrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3unViZXPrILVg90H21EOLACvtfcHk0lhwBoneBve52Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXovFeqsrs%253D&md5=08cdc41a8f08ebe58dfa3ec62d24bbb6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2014.87&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2014.87%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DS.%2BC.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DL.%26atitle%3DpH-Dependent%2520Drug-Drug%2520Interactions%2520for%2520Weak%2520Base%2520Drugs%253A%2520Potential%2520Implications%2520for%2520New%2520Drug%2520Development%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2014%26volume%3D96%26spage%3D266%26epage%3D277%26doi%3D10.1038%2Fclpt.2014.87" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiu, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beck, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Causemaker, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esslinger, H.-U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Podsadecki, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, G. J.</span></span> <span> </span><span class="NLM_article-title">Effects of Acid-Reducing Agents on the Pharmacokinetics of Lopinavir/Ritonavir and Ritonavir-Boosted Atazanavir</span>. <i>J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">553</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1177/0091270007313392</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1177%2F0091270007313392" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18440920" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVGqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2008&pages=553-562&author=C.+E.+Kleinauthor=Y.-L.+Chiuauthor=Y.+Caiauthor=K.+Beckauthor=K.+R.+Kingauthor=S.+J.+Causemakerauthor=T.+Doanauthor=H.-U.+Esslingerauthor=T.+J.+Podsadeckiauthor=G.+J.+Hanna&title=Effects+of+Acid-Reducing+Agents+on+the+Pharmacokinetics+of+Lopinavir%2FRitonavir+and+Ritonavir-Boosted+Atazanavir&doi=10.1177%2F0091270007313392"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir</span></div><div class="casAuthors">Klein, Cheri E.; Chiu, Yi-Lin; Cai, Yan; Beck, Katrin; King, Kathryn R.; Causemaker, Sonja J.; Doan, Thao; Esslinger, Hans-Ulrich; Podsadecki, Thomas J.; Hanna, George J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">553-562</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A total of 71 HIV-neg. healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg once daily (qd) or atazanavir 300 mg + ritonavir 100 mg qd from study days 1 to 15 with a moderate-fat meal.  One hour before breakfast, either omeprazole 40 mg qd was administered on study days 11 through 15, or a single dose of ranitidine 150 mg was administered on study day 11.  Lopinavir, atazanavir, and ritonavir pharmacokinetics were detd. on study days 10, 11, and 15 and compared using point ests. and 90% confidence intervals (CIs).  The point ests. for lopinavir Cmax and AUCτ were in the range of 0.92 to 1.08, with 90% CI contained within the range of 0.80 to 1.25 after coadministration of omeprazole or ranitidine.  The point ests. for atazanavir Cmax and AUCτ were decreased by 48% to 62% with the upper bound of the 90% CI ≤0.55 after coadministration of omeprazole or ranitidine.  The results indicated that lopinavir bioavailability was not affected by the coadministration of omeprazole or ranitidine.  In contrast, atazanavir bioavailability was decreased by 48% to 62% when coadministered with ritonavir and either omeprazole or ranitidine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2f0nv0c5je7Vg90H21EOLACvtfcHk0lhwBoneBve52Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVGqsb8%253D&md5=ac4c7748d69adbe54169aa8241f0acad</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1177%2F0091270007313392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270007313392%26sid%3Dliteratum%253Aachs%26aulast%3DKlein%26aufirst%3DC.%2BE.%26aulast%3DChiu%26aufirst%3DY.-L.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DBeck%26aufirst%3DK.%26aulast%3DKing%26aufirst%3DK.%2BR.%26aulast%3DCausemaker%26aufirst%3DS.%2BJ.%26aulast%3DDoan%26aufirst%3DT.%26aulast%3DEsslinger%26aufirst%3DH.-U.%26aulast%3DPodsadecki%26aufirst%3DT.%2BJ.%26aulast%3DHanna%26aufirst%3DG.%2BJ.%26atitle%3DEffects%2520of%2520Acid-Reducing%2520Agents%2520on%2520the%2520Pharmacokinetics%2520of%2520Lopinavir%252FRitonavir%2520and%2520Ritonavir-Boosted%2520Atazanavir%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2008%26volume%3D48%26spage%3D553%26epage%3D562%26doi%3D10.1177%2F0091270007313392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertz, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrath, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grasela, D.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetics and Pharmacodynamics of Atazanavir-Containing Antiretroviral Regimens, With or Without Ritonavir, in Patients Who Are HIV-Positive and Treatment-Naive</span>. <i>Pharmacotherapy</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1002/phar.1205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fphar.1205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23456732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2013&pages=284-294&author=R.+J.+Bertzauthor=A.+Perssonauthor=E.+Chungauthor=L.+Zhuauthor=J.+Zhangauthor=D.+McGrathauthor=D.+Grasela&title=Pharmacokinetics+and+Pharmacodynamics+of+Atazanavir-Containing+Antiretroviral+Regimens%2C+With+or+Without+Ritonavir%2C+in+Patients+Who+Are+HIV-Positive+and+Treatment-Naive&doi=10.1002%2Fphar.1205"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naive</span></div><div class="casAuthors">Bertz, Richard J.; Persson, Anna; Chung, Ellen; Zhu, Li; Zhang, Jenny; McGrath, Donnie; Grasela, Dennis</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">PHPYDQ</span>;
        ISSN:<span class="NLM_cas:issn">1875-9114</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Study Objective. To investigate the pharmacokinetic and pharmacodynamic relationships of the human immunodeficiency virus (HIV)-protease inhibitor atazanavir (ATV) in the presence and absence of the pharmacokinetic booster ritonavir, utilizing ATV plasma trough concns. (Ctrough) and clin. biomarkers of antiviral efficacy and safety over 48 wk.  Design. Randomized, open-label, multicenter, study designed to compare the efficacy and safety of ATV 300 mg plus ritonavir 100 mg (ATV300/r) with that of ATV 400 mg (ATV400).  Setting. Thirty clinic sites across 10 countries in Africa, Europe, North America, and South America.  Patients. Patients who were HIV-pos. and treatment-naive.  Interventions. Randomized to once-daily ATV400 (105 patients) or ATV300/r (95 patients) plus lamivudine and extended-release stavudine.  Measurements and Main Results. The Ctrough approx. 24 h after the prior unobserved dose was measured through week 48.  Composite Ctrough (i.e., the geometric mean of all trough concns. over the 48 wk), population inhibitory quotient ([IQ], i.e., Ctrough divided population estd. protein binding adjusted effective concn. at 90% [EC90, 14 ng/mL]), composite population IQ (i.e., ATV composite trough divided by population estd. protein binding adjusted EC90), HIV RNA, CD4 cell counts, and metabolic and safety parameters were also assessed.  For ATV400 and ATV300/r, resp., geometric mean composite Ctrough (CV%) were 127 (106) ng/mL and 670 (63) ng/mL, geometric mean composite population IQ were 9 and 48, and composite Ctrough values of HIV EC90 or more were achieved in 98% and 100% of patients.  High ATV Ctrough was assocd. with low HIV RNA at week 48; however, 88% of patients had HIV RNA less than 400 copies/mL in the lowest composite Ctrough quartile.  There was no clear relationship between ATV Ctrough and changes in CD4 cell count.  Increases in total bilirubin or jaundice were assocd. with higher Ctrough.  Modest increases in triglycerides and cholesterol were assocd. with the addn. of ritonavir.  Conclusion. ATV-contg. regimens with or without ritonavir achieved ATV exposures that provide robust antiretroviral efficacy and acceptable tolerability in treatment-naive patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpw5YndphA5LLVg90H21EOLACvtfcHk0lhwBoneBve52Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFKgu78%253D&md5=4f3b45514c9157203f76f8911aada1a0</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fphar.1205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1205%26sid%3Dliteratum%253Aachs%26aulast%3DBertz%26aufirst%3DR.%2BJ.%26aulast%3DPersson%26aufirst%3DA.%26aulast%3DChung%26aufirst%3DE.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DMcGrath%26aufirst%3DD.%26aulast%3DGrasela%26aufirst%3DD.%26atitle%3DPharmacokinetics%2520and%2520Pharmacodynamics%2520of%2520Atazanavir-Containing%2520Antiretroviral%2520Regimens%252C%2520With%2520or%2520Without%2520Ritonavir%252C%2520in%2520Patients%2520Who%2520Are%2520HIV-Positive%2520and%2520Treatment-Naive%26jtitle%3DPharmacotherapy%26date%3D2013%26volume%3D33%26spage%3D284%26epage%3D294%26doi%3D10.1002%2Fphar.1205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furfine, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hale, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salisbury, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searle, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studenberg, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Todd, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaltenstein, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">798</span>, <span class="refDoi"> DOI: 10.1128/aac.48.3.791-798.2004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1128%2Faac.48.3.791-798.2004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2004&pages=791-798&author=E.+S.+Furfineauthor=C.+T.+Bakerauthor=M.+R.+Haleauthor=D.+J.+Reynoldsauthor=J.+A.+Salisburyauthor=A.+D.+Searleauthor=S.+D.+Studenbergauthor=D.+Toddauthor=R.+D.+Tungauthor=A.+Spaltenstein&title=Preclinical+Pharmacology+and+Pharmacokinetics+of+GW433908%2C+a+Water-Soluble+Prodrug+of+the+Human+Immunodeficiency+Virus+Protease+Inhibitor+Amprenavir&doi=10.1128%2Faac.48.3.791-798.2004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1128%2Faac.48.3.791-798.2004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Faac.48.3.791-798.2004%26sid%3Dliteratum%253Aachs%26aulast%3DFurfine%26aufirst%3DE.%2BS.%26aulast%3DBaker%26aufirst%3DC.%2BT.%26aulast%3DHale%26aufirst%3DM.%2BR.%26aulast%3DReynolds%26aufirst%3DD.%2BJ.%26aulast%3DSalisbury%26aufirst%3DJ.%2BA.%26aulast%3DSearle%26aufirst%3DA.%2BD.%26aulast%3DStudenberg%26aufirst%3DS.%2BD.%26aulast%3DTodd%26aufirst%3DD.%26aulast%3DTung%26aufirst%3DR.%2BD.%26aulast%3DSpaltenstein%26aufirst%3DA.%26atitle%3DPreclinical%2520Pharmacology%2520and%2520Pharmacokinetics%2520of%2520GW433908%252C%2520a%2520Water-Soluble%2520Prodrug%2520of%2520the%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Inhibitor%2520Amprenavir%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2004%26volume%3D48%26spage%3D791%26epage%3D798%26doi%3D10.1128%2Faac.48.3.791-798.2004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeGoey, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grampovnik, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flosi, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molla, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempf, D. J.</span></span> <span> </span><span class="NLM_article-title">Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2964</span>– <span class="NLM_lpage">2970</span>, <span class="refDoi"> DOI: 10.1021/jm900080g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900080g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFeltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2964-2970&author=D.+A.+DeGoeyauthor=D.+J.+Grampovnikauthor=W.+J.+Flosiauthor=K.+C.+Marshauthor=X.+C.+Wangauthor=L.+L.+Kleinauthor=K.+F.+McDanielauthor=Y.+Liuauthor=M.+A.+Longauthor=W.+M.+Katiauthor=A.+Mollaauthor=D.+J.+Kempf&title=Water-Soluble+Prodrugs+of+the+Human+Immunodeficiency+Virus+Protease+Inhibitors+Lopinavir+and+Ritonavir&doi=10.1021%2Fjm900080g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir</span></div><div class="casAuthors">DeGoey, David A.; Grampovnik, David J.; Flosi, William J.; Marsh, Kennan C.; Wang, Xiu C.; Klein, Larry L.; McDaniel, Keith F.; Liu, Yaya; Long, Michelle A.; Kati, Warren M.; Molla, Akhteruzzaman; Kempf, Dale J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2964-2970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We studied the synthesis, cleavage rates, and oral administration of prodrugs of the HIV protease inhibitors (PIs) lopinavir and ritonavir.  Phosphate esters attached directly to the central hydroxyl groups of these PIs did not demonstrate enzyme-mediated cleavage in vitro and did not provide measurable plasma levels of the parent drugs in vivo.  However, oxymethylphosphate (OMP) and oxyethylphosphate (OEP) prodrugs provided improved rates of cleavage, high levels of aq. soly., and high plasma levels of the parent drugs when dosed orally in rats and dogs.  Dosing unformulated capsules contg. the solid prodrugs led to plasma levels equiv. to those obsd. for dosing formulated solns. of the parent drugs.  A direct synthetic process for the prepn. of OMP and OEP prodrugs was developed, and the improved synthetic method may be applicable to the prepn. of analogous sol. prodrugs of other drug classes with limited soly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeiB07ekQMJ7Vg90H21EOLACvtfcHk0lg2vFwmVtBqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFeltLs%253D&md5=6e64ddfeabd5725929cac142bdfe782d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm900080g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900080g%26sid%3Dliteratum%253Aachs%26aulast%3DDeGoey%26aufirst%3DD.%2BA.%26aulast%3DGrampovnik%26aufirst%3DD.%2BJ.%26aulast%3DFlosi%26aufirst%3DW.%2BJ.%26aulast%3DMarsh%26aufirst%3DK.%2BC.%26aulast%3DWang%26aufirst%3DX.%2BC.%26aulast%3DKlein%26aufirst%3DL.%2BL.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLong%26aufirst%3DM.%2BA.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMolla%26aufirst%3DA.%26aulast%3DKempf%26aufirst%3DD.%2BJ.%26atitle%3DWater-Soluble%2520Prodrugs%2520of%2520the%2520Human%2520Immunodeficiency%2520Virus%2520Protease%2520Inhibitors%2520Lopinavir%2520and%2520Ritonavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2964%26epage%3D2970%26doi%3D10.1021%2Fjm900080g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annadurai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padmanabhan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhutani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystal, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarabu, R.</span></span> <span> </span><span class="NLM_article-title">Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">4176</span>– <span class="NLM_lpage">4188</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00277</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00277" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotFOhu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=4176-4188&author=M.+A.+M.+Subbaiahauthor=N.+A.+Meanwellauthor=J.+F.+Kadowauthor=L.+Subramaniauthor=M.+Annaduraiauthor=T.+Ramarauthor=S.+D.+Desaiauthor=S.+Sinhaauthor=M.+Subramanianauthor=S.+Mandlekarauthor=S.+Sridharauthor=S.+Padmanabhanauthor=P.+Bhutaniauthor=R.+Arlaauthor=S.+M.+Jenkinsauthor=M.+R.+Krystalauthor=C.+Wangauthor=R.+Sarabu&title=Coupling+of+an+Acyl+Migration+Prodrug+Strategy+with+Bio-activation+To+Improve+Oral+Delivery+of+the+HIV-1+Protease+Inhibitor+Atazanavir&doi=10.1021%2Facs.jmedchem.8b00277"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Coupling of an Acyl Migration Prodrug Strategy with Bio-activation To Improve Oral Delivery of the HIV-1 Protease Inhibitor Atazanavir</span></div><div class="casAuthors">Subbaiah, Murugaiah A. M.; Meanwell, Nicholas A.; Kadow, John F.; Subramani, Lakshumanan; Annadurai, Mathiazhagan; Ramar, Thangeswaran; Desai, Salil D.; Sinha, Sarmistha; Subramanian, Murali; Mandlekar, Sandhya; Sridhar, Srikanth; Padmanabhan, Shweta; Bhutani, Priyadeep; Arla, Rambabu; Jenkins, Susan M.; Krystal, Mark R.; Wang, Chunfu X.; Sarabu, Ramakanth</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4176-4188</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">HIV-1 protease inhibitors (PIs), which include atazanavir (ATV, 1), remain important medicines to treat HIV-1 infection.  However, they are characterized by poor oral bioavailability and a need for boosting with a pharmacokinetic enhancer, which results in addnl. drug-drug interactions that are sometimes difficult to manage.  We investigated a chemo-activated, acyl migration-based prodrug design approach to improve the pharmacokinetic profile of 1 but failed to obtain improved oral bioavailability over dosing the parent drug in rats.  This strategy was refined by conjugating the amine with a promoiety designed to undergo bio-activation, as a means of modulating the subsequent chemo-activation.  This culminated in a lead prodrug that (1) yielded substantially better oral drug delivery of 1 when compared to the parent itself, the simple acyl migration-based prodrug, and the corresponding simple L-Val prodrug, (2) acted as a depot which resulted in a sustained release of the parent drug in vivo, and (3) offered the benefit of mitigating the pH-dependent absorption assocd. with 1, thereby potentially reducing the risk of decreased bioavailability with concurrent use of stomach-acid-reducing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDHg6TEf3Z8rVg90H21EOLACvtfcHk0lg2vFwmVtBqNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotFOhu74%253D&md5=eba90dbf8098b7062b869684569217cc</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00277&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00277%26sid%3Dliteratum%253Aachs%26aulast%3DSubbaiah%26aufirst%3DM.%2BA.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26aulast%3DSubramani%26aufirst%3DL.%26aulast%3DAnnadurai%26aufirst%3DM.%26aulast%3DRamar%26aufirst%3DT.%26aulast%3DDesai%26aufirst%3DS.%2BD.%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DSridhar%26aufirst%3DS.%26aulast%3DPadmanabhan%26aufirst%3DS.%26aulast%3DBhutani%26aufirst%3DP.%26aulast%3DArla%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DS.%2BM.%26aulast%3DKrystal%26aufirst%3DM.%2BR.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSarabu%26aufirst%3DR.%26atitle%3DCoupling%2520of%2520an%2520Acyl%2520Migration%2520Prodrug%2520Strategy%2520with%2520Bio-activation%2520To%2520Improve%2520Oral%2520Delivery%2520of%2520the%2520HIV-1%2520Protease%2520Inhibitor%2520Atazanavir%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D4176%26epage%3D4188%26doi%3D10.1021%2Facs.jmedchem.8b00277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">FDA</span>. <span> </span><span class="NLM_article-title">Website: Atazanavir Documents</span>. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf" class="extLink">https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-567_Reyataz_BioPharmr_P1.pdf</a> (accessed June 09, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=FDA&title=Website%3A+Atazanavir+Documents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26aulast%3D%26atitle%3DWebsite%253A%2520Atazanavir%2520Documents%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gokulgandhi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, Lopinavir</span>. <i>Pharmaceuticals</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">433</span>– <span class="NLM_lpage">452</span>, <span class="refDoi"> DOI: 10.3390/ph7040433</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2Fph7040433" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2014&pages=433-452&author=M.+Patelauthor=N.+Mandavaauthor=M.+Gokulgandhiauthor=D.+Palauthor=A.+Mitra&title=Amino+Acid+Prodrugs%3A+An+Approach+to+Improve+the+Absorption+of+HIV-1+Protease+Inhibitor%2C+Lopinavir&doi=10.3390%2Fph7040433"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.3390%2Fph7040433&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fph7040433%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DMandava%26aufirst%3DN.%26aulast%3DGokulgandhi%26aufirst%3DM.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%26atitle%3DAmino%2520Acid%2520Prodrugs%253A%2520An%2520Approach%2520to%2520Improve%2520the%2520Absorption%2520of%2520HIV-1%2520Protease%2520Inhibitor%252C%2520Lopinavir%26jtitle%3DPharmaceuticals%26date%3D2014%26volume%3D7%26spage%3D433%26epage%3D452%26doi%3D10.3390%2Fph7040433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Interaction of Dipeptide Prodrugs of Saquinavir with Multidrug Resistance Protein-2 (MRP-2): Evasion of MRP-2 Mediated Efflux</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>362</i></span>,  <span class="NLM_fpage">44</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2008.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18620036" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVGjsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2008&pages=44-51&author=R.+Jainauthor=S.+Agarwalauthor=N.+K.+Mandavaauthor=Y.+Shengauthor=A.+K.+Mitra&title=Interaction+of+Dipeptide+Prodrugs+of+Saquinavir+with+Multidrug+Resistance+Protein-2+%28MRP-2%29%3A+Evasion+of+MRP-2+Mediated+Efflux&doi=10.1016%2Fj.ijpharm.2008.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of dipeptide prodrugs of saquinavir with multidrug resistance protein-2 (MRP-2): Evasion of MRP-2 mediated efflux</span></div><div class="casAuthors">Jain, Ritesh; Agarwal, Sheetal; Mandava, Nanda Kishore; Sheng, Ye; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">44-51</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Saquinavir (SQV), the first protease inhibitor approved by FDA to treat HIV-1 infection.  This drug is a well-known substrate for multidrug resistance protein-2 (MRP-2).  The objective of this study was to investigate whether derivatization of SQV to dipeptide prodrugs, valine-valine-saquinavir (Val-Val-SQV) and glycine-valine-saquinavir (Gly-Val-SQV), targeting peptide transporter can circumvent MRP-2 mediated efflux.  Uptake and transport studies were carried out across MDCKII-MRP2 cell monolayers to investigate the interaction of SQV and its prodrugs with MRP-2.  In situ single pass intestinal perfusion expts. in rat jejunum were performed to calc. intestinal absorption rate consts. and permeabilities of SQV, Val-Val-SQV and Gly-Val-SQV.  Uptake studies demonstrated that the prodrugs have significantly lower interaction with MRP-2 relative to SQV.  Transepithelial transport of Val-Val-SQV and Gly-Val-SQV across MDCKII-MRP2 cells exhibited an enhanced absorptive flux and reduced secretory flux as compared to SQV.  Intestinal perfusion studies revealed that synthesized prodrugs have higher intestinal permeabilities relative to SQV.  Enhanced absorption of Val-Val-SQV and Gly-Val-SQV relative to SQV can be attributed to their translocation by the peptide transporter in the jejunum.  In the presence of MK-571, a MRP family inhibitor, there was a significant increase in the permeabilities of SQV and Gly-Val-SQV indicating that these compds. are probably substrates for MRP-2.  However, there was no change in the permeability of Val-Val-SQV with MK-571 indicating lack of any interaction of Val-Val-SQV with MRP-2.  In conclusion, peptide transporter targeted prodrug modification of MRP-2 substrates may lead to shielding of these drug mols. from MRP-2 efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB0DXWIBhdRbVg90H21EOLACvtfcHk0ljeCP1ggEW_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVGjsL3P&md5=99ce56ebbefb0dc21cf9ee8d3458246b</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DMandava%26aufirst%3DN.%2BK.%26aulast%3DSheng%26aufirst%3DY.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DInteraction%2520of%2520Dipeptide%2520Prodrugs%2520of%2520Saquinavir%2520with%2520Multidrug%2520Resistance%2520Protein-2%2520%2528MRP-2%2529%253A%2520Evasion%2520of%2520MRP-2%2520Mediated%2520Efflux%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D362%26spage%3D44%26epage%3D51%26doi%3D10.1016%2Fj.ijpharm.2008.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvvuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kansara, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandava, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Intestinal Absorption of Novel-Dipeptide Prodrugs of Saquinavir in Rats</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>336</i></span>,  <span class="NLM_fpage">233</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2006.11.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2006.11.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=17207946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFWqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=336&publication_year=2007&pages=233-240&author=R.+Jainauthor=S.+Duvvuriauthor=V.+Kansaraauthor=N.+K.+Mandavaauthor=A.+K.+Mitra&title=Intestinal+Absorption+of+Novel-Dipeptide+Prodrugs+of+Saquinavir+in+Rats&doi=10.1016%2Fj.ijpharm.2006.11.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Intestinal absorption of novel-dipeptide prodrugs of saquinavir in rats</span></div><div class="casAuthors">Jain, Ritesh; Duvvuri, Sridhar; Kansara, Viral; Mandava, Nanda Kishore; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">336</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-240</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Saquinavir (SQV) was the first human immunovirus-1 (HIV-1) protease inhibitor approved by FDA.  However, P-glycoprotein (P-gp), an efflux pump limits its oral and brain bioavailabilities.  The objective of this study was to investigate whether prodrug modification of SQV to dipeptide prodrugs Valine-Valine-Saquinavir (Val-Val-SQV) and Glycine-Valine-Saquinavir (Gly-Val-SQV) targeting intestinal peptide transporter can enhance intestinal permeability of SQV by circumventing P-gp mediated efflux.  Single pass intestinal perfusion expts. in rat jejunum were performed to calc. the absorption rate const. and intestinal permeability of SQV, Val-Val-SQV and Gly-Val-SQV.  Equimolar concn. (25 μM) of SQV, Val-Val-SQV and Gly-Val-SQV were employed in the perfusion studies.  Perfusion expts. were also carried out in the presence of cyclosporine (10 μM) and glycyl-sarcosine (20 mM).  Absorption rate consts. in rat jejunum (ka) for SQV, Val-Val-SQV and Gly-Val-SQV were found to be 14.1±3.4 × 10-3, 65.8±4.3 × 10-3, and 25.6±5.7 × 10-3 min-1, resp.  Enhanced absorption of Val-Val-SQV and Gly-Val-SQV relative to SQV can be attributed to their translocation by the peptide transporter in the jejunum.  Significant permeability enhancement of SQV across rat jejunum was obsd. in the presence of cyclosporine 10 μM (P-gp inhibitor).  However, permeability of Val-Val-SQV was unchanged in the presence of cyclosporine suggesting lack of any interaction of the prodrug with efflux pump.  Intestinal absorption of Val-Val-SQV was significantly inhibited in the presence of gly-sar indicating the involvement of peptide transporter in intestinal absorption.  In conclusion, peptide transporter targeted prodrug modification of P-gp substrates could lead to shielding of these drug mols. from efflux pumps.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWCQlWPmIAp7Vg90H21EOLACvtfcHk0ljeCP1ggEW_LQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFWqur4%253D&md5=4dd0fadb9e584c506d43696afa24cc98</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2006.11.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2006.11.058%26sid%3Dliteratum%253Aachs%26aulast%3DJain%26aufirst%3DR.%26aulast%3DDuvvuri%26aufirst%3DS.%26aulast%3DKansara%26aufirst%3DV.%26aulast%3DMandava%26aufirst%3DN.%2BK.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DIntestinal%2520Absorption%2520of%2520Novel-Dipeptide%2520Prodrugs%2520of%2520Saquinavir%2520in%2520Rats%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2007%26volume%3D336%26spage%3D233%26epage%3D240%26doi%3D10.1016%2Fj.ijpharm.2006.11.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hamada, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiso, Y.</span></span> <span> </span><span class="NLM_article-title">Water-Soluble Prodrugs of Dipeptide HIV Protease Inhibitors Based on O→N Intramolecular Acyl Migration: Design, Synthesis and Kinetic Study</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2003.10.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.bmc.2003.10.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=159-170&author=Y.+Hamadaauthor=H.+Matsumotoauthor=S.+Yamaguchiauthor=T.+Kimuraauthor=Y.+Hayashiauthor=Y.+Kiso&title=Water-Soluble+Prodrugs+of+Dipeptide+HIV+Protease+Inhibitors+Based+on+O%E2%86%92N+Intramolecular+Acyl+Migration%3A+Design%2C+Synthesis+and+Kinetic+Study&doi=10.1016%2Fj.bmc.2003.10.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2003.10.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2003.10.026%26sid%3Dliteratum%253Aachs%26aulast%3DHamada%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DYamaguchi%26aufirst%3DS.%26aulast%3DKimura%26aufirst%3DT.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DKiso%26aufirst%3DY.%26atitle%3DWater-Soluble%2520Prodrugs%2520of%2520Dipeptide%2520HIV%2520Protease%2520Inhibitors%2520Based%2520on%2520O%25E2%2586%2592N%2520Intramolecular%2520Acyl%2520Migration%253A%2520Design%252C%2520Synthesis%2520and%2520Kinetic%2520Study%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D159%26epage%3D170%26doi%3D10.1016%2Fj.bmc.2003.10.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashuba, A. D.</span></span> <span> </span><span class="NLM_article-title">Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline</span>. <i>Curr. Opin. Investig. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">384</span>– <span class="NLM_lpage">390</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=384-390&author=A.+H.+Corbettauthor=A.+D.+Kashuba&title=Fosamprenavir.+Vertex+Pharmaceuticals%2FGlaxoSmithKline"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCorbett%26aufirst%3DA.%2BH.%26aulast%3DKashuba%26aufirst%3DA.%2BD.%26atitle%3DFosamprenavir.%2520Vertex%2520Pharmaceuticals%252FGlaxoSmithKline%26jtitle%3DCurr.%2520Opin.%2520Investig.%2520Drugs%26date%3D2002%26volume%3D3%26spage%3D384%26epage%3D390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subbaiah, M. A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadow, J. F.</span></span> <span> </span><span class="NLM_article-title">Design Strategies in the Prodrugs of HIV-1 Protease Inhibitors to Improve the Pharmaceutical Properties</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">883</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2017.07.044" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28865281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=865-883&author=M.+A.+M.+Subbaiahauthor=N.+A.+Meanwellauthor=J.+F.+Kadow&title=Design+Strategies+in+the+Prodrugs+of+HIV-1+Protease+Inhibitors+to+Improve+the+Pharmaceutical+Properties&doi=10.1016%2Fj.ejmech.2017.07.044"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies in the prodrugs of HIV-1 protease inhibitors to improve the pharmaceutical properties</span></div><div class="casAuthors">Subbaiah, Murugaiah A. M.; Meanwell, Nicholas A.; Kadow, John F.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">865-883</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Combination antiretroviral therapy (cART) is currently the most effective treatment for HIV-1 infection.  HIV-1 protease inhibitors (PIs) are an important component of some regimens of cART.  However, PIs are known for sub-optimal ADME properties, resulting in poor oral bioavailability.  This often necessitates high drug doses, combination with pharmacokinetic enhancers and/or special formulations in order to effectively deliver PIs, which may lead to a high pill burden and reduced patient compliance.  As a remedy, improving the ADME properties of existing drugs via prodrug and other approaches has been pursued in addn. to the development of next generation PIs with improved pharmacokinetic, resistance and side effect profiles.  Phosphate prodrugs have been explored to address the soly.-limiting absorption and high excipient load.  Prodrug design to target carrier-mediated drug delivery has also been explored.  Amino acid prodrugs have been shown to improve permeability by engaging active transport mechanisms, reduce efflux and mitigate first pass metab. while acyl migration prodrugs have been shown to improve soly.  Prodrug design efforts have led to the identification of one marketed agent, fosamprenavir, and clin. studies with two other prodrugs.  Several of the reported approaches lack detailed in vivo characterization and hence the potential preclin. or clin. benefits of these approaches are yet to be fully detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTXFlPJppF87Vg90H21EOLACvtfcHk0ljV4rZgcnjCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7vP&md5=89e387c7e8056efc76e6bbcb39f2745b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.044%26sid%3Dliteratum%253Aachs%26aulast%3DSubbaiah%26aufirst%3DM.%2BA.%2BM.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DKadow%26aufirst%3DJ.%2BF.%26atitle%3DDesign%2520Strategies%2520in%2520the%2520Prodrugs%2520of%2520HIV-1%2520Protease%2520Inhibitors%2520to%2520Improve%2520the%2520Pharmaceutical%2520Properties%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D865%26epage%3D883%26doi%3D10.1016%2Fj.ejmech.2017.07.044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harbeson, S. L.</span>; <span class="NLM_string-name">Tung, R. D.</span></span> <span> </span><span class="NLM_article-title">Azapeptide Derivatives</span>. U.S. Patent <span class="NLM_patent">8,158,805 B2</span>, Apr 17, <span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=S.+L.+Harbeson&author=R.+D.+Tung&title=Azapeptide+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DHarbeson%26aufirst%3DS.%2BL.%26atitle%3DAzapeptide%2520Derivatives%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span> </span><span class="NLM_article-title">Concert Pharmaceuticals,
Inc.’s Patent Owner Preliminary Response</span>. <a href="https://www.concertpharma.com/wp-content/uploads/2017/07/Concert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf" class="extLink">https://www.concertpharma.com/wp-content/uploads/2017/07/Concert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf</a> (accessed Oct 6, <span class="NLM_year">2018</span>).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Concert+Pharmaceuticals%2C%0AInc.%E2%80%99s+Patent+Owner+Preliminary+Response.+https%3A%2F%2Fwww.concertpharma.com%2Fwp-content%2Fuploads%2F2017%2F07%2FConcert-IPR2017-01256-Patent-Owners-Preliminary-Response.pdf+%28accessed+Oct+6%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26atitle%3DConcert%2520Pharmaceuticals%252C%250AInc.%25E2%2580%2599s%2520Patent%2520Owner%2520Preliminary%2520Response%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clas, S.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nofsinger, R.</span></span> <span> </span><span class="NLM_article-title">Chemistry-enabled drug delivery (prodrugs): recent progress and challenges</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">79</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.08.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.drudis.2013.08.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23993918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVKks7%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=79-87&author=S.-D.+Clasauthor=R.+I.+Sanchezauthor=R.+Nofsinger&title=Chemistry-enabled+drug+delivery+%28prodrugs%29%3A+recent+progress+and+challenges&doi=10.1016%2Fj.drudis.2013.08.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry-enabled drug delivery (prodrugs): recent progress and challenges</span></div><div class="casAuthors">Clas, Sophie-Dorothee; Sanchez, Rosa I.; Nofsinger, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">79-87</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Prodrugs can be used to enhance the properties of an active pharmaceutical ingredient or drug, generally by improving soly. and/or permeability of the compd.  However, discovery teams duly spend considerable time and resources on structure-activity optimization and formulation-enabled drug delivery technologies to achieve the target exposures and biopharmaceutical properties, when early implementation of prodrugs could lead to an improved drug mol.  The goal of this review is to provide an overview of the achievements during the past few years in developing prodrugs and highlighting the challenges of following this approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1m5igWvkrd7Vg90H21EOLACvtfcHk0ljV4rZgcnjCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVKks7%252FE&md5=5cb21edde8503992ffd6e990bfb7361c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.08.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.08.014%26sid%3Dliteratum%253Aachs%26aulast%3DClas%26aufirst%3DS.-D.%26aulast%3DSanchez%26aufirst%3DR.%2BI.%26aulast%3DNofsinger%26aufirst%3DR.%26atitle%3DChemistry-enabled%2520drug%2520delivery%2520%2528prodrugs%2529%253A%2520recent%2520progress%2520and%2520challenges%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D79%26epage%3D87%26doi%3D10.1016%2Fj.drudis.2013.08.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kärkkäinen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, K. B.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - Recent Approvals and a Glimpse of the Pipeline</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">146</span>– <span class="NLM_lpage">161</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2017.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejps.2017.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28782609" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlCltL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2017&pages=146-161&author=J.+Rautioauthor=J.+K%C3%A4rkk%C3%A4inenauthor=K.+B.+Sloan&title=Prodrugs+-+Recent+Approvals+and+a+Glimpse+of+the+Pipeline&doi=10.1016%2Fj.ejps.2017.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - Recent approvals and a glimpse of the pipeline</span></div><div class="casAuthors">Rautio, Jarkko; Karkkainen, Jussi; Sloan, Kenneth B.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">Suppl.</span>),
    <span class="NLM_cas:pages">146-161</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prodrugs offer a versatile strategy to overcome flaws of viable drug candidates or clin. approved drugs.  However, the strategic importance of prodrugs in the pharmaceutical industry has often been challenged, and prodrugs are often considered as the last option after lead optimization and when the selected drug candidate has faced significant pharmaceutical and pharmacokinetic limitations.  Based on recent success in marketed drugs, prodrug strategy should clearly be considered already in early stages of lead optimization.  During the past five years or so, prodrugs have accounted for about 10% of all small mol. wt. drugs that have come to the market.  In 2015 alone, the FDA approved seven prodrugs, which gives a prodrug prevalence of over 20% among the small mols. or over 15% among the total amt. of the FDA approved drugs that year.  A great no. of various prodrugs are also undergoing late stage clin. trials.  The pharmaceutical industry will therefore continue to depend on prodrugs for the foreseeable future.  In this review, we will present the state of the art in the design of the prodrugs launched by the FDA since 2015.  We will also provide an overview of some interesting late stage clin. prodrug candidates.  We hope this review will demonstrate potential of prodrug strategies and facilitates the use of prodrugs in drug discovery projects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLKCLtvVGvnrVg90H21EOLACvtfcHk0ljV4rZgcnjCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlCltL3I&md5=2b46aa04e046ad089828ca95e40762a3</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2017.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2017.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DK%25C3%25A4rkk%25C3%25A4inen%26aufirst%3DJ.%26aulast%3DSloan%26aufirst%3DK.%2BB.%26atitle%3DProdrugs%2520-%2520Recent%2520Approvals%2520and%2520a%2520Glimpse%2520of%2520the%2520Pipeline%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D109%26spage%3D146%26epage%3D161%26doi%3D10.1016%2Fj.ejps.2017.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walther, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelikin, A. N.</span></span> <span> </span><span class="NLM_article-title">Prodrugs in Medicinal Chemistry and Enzyme Prodrug Therapies</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2017.06.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.addr.2017.06.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28676386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSiur7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2017&pages=65-77&author=R.+Waltherauthor=J.+Rautioauthor=A.+N.+Zelikin&title=Prodrugs+in+Medicinal+Chemistry+and+Enzyme+Prodrug+Therapies&doi=10.1016%2Fj.addr.2017.06.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs in medicinal chemistry and enzyme prodrug therapies</span></div><div class="casAuthors">Walther, Raoul; Rautio, Jarkko; Zelikin, Alexander N.</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">65-77</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Prodrugs are cunning derivs. of therapeutic agents designed to improve the pharmacokinetics profile of the drug.  Within a prodrug, pharmacol. activity of the drug is masked and is recovered within the human body upon bioconversion of the prodrug, a process that is typically mediated by enzymes.  This concept is highly successful and a significant fraction of marketed therapeutic formulations is based on prodrugs.  An advanced subset of prodrugs can be engineered such as to achieve site-specific bioconversion of the prodrug - to comprise the highly advantageous "enzyme prodrug therapy", EPT.  Design of prodrugs for EPT is similar to the prodrugs in general medicinal use in that the pharmacol. activity of the drug is masked, but differs significantly in that site-specific bioconversion is a prime consideration, and the enzymes typically used for EPT are non-mammalian and/or with low systemic abundance in the human body.  This review focuses on the design of prodrugs for EPT in terms of the choice of an enzyme and the corresponding prodrug for bioconversion.  We also discuss the recent success of "self immolative linkers" which significantly empower and diversify the prodrug design, and present methodologies for the design of prodrugs with extended blood residence time.  The review aims to be of specific interest for medicinal chemists, biomedical engineers, and pharmaceutical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocjq5rReX-uLVg90H21EOLACvtfcHk0lg1By87bKR8ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSiur7P&md5=38f4eda3c05eb3c3917410e695749761</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2017.06.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2017.06.013%26sid%3Dliteratum%253Aachs%26aulast%3DWalther%26aufirst%3DR.%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DZelikin%26aufirst%3DA.%2BN.%26atitle%3DProdrugs%2520in%2520Medicinal%2520Chemistry%2520and%2520Enzyme%2520Prodrug%2520Therapies%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2017%26volume%3D118%26spage%3D65%26epage%3D77%26doi%3D10.1016%2Fj.addr.2017.06.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hageman, M. J.</span></span> <span> </span><span class="NLM_article-title">The Expanding Role of Prodrugs in Contemporary Drug Design and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">559</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1038/nrd.2018.46</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fnrd.2018.46" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=29700501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=559-587&author=J.+Rautioauthor=N.+A.+Meanwellauthor=L.+Diauthor=M.+J.+Hageman&title=The+Expanding+Role+of+Prodrugs+in+Contemporary+Drug+Design+and+Development&doi=10.1038%2Fnrd.2018.46"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The expanding role of prodrugs in contemporary drug design and development</span></div><div class="casAuthors">Rautio, Jarkko; Meanwell, Nicholas A.; Di, Li; Hageman, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">559-587</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Prodrugs are mols. with little or no pharmacol. activity that are converted to the active parent drug in vivo by enzymic or chem. reactions or by a combination of the two.  Prodrugs have evolved from being serendipitously discovered or used as a salvage effort to being intentionally designed.  Such efforts can avoid drug development challenges that limit formulation options or result in unacceptable biopharmaceutical or pharmacokinetic performance, or poor targeting.  In the past 10 years, the US Food and Drug Administration has approved at least 30 prodrugs, which accounts for more than 12% of all approved small-mol. new chem. entities.  In this Review, we highlight prodrug design strategies for improved formulation and pharmacokinetic and targeting properties, with a focus on the most recently marketed prodrugs.  We also discuss preclin. and clin. challenges and considerations in prodrug design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKsM1lriJObVg90H21EOLACvtfcHk0lg1By87bKR8ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCgsL0%253D&md5=9dea9fd2f30779f4ce182b822f2c9539</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.46%26sid%3Dliteratum%253Aachs%26aulast%3DRautio%26aufirst%3DJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DHageman%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520Expanding%2520Role%2520of%2520Prodrugs%2520in%2520Contemporary%2520Drug%2520Design%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2018%26volume%3D17%26spage%3D559%26epage%3D587%26doi%3D10.1038%2Fnrd.2018.46" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder Tagore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anumula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmaiah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, P. P. B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kallipatti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selvam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamurthy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramarao, M.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of Rat Intestinal Alkaline Phosphatase - Role of Crown Domain in Mammalian Alkaline Phosphatases</span>. <i>J. Struct. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">182</span>– <span class="NLM_lpage">192</span>, <span class="refDoi"> DOI: 10.1016/j.jsb.2013.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.jsb.2013.09.017" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2013&pages=182-192&author=K.+Ghoshauthor=D.+Mazumder+Tagoreauthor=R.+Anumulaauthor=B.+Lakshmaiahauthor=P.+P.+B.+S.+Kumarauthor=S.+Singaramauthor=T.+Matanauthor=S.+Kallipattiauthor=S.+Selvamauthor=P.+Krishnamurthyauthor=M.+Ramarao&title=Crystal+Structure+of+Rat+Intestinal+Alkaline+Phosphatase+-+Role+of+Crown+Domain+in+Mammalian+Alkaline+Phosphatases&doi=10.1016%2Fj.jsb.2013.09.017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2013.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2013.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMazumder%2BTagore%26aufirst%3DD.%26aulast%3DAnumula%26aufirst%3DR.%26aulast%3DLakshmaiah%26aufirst%3DB.%26aulast%3DKumar%26aufirst%3DP.%2BP.%2BB.%2BS.%26aulast%3DSingaram%26aufirst%3DS.%26aulast%3DMatan%26aufirst%3DT.%26aulast%3DKallipatti%26aufirst%3DS.%26aulast%3DSelvam%26aufirst%3DS.%26aulast%3DKrishnamurthy%26aufirst%3DP.%26aulast%3DRamarao%26aufirst%3DM.%26atitle%3DCrystal%2520Structure%2520of%2520Rat%2520Intestinal%2520Alkaline%2520Phosphatase%2520-%2520Role%2520of%2520Crown%2520Domain%2520in%2520Mammalian%2520Alkaline%2520Phosphatases%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2013%26volume%3D184%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.jsb.2013.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruchury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratap Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pahwa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jana, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katnapally, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoganand, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lakshmaiah, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazumder Tagore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span> <span> </span><span class="NLM_article-title">Characterization of Recombinantly Expressed Rat and Monkey Intestinal Alkaline Phosphatases: In Vitro Studies and In Vivo Correlations</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1425</span>– <span class="NLM_lpage">1432</span>, <span class="refDoi"> DOI: 10.1124/dmd.113.051987</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.113.051987" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2013&pages=1425-1432&author=M.+Subramanianauthor=S.+Paruchuryauthor=S.+Pratap+Singhauthor=R.+Arlaauthor=S.+Pahwaauthor=S.+Janaauthor=P.+Katnapallyauthor=V.+Yoganandauthor=B.+Lakshmaiahauthor=D.+Mazumder+Tagoreauthor=K.+Ghoshauthor=P.+Maratheauthor=S.+Mandlekar&title=Characterization+of+Recombinantly+Expressed+Rat+and+Monkey+Intestinal+Alkaline+Phosphatases%3A+In+Vitro+Studies+and+In+Vivo+Correlations&doi=10.1124%2Fdmd.113.051987"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1124%2Fdmd.113.051987&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.113.051987%26sid%3Dliteratum%253Aachs%26aulast%3DSubramanian%26aufirst%3DM.%26aulast%3DParuchury%26aufirst%3DS.%26aulast%3DPratap%2BSingh%26aufirst%3DS.%26aulast%3DArla%26aufirst%3DR.%26aulast%3DPahwa%26aufirst%3DS.%26aulast%3DJana%26aufirst%3DS.%26aulast%3DKatnapally%26aufirst%3DP.%26aulast%3DYoganand%26aufirst%3DV.%26aulast%3DLakshmaiah%26aufirst%3DB.%26aulast%3DMazumder%2BTagore%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DK.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DMandlekar%26aufirst%3DS.%26atitle%3DCharacterization%2520of%2520Recombinantly%2520Expressed%2520Rat%2520and%2520Monkey%2520Intestinal%2520Alkaline%2520Phosphatases%253A%2520In%2520Vitro%2520Studies%2520and%2520In%2520Vivo%2520Correlations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2013%26volume%3D41%26spage%3D1425%26epage%3D1432%26doi%3D10.1124%2Fdmd.113.051987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.-h.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloysius, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoyama, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.-q.</span></span> <span> </span><span class="NLM_article-title">Enzyme-Mediated Hydrolytic Activation of Prodrugs</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">143</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.apsb.2011.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.apsb.2011.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVyns73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2011&pages=143-159&author=Y.-h.+Yangauthor=H.+Aloysiusauthor=D.+Inoyamaauthor=Y.+Chenauthor=L.-q.+Hu&title=Enzyme-Mediated+Hydrolytic+Activation+of+Prodrugs&doi=10.1016%2Fj.apsb.2011.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Enzyme-mediated hydrolytic activation of prodrugs</span></div><div class="casAuthors">Yang, Yan-Hui; Aloysius, Herve; Inoyama, Daigo; Chen, Yu; Hu, Long-qin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmaceutica Sinica B</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">143-159</span>CODEN:
                <span class="NLM_cas:coden">APSBCW</span>;
        ISSN:<span class="NLM_cas:issn">2211-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Prodrug design is an important part of drug discovery.  Prodrugs can offer many advantages over parent drugs such as increased soly., enhanced stability, improved bioavailability, reduced side effects and better selectivity.  Many prodrugs have been used successfully in the clinic; examples include oseltamivir in anti-influenza therapy, enalapril in anti-hypertension therapy, capecitabine in cancer therapy and omeprazole in the treatment of peptic ulcer.  A key step in prodrug design is the incorporation of an activation mechanism that can convert the prodrug into the active species in an efficient and/or controlled manner to meet the needs of a given medical application.  Prodrug activation can be achieved through enzyme-mediated hydrolytic or oxido-reductive processes while activation of some prodrugs may proceed through pure chem. nonenzymic processes.  This review focuses on the hydrolytic enzymes that have been used in prodrug activation, including transferases, hydrolases and lyases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrT-fkNcjO57Vg90H21EOLACvtfcHk0lgoiVfsyBLezw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVyns73N&md5=d9f6bcace0e13b232b258db4592421c1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2011.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2011.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DY.-h.%26aulast%3DAloysius%26aufirst%3DH.%26aulast%3DInoyama%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.-q.%26atitle%3DEnzyme-Mediated%2520Hydrolytic%2520Activation%2520of%2520Prodrugs%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2011%26volume%3D1%26spage%3D143%26epage%3D159%26doi%3D10.1016%2Fj.apsb.2011.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riggs-Sauthier, J.</span></span> <span> </span><span class="NLM_article-title">Water Soluble Non-Peptidic Oligomer-Lipophilic Moieties-Protease Inhibitor Conjugates, Especially Containing Atazanavir and Tipranavir as the Protease Inhibitors, Their Preparation, Pharmacokinetics and Anti-HIV-1 Agents</span>. WO <span class="NLM_patent">2010144869 A2</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=J.+Riggs-Sauthier&title=Water+Soluble+Non-Peptidic+Oligomer-Lipophilic+Moieties-Protease+Inhibitor+Conjugates%2C+Especially+Containing+Atazanavir+and+Tipranavir+as+the+Protease+Inhibitors%2C+Their+Preparation%2C+Pharmacokinetics+and+Anti-HIV-1+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DRiggs-Sauthier%26aufirst%3DJ.%26atitle%3DWater%2520Soluble%2520Non-Peptidic%2520Oligomer-Lipophilic%2520Moieties-Protease%2520Inhibitor%2520Conjugates%252C%2520Especially%2520Containing%2520Atazanavir%2520and%2520Tipranavir%2520as%2520the%2520Protease%2520Inhibitors%252C%2520Their%2520Preparation%252C%2520Pharmacokinetics%2520and%2520Anti-HIV-1%2520Agents%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dhareshwar, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, V. J.</span></span> <span> </span><span class="NLM_article-title">Your Prodrug Releases Formaldehyde: Should You be Concerned? No!</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">4184</span>– <span class="NLM_lpage">4193</span>, <span class="refDoi"> DOI: 10.1002/jps.21319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fjps.21319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2008&pages=4184-4193&author=S.+S.+Dhareshwarauthor=V.+J.+Stella&title=Your+Prodrug+Releases+Formaldehyde%3A+Should+You+be+Concerned%3F+No%21&doi=10.1002%2Fjps.21319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fjps.21319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.21319%26sid%3Dliteratum%253Aachs%26aulast%3DDhareshwar%26aufirst%3DS.%2BS.%26aulast%3DStella%26aufirst%3DV.%2BJ.%26atitle%3DYour%2520Prodrug%2520Releases%2520Formaldehyde%253A%2520Should%2520You%2520be%2520Concerned%253F%2520No%2521%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2008%26volume%3D97%26spage%3D4184%26epage%3D4193%26doi%3D10.1002%2Fjps.21319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagase, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, Y.</span></span> <span> </span><span class="NLM_article-title">Protection of Tertiary Hydroxyl Groups as Methylthiomethyl Ethers</span>. <i>Tetrahedron Lett.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">66</span>, <span class="refDoi"> DOI: 10.1016/s0040-4039(00)71324-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fs0040-4039%2800%2971324-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1976&pages=65-66&author=K.+Yamadaauthor=K.+Katoauthor=H.+Nagaseauthor=Y.+Hirata&title=Protection+of+Tertiary+Hydroxyl+Groups+as+Methylthiomethyl+Ethers&doi=10.1016%2Fs0040-4039%2800%2971324-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fs0040-4039%2800%2971324-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0040-4039%252800%252971324-4%26sid%3Dliteratum%253Aachs%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DKato%26aufirst%3DK.%26aulast%3DNagase%26aufirst%3DH.%26aulast%3DHirata%26aufirst%3DY.%26atitle%3DProtection%2520of%2520Tertiary%2520Hydroxyl%2520Groups%2520as%2520Methylthiomethyl%2520Ethers%26jtitle%3DTetrahedron%2520Lett.%26date%3D1976%26volume%3D17%26spage%3D65%26epage%3D66%26doi%3D10.1016%2Fs0040-4039%2800%2971324-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Prodrugs - an Efficient Way to Breach Delivery and Targeting Barriers</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2265</span>– <span class="NLM_lpage">2287</span>, <span class="refDoi"> DOI: 10.2174/156802611797183230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F156802611797183230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=21671868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2011&pages=2265-2287&author=K.+M.+Huttunenauthor=J.+Rautio&title=Prodrugs+-+an+Efficient+Way+to+Breach+Delivery+and+Targeting+Barriers&doi=10.2174%2F156802611797183230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs - an efficient way to breach delivery and targeting barriers</span></div><div class="casAuthors">Huttunen, Kristiina M.; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">2265-2287</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The study of prodrugs that are chem. modified bioreversible derivs. of active drug compds. to alter their undesired properties has been expanded widely during the last decades.  Despite the com. success the prodrugs have afforded, the concept is still quite unknown among many scientist.  Furthermore, many scientists regard prodrugs as a pure interest of academic research groups and not as a feasible soln. to improve the delivery or targeting properties of new chem. entities, drug candidates failed in clin. trials, or drugs withdrawn from the market.  Although there are still unmet needs that require addressing, prodrugs should be seen as fine-tuning tools for the successful drug research and development.  This review represents the potential of prodrugs to improve the drug delivery by enhanced aq. soly. or permeability as well as describes several targeted prodrug strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkj5wHsNs0rbVg90H21EOLACvtfcHk0lgoiVfsyBLezw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Omt7%252FL&md5=9674c0c859bbc3b33dce4caac8e8add3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F156802611797183230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802611797183230%26sid%3Dliteratum%253Aachs%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DProdrugs%2520-%2520an%2520Efficient%2520Way%2520to%2520Breach%2520Delivery%2520and%2520Targeting%2520Barriers%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2011%26volume%3D11%26spage%3D2265%26epage%3D2287%26doi%3D10.2174%2F156802611797183230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larson, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delille, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otofokun, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Acosta, E. P.</span></span> <span> </span><span class="NLM_article-title">Pharmacokinetic Enhancers in HIV Therapeutics</span>. <i>Clin. Pharmacokinet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">865</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1007/s40262-014-0167-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs40262-014-0167-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=25164142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2014&pages=865-872&author=K.+B.+Larsonauthor=K.+Wangauthor=C.+Delilleauthor=I.+Otofokunauthor=E.+P.+Acosta&title=Pharmacokinetic+Enhancers+in+HIV+Therapeutics&doi=10.1007%2Fs40262-014-0167-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetic Enhancers in HIV Therapeutics</span></div><div class="casAuthors">Larson, Kajal B.; Wang, Kun; Delille, Cecile; Otofokun, Igho; Acosta, Edward P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacokinetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">865-872</span>CODEN:
                <span class="NLM_cas:coden">CPKNDH</span>;
        ISSN:<span class="NLM_cas:issn">0312-5963</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Maximal and durable viral load suppression is one of the most important goals of HIV therapy and is directly related to adequate drug exposure.  Protease inhibitors (PIs), an important component of the antiretroviral armada, were historically assocd. with poor oral bioavailability and high pill burden.  However, because the PIs are metabolized by cytochrome P 450 (CYP) 3A enzymes, intentional inhibition of these enzymes leads to higher drug exposure, lower pill burden, and therefore simplified dosing schedules with this class of drug.  This is the basis of pharmacokinetic enhancement.  In HIV therapy, two pharmacokinetic enhancers or boosting agents are used: ritonavir and cobicistat.  Both agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than ritonavir.  Unlike ritonavir, cobicistat does not have antiretroviral activity.  Cobicistat has been evaluated in clin. trials and was recently approved in the USA as a fixed-dose combination with the integrase inhibitor, elvitegravir and two nucleos(t)ide analogs.  Addnl. studies are examg. cobicistat in fixed-dose combinations with various PIs.  In this review, we summarize current knowledge of these agents and clin. relevant drug regimens and ongoing trials.  Studies with elvitegravir and the novel PI TMC319011 are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgjPsIIAS3K7Vg90H21EOLACvtfcHk0lgoiVfsyBLezw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVCrtrfK&md5=b4fe83cebea17842fa9cda633e76ff2e</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1007%2Fs40262-014-0167-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40262-014-0167-9%26sid%3Dliteratum%253Aachs%26aulast%3DLarson%26aufirst%3DK.%2BB.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DDelille%26aufirst%3DC.%26aulast%3DOtofokun%26aufirst%3DI.%26aulast%3DAcosta%26aufirst%3DE.%2BP.%26atitle%3DPharmacokinetic%2520Enhancers%2520in%2520HIV%2520Therapeutics%26jtitle%3DClin.%2520Pharmacokinet.%26date%3D2014%26volume%3D53%26spage%3D865%26epage%3D872%26doi%3D10.1007%2Fs40262-014-0167-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vig, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huttunen, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laine, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rautio, J.</span></span> <span> </span><span class="NLM_article-title">Amino Acids as Promoieties in Prodrug Design and Development</span>. <i>Adv. Drug Delivery Rev.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1370</span>– <span class="NLM_lpage">1385</span>, <span class="refDoi"> DOI: 10.1016/j.addr.2012.10.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.addr.2012.10.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=23099277" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1Onu77E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1370-1385&author=B.+S.+Vigauthor=K.+M.+Huttunenauthor=K.+Laineauthor=J.+Rautio&title=Amino+Acids+as+Promoieties+in+Prodrug+Design+and+Development&doi=10.1016%2Fj.addr.2012.10.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Amino acids as promoieties in prodrug design and development</span></div><div class="casAuthors">Vig, Balvinder S.; Huttunen, Kristiina M.; Laine, Krista; Rautio, Jarkko</div><div class="citationInfo"><span class="NLM_cas:title">Advanced Drug Delivery Reviews</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1370-1385</span>CODEN:
                <span class="NLM_cas:coden">ADDREP</span>;
        ISSN:<span class="NLM_cas:issn">0169-409X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Prodrugs are biol. inactive agents that upon biotransformation in vivo result in active drug mols.  Since prodrugs might alter the tissue distribution, efficacy and the toxicity of the parent drug, prodrug design should be considered at the early stages of preclin. development.  In this regard, natural and synthetic amino acids offer wide structural diversity and physicochem. properties.  This review covers the use of amino acid prodrugs to improve poor soly., poor permeability, sustained release, i.v. delivery, drug targeting, and metabolic stability of the parent drug.  In addn., practical considerations and challenges assocd. with the development of amino acid prodrugs are also covered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEHefiEPLfVLVg90H21EOLACvtfcHk0liOwFG6wOijnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1Onu77E&md5=96ed2b459752d10fd7dc0cba6147dd01</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.addr.2012.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.addr.2012.10.001%26sid%3Dliteratum%253Aachs%26aulast%3DVig%26aufirst%3DB.%2BS.%26aulast%3DHuttunen%26aufirst%3DK.%2BM.%26aulast%3DLaine%26aufirst%3DK.%26aulast%3DRautio%26aufirst%3DJ.%26atitle%3DAmino%2520Acids%2520as%2520Promoieties%2520in%2520Prodrug%2520Design%2520and%2520Development%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D2013%26volume%3D65%26spage%3D1370%26epage%3D1385%26doi%3D10.1016%2Fj.addr.2012.10.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krečmerová, M.</span></span> <span> </span><span class="NLM_article-title">Amino Acid Ester Prodrugs of Nucleoside and Nucleotide Antivirals</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">818</span>– <span class="NLM_lpage">833</span>, <span class="refDoi"> DOI: 10.2174/1389557517666170216151601</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F1389557517666170216151601" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=818-833&author=M.+Kre%C4%8Dmerov%C3%A1&title=Amino+Acid+Ester+Prodrugs+of+Nucleoside+and+Nucleotide+Antivirals&doi=10.2174%2F1389557517666170216151601"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.2174%2F1389557517666170216151601&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557517666170216151601%26sid%3Dliteratum%253Aachs%26aulast%3DKre%25C4%258Dmerov%25C3%25A1%26aufirst%3DM.%26atitle%3DAmino%2520Acid%2520Ester%2520Prodrugs%2520of%2520Nucleoside%2520and%2520Nucleotide%2520Antivirals%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D818%26epage%3D833%26doi%3D10.2174%2F1389557517666170216151601" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, T.</span></span> <span> </span><span class="NLM_article-title">A Mini-Review: Usefulness of Transporter-Targeted Prodrugs in Enhancing Membrane Permeability</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2515</span>– <span class="NLM_lpage">2526</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2016.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.xphs.2016.05.012" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2016&pages=2515-2526&author=T.+Murakami&title=A+Mini-Review%3A+Usefulness+of+Transporter-Targeted+Prodrugs+in+Enhancing+Membrane+Permeability&doi=10.1016%2Fj.xphs.2016.05.012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2016.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2016.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DMurakami%26aufirst%3DT.%26atitle%3DA%2520Mini-Review%253A%2520Usefulness%2520of%2520Transporter-Targeted%2520Prodrugs%2520in%2520Enhancing%2520Membrane%2520Permeability%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2016%26volume%3D105%26spage%3D2515%26epage%3D2526%26doi%3D10.1016%2Fj.xphs.2016.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubertin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro Biological Evaluation of Valine-Containing Prodrugs Derived From Clinically Used HIV-Protease Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1506</span>– <span class="NLM_lpage">1518</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2007.08.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2007.08.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2008&pages=1506-1518&author=D.+Rocheauthor=J.+Greinerauthor=A.-M.+Aubertinauthor=P.+Vierling&title=Synthesis+and+in+vitro+Biological+Evaluation+of+Valine-Containing+Prodrugs+Derived+From+Clinically+Used+HIV-Protease+Inhibitors&doi=10.1016%2Fj.ejmech.2007.08.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.08.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.08.016%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DAubertin%26aufirst%3DA.-M.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520Biological%2520Evaluation%2520of%2520Valine-Containing%2520Prodrugs%2520Derived%2520From%2520Clinically%2520Used%2520HIV-Protease%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2008%26volume%3D43%26spage%3D1506%26epage%3D1518%26doi%3D10.1016%2Fj.ejmech.2007.08.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Stereoselective Evasion of P-Glycoprotein, Cytochrome P450 3A, and Hydrolases by Peptide Prodrug Modification of Saquinavir</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">3199</span>– <span class="NLM_lpage">3213</span>, <span class="refDoi"> DOI: 10.1002/jps.23193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fjps.23193" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=3199-3213&author=Z.+Wangauthor=D.+Palauthor=A.+K.+Mitra&title=Stereoselective+Evasion+of+P-Glycoprotein%2C+Cytochrome+P450+3A%2C+and+Hydrolases+by+Peptide+Prodrug+Modification+of+Saquinavir&doi=10.1002%2Fjps.23193"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1002%2Fjps.23193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23193%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DStereoselective%2520Evasion%2520of%2520P-Glycoprotein%252C%2520Cytochrome%2520P450%25203A%252C%2520and%2520Hydrolases%2520by%2520Peptide%2520Prodrug%2520Modification%2520of%2520Saquinavir%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D3199%26epage%3D3213%26doi%3D10.1002%2Fjps.23193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivier, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pariat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couet, W.</span></span> <span> </span><span class="NLM_article-title">Investigation of Oral Bioavailability and Brain Distribution of the Ind(8)-Val Conjugate of Indinavir in Rodents</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">453</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1211/0022357055786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1211%2F0022357055786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=15831205" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2MXktFegu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2005&pages=453-458&author=M.+P.+de+Oliveiraauthor=J.-C.+Olivierauthor=C.+Pariatauthor=D.+Rocheauthor=J.+Greinerauthor=P.+Vierlingauthor=W.+Couet&title=Investigation+of+Oral+Bioavailability+and+Brain+Distribution+of+the+Ind%288%29-Val+Conjugate+of+Indinavir+in+Rodents&doi=10.1211%2F0022357055786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Investigation of oral bioavailability and brain distribution of the ind(8)-val conjugate of indinavir in rodents</span></div><div class="casAuthors">de Oliveira, Manuela; Olivier, Jean-Christophe; Pariat, Claudine; Roche, Dominique; Greiner, Jacques; Vierling, Pierre; Couet, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">453-458</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">Protease inhibitors are successfully used for the treatment of acquired immune deficiency syndrome (AIDS) although their biopharmaceutical characteristics are not optimal.  Prodrugs have therefore been synthesized to increase protease inhibitor bioavailability and brain distribution.  Among several compds. tested, a valine deriv. of indinavir (Ind(8)-Val) showed promising characteristics using an in-vitro Caco-2 cell model.  The objective of this study was to further investigate this compd. using in-situ and in-vivo approaches.  The pharmacokinetics of indinavir (Ind) and Ind(8)-Val were investigated in rats after i.v. and oral administration.  Free indinavir resulting from in-vivo hydrolysis of Ind(8)-Val could not be detected in the plasma of rats receiving Ind(8)-Val.  Furthermore Ind(8)-Val bioavailability was only 32% on av. compared with 76% for indinavir, and effective permeability coeffs. detd. with a single-pass intestinal perfusion method were close to 25×106 cm s-1 for the two compds.  Brain-to-plasma concn. ratios in the post equil. phase after i.v. administration to mice were 9.7±8.1% for indinavir and 2.5±2.7% for Ind(8)-Val.  In conclusion, the promising biopharmaceutical characteristics of Ind(8)-Val suggested from previous in-vitro expts. with the Caco-2 cell model were not confirmed by in-situ and in-vivo expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW3fvBpyh6JbVg90H21EOLACvtfcHk0liOwFG6wOijnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXktFegu7w%253D&md5=76c7d7a56a8335e40fcd3362e672a3c5</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1211%2F0022357055786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252F0022357055786%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BOliveira%26aufirst%3DM.%2BP.%26aulast%3DOlivier%26aufirst%3DJ.-C.%26aulast%3DPariat%26aufirst%3DC.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DVierling%26aufirst%3DP.%26aulast%3DCouet%26aufirst%3DW.%26atitle%3DInvestigation%2520of%2520Oral%2520Bioavailability%2520and%2520Brain%2520Distribution%2520of%2520the%2520Ind%25288%2529-Val%2520Conjugate%2520of%2520Indinavir%2520in%2520Rodents%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2005%26volume%3D57%26spage%3D453%26epage%3D458%26doi%3D10.1211%2F0022357055786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agarwal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boddu, S. H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samanta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitra, A. K.</span></span> <span> </span><span class="NLM_article-title">Peptide Prodrugs: Improved Oral Absorption of Lopinavir, a HIV Protease Inhibitor</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>359</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2008.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2008.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18455890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmvVemsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=359&publication_year=2008&pages=7-14&author=S.+Agarwalauthor=S.+H.+S.+Bodduauthor=R.+Jainauthor=S.+Samantaauthor=D.+Palauthor=A.+K.+Mitra&title=Peptide+Prodrugs%3A+Improved+Oral+Absorption+of+Lopinavir%2C+a+HIV+Protease+Inhibitor&doi=10.1016%2Fj.ijpharm.2008.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Peptide prodrugs: Improved oral absorption of lopinavir, a HIV protease inhibitor</span></div><div class="casAuthors">Agarwal, Sheetal; Boddu, S. H. S.; Jain, Ritesh; Samanta, Swapan; Pal, Dhananjay; Mitra, Ashim K.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">359</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">7-14</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Lopinavir (LVR) is extensively metabolized by CYP3A4 and is prevented from entering the cells by membrane efflux pumps such as P-gp and MRP2.  In an approach to evade the first-pass metab. and efflux of LVR, peptide prodrugs of LVR [valine-valine-lopinavir (VVL) and glycine-valine-lopinavir (GVL)] were synthesized.  Prodrugs were identified with 1H and 13C NMR spectra and LC/MS/MS was employed to evaluate their mass and purity.  Soly. studies indicated that the prodrugs have enhanced aq. solubilities relative to parent LVR.  Accumulation and transport data of VVL and GVL across MDCKII-MDR1 and MDCKII-MRP2 cells indicated evasion of prodrugs' efflux by P-gp and MRP2 significantly.  Permeability studies across Caco-2 cells indicated that the prodrugs are transported by peptide transporters and have increased permeability as compared with LVR.  VVL and GVL exhibited significantly better degrdn. rate consts. as compared with LVR in rat liver microsomes.  Enzymic stability studies in Caco-2 cell homogenate indicated that the peptide prodrugs are first converted to the ester intermediate (amino acid prodrug VL) and then finally to the parent drug.  Overall, the advantages of utilizing peptide prodrugs include chem. modification of the compd. to achieve targeted delivery via peptide transporters present across the intestinal epithelium, significant evasion of efflux and CYP3A4 mediated metab. and significantly better soly. profiles.  Therefore, in vitro studies demonstrated that peptide prodrug derivatization of LVR may be an effective strategy for evading its efflux and enhancing its systemic concns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1bkGqQyezkLVg90H21EOLACvtfcHk0lg6iI1zA6XCKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmvVemsL8%253D&md5=acf0ec922a0871812c5b2c848015dba0</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2008.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2008.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DAgarwal%26aufirst%3DS.%26aulast%3DBoddu%26aufirst%3DS.%2BH.%2BS.%26aulast%3DJain%26aufirst%3DR.%26aulast%3DSamanta%26aufirst%3DS.%26aulast%3DPal%26aufirst%3DD.%26aulast%3DMitra%26aufirst%3DA.%2BK.%26atitle%3DPeptide%2520Prodrugs%253A%2520Improved%2520Oral%2520Absorption%2520of%2520Lopinavir%252C%2520a%2520HIV%2520Protease%2520Inhibitor%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2008%26volume%3D359%26spage%3D7%26epage%3D14%26doi%3D10.1016%2Fj.ijpharm.2008.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amidon, G. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis of Prodrug Activation by Human Valacyclovirase, an α-Amino Acid Ester Hydrolase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">9318</span>– <span class="NLM_lpage">9327</span>, <span class="refDoi"> DOI: 10.1074/jbc.m709530200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1074%2Fjbc.m709530200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=9318-9327&author=L.+Laiauthor=Z.+Xuauthor=J.+Zhouauthor=K.-D.+Leeauthor=G.+L.+Amidon&title=Molecular+Basis+of+Prodrug+Activation+by+Human+Valacyclovirase%2C+an+%CE%B1-Amino+Acid+Ester+Hydrolase&doi=10.1074%2Fjbc.m709530200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1074%2Fjbc.m709530200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.m709530200%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.-D.%26aulast%3DAmidon%26aufirst%3DG.%2BL.%26atitle%3DMolecular%2520Basis%2520of%2520Prodrug%2520Activation%2520by%2520Human%2520Valacyclovirase%252C%2520an%2520%25CE%25B1-Amino%2520Acid%2520Ester%2520Hydrolase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D9318%26epage%3D9327%26doi%3D10.1074%2Fjbc.m709530200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouquayrol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubertin, A.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Prodrugs of HIV Protease Inhibitors-Saquinavir, Indinavir and Nelfinavir-Derived from Diglycerides or Amino Acids: Synthesis, Stability and Anti-HIV Activity</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1039/b313119j</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1039%2Fb313119j" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=14747863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFaktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2004&pages=345-357&author=B.+Gaucherauthor=M.+Rouquayrolauthor=D.+Rocheauthor=J.+Greinerauthor=A.-M.+Aubertinauthor=P.+Vierling&title=Prodrugs+of+HIV+Protease+Inhibitors-Saquinavir%2C+Indinavir+and+Nelfinavir-Derived+from+Diglycerides+or+Amino+Acids%3A+Synthesis%2C+Stability+and+Anti-HIV+Activity&doi=10.1039%2Fb313119j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity</span></div><div class="casAuthors">Gaucher, Berangere; Rouquayrol, Marielle; Roche, Dominique; Greiner, Jacques; Aubertin, Anne-Marie; Vierling, Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">345-357</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">With the aim of improving the pharmacol. properties of current protease inhibitors (PIs), the synthesis of various acyl and carbamate amino acid- or diglyceride-contg. prodrugs derived from saquinavir, indinavir and nelfinavir, their in vitro stability with respect to hydrolysis and their anti-HIV activity in CEM-SS and MT4 cells have been investigated.  L-Leucine (Leu) and L-phenylalanine (Phe) were connected through their carboxyl to the PIs while L-tyrosine (Tyr) was conjugated through its arom. hydroxyl via various spacer units.  Hydrolysis of the prodrug with liberation of the active free drug was crucial for antiviral activity.  The Leu- and Phe-PI prodrugs released the active free drug very rapidly (half-lives of hydrolysis in buffer at 37 °C of 3-4 h).  The Tyr-PI conjugates with a -C(O)(CH2)4- linker exhibited half-lives in the 40-70 h range and antiviral activities in the 21-325 nM range (from 2 to 22 nM for the free PIs).  The chem. very stable carbamate "peptidomimetic" Tyr-PI prodrugs (no hydrolysis detected after 7 days in buffer) displayed a very low anti-HIV activity or were even inactive (EC50 from 2300 nM to >10 μM).  A very low antiviral activity was measured for the diglyceride-substituted saquinavir and for all of the disubstituted indinavir and nelfinavir prodrugs.  All these prodrugs probably released the active parent PI too slowly under the antiviral assay conditions.  These results combined with those from transepithelial transport studies (Rouquayrol et al., 2002) indicate that conjugation of amino acids (through their carboxyl) to the PIs constitutes a most appealing alternative which could improve the intestinal absorption of the PIs and reduce their recognition by efflux carriers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC3qjx69Fa-rVg90H21EOLACvtfcHk0lg6iI1zA6XCKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFaktA%253D%253D&md5=00f94d6f534db3eea634f640f323a010</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1039%2Fb313119j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb313119j%26sid%3Dliteratum%253Aachs%26aulast%3DGaucher%26aufirst%3DB.%26aulast%3DRouquayrol%26aufirst%3DM.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DAubertin%26aufirst%3DA.-M.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DProdrugs%2520of%2520HIV%2520Protease%2520Inhibitors-Saquinavir%252C%2520Indinavir%2520and%2520Nelfinavir-Derived%2520from%2520Diglycerides%2520or%2520Amino%2520Acids%253A%2520Synthesis%252C%2520Stability%2520and%2520Anti-HIV%2520Activity%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2004%26volume%3D2%26spage%3D345%26epage%3D357%26doi%3D10.1039%2Fb313119j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rouquayrol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaucher, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vierling, P.</span></span> <span> </span><span class="NLM_article-title">Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1704</span>– <span class="NLM_lpage">1712</span>, <span class="refDoi"> DOI: 10.1023/a:1020913631309</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1023%2Fa%3A1020913631309" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=1704-1712&author=M.+Rouquayrolauthor=B.+Gaucherauthor=D.+Rocheauthor=J.+Greinerauthor=P.+Vierling&title=Transepithelial+Transport+of+Prodrugs+of+the+HIV+Protease+Inhibitors+Saquinavir%2C+Indinavir%2C+and+Nelfinavir+Across+Caco-2+Cell+Monolayers&doi=10.1023%2Fa%3A1020913631309"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1023%2Fa%3A1020913631309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252Fa%253A1020913631309%26sid%3Dliteratum%253Aachs%26aulast%3DRouquayrol%26aufirst%3DM.%26aulast%3DGaucher%26aufirst%3DB.%26aulast%3DRoche%26aufirst%3DD.%26aulast%3DGreiner%26aufirst%3DJ.%26aulast%3DVierling%26aufirst%3DP.%26atitle%3DTransepithelial%2520Transport%2520of%2520Prodrugs%2520of%2520the%2520HIV%2520Protease%2520Inhibitors%2520Saquinavir%252C%2520Indinavir%252C%2520and%2520Nelfinavir%2520Across%2520Caco-2%2520Cell%2520Monolayers%26jtitle%3DPharm.%2520Res.%26date%3D2002%26volume%3D19%26spage%3D1704%26epage%3D1712%26doi%3D10.1023%2Fa%3A1020913631309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Usansky, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sinko, P. J.</span></span> <span> </span><span class="NLM_article-title">Differential Roles of P-Glycoprotein, Multidrug Resistance-Associated Protein 2, and CYP3A on Saquinavir Oral Absorption in Sprague-Dawley Rats</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">863</span>– <span class="NLM_lpage">869</span>, <span class="refDoi"> DOI: 10.1124/dmd.107.017483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.107.017483" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2008&pages=863-869&author=H.+H.+Usanskyauthor=P.+Huauthor=P.+J.+Sinko&title=Differential+Roles+of+P-Glycoprotein%2C+Multidrug+Resistance-Associated+Protein+2%2C+and+CYP3A+on+Saquinavir+Oral+Absorption+in+Sprague-Dawley+Rats&doi=10.1124%2Fdmd.107.017483"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1124%2Fdmd.107.017483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.107.017483%26sid%3Dliteratum%253Aachs%26aulast%3DUsansky%26aufirst%3DH.%2BH.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DSinko%26aufirst%3DP.%2BJ.%26atitle%3DDifferential%2520Roles%2520of%2520P-Glycoprotein%252C%2520Multidrug%2520Resistance-Associated%2520Protein%25202%252C%2520and%2520CYP3A%2520on%2520Saquinavir%2520Oral%2520Absorption%2520in%2520Sprague-Dawley%2520Rats%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2008%26volume%3D36%26spage%3D863%26epage%3D869%26doi%3D10.1124%2Fdmd.107.017483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caceres-Cortes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christopher, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arora, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pursley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lago, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, R. A.</span></span> <span> </span><span class="NLM_article-title">Metabolism and Disposition of [14C]Brivanib Alaninate after Oral Administration to Rats, Monkeys, and Humans</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">891</span>– <span class="NLM_lpage">903</span>, <span class="refDoi"> DOI: 10.1124/dmd.110.037341</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.110.037341" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=891-903&author=J.+Gongauthor=J.+Ganauthor=J.+Caceres-Cortesauthor=L.+J.+Christopherauthor=V.+Aroraauthor=E.+Massonauthor=D.+Williamsauthor=J.+Pursleyauthor=A.+Allentoffauthor=M.+Lagoauthor=S.+B.+Tranauthor=R.+A.+Iyer&title=Metabolism+and+Disposition+of+%5B14C%5DBrivanib+Alaninate+after+Oral+Administration+to+Rats%2C+Monkeys%2C+and+Humans&doi=10.1124%2Fdmd.110.037341"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1124%2Fdmd.110.037341&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.110.037341%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DGan%26aufirst%3DJ.%26aulast%3DCaceres-Cortes%26aufirst%3DJ.%26aulast%3DChristopher%26aufirst%3DL.%2BJ.%26aulast%3DArora%26aufirst%3DV.%26aulast%3DMasson%26aufirst%3DE.%26aulast%3DWilliams%26aufirst%3DD.%26aulast%3DPursley%26aufirst%3DJ.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DLago%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DS.%2BB.%26aulast%3DIyer%26aufirst%3DR.%2BA.%26atitle%3DMetabolism%2520and%2520Disposition%2520of%2520%255B14C%255DBrivanib%2520Alaninate%2520after%2520Oral%2520Administration%2520to%2520Rats%252C%2520Monkeys%252C%2520and%2520Humans%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D891%26epage%3D903%26doi%3D10.1124%2Fdmd.110.037341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borzilleri, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wautlet, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mortillo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeyaseelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukral, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamath, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marathe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Derbin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robl, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fargnoli, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhide, R. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Brivanib Alaninate ((<i>S</i>)-((<i>R</i>)-1-(4-(4-Fluoro-2-methyl-1<i>H</i>-indol-5-yloxy)-5-methylpyrrolo[2,1-<i>f</i>][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), A Novel Prodrug of Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinase Inhibitor (BMS-540215)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1976</span>– <span class="NLM_lpage">1980</span>, <span class="refDoi"> DOI: 10.1021/jm7013309</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7013309" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=1976-1980&author=Z.-w.+Caiauthor=Y.+Zhangauthor=R.+M.+Borzilleriauthor=L.+Qianauthor=S.+Barbosaauthor=D.+Weiauthor=X.+Zhengauthor=L.+Wuauthor=J.+Fanauthor=Z.+Shiauthor=B.+S.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+W.+Kukralauthor=A.+Kamathauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+C.+Barrishauthor=J.+A.+Roblauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+S.+Bhide&title=Discovery+of+Brivanib+Alaninate+%28%28S%29-%28%28R%29-1-%284-%284-Fluoro-2-methyl-1H-indol-5-yloxy%29-5-methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-2-yl%292-aminopropanoate%29%2C+A+Novel+Prodrug+of+Dual+Vascular+Endothelial+Growth+Factor+Receptor-2+and+Fibroblast+Growth+Factor+Receptor-1+Kinase+Inhibitor+%28BMS-540215%29&doi=10.1021%2Fjm7013309"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm7013309&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7013309%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.-w.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%2BW.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DRobl%26aufirst%3DJ.%2BA.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBhide%26aufirst%3DR.%2BS.%26atitle%3DDiscovery%2520of%2520Brivanib%2520Alaninate%2520%2528%2528S%2529-%2528%2528R%2529-1-%25284-%25284-Fluoro-2-methyl-1H-indol-5-yloxy%2529-5-methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-2-yl%25292-aminopropanoate%2529%252C%2520A%2520Novel%2520Prodrug%2520of%2520Dual%2520Vascular%2520Endothelial%2520Growth%2520Factor%2520Receptor-2%2520and%2520Fibroblast%2520Growth%2520Factor%2520Receptor-1%2520Kinase%2520Inhibitor%2520%2528BMS-540215%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D1976%26epage%3D1980%26doi%3D10.1021%2Fjm7013309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bou-Chacra, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melo, K. J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales, I. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stippler, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kesisoglou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yazdanian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löbenberg, R.</span></span> <span> </span><span class="NLM_article-title">Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System</span>. <i>AAPS J</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">1001</span>, <span class="refDoi"> DOI: 10.1208/s12248-017-0085-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1208%2Fs12248-017-0085-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28516359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotVKnt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2017&pages=989-1001&author=N.+Bou-Chacraauthor=K.+J.+C.+Meloauthor=I.+A.+C.+Moralesauthor=E.+S.+Stipplerauthor=F.+Kesisoglouauthor=M.+Yazdanianauthor=R.+L%C3%B6benberg&title=Evolution+of+Choice+of+Solubility+and+Dissolution+Media+After+Two+Decades+of+Biopharmaceutical+Classification+System&doi=10.1208%2Fs12248-017-0085-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System</span></div><div class="casAuthors">Bou-Chacra, Nadia; Melo, Katherine Jasmine Curo; Morales, Ivan Andres Cordova; Stippler, Erika S.; Kesisoglou, Filippos; Yazdanian, Mehran; Lobenberg, Raimar</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">989-1001</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The introduction of the biopharmaceutics drug classification system (Biopharmaceutics Classification System (BCS)), in 1995, provided a simple way to describe the biopharmaceutics behavior of a drug.  Soly. and permeability are among the major parameters, which det. the fraction dose absorbed of a drug substance and consequently its chances to be bioavailable.  The purpose of this review is to summarize the evolution of the media used for detg. soly. and dissoln. and how this can be used in modern drug development.  Over the years, physiol. adapted media and buffers were introduced with the intention to better predict the in vivo soly. and dissoln. of drug substances.  Water, buffer solns., compendial media, micellar solubilization media, and biorelevant media are reviewed.  At this time point, there is no universal medium available which can be used to predict every drug substance's soly. or a drug product's in vivo dissoln. behavior.  However, there have been many improvements and addns. made to media to optimize their in vivo predictability; for example, the current phosphate concns. in buffers seem to be too high to correlate with the carbonate buffer concns. in vivo.  Biorelevant media were updated to correlate them better with the compn. of human intestinal fluids.  The BCS was introduced into regulatory sciences as a scientific risk management tool to waive bioequivalence studies under certain conditions.  Today's different guidance documents define the dose-soly. ratio differently.  As shown for amoxicillin, this can cause more confusion than certainty for globally operating companies.  Harmonization of BCS guidelines is highly desirable.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEO5cC3Eo0TLVg90H21EOLACvtfcHk0lhISVWmZUMPbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotVKnt7Y%253D&md5=e687a9536f08f2fc2cab0503fc5c2795</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1208%2Fs12248-017-0085-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-017-0085-5%26sid%3Dliteratum%253Aachs%26aulast%3DBou-Chacra%26aufirst%3DN.%26aulast%3DMelo%26aufirst%3DK.%2BJ.%2BC.%26aulast%3DMorales%26aufirst%3DI.%2BA.%2BC.%26aulast%3DStippler%26aufirst%3DE.%2BS.%26aulast%3DKesisoglou%26aufirst%3DF.%26aulast%3DYazdanian%26aufirst%3DM.%26aulast%3DL%25C3%25B6benberg%26aufirst%3DR.%26atitle%3DEvolution%2520of%2520Choice%2520of%2520Solubility%2520and%2520Dissolution%2520Media%2520After%2520Two%2520Decades%2520of%2520Biopharmaceutical%2520Classification%2520System%26jtitle%3DAAPS%2520J%26date%3D2017%26volume%3D19%26spage%3D989%26epage%3D1001%26doi%3D10.1208%2Fs12248-017-0085-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yadav, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smart, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajiri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basit, A. W.</span></span> <span> </span><span class="NLM_article-title">Toward Oral Delivery of Biopharmaceuticals: an Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span>. <i>Mol. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">966</span>– <span class="NLM_lpage">973</span>, <span class="refDoi"> DOI: 10.1021/mp500809f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500809f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=966-973&author=J.+Wangauthor=V.+Yadavauthor=A.+L.+Smartauthor=S.+Tajiriauthor=A.+W.+Basit&title=Toward+Oral+Delivery+of+Biopharmaceuticals%3A+an+Assessment+of+the+Gastrointestinal+Stability+of+17+Peptide+Drugs&doi=10.1021%2Fmp500809f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Oral Delivery of Biopharmaceuticals: An Assessment of the Gastrointestinal Stability of 17 Peptide Drugs</span></div><div class="casAuthors">Wang, Jie; Yadav, Vipul; Smart, Alice L.; Tajiri, Shinichiro; Basit, Abdul W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">966-973</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A major barrier to successful oral delivery of peptide and protein mols. is their inherent instability in the lumen of the gastrointestinal tract.  The aim of this study was to det. the stability of 17 disparate peptide drugs (insulin, calcitonin, glucagon, secretin, somatostatin, desmopressin, oxytocin, [Arg8]-vasopressin, octreotide, ciclosporin, leuprolide, nafarelin, buserelin, histrelin, [D-Ser]4-gonadorelin, deslorelin, and goserelin) in gastric and small intestinal fluids from both humans and pigs, and in simulated gastric and intestinal fluids.  In human gastric fluid, the larger peptides including somatostatin, calcitonin, secretin, glucagon, and insulin were metabolized rapidly, while the smaller peptides showed good stability.  In human small intestinal fluid, however, both small and large peptides degraded rapidly with the exception of the cyclic peptide ciclosporin and the disulfide-bridge contg. peptides octreotide and desmopressin, which showed good stability.  The stability of peptides in both simulated gastric fluid and pig gastric fluid correlated well with stability in human gastric fluid.  However, it was not possible to establish such a correlation with the small intestinal fluids because of the rapid rate of peptide degrdn.  This work has identified the mol. features in the structure of a wide range of peptides that influence their stability in the environment of the gastrointestinal tract, which in turn will allow for better selection of peptide candidates for oral delivery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraciXJLe-z4rVg90H21EOLACvtfcHk0lhsESVwL1KWmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlyqsb8%253D&md5=a29abd913a44604892e879e735818ff9</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fmp500809f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500809f%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DYadav%26aufirst%3DV.%26aulast%3DSmart%26aufirst%3DA.%2BL.%26aulast%3DTajiri%26aufirst%3DS.%26aulast%3DBasit%26aufirst%3DA.%2BW.%26atitle%3DToward%2520Oral%2520Delivery%2520of%2520Biopharmaceuticals%253A%2520an%2520Assessment%2520of%2520the%2520Gastrointestinal%2520Stability%2520of%252017%2520Peptide%2520Drugs%26jtitle%3DMol.%2520Pharm.%26date%3D2015%26volume%3D12%26spage%3D966%26epage%3D973%26doi%3D10.1021%2Fmp500809f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parrish, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaochico, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, M.</span></span> <span> </span><span class="NLM_article-title">In Vitro and in Vivo Characterization of CYP Inhibition by 1-Aminobenzotriazole in Rats</span>. <i>Biopharm. Drug Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">200</span>– <span class="NLM_lpage">211</span>, <span class="refDoi"> DOI: 10.1002/bdd.2000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fbdd.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26637499" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC28Xot1Kgtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2016&pages=200-211&author=K.+E.+Parrishauthor=J.+Maoauthor=J.+Chenauthor=A.+Jaochicoauthor=J.+Lyauthor=Q.+Hoauthor=S.+Mukadamauthor=M.+Wright&title=In+Vitro+and+in+Vivo+Characterization+of+CYP+Inhibition+by+1-Aminobenzotriazole+in+Rats&doi=10.1002%2Fbdd.2000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of CYP inhibition by 1-aminobenzotriazole in rats</span></div><div class="casAuthors">Parrish, Karen E.; Mao, Jialin; Chen, Jacob; Jaochico, Allan; Ly, Justin; Ho, Quynh; Mukadam, Sophie; Wright, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Biopharmaceutics & Drug Disposition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">200-211</span>CODEN:
                <span class="NLM_cas:coden">BDDID8</span>;
        ISSN:<span class="NLM_cas:issn">0142-2782</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">1-Aminobenzotriazole (ABT) is a non-isoform specific, time-dependent inhibitor of cytochrome P 450 (CYP) enzymes used extensively in preclin. studies to det. the relative contribution of oxidative metab.  Although ABT has been widely used, the extent and duration of its inhibitory effect is not well understood.  The purpose of this study is to characterize ABT inhibition of CYP in rats at both the hepatic and intestinal levels.  In vivo studies using midazolam (p.o. and i.v.), as a probe for CYP activity, demonstrated that CYP inhibition was not complete even at the highest dose (300 mg/kg).  Addnl. in vivo studies demonstrated that even at 26 h following ABT administration, there was significant CYP inhibition remaining.  In vitro studies, conducted in both rat liver microsomes and rat hepatocytes, confirm that ABT is a time-dependent inhibitor of rat CYP orthologs.  However, in rat liver microsomes, there was more than 15% CYP activity remaining following a 60 min preincubation at 2 mM ABT and 5-10% of CYP activity was remaining in rat hepatocytes suspended in rat plasma following a 60 min preincubation at 2 mM ABT. 1-Aminobenzotriazole is a useful tool in elucidating the oxidative component of metab. in preclin. species; however, conclusions made from the preclin. use of ABT should not operate under the assumption that CYP enzymic activity is completely inhibited.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCr2m85zI_mrVg90H21EOLACvtfcHk0lhsESVwL1KWmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xot1Kgtbg%253D&md5=2e90ecb17737f79dd6dca368150f0f94</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1002%2Fbdd.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbdd.2000%26sid%3Dliteratum%253Aachs%26aulast%3DParrish%26aufirst%3DK.%2BE.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DJaochico%26aufirst%3DA.%26aulast%3DLy%26aufirst%3DJ.%26aulast%3DHo%26aufirst%3DQ.%26aulast%3DMukadam%26aufirst%3DS.%26aulast%3DWright%26aufirst%3DM.%26atitle%3DIn%2520Vitro%2520and%2520in%2520Vivo%2520Characterization%2520of%2520CYP%2520Inhibition%2520by%25201-Aminobenzotriazole%2520in%2520Rats%26jtitle%3DBiopharm.%2520Drug%2520Dispos.%26date%3D2016%26volume%3D37%26spage%3D200%26epage%3D211%26doi%3D10.1002%2Fbdd.2000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vockley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antshel, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braverman, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burton, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, W. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, S. A.</span></span> <span> </span><span class="NLM_article-title">Phenylalanine Hydroxylase Deficiency: Diagnosis and Management Guideline</span>. <i>Genet. Med.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">200</span>, <span class="refDoi"> DOI: 10.1038/gim.2013.157</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1038%2Fgim.2013.157" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=24385074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmt1Wktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2014&pages=188-200&author=J.+Vockleyauthor=H.+C.+Anderssonauthor=K.+M.+Antshelauthor=N.+E.+Bravermanauthor=B.+K.+Burtonauthor=D.+M.+Frazierauthor=J.+Mitchellauthor=W.+E.+Smithauthor=B.+H.+Thompsonauthor=S.+A.+Berry&title=Phenylalanine+Hydroxylase+Deficiency%3A+Diagnosis+and+Management+Guideline&doi=10.1038%2Fgim.2013.157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Phenylalanine hydroxylase deficiency: diagnosis and management guideline</span></div><div class="casAuthors">Vockley, Jerry; Andersson, Hans C.; Antshel, Kevin M.; Braverman, Nancy E.; Burton, Barbara K.; Frazier, Dianne M.; Mitchell, John; Smith, Wendy E.; Thompson, Barry H.; Berry, Susan A.</div><div class="citationInfo"><span class="NLM_cas:title">Genetics in Medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">188-200</span>CODEN:
                <span class="NLM_cas:coden">GEMEF3</span>;
        ISSN:<span class="NLM_cas:issn">1098-3600</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Phenylalanine hydroxylase deficiency, traditionally known as phenylketonuria, results in the accumulation of phenylalanine in the blood of affected individuals and was the first inborn error of metab. to be identified through population screening.  Early identification and treatment prevent the most dramatic clin. sequelae of the disorder, but new neurodevelopmental and psychol. problems have emerged in individuals treated from birth.  The addnl. unanticipated recognition of a toxic effect of elevated maternal phenylalanine on fetal development has added to a general call in the field for treatment for life.  Two major conferences sponsored by the National Institutes of Health held >10 years apart reviewed the state of knowledge in the field of phenylalanine hydroxylase deficiency, but there are no generally accepted recommendations for therapy.  The purpose of this guideline is to review the strength of the medical literature relative to the treatment of phenylalanine hydroxylase deficiency and to develop recommendations for diagnosis and therapy of this disorder.  Evidence review from the original National Institutes of Health consensus conference and a recent update by the Agency for Healthcare Research and Quality was used to address key questions in the diagnosis and treatment of phenylalanine hydroxylase deficiency by a working group established by the American College of Medical Genetics and Genomics.  The group met by phone and in person over the course of a year to review these reports, develop recommendations, and identify key gaps in our knowledge of this disorder.  Above all, treatment of phenylalanine hydroxylase deficiency must be life long, with a goal of maintaining blood phenylalanine in the range of 120-360 μmol/l.  Treatment has predominantly been dietary manipulation, and use of low protein and phenylalanine medical foods is likely to remain a major component of therapy for the immediate future.  Pharmacotherapy for phenylalanine hydroxylase deficiency is in early stages with one approved medication (sapropterin, a deriv. of the natural cofactor of phenylalanine hydroxylase) and others under development.  Eventually, treatment of phenylalanine hydroxylase deficiency will be individualized with multiple medications and alternative medical foods available to tailor therapy.  The primary goal of therapy should be to lower blood phenylalanine, and any interventions, including medications, or combination of therapies that help to achieve that goal in an individual, without other neg. consequences, should be considered appropriate therapy.  Significant evidence gaps remain in our understanding of the optimum therapies for phenylalanine hydroxylase deficiency, nonphenylalanine effects of these therapies, and long-term sequelae of even well-treated disease in children and adults.  Genet Med16 2, 188-200.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp64nbBJSww4rVg90H21EOLACvtfcHk0lhsESVwL1KWmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmt1Wktrw%253D&md5=f156c3f31bd14daa6f439b19c120727d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1038%2Fgim.2013.157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fgim.2013.157%26sid%3Dliteratum%253Aachs%26aulast%3DVockley%26aufirst%3DJ.%26aulast%3DAndersson%26aufirst%3DH.%2BC.%26aulast%3DAntshel%26aufirst%3DK.%2BM.%26aulast%3DBraverman%26aufirst%3DN.%2BE.%26aulast%3DBurton%26aufirst%3DB.%2BK.%26aulast%3DFrazier%26aufirst%3DD.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DW.%2BE.%26aulast%3DThompson%26aufirst%3DB.%2BH.%26aulast%3DBerry%26aufirst%3DS.%2BA.%26atitle%3DPhenylalanine%2520Hydroxylase%2520Deficiency%253A%2520Diagnosis%2520and%2520Management%2520Guideline%26jtitle%3DGenet.%2520Med.%26date%3D2014%26volume%3D16%26spage%3D188%26epage%3D200%26doi%3D10.1038%2Fgim.2013.157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stappaerts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouwers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Annaert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Augustijns, P.</span></span> <span> </span><span class="NLM_article-title">In Situ Perfusion in Rodents to Explore Intestinal Drug Absorption: Challenges and Opportunities</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>478</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">681</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2014.11.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ijpharm.2014.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=25448559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=478&publication_year=2015&pages=665-681&author=J.+Stappaertsauthor=J.+Brouwersauthor=P.+Annaertauthor=P.+Augustijns&title=In+Situ+Perfusion+in+Rodents+to+Explore+Intestinal+Drug+Absorption%3A+Challenges+and+Opportunities&doi=10.1016%2Fj.ijpharm.2014.11.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities</span></div><div class="casAuthors">Stappaerts, Jef; Brouwers, Joachim; Annaert, Pieter; Augustijns, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">478</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">665-681</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The in situ intestinal perfusion technique in rodents is a very important absorption model, not only because of its predictive value, but it is also very suitable to unravel the mechanisms underlying intestinal drug absorption.  This literature overview covers a no. of specific applications for which the in situ intestinal perfusion set-up can be applied in favor of established in vitro absorption tools, such as the Caco-2 cell model.  Qualities including the expression of drug transporters and metabolizing enzymes relevant for human intestinal absorption and compatibility with complex solvent systems render the in situ technique the most designated absorption model to perform transporter-metab. studies or to evaluate the intestinal absorption from biorelevant media.Over the years, the in situ intestinal perfusion model has exhibited an exceptional ability to adapt to the latest challenges in drug absorption profiling.  For instance, the introduction of the mesenteric vein cannulation allows detg. the appearance of compds. in the blood and is of great use, esp. when evaluating the absorption of compds. undergoing intestinal metab.  Moreover, the use of the closed loop intestinal perfusion set-up is interesting when compds. or perfusion media are scarce.  Compatibility with emerging trends in pharmaceutical profiling, such as the use of knockout or transgenic animals, generates unparalleled possibilities to gain mechanistic insight into specific absorption processes.Notwithstanding the fact that the in situ expts. are tech. challenging and relatively time-consuming, the model offers great opportunities to gain insight into the processes detg. intestinal drug absorption.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0fIWKFc_khrVg90H21EOLACvtfcHk0li-XqyxUhY75A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFegt7vL&md5=54243d5d40352b910b434b41d8059b8c</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2014.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2014.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DStappaerts%26aufirst%3DJ.%26aulast%3DBrouwers%26aufirst%3DJ.%26aulast%3DAnnaert%26aufirst%3DP.%26aulast%3DAugustijns%26aufirst%3DP.%26atitle%3DIn%2520Situ%2520Perfusion%2520in%2520Rodents%2520to%2520Explore%2520Intestinal%2520Drug%2520Absorption%253A%2520Challenges%2520and%2520Opportunities%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2015%26volume%3D478%26spage%3D665%26epage%3D681%26doi%3D10.1016%2Fj.ijpharm.2014.11.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chando, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Everett, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patten, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehal, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span> <span> </span><span class="NLM_article-title">In vitro Inhibition of UDP Glucuronosyltransferases by Atazanavir and Other HIV Protease Inhibitors and the Relationship of This Property to In Vivo Bilirubin Glucuronidation</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">1729</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1124/dmd.105.005447</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1124%2Fdmd.105.005447" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=1729-1739&author=D.+Zhangauthor=T.+J.+Chandoauthor=D.+W.+Everettauthor=C.+J.+Pattenauthor=S.+S.+Dehalauthor=W.+G.+Humphreys&title=In+vitro+Inhibition+of+UDP+Glucuronosyltransferases+by+Atazanavir+and+Other+HIV+Protease+Inhibitors+and+the+Relationship+of+This+Property+to+In+Vivo+Bilirubin+Glucuronidation&doi=10.1124%2Fdmd.105.005447"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fdmd.105.005447&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.105.005447%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DChando%26aufirst%3DT.%2BJ.%26aulast%3DEverett%26aufirst%3DD.%2BW.%26aulast%3DPatten%26aufirst%3DC.%2BJ.%26aulast%3DDehal%26aufirst%3DS.%2BS.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26atitle%3DIn%2520vitro%2520Inhibition%2520of%2520UDP%2520Glucuronosyltransferases%2520by%2520Atazanavir%2520and%2520Other%2520HIV%2520Protease%2520Inhibitors%2520and%2520the%2520Relationship%2520of%2520This%2520Property%2520to%2520In%2520Vivo%2520Bilirubin%2520Glucuronidation%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D1729%26epage%3D1739%26doi%3D10.1124%2Fdmd.105.005447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gammal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Court, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haidar, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwuchukwu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarellos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whirl-Carrillo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brummel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratain, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schackman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caudle, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D.</span></span> <span> </span><span class="NLM_article-title">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forUGT1A1and Atazanavir Prescribing</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">363</span>– <span class="NLM_lpage">369</span>, <span class="refDoi"> DOI: 10.1002/cpt.269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fcpt.269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26417955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A280%3ADC%252BC283mslSktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=363-369&author=R.+Gammalauthor=M.+Courtauthor=C.+Haidarauthor=O.+Iwuchukwuauthor=A.+Gaurauthor=M.+Alvarellosauthor=C.+Guillemetteauthor=J.+Lennoxauthor=M.+Whirl-Carrilloauthor=S.+Brummelauthor=M.+Ratainauthor=T.+Kleinauthor=B.+Schackmanauthor=K.+Caudleauthor=D.+Haas&title=Clinical+Pharmacogenetics+Implementation+Consortium+%28CPIC%29+Guideline+forUGT1A1and+Atazanavir+Prescribing&doi=10.1002%2Fcpt.269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing</span></div><div class="casAuthors">Gammal R S; Haidar C E; Caudle K E; Court M H; Iwuchukwu O F; Iwuchukwu O F; Gaur A H; Alvarellos M; Whirl-Carrillo M; Klein T E; Guillemette C; Lennox J L; Brummel S S; Ratain M J; Schackman B R; Haas D W</div><div class="citationInfo"><span class="NLM_cas:title">Clinical pharmacology and therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">363-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The antiretroviral protease inhibitor atazanavir inhibits hepatic uridine diphosphate glucuronosyltransferase (UGT) 1A1, thereby preventing the glucuronidation and elimination of bilirubin.  Resultant indirect hyperbilirubinemia with jaundice can cause premature discontinuation of atazanavir.  Risk for bilirubin-related discontinuation is highest among individuals who carry two UGT1A1 decreased function alleles (UGT1A1*28 or *37).  We summarize published literature that supports this association and provide recommendations for atazanavir prescribing when UGT1A1 genotype is known (updates at www.pharmgkb.org).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvlVeXfe9CxVWTCLT8lX9SfW6udTcc2ea7JNts_lhDvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC283mslSktQ%253D%253D&md5=1bdc1d8bcc2d722fe6ac0c3ce8b65880</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1002%2Fcpt.269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.269%26sid%3Dliteratum%253Aachs%26aulast%3DGammal%26aufirst%3DR.%26aulast%3DCourt%26aufirst%3DM.%26aulast%3DHaidar%26aufirst%3DC.%26aulast%3DIwuchukwu%26aufirst%3DO.%26aulast%3DGaur%26aufirst%3DA.%26aulast%3DAlvarellos%26aufirst%3DM.%26aulast%3DGuillemette%26aufirst%3DC.%26aulast%3DLennox%26aufirst%3DJ.%26aulast%3DWhirl-Carrillo%26aufirst%3DM.%26aulast%3DBrummel%26aufirst%3DS.%26aulast%3DRatain%26aufirst%3DM.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DSchackman%26aufirst%3DB.%26aulast%3DCaudle%26aufirst%3DK.%26aulast%3DHaas%26aufirst%3DD.%26atitle%3DClinical%2520Pharmacogenetics%2520Implementation%2520Consortium%2520%2528CPIC%2529%2520Guideline%2520forUGT1A1and%2520Atazanavir%2520Prescribing%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2016%26volume%3D99%26spage%3D363%26epage%3D369%26doi%3D10.1002%2Fcpt.269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, D.-Y.</span></span> <span> </span><span class="NLM_article-title">Application of Fluorine in Drug Design During 2010-2015 Years: A Mini-Review</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.2174/1389557515666151016124957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.2174%2F1389557515666151016124957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=26471967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFGisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=683-692&author=B.-C.+Wangauthor=L.-J.+Wangauthor=B.+Jiangauthor=S.-Y.+Wangauthor=N.+Wuauthor=X.-Q.+Liauthor=D.-Y.+Shi&title=Application+of+Fluorine+in+Drug+Design+During+2010-2015+Years%3A+A+Mini-Review&doi=10.2174%2F1389557515666151016124957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Application of Fluorine in Drug Design During 2010-2015 Years: A Mini-Review</span></div><div class="casAuthors">Wang, Bao-Cheng; Wang, Li-Jun; Jiang, Bo; Wang, Shuai-Yu; Wu, Ning; Li, Xiang-Qian; Shi, Da-Yong</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">683-692</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Background: The widespread application of fluorine in drug design benefits from distinctive properties.  Incorporation of fluorine can pos. modulate certain pharmacokinetics properties, including lipophilicity, eletrophilicity, metabolic stability, chem. stability, et al., which were of interest to medicinal chemists.  Herein, fluorinated compds., which have been designed and evaluated for anticancer, antimicrobial, anti-inflammatory and antivirus activity, et al. during the last 6 years (2010-2015) are summarized.  Conclusion: The emphasis is to highlight the importance of fluorinated compds. and the changes in the properties of compds. when introducing fluorine atom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf6wbFwaGSx7Vg90H21EOLACvtfcHk0lgY40YuhIWB1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFGisbc%253D&md5=a2061775cb12ab5e2bf264f2a6727bf2</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2174%2F1389557515666151016124957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389557515666151016124957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.-C.%26aulast%3DWang%26aufirst%3DL.-J.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DS.-Y.%26aulast%3DWu%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DX.-Q.%26aulast%3DShi%26aufirst%3DD.-Y.%26atitle%3DApplication%2520of%2520Fluorine%2520in%2520Drug%2520Design%2520During%25202010-2015%2520Years%253A%2520A%2520Mini-Review%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D683%26epage%3D692%26doi%3D10.2174%2F1389557515666151016124957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojima, I.</span></span> <span> </span><span class="NLM_article-title">Strategic Incorporation of Fluorine into Taxoid Anticancer Agents for Medicinal Chemistry and Chemical Biology Studies</span>. <i>J. Fluorine Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>198</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.jfluchem.2016.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.jfluchem.2016.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28824201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXotlGntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=198&publication_year=2017&pages=10-23&author=I.+Ojima&title=Strategic+Incorporation+of+Fluorine+into+Taxoid+Anticancer+Agents+for+Medicinal+Chemistry+and+Chemical+Biology+Studies&doi=10.1016%2Fj.jfluchem.2016.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Strategic incorporation of fluorine into taxoid anticancer agents for medicinal chemistry and chemical biology studies</span></div><div class="casAuthors">Ojima, Iwao</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Fluorine Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">198</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-23</span>CODEN:
                <span class="NLM_cas:coden">JFLCAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-1139</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">This account exemplifies our recent progress on the strategic incorporation of fluorine and organofluorine groups to taxoid anticancer agents and their tumor-targeted drug delivery systems (TTDDSs) for medicinal chem. and chem. biol. studies.  Novel 3'-difluorovinyltaxoids were strategically designed to block the metab. by cytochrome P 450, synthesized, and evaluated for their cytotoxicity against drug-sensitive and multidrug-resistant (MDR) human cancer cell lines. 3'-Difluorovinyltaxoids exhibited impressive activities against these cancer cell lines.  More significantly, a representative 3'-difluorovinyltaxoid exhibited 230-33,000 times higher potency than conventional anticancer drugs against cancer stem cell-enriched HCT-116 cell line.  Studies on the mechanism of action (MOA) of these fluorotaxoids were performed by tubulin polymn. assay, morphol. anal. by electron microscopy (EM) and protein binding assays.  Novel 19F NMR probes, BLT-F2 and BLT-S-F6, were designed by strategically incorporating fluorine, CF3 and CF3O groups into tumor-targeting drug conjugates.  These 19F-probes were designed and synthesized to investigate the mechanism of linker cleavage and factors that influence their plasma and metabolic stability by real-time 19F NMR anal.  Time-resolved 19F NMR study on probe BLT-F2 revealed a stepwise mechanism for the release of a fluorotaxoid, which might not be detected by other anal. methods.  Probe BLT-S-F6 were very useful to study the stability and reactivity of the drug delivery system in human blood plasma by 19F NMR.  The clean anal. of the linker stability and reactivity of drug conjugates in blood plasma by HPLC and 1H NMR is very challenging, but the use of 19F NMR and suitable 19F probes can provide a practical soln. to this problem.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrq2bDu_ckk8bVg90H21EOLACvtfcHk0lgY40YuhIWB1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXotlGntw%253D%253D&md5=b421b53c8371829b4ca44bbec7980a0e</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.jfluchem.2016.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jfluchem.2016.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DOjima%26aufirst%3DI.%26atitle%3DStrategic%2520Incorporation%2520of%2520Fluorine%2520into%2520Taxoid%2520Anticancer%2520Agents%2520for%2520Medicinal%2520Chemistry%2520and%2520Chemical%2520Biology%2520Studies%26jtitle%3DJ.%2520Fluorine%2520Chem.%26date%3D2017%26volume%3D198%26spage%3D10%26epage%3D23%26doi%3D10.1016%2Fj.jfluchem.2016.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gillis, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastman, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Applications of Fluorine in Medicinal Chemistry</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">8315</span>– <span class="NLM_lpage">8359</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00258</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00258" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=8315-8359&author=E.+P.+Gillisauthor=K.+J.+Eastmanauthor=M.+D.+Hillauthor=D.+J.+Donnellyauthor=N.+A.+Meanwell&title=Applications+of+Fluorine+in+Medicinal+Chemistry&doi=10.1021%2Facs.jmedchem.5b00258"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Applications of Fluorine in Medicinal Chemistry</span></div><div class="casAuthors">Gillis, Eric P.; Eastman, Kyle J.; Hill, Matthew D.; Donnelly, David J.; Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8315-8359</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with meta-anal. The role of fluorine in drug design and development is expanding rapidly as we learn more about the unique properties assocd. with this unusual element and how to deploy it with greater sophistication.  The judicious introduction of fluorine into a mol. can productively influence conformation, pKa, intrinsic potency, membrane permeability, metabolic pathways, and pharmacokinetic properties.  In addn., 18F has been established as a useful positron emitting isotope for use with in vivo imaging technol. that potentially has extensive application in drug discovery and development, often limited only by convenient synthetic accessibility to labeled compds.  The wide ranging applications of fluorine in drug design are providing a strong stimulus for the development of new synthetic methodologies that allow more facile access to a wide range of fluorinated compds.  In this review, we provide an update on the effects of the strategic incorporation of fluorine in drug mols. and applications in positron emission tomog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8fUUtkPB4L7Vg90H21EOLACvtfcHk0lgY40YuhIWB1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ajs7%252FK&md5=9995829a94a8c0b8d9fb0d21bdfd5a1d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00258%26sid%3Dliteratum%253Aachs%26aulast%3DGillis%26aufirst%3DE.%2BP.%26aulast%3DEastman%26aufirst%3DK.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BD.%26aulast%3DDonnelly%26aufirst%3DD.%2BJ.%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DApplications%2520of%2520Fluorine%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D8315%26epage%3D8359%26doi%3D10.1021%2Facs.jmedchem.5b00258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meanwell, N. A.</span></span> <span> </span><span class="NLM_article-title">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">5822</span>– <span class="NLM_lpage">5880</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01788</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01788" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=5822-5880&author=N.+A.+Meanwell&title=Fluorine+and+Fluorinated+Motifs+in+the+Design+and+Application+of+Bioisosteres+for+Drug+Design&doi=10.1021%2Facs.jmedchem.7b01788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5822-5880</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the Me group while also acting as a functional mimetic of the carbonyl, carbinol, andnitrile moieties.  In this context, fluorine substitution can influence the potency, conformation, metab., membrane permeability, and P-gp recognition of a mol. and temper inhibition of the hERG channel by basic amines.  However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated mol. construction that broadens biol. mimesis.  In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a mol. are summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoQvY950L3LVg90H21EOLACvtfcHk0lgY4PKIUV5xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitV2qu7w%253D&md5=2d0ce3326c7ff932da8d7d26972ced14</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01788%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DFluorine%2520and%2520Fluorinated%2520Motifs%2520in%2520the%2520Design%2520and%2520Application%2520of%2520Bioisosteres%2520for%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D5822%26epage%3D5880%26doi%3D10.1021%2Facs.jmedchem.7b01788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macdonald, S. J. F.</span></span> <span> </span><span class="NLM_article-title">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7206</span>– <span class="NLM_lpage">7215</span>, <span class="refDoi"> DOI: 10.1021/jm500515d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500515d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7206-7215&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonald&title=Physicochemical+Descriptors+of+Aromatic+Character+and+Their+Use+in+Drug+Discovery&doi=10.1021%2Fjm500515d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Physicochemical Descriptors of Aromatic Character and Their Use in Drug Discovery</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7206-7215</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Published physicochem. descriptors of mols. that convey aromaticity-related character are reviewed in the context of drug design and discovery.  Studies that have employed arom. descriptors are discussed, and several descriptors are compared and contrasted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogc1vxNtUQl7Vg90H21EOLACvtfcHk0lgY4PKIUV5xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXos1Wmsbw%253D&md5=7aca9f7309bb5dd806aeb4c2b4ff8eab</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm500515d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500515d%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26atitle%3DPhysicochemical%2520Descriptors%2520of%2520Aromatic%2520Character%2520and%2520Their%2520Use%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7206%26epage%3D7215%26doi%3D10.1021%2Fjm500515d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrobel, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reitz, A. B.</span></span> <span> </span><span class="NLM_article-title">Dipeptide Prodrugs of the Glutamate Modulator Riluzole</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">756</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00189</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00189" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=752-756&author=J.+C.+Pelletierauthor=S.+Chenauthor=H.+Bianauthor=R.+Shahauthor=G.+R.+Smithauthor=J.+E.+Wrobelauthor=A.+B.+Reitz&title=Dipeptide+Prodrugs+of+the+Glutamate+Modulator+Riluzole&doi=10.1021%2Facsmedchemlett.8b00189"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00189%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DBian%26aufirst%3DH.%26aulast%3DShah%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DG.%2BR.%26aulast%3DWrobel%26aufirst%3DJ.%2BE.%26aulast%3DReitz%26aufirst%3DA.%2BB.%26atitle%3DDipeptide%2520Prodrugs%2520of%2520the%2520Glutamate%2520Modulator%2520Riluzole%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D752%26epage%3D756%26doi%3D10.1021%2Facsmedchemlett.8b00189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vale, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span> <span> </span><span class="NLM_article-title">Cyclization-Activated Prodrugs</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2484</span>– <span class="NLM_lpage">2506</span>, <span class="refDoi"> DOI: 10.3390/12112484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2F12112484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=18065953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1cXjs1Ontg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=2484-2506&author=P.+Gomesauthor=N.+Valeauthor=R.+Moreira&title=Cyclization-Activated+Prodrugs&doi=10.3390%2F12112484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclization-activated prodrugs</span></div><div class="casAuthors">Gomes, Paula; Vale, Nuno; Moreira, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2484-2506</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  Many drugs suffer from an extensive 1st-pass metab. leading to drug inactivation and/or prodn. of toxic metabolites, which makes them attractive targets for prodrug design.  The classical prodrug approach, which involves enzyme-sensitive covalent linkage between the parent drug and a carrier moiety, is a well established strategy to overcome bioavailability/toxicity issues.  However, the development of prodrugs that can regenerate the parent drug through non-enzymic pathways has emerged as an alternative approach in which prodrug activation is not influenced by inter- and intraindividual variability that affects enzymic activity.  Cyclization-activated prodrugs were capturing the attention of medicinal chemists since the middle-1980s, and reached maturity in prodrug design in the late 1990s.  Many different strategies were exploited in recent years concerning the development of intramolecularly-activated prodrugs spanning from analgesics to anti-HIV therapeutic agents.  Intramol. pathways have also a key role in 2-step prodrug activation, where an initial enzymic cleavage step is followed by a cyclization-elimination reaction that releases the active drug.  This work is a brief overview of research on cyclization-activated prodrugs from the last 2 decades.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLCsEijlOS_bVg90H21EOLACvtfcHk0lgY4PKIUV5xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXjs1Ontg%253D%253D&md5=6e16d7b3a7d3914f60b84acc24a2339c</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2F12112484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252F12112484%26sid%3Dliteratum%253Aachs%26aulast%3DGomes%26aufirst%3DP.%26aulast%3DVale%26aufirst%3DN.%26aulast%3DMoreira%26aufirst%3DR.%26atitle%3DCyclization-Activated%2520Prodrugs%26jtitle%3DMolecules%26date%3D2007%26volume%3D12%26spage%3D2484%26epage%3D2506%26doi%3D10.3390%2F12112484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mateus, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Oliveira, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Cyclization-Activated Prodrugs. Synthesis, Reactivity and Toxicity of Dipeptide Esters of Paracetamol</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1595</span>– <span class="NLM_lpage">1598</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2005.01.065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.bmcl.2005.01.065" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1595-1598&author=C.+Santosauthor=M.+L.+Mateusauthor=A.+P.+Santosauthor=R.+Moreiraauthor=E.+de+Oliveiraauthor=P.+Gomes&title=Cyclization-Activated+Prodrugs.+Synthesis%2C+Reactivity+and+Toxicity+of+Dipeptide+Esters+of+Paracetamol&doi=10.1016%2Fj.bmcl.2005.01.065"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2005.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2005.01.065%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DMateus%26aufirst%3DM.%2BL.%26aulast%3DSantos%26aufirst%3DA.%2BP.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3Dde%2BOliveira%26aufirst%3DE.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DCyclization-Activated%2520Prodrugs.%2520Synthesis%252C%2520Reactivity%2520and%2520Toxicity%2520of%2520Dipeptide%2520Esters%2520of%2520Paracetamol%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1595%26epage%3D1598%26doi%3D10.1016%2Fj.bmcl.2005.01.065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meibom, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht-Küpper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diedrichs, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübsch, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krenz, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerchen, H.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittendorf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nell, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Süssmeier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vakalopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, K.</span></span> <span> </span><span class="NLM_article-title">Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">728</span>– <span class="NLM_lpage">737</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1002%2Fcmdc.201700151" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=28488817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntl2isb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=728-737&author=D.+Meibomauthor=B.+Albrecht-K%C3%BCpperauthor=N.+Diedrichsauthor=W.+H%C3%BCbschauthor=R.+Kastauthor=T.+Kr%C3%A4merauthor=U.+Krenzauthor=H.-G.+Lerchenauthor=J.+Mittendorfauthor=P.+G.+Nellauthor=F.+S%C3%BCssmeierauthor=A.+Vakalopoulosauthor=K.+Zimmermann&title=Neladenoson+Bialanate+Hydrochloride%3A+A+Prodrug+of+a+Partial+Adenosine+A1+Receptor+Agonist+for+the+Chronic+Treatment+of+Heart+Diseases&doi=10.1002%2Fcmdc.201700151"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases</span></div><div class="casAuthors">Meibom, Daniel; Albrecht-Kuepper, Barbara; Diedrichs, Nicole; Huebsch, Walter; Kast, Raimund; Kraemer, Thomas; Krenz, Ursula; Lerchen, Hans-Georg; Mittendorf, Joachim; Nell, Peter G.; Suessmeier, Frank; Vakalopoulos, Alexandros; Zimmermann, Katja</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">728-737</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Adenosine is known to be released under a variety of physiol. and pathophysiol. conditions to facilitate the protection and regeneration of injured ischemic tissues.  The activation of myocardial adenosine A1 receptors (A1Rs) has been shown to inhibit myocardial pathologies assocd. with ischemia and reperfusion injury, suggesting several options for new cardiovascular therapies.  When full A1R agonists are used, the desired protective and regenerative cardiovascular effects are usually overshadowed by unintended pharmacol. effects such as induction of bradycardia, atrioventricular (AV) blocks, and sedation.  These unwanted effects can be overcome by using partial A1R agonists.  Starting from previously reported capadenoson we evaluated options to tailor A1R agonists to a specific partiality range, thereby optimizing the therapeutic window.  This led to the identification of the potent and selective agonist neladenoson, which shows the desired partial response on the A1R, resulting in cardioprotection without sedative effects or cardiac AV blocks.  To circumvent soly. and formulation issues for neladenoson, a prodrug approach was pursued.  The dipeptide ester neladenoson bialanate hydrochloride showed significantly improved soly. and exposure after oral administration.  Neladenoson bialanate hydrochloride is currently being evaluated in clin. trials for the treatment of heart failure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo712AVDyOUF7Vg90H21EOLACvtfcHk0ljn40zAhOYhiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntl2isb8%253D&md5=e913933109888fd5897ab943605b2a65</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700151%26sid%3Dliteratum%253Aachs%26aulast%3DMeibom%26aufirst%3DD.%26aulast%3DAlbrecht-K%25C3%25BCpper%26aufirst%3DB.%26aulast%3DDiedrichs%26aufirst%3DN.%26aulast%3DH%25C3%25BCbsch%26aufirst%3DW.%26aulast%3DKast%26aufirst%3DR.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DT.%26aulast%3DKrenz%26aufirst%3DU.%26aulast%3DLerchen%26aufirst%3DH.-G.%26aulast%3DMittendorf%26aufirst%3DJ.%26aulast%3DNell%26aufirst%3DP.%2BG.%26aulast%3DS%25C3%25BCssmeier%26aufirst%3DF.%26aulast%3DVakalopoulos%26aufirst%3DA.%26aulast%3DZimmermann%26aufirst%3DK.%26atitle%3DNeladenoson%2520Bialanate%2520Hydrochloride%253A%2520A%2520Prodrug%2520of%2520a%2520Partial%2520Adenosine%2520A1%2520Receptor%2520Agonist%2520for%2520the%2520Chronic%2520Treatment%2520of%2520Heart%2520Diseases%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D728%26epage%3D737%26doi%3D10.1002%2Fcmdc.201700151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capela, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, C. S. G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gouveia, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pannecouque, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreira, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomes, P.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships for Dipeptide Prodrugs of Acyclovir: Implications for Prodrug Design</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2339</span>– <span class="NLM_lpage">2346</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2008.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1016%2Fj.ejmech.2008.08.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=2339-2346&author=C.+R.+Santosauthor=R.+Capelaauthor=C.+S.+G.+P.+Pereiraauthor=E.+Valenteauthor=L.+Gouveiaauthor=C.+Pannecouqueauthor=E.+De+Clercqauthor=R.+Moreiraauthor=P.+Gomes&title=Structure-Activity+Relationships+for+Dipeptide+Prodrugs+of+Acyclovir%3A+Implications+for+Prodrug+Design&doi=10.1016%2Fj.ejmech.2008.08.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2008.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2008.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DSantos%26aufirst%3DC.%2BR.%26aulast%3DCapela%26aufirst%3DR.%26aulast%3DPereira%26aufirst%3DC.%2BS.%2BG.%2BP.%26aulast%3DValente%26aufirst%3DE.%26aulast%3DGouveia%26aufirst%3DL.%26aulast%3DPannecouque%26aufirst%3DC.%26aulast%3DDe%2BClercq%26aufirst%3DE.%26aulast%3DMoreira%26aufirst%3DR.%26aulast%3DGomes%26aufirst%3DP.%26atitle%3DStructure-Activity%2520Relationships%2520for%2520Dipeptide%2520Prodrugs%2520of%2520Acyclovir%253A%2520Implications%2520for%2520Prodrug%2520Design%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D2339%26epage%3D2346%26doi%3D10.1016%2Fj.ejmech.2008.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Picaso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escalante, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rios, M. Y.</span></span> <span> </span><span class="NLM_article-title">Efficient Microwave Assisted Syntheses of 2,5-Diketopiperazines in Aqueous Media</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">2836</span>– <span class="NLM_lpage">2849</span>, <span class="refDoi"> DOI: 10.3390/molecules14082836</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.3390%2Fmolecules14082836" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=19701127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVShtbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=2836-2849&author=L.+P%C3%A9rez-Picasoauthor=J.+Escalanteauthor=H.+Olivoauthor=M.+Y.+Rios&title=Efficient+Microwave+Assisted+Syntheses+of+2%2C5-Diketopiperazines+in+Aqueous+Media&doi=10.3390%2Fmolecules14082836"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient microwave assisted syntheses of 2,5-diketopiperazines in aqueous media</span></div><div class="casAuthors">Perez-Picaso, Lemuel; Escalante, Jaime; Olivo, Horacio F.; Rios, Maria Yolanda</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2836-2849</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">Aq. in situ one-pot N-Boc-deprotection-cyclization of Nα-Boc-dipeptidyl-tert-Bu (Boc = tert-butoxycarbonyl) and Me esters under microwave irradn. afforded 2,5-diketopiperazines (DKPs) in excellent yields.  This protocol is rapid, safe, environmentally friendly, and highly efficient, and showed that the tert-butoxy moiety is also an excellent leaving group for these cyclizations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLNSJTOYunB7Vg90H21EOLACvtfcHk0ljn40zAhOYhiA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVShtbrM&md5=cc9d2776dc2c2712ccf13e641853c945</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.3390%2Fmolecules14082836&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules14082836%26sid%3Dliteratum%253Aachs%26aulast%3DP%25C3%25A9rez-Picaso%26aufirst%3DL.%26aulast%3DEscalante%26aufirst%3DJ.%26aulast%3DOlivo%26aufirst%3DH.%26aulast%3DRios%26aufirst%3DM.%2BY.%26atitle%3DEfficient%2520Microwave%2520Assisted%2520Syntheses%2520of%25202%252C5-Diketopiperazines%2520in%2520Aqueous%2520Media%26jtitle%3DMolecules%26date%3D2009%26volume%3D14%26spage%3D2836%26epage%3D2849%26doi%3D10.3390%2Fmolecules14082836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robillard, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, G. N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">la Porte, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">Role of P-Glycoprotein in the Distribution of the HIV Protease Inhibitor Atazanavir in the Brain and Male Genital Tract</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">1713</span>– <span class="NLM_lpage">1722</span>, <span class="refDoi"> DOI: 10.1128/aac.02031-13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1128%2Faac.02031-13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2014&pages=1713-1722&author=K.+R.+Robillardauthor=G.+N.+Y.+Chanauthor=G.+Zhangauthor=W.+la+Porteauthor=R.+Bendayan&title=Role+of+P-Glycoprotein+in+the+Distribution+of+the+HIV+Protease+Inhibitor+Atazanavir+in+the+Brain+and+Male+Genital+Tract&doi=10.1128%2Faac.02031-13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1128%2Faac.02031-13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252Faac.02031-13%26sid%3Dliteratum%253Aachs%26aulast%3DRobillard%26aufirst%3DK.%2BR.%26aulast%3DChan%26aufirst%3DG.%2BN.%2BY.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3Dla%2BPorte%26aufirst%3DW.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DRole%2520of%2520P-Glycoprotein%2520in%2520the%2520Distribution%2520of%2520the%2520HIV%2520Protease%2520Inhibitor%2520Atazanavir%2520in%2520the%2520Brain%2520and%2520Male%2520Genital%2520Tract%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2014%26volume%3D58%26spage%3D1713%26epage%3D1722%26doi%3D10.1128%2Faac.02031-13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kis, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walmsley, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bendayan, R.</span></span> <span> </span><span class="NLM_article-title">In vitro and In situ Evaluation of pH-Dependence of Atazanavir Intestinal Permeability and Interactions with Acid-Reducing Agents</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">2404</span>– <span class="NLM_lpage">2419</span>, <span class="refDoi"> DOI: 10.1007/s11095-014-1336-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;key=10.1007%2Fs11095-014-1336-0" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=2404-2419&author=O.+Kisauthor=S.+L.+Walmsleyauthor=R.+Bendayan&title=In+vitro+and+In+situ+Evaluation+of+pH-Dependence+of+Atazanavir+Intestinal+Permeability+and+Interactions+with+Acid-Reducing+Agents&doi=10.1007%2Fs11095-014-1336-0"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1007%2Fs11095-014-1336-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-014-1336-0%26sid%3Dliteratum%253Aachs%26aulast%3DKis%26aufirst%3DO.%26aulast%3DWalmsley%26aufirst%3DS.%2BL.%26aulast%3DBendayan%26aufirst%3DR.%26atitle%3DIn%2520vitro%2520and%2520In%2520situ%2520Evaluation%2520of%2520pH-Dependence%2520of%2520Atazanavir%2520Intestinal%2520Permeability%2520and%2520Interactions%2520with%2520Acid-Reducing%2520Agents%26jtitle%3DPharm.%2520Res.%26date%3D2014%26volume%3D31%26spage%3D2404%26epage%3D2419%26doi%3D10.1007%2Fs11095-014-1336-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i43"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00002">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_37041"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00002">10.1021/acs.jmedchem.9b00002</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_001.csv">CSV</a>)</p></li><li><p class="inline">Figures 3−11 and Table 13; experimental section (synthesis) = experimental procedures of prodrugs (<b>23</b>, <b>30</b>, <b>31</b>, <b>32</b>, <b>46</b>, <b>47</b>, <b>48</b>, <b>49</b>, <b>51</b>, <b>52</b>, <b>54</b>, <b>59</b>, <b>64</b>, <b>66</b>, <b>71</b>, <b>78</b>, <b>81</b>, and <b>82</b>);  details of in vitro and in vivo experiments = stability evaluation in aqueous buffer; stability evaluation in bio-relevant media; solubility evaluation in aqueous buffer; pharmacokinetic evaluation; ex vivo stability in whole blood; alkaline phosphatase assay: determination of prodrug cleavage rate in vitro; rat hepatocyte study with and without PMSF/ABT; procedure for UGT1A1 assay; antiviral assays (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_001.csv">jm9b00002_si_001.csv (10.24 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00002/suppl_file/jm9b00002_si_002.pdf">jm9b00002_si_002.pdf (1.35 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00002&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00002%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-7%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00002" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679ab39d9b75d1cb","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
